

2019

Cellular mechanisms that establish HIV-1 latency in CD4+ T cells and the potential for their manipulation as a therapeutic strategy

<https://hdl.handle.net/2144/36677>

Boston University

BOSTON UNIVERSITY
SCHOOL OF MEDICINE

Dissertation

**CELLULAR MECHANISMS THAT ESTABLISH HIV-1 LATENCY IN CD4+ T
CELLS AND THE POTENTIAL FOR THEIR MANIPULATION AS A
THERAPEUTIC STRATEGY**

by

MATTHEW GAGNE

B.A., Boston University, 2009

Submitted in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy

2019

Approved by

First Reader

Andrew J. Henderson, Ph.D.
Associate Professor of Medicine
Associate Professor of Microbiology

Second Reader

Suryaram Gummuluru, Ph.D.
Associate Professor of Microbiology

*“Every great and deep difficulty bears in itself its own solution. It forces us to change our
thinking in order to find it.”*

- Attributed to Niels Bohr, Ph.D.

Nobel Laureate, 1922

DEDICATION

For my parents, James and Monique Gagne, who introduced me to research.

For my mentors and classmates, who inspired me to persevere through my research.

For Myung-Eun, my life long research partner.

ACKNOWLEDGMENTS

The work presented in this dissertation is the result of years spent in the lab surrounded by postdoctoral researchers, fellow graduate students, technicians, and mentors without whom none of this would have been possible. While there are many individuals who contributed to my progress both scientifically and educationally, I would particularly like to thank Luis Agosto, Ph.D., who extensively helped with my nested *Alu*-PCR and cell sorting strategies, and Gillian Schiralli Lester, Ph.D., who helped formulate some of the earliest iterations of this work. Two former graduate students, Katarzyna Kaczmarek Michaels, Ph.D., and Daniele Cary, Ph.D., also provided extensive guidance regarding experimental techniques and the graduate school process. Dan Michaels performed the chromatin immunoprecipitations described in this dissertation and entertained me with hilarious stories on the slowest days in lab. Alex Olson and Binita Basukala worked tirelessly on the disabled Cas9 experiments and were great labmates; I look forward to seeing where their scientific careers take them. Kyle Pedro was my fellow Microbiology graduate student in the Henderson lab and a constant advocate for improved science policies. Melissa Herring, Hasahn Conway, Carolyn Coote, and Xianbao He were all amazing lab members and thoughtful scientists. Finally, I owe most of my progress as a scientist to my mentor, Andrew J. Henderson, Ph.D., who provided constructive criticism and softened the blow with his unlimited supply of bagels, Chinese pastries, and Blackbird doughnuts. He spent countless hours not only by helping me design my experiments, but also by teaching me about grant writing, career

development, and presentation skills. I am a much better scientist because I was in his laboratory.

One of the joys of a scientific education is the access to wonderful professors and researchers outside of your specific lab. Shoumita Dasgupta, Ph.D., and Gregory Viglianti, Ph.D., were particularly involved educators who gave me multiple opportunities to practice and improve my teaching techniques. Wilson Wong, Ph.D., designed both the chimeric antigen receptors and the disabled Cas9 constructs. Without the assistance of him and his graduate students, none of this work would have been possible. Björn Reinhard, Dr. rer. nat., collaborated with our lab in the formulation of the chimeric antigen receptor project. Likewise, Jennifer Snyder-Cappione, Ph.D., had a significant impact on this work through her advice and assistance as the director of the Boston University Flow Cytometry Core Facility. The entire BU flow core, including Anna Belkina, M.D., Ph.D., and especially Brian Tilton, the director of cell sorting, are owed a big debt of gratitude. Likewise, the BU Microarray and Sequencing Resource Core Facility was invaluable due to their assistance with both the microarray assay and the voluminous analysis that they provided with it. Suryaram Gummuluru, Ph.D., along with his entire lab, helped formulate the experiments and hypotheses discussed in this dissertation and in my various oral presentations at Cold Spring Harbor Laboratory. In addition, I would like to acknowledge the mentorship and insights provided by my Dissertation Advisory Committee: Dr. Viglianti (chair), Dr. Henderson, Dr. Gummuluru, Dr. Cappione, Rachel Fearn, Ph.D. (Director of Graduate Studies), and Susan Winandy, Ph.D.

One of the benefits of the Microbiology Department at the Boston University School of Medicine is its close collaboration with the Section of Infectious Diseases at Boston Medical Center. Through this collaboration, I obtained a Ruth L. Kirschstein Predoctoral Individual National Research Service Award (F31). This grant from the National Institute of Allergy and Infectious Diseases provided funding for my project and could not have been awarded without the assistance of Stephanie Hitchings and Thuy-Chi Ly, the BMC Section Research Administrator. In addition, I received valuable feedback on the creation of my F31 grant through participation in a grant writing workshop provided by BU's BEST under the direction of Chelsea Barbercheck, Ph.D. Another advantage to the strong relationship between Boston University School of Medicine and Boston Medical Center is the opportunity to discuss your work with clinicians as well as researchers. Manish Sagar, M.D., and Lee Wetzler, M.D., fostered a collaborative environment between their laboratories and the Henderson lab; interactions like these significantly improved the quality of my work.

The strongest resource within Boston University School of Medicine is the student body. Every fellow graduate student that I interacted with was influential in my career development. I would particularly like to acknowledge my initial student mentor, Obi Onochie, Ph.D., and my fellow classmates from the Program in Biomedical Sciences, including Alicia Wooten, Grace Olinger, and Yuri Kim. The Microbiology Department has been my home for the past five years, and I would like to thank Ronald Corley, Ph.D., for his leadership of the department. Kathleen Marinelli and Linda Parlee were indispensable in their knowledge of the department and their assistance in all

administrative matters. Finally, micro (and associated) students Caitlin Miller, Ph.D., Melissa Ghulam-Smith, Stephanie Pavlovich, Sarah Nodder, Allison Thomas, and Ian Francis enabled me to persevere through my graduate education. All of these relationships are testament to the resources and community provided me by Boston University, where I also obtained my undergraduate degree.

Any scientist would acknowledge that the majority of the work put into a Ph.D. occurs outside of the lab. My friends, especially Derek and Michelle Sung, Christopher and Becky Bucchianeri, Evan McCann, and the trivia all-stars Casey Teal, Samantha Sissel, and Michelle Ejiofor supported me and let me talk endlessly about very random scientific facts. My parents and grandparents not only helped me through the transition into graduate school, but also encouraged me to pursue my dreams of becoming a scientist even when I felt like giving up. They have always been advocates for me, and I am happy to dedicate this dissertation to them. Finally, my wife, Jennifer Myung-Eun Kim-Gagne, practiced all of my seminars and presentations with me. They say that a Ph.D. is an expert in a field of only one person; but at this point, Jenn knows as much about HIV as I do.

**CELLULAR MECHANISMS THAT ESTABLISH HIV-1 LATENCY IN CD4+ T
CELLS AND THE POTENTIAL FOR THEIR MANIPULATION AS A
THERAPEUTIC STRATEGY**

MATTHEW GAGNE

Boston University School of Medicine, 2019

Major Professor: Andrew J. Henderson, Ph.D., Associate Professor of Medicine and
Microbiology

ABSTRACT

Human Immunodeficiency Virus 1 (HIV-1) remains a significant public health concern due to the lack of a cure. In spite of anti-retroviral therapies, HIV-1 persists within infected cells as integrated transcriptionally silent proviruses. Re-activation after therapy interruption results in new HIV-1 replication. Attempts to clear this reservoir through the use of latency reversing agents by targeting cellular mechanisms that maintain HIV-1 in a latent state have been unsuccessful. In addition, subsets of latently infected cells exist within the reservoir that display differential capacities for provirus induction. In order to understand the nature of the reservoir and manipulate it therapeutically, more knowledge is needed regarding factors that bias a virus towards latency or replication at the time of infection.

Because multiple mechanisms that regulate HIV-1 transcription, including chromatin remodeling, transcription factor activation and polymerase pausing, are regulated by the T cell receptor (TCR), I hypothesized that signaling at the time of infection determines proviral fate. I transduced Jurkat cell lines and primary CD4+ T

cells with chimeric antigen receptors (CARs) that mimicked signaling from the TCR. These CARs spanned a 3-log range of binding affinities for their ligand, providing a tunable model. High levels of TCR stimulation during infection biased cells towards productive replication and the formation of an inducible latent reservoir. Examination of the mechanisms downstream from TCR signaling revealed that robust cellular activation led to a release of the repressor Negative Elongation Factor from the paused RNA Polymerase II, facilitating transcriptional elongation.

Because signaling determined the presence of repressive factors, I sought to manipulate the balance between latency and expression through recruitment of repressors to the HIV-1 provirus using a nuclease-deficient CRISPR Associated Protein 9 fused to a Krüppel Associated Box Domain. I screened a pool of guide RNAs that mediated transcriptional repression of HIV-1. Our lab discovered that guides bound to the HIV-1 Long Terminal Repeat prevented viral re-activation in an integrated cell model of HIV-1 latency.

The research presented here confirms my hypothesis that signals during infection have prolonged effects on latency reversal. I provide evidence that manipulation of these mechanisms represent therapeutic targets for cure efforts.

TABLE OF CONTENTS

| | |
|---|------|
| DEDICATION | v |
| ACKNOWLEDGMENTS | vi |
| ABSTRACT | x |
| TABLE OF CONTENTS..... | xii |
| LIST OF TABLES..... | xvi |
| LIST OF FIGURES | xvii |
| LIST OF ILLUSTRATIONS | xix |
| LIST OF ABBREVIATIONS..... | xx |
| CHAPTER ONE: INTRODUCTION..... | 1 |
| The Emergence and Pathology of Human Immunodeficiency Virus-1 | 1 |
| The Life Cycle of HIV-1..... | 4 |
| HIV-1 Latency | 10 |
| Biology and Model Systems | 10 |
| “Shock and Kill” | 17 |
| Establishment of Latent HIV-1 and the Role of T Cell Signaling..... | 19 |
| “Block and Lock” | 23 |
| Specific Aims and Hypothesis | 27 |
| CHAPTER TWO: MATERIALS AND METHODS | 31 |

| | |
|--|----|
| Cells | 31 |
| sgRNA Screen..... | 32 |
| Viruses, Transfections, and Transductions | 34 |
| CAR Stimulation and Infections..... | 35 |
| Electroporations | 36 |
| Latency Reversal..... | 36 |
| Luciferase Analysis..... | 37 |
| Flow Cytometry | 37 |
| Microarray Analysis and Heatmap Formulation..... | 38 |
| Measurement of HIV-1 Provirus Using Nested <i>Alu</i> -PCR | 40 |
| Measurement of HIV-1 mRNA by RT-PCR | 41 |
| RT-PCR for Chapter Three..... | 41 |
| RT-PCR for Chapter Four..... | 42 |
| Chromatin Immunoprecipitation (ChIP)..... | 43 |
| Statistical Analysis..... | 45 |
| | |
| CHAPTER THREE: STRENGTH OF T CELL SIGNALING REGULATES HIV-1 | |
| REPLICATION AND ESTABLISHMENT OF LATENCY | 46 |
| INTRODUCTION | 46 |
| Experimental Rationale..... | 46 |
| Chimeric Antigen Receptors..... | 48 |
| RESULTS | 50 |
| CARs Induce T Cell Signaling | 50 |

| | |
|---|----|
| T Cell Signaling at the Time of HIV-1 Infection Regulates Provirus Expression.... | 58 |
| Robust Signals During HIV-1 Infection Establishes an Inducible Latent Reservoir | 65 |
| RNAPII Processivity Limits HIV-1 Transcription in the Absence of Robust Signaling | 67 |
| DISCUSSION | 70 |
| CHAPTER FOUR: NUCLEASE-DEFICIENT CAS9-KRAB CAN BE USED TO SILENCE HIV-1 EXPRESSION THROUGH REDUCTION IN RNAPII | |
| INITIATION..... | 74 |
| INTRODUCTION | 74 |
| Discovery of CRISPR-Cas9 and Use as an HIV-1 Therapeutic | 74 |
| Cas9-KRAB Construct for Targeted Gene Repression | 76 |
| RESULTS | 77 |
| Nuclease-Deficient Cas9-KRAB Suppresses HIV-1 Expression | 77 |
| Nuclease-Deficient Cas9-KRAB Prevents Latent HIV-1 Reactivation..... | 81 |
| DISCUSSION | 82 |
| CHAPTER FIVE: DISCUSSION AND FUTURE IMPLICATIONS | |
| Summary of Results | 85 |
| Latency: A Goal or an Obstacle? | 87 |
| Remaining Mechanistic Questions | 89 |
| The Impact of TCR Signaling on T Cell Function and Differentiation | 90 |
| Study Limitations..... | 92 |

| | |
|--|-----|
| Clinical Implications | 95 |
| APPENDIX: MICROARRAY ANALYSIS OF DIFFERENTIALLY STIMULATED | |
| CD4+ T CELLS IN CHAPTER THREE | 97 |
| Principal Component Analysis | 97 |
| Microarray Analysis..... | 99 |
| BIBLIOGRAPHY | 176 |
| CURRICULUM VITAE | 206 |

LIST OF TABLES

| | |
|---|----|
| Table 1.1: Commonly used models of HIV-1 latency | 15 |
| Table 2.1: Sequences used for crRNA screen..... | 33 |
| Table 2.2: Oligos used for <i>Alu</i> -PCR | 41 |
| Table 2.3: Oligos used for RT-PCR in Chapter Three..... | 42 |
| Table 2.4: Oligos used for RT-PCR in Chapter Four | 43 |
| Table 2.5: Oligos used for chromatin immunoprecipitation | 45 |
| Table 3.1: Log2 expression of differentially regulated genes upon cell activation | 53 |
| Table A.1: List of genes whose expression is significantly altered upon TCR stimulation..... | 99 |

LIST OF FIGURES

| | |
|--|----|
| Figure 1.1: Binding sites of a select number of key transcription factors to the HIV-1 | |
| LTR..... | 8 |
| Figure 1.2: Life cycle of HIV-1 | 10 |
| Figure 1.3: HIV-1 rebounds after cART interruption..... | 11 |
| Figure 1.4: T cell receptor signaling results in activation of multiple pathways..... | 21 |
| Figure 1.5: A significant portion of the latent reservoir consists of non-inducible fully | |
| competent proviruses | 23 |
| Figure 3.1: Chimeric antigen receptors used for tunable T cell signaling..... | 51 |
| Figure 3.2: Signaling through chimeric antigen receptors alters the expression of genes | |
| downstream from the T cell receptor..... | 55 |
| Figure 3.3: Differential signaling through chimeric antigen receptors..... | 56 |
| Figure 3.4: Signaling through chimeric antigen receptors polarizes cells towards a central | |
| memory phenotype..... | 57 |
| Figure 3.5: T cell signaling at the time of HIV-1 infection regulates provirus | |
| expression | 60 |
| Figure 3.6: Src kinase inhibitor PP2 inhibits CAR-mediated HIV-1 transcription | 62 |
| Figure 3.7: T cell signaling at the time of HIV-1 infection regulates provirus expression | |
| by inducing transcription | 63 |
| Figure 3.8: Robust T cell signaling is required for HIV-1 transcription | 64 |
| Figure 3.9: Robust signals during HIV-1 infection establish an inducible latent | |
| reservoir | 67 |

| | |
|---|----|
| Figure 3.10: RNAPII processivity limits HIV-1 transcription in the absence of robust signaling..... | 69 |
| Figure 4.1: KRAB binding to the HIV-1 LTR inhibits viral expression. | 81 |
| Figure 4.2: KRAB-Kap1 blocks HIV-1 latency reversal in J-Lat cells | 82 |
| Figure A.1: Magnitude of T cell signaling differentially regulates genes in a gradient fashion..... | 98 |

LIST OF ILLUSTRATIONS

| | |
|---|----|
| Illustration 1.1: dCas9-targeted repression of HIV-1 | 26 |
| Illustration 3.1: T cell signaling during HIV-1 infection drives viral fate..... | 73 |
| Illustration 4.1: Selection of HIV-1 binding sgRNAs for CRISPR-mediated epigenetic silencing | 78 |

LIST OF ABBREVIATIONS

| | |
|----------------------|---|
| AIDS | Acquired Immunodeficiency Syndrome |
| ANOVA | Analysis of Variance |
| AP-1 | Activator Protein 1 |
| APC | Antigen-Presenting Cell |
| ART | Antiretroviral Therapy |
| BET | Bromodomain and Extra-Terminal Motif |
| BRD4 | Bromodomain-Containing Protein 4 |
| BU | Boston University |
| CAR | Chimeric Antigen Receptor |
| cART | Combination Antiretroviral Therapy |
| dCas9 | Disabled (Nuclease-Deficient) CRISPR Associated Protein 9 |
| CRISPR | Clustered Regularly Interspaced Short Palindromic Repeats |
| DSIF | DRB Sensitivity Inducing Factor |
| Efz | Efavirenz |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| ESCRT | Endosomal Sorting Complexes Required for Transport |
| FDR | False Discovery Rate |
| $\gamma\delta$ | Gammadelta T Cells |
| GFP | Green Fluorescent Protein |
| HATs | Histone Acetyltransferases |
| HDAC | Histone Deacetylase |

| | |
|----------------------|--|
| HDACi | Histone Deacetylase Inhibitor |
| Her2..... | Human Epidermal Growth Factor Receptor 2 |
| HIV-1 | Human Immunodeficiency Virus 1 |
| HMT..... | Histone Methyltransferase |
| HUSH..... | Human Silencing Hub |
| ITAM | Immunoreceptor Tyrosine-Based Activation Motif |
| Kap1 | KRAB-Associated Protein-1 (Trim28) |
| KRAB | Krüppel Associated Box Domain |
| LAT..... | Linker of Activated T Cells |
| Lck | Lymphocyte-Specific Protein Tyrosine Kinase |
| LRA..... | Latency Reversing Agent |
| LTR..... | Long Terminal Repeat |
| MAPK..... | Mitogen-Activated Protein Kinase |
| MHC | Major Histocompatibility Complex |
| NF- κ B | Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells |
| NFAT | Nuclear Factor of Activated T Cells |
| Nef..... | HIV Negative Regulatory Factor |
| NELF..... | Negative Elongation Factor |
| PBMCs..... | Peripheral Blood Mononuclear Cells |
| PHA | Phytohaemagglutinin |
| PKC..... | Protein Kinase C |
| PLC γ 1 | Phosphoinositide Phospholipase C Gamma 1 |

| | |
|---------------------------------|--|
| PMA | Phorbol Myristate Acetate |
| PrEP | Pre-Exposure Prophylaxis |
| PtdIns(4,5)P ₂ | Phosphatidylinositol 4,5-Bisphosphate |
| P-TEFb | Positive Transcription Elongation Factor |
| RNAPII | RNA Polymerase II |
| SAHA | Suberanilohydroxamic Acid (Vorinostat) |
| SBHA | Suberoyl Bis-Hydroxamic Acid |
| scFv | Single-Chain Variable Fragment |
| Sh2 | Src Homology 2 |
| SIV | Simian Immunodeficiency Virus |
| SP1 | Specificity Protein 1 |
| Src | Proto-Oncogene Tyrosine-Protein Kinase Src |
| SWI/SNF | Switch / Sucrose Non-Fermentable |
| Tat | HIV Transactivator of Transcription |
| TCR | T Cell Receptor |
| TNF α | Tumor Necrosis Factor Alpha |
| VOA | Viral Outgrowth Assay |
| Vpr | HIV Viral Protein R |
| Vpx | HIV Viral Protein X |
| VSVG | Vesicular Stomatitis Virus Envelope Glycoprotein G |
| Zap70 | Zeta-Chain-Associated Protein Kinase 70 |

CHAPTER ONE: INTRODUCTION

The Emergence and Pathology of Human Immunodeficiency Virus-1

Human Immunodeficiency Virus-1 (HIV-1) was first reported in a notice from the Centers of Disease Control on June 5, 1981 (CDC, 1981). This medical newsletter, which identified an outbreak of *Pneumocystis* pneumonia among homosexual men in Los Angeles, quickly brought attention to the spread of a contagious immunodeficiency. The underlying immune dysfunction, Acquired Immunodeficiency Syndrome, would later be discovered to be caused by the virus now known as HIV-1 (Gallo and Montagnier, 2003).

HIV-1 evolved from SIV or Simian Immunodeficiency Virus (Ringler *et al.*, 1987; Smith *et al.*, 1988). SIV consists of several species-specific strains that circulate among non-human primates, usually resulting in minimal symptoms and long-term tolerance (Bostik *et al.*, 2001). Cross-species jumps of these various strains from non-human primates into human hosts have led to the emergence of both HIV-1 and the related virus HIV-2. HIV-1 shares significant homology with the chimpanzee variant of SIV, known as SIVcpz, and most likely originated in central Africa in the first half of the 20th century (Gao *et al.*, 1999). The HIV-1 major groups M, N, O, and P arose from separate evolutionary cross-over events from SIVcpz or SIVgor (gorilla) and required the acquisition of the ability to inhibit key human restriction factors, so named for the ability to restrict viral replication (Sauter and Kirchhoff, 2019). In particular, HIV-1 Group M, which evolved from SIVcpz, can robustly inhibit a key restriction factor, tetherin, and

thus constitutes the majority of viruses responsible for the current human pandemic (Sauter *et al.*, 2009)

HIV-1 spread to North America due to increased travel and globalized commerce in the mid-1900's. Once in the United States, the virus spread quickly among Haitian immigrants, men who have sex with men (MSM), and hemophiliacs, who were susceptible to infection due to their need for frequent blood transfusions (De Cock, Jaffe and Curran, 2012). Mass hysteria over both the source of AIDS as well as the mode of transmission led to a concerted effort by the National Institutes of Health, the Centers for Disease Control, and the Institut Pasteur in Paris to fund AIDS-related research. These experiments culminated in the landmark discovery of HIV-1 in 1983 as the causative agent of AIDS in North America and Europe by Luc Montagnier and Françoise Barré-Sinoussi (Barré-Sinoussi *et al.*, 1983).

We now know that HIV-1 results in a depletion of the lymphocytic CD4+ T cell population. This weakens the adaptive immune response, rendering the host vulnerable to a wide variety of opportunistic infections (Frazer *et al.*, 1986; Shearer *et al.*, 1986). Early AIDS-identifying diseases included *Pneumocystis pneumonia*, Kaposi's sarcoma, and toxoplasmosis from *Toxoplasma gondii* (Pitchenik *et al.*, 1983). With the advent of antiretroviral therapies or ART in 1986, remarkable progress has been achieved in preventing the onset of AIDS (Mitsuya *et al.*, 1985). This progress was particularly enhanced with the design of combination therapy involving cocktails of inhibitors (Tisdale *et al.*, 1993). However, in spite of cART, lifelong infection with HIV-1 still results in greater risk of cardiovascular disease, kidney failure, and neurocognitive

impairments (Freiberg *et al.*, 2013; Guaraldi *et al.*, 2011; Simioni *et al.*, 2010). Patients experience permanent immune dysfunction, even after full viral suppression. Persistent exposure to viral antigens results in both immune exhaustion and constant inflammation (Hunt *et al.*, 2003; French *et al.*, 2009; Hatano *et al.*, 2013). Antiretroviral therapies, while essential to prevent progression to AIDS, also cause a number of serious side effects including loss of bone density, gastrointestinal discomfort, and hypersensitivity (Güerri-Fernández *et al.*, 2017; Santos *et al.*, 2017; Wu *et al.*, 2017).

The use of Truvada as pre-exposure prophylaxis (PrEP) beginning in 2012 has dramatically changed the trajectory of the HIV public health epidemic. Prescribing Truvada to high-risk populations has substantially reduced the spread of the virus (Grant *et al.*, 2010). However, neither cART nor PrEP has resulted in a cure for HIV-1 or the end of its transmission. In fact, although new infections of HIV-1 within the United States have plateaued, infection with HIV-1 is still a matter of much stigma and remains prevalent both in poorer regions of the southeastern United States (CDC, 2018) as well as Southeast Asia, Eastern Europe, and sub-Saharan Africa (Stuart *et al.*, 2018). Seventy percent of all HIV cases occur in sub-Saharan Africa where access to PrEP is extremely limited (Kharsany and Karim, 2016). Other groups that are still particularly susceptible to infection include MSM, sex-workers, IV-drug users, and minority women (CDC, 2018; UNAIDS, Guidance Note on HIV and Sex Work, 2019). Even with proper education and increased societal awareness, adherence to medication remains a major barrier to viral suppression. Thus, eradication of HIV-1 remains a significant challenge. The United Nations has prioritized a strategy, referred to as 90-90-90, in which the global medical

community aims to achieve 90% diagnosis of HIV, 90% ART-treatment among those diagnoses, and 90% viral suppression among those taking ART (Stover *et al.*, 2016). In tandem with this approach, there have been significant efforts to create a broad spectrum HIV-1 vaccine, but none of these strategies have so far completely prevented the spread of HIV-1 or led to a cure (Rerks-Ngarm *et al.*, 2009; Gray *et al.*, 2011). These factors all indicate that continued efforts must be made to eradicate HIV-1 and end both the terrible medical burden and social stigma caused by this virus. At the time of this publication, more than 35 million people have died from AIDS-related illnesses, including 1 million people in 2017 alone (UNAIDS, Global HIV & AIDS Statistics, 2019).

The Life Cycle of HIV-1

When HIV-1 enters the human body, it is presumably trafficked through the mucosa by antigen-presenting cells or APCs (Hladik *et al.*, 2007). These APCs, including dendritic cells, Langerhans cells, and macrophages, play an important role in bridging the innate and adaptive immune responses. They endocytose pathogens before trafficking them to the cell surface in conjunction with an MHC Class II complex (Roche and Furuta, 2015). This presentation along with secondary stimulation by cytokines or cell surface receptors can trigger a specific response in lymphocytes for which the epitope of interest acts as the cognate antigen.

Eventually, HIV-1 is delivered by APCs to the lymph nodes, where it spreads to various target cells including macrophages, dendritic cells, and the primary reservoir of

CD4⁺ T cells (Barré-Sinoussi *et al.*, 1983; Armstrong and Horne, 1984; Koenig *et al.*, 1986). The fact that HIV-1 can infect the APCs that present it to its various target cells highlight the dual role that can occur within dendritic cells and macrophages. Both direct infection and trans-infection through antigen presentation provide two routes through which HIV-1 can spread and highlight the importance of cell interactions to viral transmission (Cameron *et al.*, 1992; McDonald *et al.*, 2003). For dendritic cells, the differentiation state determines which of these routes can occur; for instance, trans-infection via CD169, a cell surface lectin, is associated with mature DCs (Puryear *et al.*, 2013).

HIV-1 target cells contain the necessary receptors for viral entry: CD4 and a coreceptor of CCR5 or CXCR4 (Feng *et al.*, 1996; Deng *et al.*, 1996; Dragic *et al.*, 1996). Founder viruses use CCR5 for viral entry and are referred to as R5-tropic. The progression to dual-tropic or X4-tropic viruses, which exclusively use CXCR4 for entry, is associated with both onset of AIDS and a depletion of R5-expressing cells (Connor *et al.*, 1997). This coreceptor switch does not occur in all HIV-infected patients.

The HIV-1 virion is spherical and marked by a limited number of glycoprotein envelope spikes (Zhu *et al.*, 2006). It consists of a lipid membrane derived from its previous host cell (Nguyen *et al.*, 2000) and contains an internal capsid harboring two copies of its genome as viral RNA (Chen *et al.*, 2009). In addition, it packages essential proteins for its replication, including reverse transcriptase, integrase, and its transcription factor Tat (Huang *et al.*, 1994; Bosso *et al.*, 2015; Kessl *et al.*, 2016). In addition, the viral accessory protein Vpr or Viral Protein R is also packaged and is required for robust

transcription in dendritic cells (Miller *et al.*, 2017). When the HIV-1 envelope binds to its appropriate receptors, it triggers fusion with the cell membrane (Maddon *et al.*, 1988). Fusion is thought to occur through a suggested series of intermediate steps, in which the outer glycoprotein trimer, referred to as gp120, engages with CD4. This allows the coreceptor binding site to become accessible; the HIV-1 fusion peptide then can interact with the target cell, forming a hairpin which pulls apart the cell membrane and facilitating the delivery of the virion (Chan and Kim, 1998; Wang H *et al.*, 2016).

Upon entry, HIV-1 unloads its capsid into the cell cytoplasm. Within the capsid, the RNA genome is reverse-transcribed into complementary DNA. Although the exact timing of reverse transcription has not yet been elucidated, it is believed that reverse transcription is completed by the time of nuclear entry (Rankovic *et al.*, 2017). Reverse transcription and capsid disruption is tightly correlated as revealed by a recent study by the Roussio lab at Ben-Gurion University using time-lapse atomic force microscopy to reveal that pressure inside the capsid increases due to the presence of newly formed DNA, eventually leading to capsid dissociation. After interaction with the nuclear pore complex, the capsid dissociates and the new cDNA is integrated into the host genome by the viral protein IN or integrase. HIV-1 is preferentially integrated into introns of actively transcribed genes (Han *et al.*, 2004), most of which would be located in euchromatic regions near the nuclear pore (Marini *et al.*, 2015; Acuthan *et al.*, 2018). The integration site is one of several key factors that determine whether HIV-1 is transcribed. At this point, HIV-1 expression is regulated not only by its transactivator Tat but also by the

general cellular factors that control gene transcription. This dependency on the host cell will be critical to the experiments I outline in this dissertation.

Once integrated, the viral genome is referred to as a provirus. This provirus is transcribed by the host RNA Polymerase II (RNAPII) for the purpose of making new viral RNA or transcribed and translated for the purpose of making new viral proteins. HIV-1 transcription is regulated by the binding of specific host factors to the 5' Long Terminal Repeat (LTR). The provirus is flanked on either end by an identical LTR that acts as the HIV-1 promoter (Patarca *et al.*, 1987). The presence of both LTRs is directly responsible for the capacity of reverse transcriptase to copy the entire genome including both the 5' and 3' untranslated regions. A number of transcription factors are known to bind to the HIV-1 LTR (and downstream sites) including NF- κ B, AP-1, SP1, and NFAT (Calman *et al.*, 1988; Franza *et al.*, 1988; Garcia *et al.*, 1987; Lu *et al.*, 1991). The binding sites of these transcription factors, as well as the structure of the entire provirus, are shown in Figure 1.1. During the early stages of transcription, the HIV-1 transactivator Tat binds to a specific stem-loop structure in the nascent RNA referred to as the TAR region (Hauber and Cullen, 1988). During this process, Tat recruits the host factor P-TEFb or Positive Transcription Elongation Factor, which hyperphosphorylates the C-terminal domain of RNAPII. Phosphorylation results in transcriptional elongation and successful polymerase processivity (Napolitano *et al.*, 2000; Barboric *et al.*, 2001). P-TEFb cycles between an active state that is free to phosphorylate RNAPII and an inactive state in which it is sequestered by the 7SK RNA complex (Yang *et al.*, 2001). While the cellular signals that permit disassembly of the 7SK RNA – P-TEFb complex are not fully

elucidated, it has been shown that UV damage or MAPK signaling as a result of TCR engagement can activate P-TEFb (Yang *et al.*, 2001; Kim *et al.*, 2011). Therefore, successful HIV-1 transcription is regulated by both Tat fluctuations and P-TEFb activity (Weinberger *et al.*, 2005). In addition, the use of dual-fluorescence viruses that contain both inducible and constitutive reporters has indicated a more general role for cellular activation on productive infection (Duverger *et al.*, 2009; Chavez, Calvanese and Verdin, 2015). Cells with high basal levels of NF- κ B are biased towards viral replication and away from transcriptional repression (Dahabieh *et al.*, 2014).




Figure 1.1: Binding sites of a select number of key transcription factors to the HIV-1 LTR. (A) HIV-1 proviral genome including both the 5' and 3' LTR's. (B) Detailed diagram of 5' LTR including binding sites of a select number of key transcription factors, transcriptional start site (referred to as TSS), and locations of U3, R, and U5 regions. This figure adapted from (Colin and Van Lint, 2009).

An additional block to HIV-1 replication occurs at the level of splicing. Because HIV-1 encodes its genome as a polycistronic RNA, efficient splicing is required for full expression of all viral products (Purcell and Martin, 1993; Emery *et al.*, 2017). The first

RNAs to emerge from the nucleus are fully spliced and contain the transcripts for HIV-1 Rev and HIV-1 Tat. This is followed by partially spliced transcripts that encode for the accessory proteins and the viral envelope. Finally, unspliced RNA enters the cytoplasm, resulting in both new copies of the viral genome along with the HIV-1 Gag and Pol polyproteins (Stoltzfus, 2009). Because only fully spliced transcripts are exported through normal cellular mechanisms, both the partially spliced and unspliced RNAs require the HIV-specific Rev-dependent export pathway (Fischer *et al.*, 1995).

While a subset of the unspliced RNA remains untranslated as viral RNA, the remaining transcripts must be translated by the cellular ribosome. Together, the viral capsid, various accessory factors, and the newly synthesized genomic RNA converge at the cellular membrane, where they bud to form a new virion (Sundquist and Kräusslich, 2012). The assembly at the lipid surface requires binding between PtdIns(4,5)P₂ and the matrix peptide of the Gag polyprotein (Saad *et al.*, 2006). The virion then co-opts the cellular ESCRT pathway due to indirect interactions between ESCRT factors and the HIV-1 p6 region of Gag to mediate scission from the cellular membrane (Sette *et al.*, 2016). In doing so, the virus acquires its outer lipid leaflet from the host cell. Further maturation by HIV-1 protease results in production of various Gag and Pol proteins, including, but not limited to, matrix (MA), capsid (CA), nucleocapsid (NC), reverse transcriptase (RT), integrase (IN), and protease (PR) (Swanstrom and Wills, 1997). Further rearrangements due to binding between these various proteins and movements of capsid into a conical structure results in the formation of a newly infectious particle,

capable of undergoing additional rounds of infection (Frank *et al.*, 2015). A depiction of the life cycle of HIV-1 is shown (Figure 1.2).




Figure 1.2: Life cycle of HIV-1. Major steps of the HIV-1 life cycle are shown, with emphasis placed on the stages where the virus is under the control of host cell machinery, including transcription / translation.

HIV-1 Latency

Biology and Model Systems

When the development of cART resulted in the suppression of viremia below the limit of detection, it was thought that a complete absence of viral replication would allow the host immune system to eradicate HIV-1 since infected cells will eventually undergo apoptosis due to either the cytopathic effects of the virus or clearance by NK cells and

CD8+ T cells (Koup *et al.*, 1994; Petravic *et al.*, 2014). If these infected cells were simultaneously blocked from producing new infectious particles, then a short course of ART would theoretically be sufficient to eliminate HIV-1 infection. However, in the years following the widespread use of ART, not one patient has achieved a cure through this mechanism (Chun *et al.*, 1997). In fact, after decades of antiretroviral treatments, even a short interruption of medication results in a predictable rebound of viremia as depicted in Figure 1.3 (Van Lint, Bouchat and Marcello, 2013). This is due primarily to the persistence of silent proviruses in long-lived memory CD4+ T cells.




Figure 1.3: HIV-1 rebounds after cART interruption. Depiction of patient viral RNA levels as measured by RT-PCR both before and after antiretroviral therapy. Figure based on (Van lint, Bouchat and Marcello, 2013).

As a component of the adaptive immune system, CD4⁺ T cells and their progeny clones survive long-term and form the basis of immunological memory (Rogers, Dubey and Swain, 2000; Boyman *et al.*, 2009). If HIV-1 is integrated into these cells and if these cells do not produce any viral products that could be recognized by the immune system, the virus can evade detection. This phenomenon, known as HIV latency, forms the primary barrier to a cure for HIV-1. Like any normal cellular gene, HIV-1 can be either expressed or repressed. This repression thus prevents viral spread but also shields infected cells from antiviral immunity (Finzi *et al.*, 1997). The HIV-1 latent reservoir is also maintained by clonal proliferation of latently infected cells, which has been shown to allow for cellular duplication without viral re-expression (Wang *et al.*, 2018).

Our understanding of the mechanisms which maintain HIV-1 in a latent state derive from a number of *in vitro* models of HIV-1 latency as well as analysis of cells removed *ex vivo* from patients on ART. Among patients with full viral suppression, latent provirus has been discovered primarily in resting memory CD4⁺ T cells. These include both transitional memory and central memory subsets (Chomont *et al.*, 2009). PCR analysis has confirmed that roughly 1 in 1000 target resting cells are latently infected, but it is estimated that only 1 in 1,000,000 target cells contain an inducible latent provirus that can easily be re-activated as measured by the viral outgrowth assay or VOA (Ho *et al.*, 2013). To perform the VOA, researchers remove peripheral blood mononuclear cells (PBMCs) and culture them in limiting dilution along with target cells for HIV-1. The PBMCs are then reactivated with phytohaemagglutinin or PHA, which although highly

toxic, is a gold standard for latency reactivation *in vitro*. HIV-1 expression is then measured by p24 ELISA (Siliciano and Siliciano, 2005).

Although latent HIV-1 has been isolated primarily in CD4⁺ T cells and is most widely studied within this population, it is important to note that this is not the only cellular reservoir for latent provirus. Gammadelta or $\gamma\delta$ T cells have been described as a target for HIV-1 infection and a source of rebounding virus following treatment interruption. $\gamma\delta$ T cells have an important role in modulating the immune system and assisting other cell types, especially at barrier sites including the skin and mucosa (Paul *et al.*, 2014). Although less than 10% of $\gamma\delta$ T cells are CD4⁺ *in vivo*, HIV-1 still requires the expression of CD4 in order to bind (Imlach *et al.*, 2003). HIV-1 can be isolated from $\gamma\delta$ T cells in patients infected with HIV-1 on ART (Soriano-Sarabia *et al.*, 2015). Therefore, more information is needed regarding the potential contribution of $\gamma\delta$ T cells to HIV-1 persistence.

Macrophages can also be infected by HIV-1 (Koenig *et al.*, 1986) and form a viral reservoir during prolonged ART. This has been identified both in humanized mouse models and in SIV-infected primates (Honeycutt *et al.*, 2017; Avalos *et al.*, 2017). Microglia, in particular, may contribute to HIV-1 persistence (Llewellyn *et al.*, 2018). However, when humanized myeloid only mice (containing human myeloid cells and human B cells) were infected with HIV-1 and given ART 5 weeks later, just 1/3 of all mice harbored latent virus (Honeycutt *et al.*, 2017). The fact that the majority of mice were not latently infected is supportive of the fact that CD4⁺ T cells, and not macrophages, are the primary reservoir for latency.

Because CD4⁺ T cells are the primary source for rebounding virus, most model systems that reproduce HIV-1 latency in a laboratory environment use primary CD4⁺ T cells or CD4⁺ T cell lines (Table 1.1). The first attempts to model HIV-1 latency were performed in A3.01 (Folks *et al.*, 1989) and Jurkat cells (Jordan, Bisgrove and Verdin, 2003) by the Fauci and Verdin laboratories. Cells with integrated virus but no clear RNA or protein production were isolated after multiple rounds of flow cytometry or reverse transcriptase activity assays. While these cells are useful for comparisons of various latency reversing agents (LRAs), they fail to adequately incorporate all of the mechanisms that contribute to HIV-1 latency *in vivo*. For instance, the A3.01 cell model, which resulted in creation of the ACH-2 line, has a defective TAR element that accounts for its propensity for latency (Emiliani *et al.*, 1996).

Other models use primary cells and attempt to either artificially prolong cell survival or infect specific types of cells known to harbor latent proviruses. The Siliciano model, for instance, uses the cell survival factor Bcl-2 to prevent cellular apoptosis (Kim *et al.*, 2014), while the O'Doherty / Greene model uses the slight perturbation caused by spinoculation to enhance viral integration into resting cells (Swiggard *et al.*, 2005; Lassen *et al.*, 2012). The Lewin model requires chemokine signaling (Saleh *et al.*, 2007), while the Planelles model directly infects certain subsets of memory cells (Bosque and Planelles, 2009).

| Commonly Used Models of HIV-1 Latency | | | |
|---------------------------------------|---------------|--|--|
| Model | Parental Cell | Mechanism to Enrich for Latency | References |
| ACH-2 (Fauci) | A3.01 | Defective TAR Element | Folks <i>et al.</i> , 1989 Emiliani <i>et al.</i> , 1996 |
| J-Lat (Verdin) | Jurkat | Multiple Rounds of Cell Sorting to Isolate TNF α – Sensitive Silent Proviruses | Jordan, Bisgrove and Verdin, 2003 |
| O'Doherty / Greene | Primary CD4+ | Spinoculation | Swiggard <i>et al.</i> , 2005 Lassen <i>et al.</i> , 2012 |
| Lewin | Primary CD4+ | Chemokine Signaling (CCL19 and CCL21) | Saleh <i>et al.</i> , 2007 |
| Planelles | Primary CD4+ | Enrichment of Central Memory Cells / Polarization Towards Th1 and Th2 | Bosque and Planelles, 2009 |
| Siliciano | Primary CD4+ | Transduction of Bcl-2 | Kim <i>et al.</i> , 2014 |

Table 1.1: Commonly used models of HIV-1 latency. Models are listed along with methods for enrichment of latently infected cells.

Using these models to gain insights into the transcriptional regulation of HIV-1, a model has emerged in which multiple mechanisms regulate viral expression including epigenetic regulation, recruitment of key transcription factors, and RNAPII pausing. A primary determinant of viral reactivation in latently infected cells is a positioned nucleosome just downstream from the HIV-1 transcriptional start site, known as nuc-1 (Verdin, Paras and Van Lint, 1993). This nucleosome appears to be remodeled during transcriptional elongation (Van Lint *et al.*, 1996). The chromatin structure is opened through the addition of acetyl groups by HATs or histone acetyltransferases, many of which are recruited by transcription factors that are induced upon T cell signaling and bind the HIV-1 LTR, including NF- κ B and AP-1 (Thierry *et al.*, 2004). In contrast, the

association of histone deacetylases or HDACs with HIV-1 inhibits transcription (Williams *et al.*, 2006). In addition, the chromatin remodeling complex SWI/SNF can directly remodel *nuc-1*, creating a transcriptional block or allowing for polymerase processivity (Mahmoudi *et al.*, 2006; Rafati *et al.*, 2011). These alternative roles are still being explored, but evidence exists that the binding to *nuc-1* of specific variants of SWI/SNF, referred to as BAF and PBAF, are responsible.

Latency is associated with a lack of histone acetylation (He and Margolis, 2002) and premature polymerase pausing. This pausing has been identified in both the Henderson and Karn laboratories to be associated with the presence of the host repressive factors Negative Elongation Factor (NELF) and DRB Sensitivity Inducing Factor (DSIF) with RNAPII (Zhang, Klatt, Gilmour and Henderson, 2007; Jadowsky *et al.*, 2014). These proteins prohibit RNAPII from proceeding downstream and ultimately recruit a third factor, Pcf11, which is known to cleave the nascent RNA, repressing HIV-1 transcription (Zhang, Klatt, Henderson and Gilmour, 2007). NELF and DSIF are both regulated by P-TEFb, which modulates their interactions with RNAPII through phosphorylation (Ping and Rana, 2001; Fujinaga *et al.*, 2004). Phosphorylated NELF can no longer bind the polymerase, while phosphorylated DSIF transitions into an activating factor that proceeds downstream with RNAPII. The HIV-1 protein Tat plays a key role in this process due to its ability to recruit P-TEFb to RNAPII once it is bound to the HIV-1 TAR region (Ping and Rana, 2001).

Each cell model system of latent HIV-1 has its advantage, although they often recapitulate only specific features of the entire latent reservoir. They exaggerate different

mechanisms that contribute to latency in order to create a large population of latently infected cells. These models are not optimal for understanding how latency is established at the time of HIV-1 infection. In particular, we do not know what signals are required for productive infection or the establishment of the reservoir. However, these cell models have been useful tools for identifying and exploring possible LRAs.

“Shock and Kill”

Based on the limited knowledge of the mechanisms that maintain latent HIV-1, several researchers proposed the use of LRAs to eradicate the viral reservoir. These LRAs were designed to prevent deacetylation of *nuc-1* or to enhance release of P-TEFb, promoting HIV-1 expression; this would allow infected cells to be recognized and cleared by the immune system. Even if full reactivation of every integrated provirus was not achieved, a functional cure was originally thought to be possible through this process, known as “shock and kill” (Hamer, 2004).

Initial LRAs were histone deacetylase inhibitors or HDACi's, including valproic acid, which prevent the removal of acetyl groups from open and accessible nucleosomes. Valproic acid was already in use as an epilepsy therapeutic and was fast-tracked for HIV-1 clinical trials (Ylisastigui *et al.*, 2004). One clinical trial indicated that valproic acid was capable of inducing a 75% reduction in the amount of inducible latent proviruses by the VOA (Lehrman *et al.*, 2005). In spite of promising early results using valproic acid, there is now contradictory evidence regarding whether valproic acid can actually reduce

the number of inducible latent proviruses, and no clinical trial has shown an effect on the size of the entire DNA viral load (Archin *et al.*, 2008; Sagot-Lerolle *et al.*, 2008; Archin *et al.*, 2010; Routy *et al.*, 2012).

Other HDACi's under consideration include SAHA or its analog SBHA. While SAHA can reactivate latent HIV-1 in HIV-infected cell lines such as J-LATs (based on Jurkat cells) and even has been shown to induce HIV-1 RNA expression in *ex vivo* PBMCs (Contreras *et al.*, 2009; Reuse *et al.*, 2009; Archin *et al.*, 2009; Barton *et al.*, 2016), it has failed to reduce the amount of total HIV-1 DNA in clinical trials (Elliott *et al.*, 2014; Barton *et al.*, 2016). Other studies have failed to detect any significant increases in the amount of HIV-1 RNA expression within *ex vivo* patient samples after stimulation with either valproic acid or SAHA (Blazkova *et al.*, 2012). As a result of these conflicting studies, the use of HDAC inhibitors as single latency reversing agents is no longer central to the “shock and kill” strategy of HIV-1 eradication.

Other LRAs being explored are known to target different mechanisms that maintain latent HIV-1. These include histone methyltransferase inhibitors (Bernhard *et al.*, 2011; Bouchat *et al.*, 2012; Friedman *et al.*, 2011; Boehm *et al.*, 2017), DNA methyltransferase inhibitors (Kauder *et al.*, 2009; Blazkova *et al.*, 2009; Friedman *et al.*, 2011), and protein kinase C activators. PKC agonists, in particular, have shown synergy with other LRAs, indicating that multiple pathways may have to be engaged in order to achieve a clinically relevant level of latency reversal (Bartholomeeusen *et al.*, 2013; Dar *et al.*, 2014).

In addition, JQ1 is being explored as a potential LRA (Banerjee *et al.*, 2012; Bartholomeeusen *et al.*, 2012; Zhu *et al.*, 2012). It is hypothesized that JQ1, a BET bromodomain inhibitor, functions by targeting BRD4, which is known to bind P-TEFb (Bisgrove *et al.*, 2007; Bartholomeeusen *et al.*, 2012; Li *et al.*, 2013). Bartholomeeusen *et al.* showed that addition of JQ1 resulted in a release of P-TEFb from the 7SK complex, resulting in HIV-1 transcriptional elongation. Melanie Ott's lab has indicated that a BRD4 variant, BRD4S, may directly inhibit HIV-1 expression by associating with the nucleosome remodeling complex SWI/SNF (Conrad *et al.*, 2017), providing further evidence that JQ1's regulation of HIV-1 transcription is due to its ability to bind BRD4. However, it should be noted that the effects of JQ1 have so far been limited to *in vitro* analysis, and there are serious concerns regarding toxicity of several of the compounds listed here, particularly PKC agonists. In spite of promising data using cell lines, no LRA has successfully led to substantial clearance of the latent reservoir in a patient as measured by PCR.


Establishment of Latent HIV-1 and the Role of T Cell Signaling

While the concentration of Tat (Donahue *et al.*, 2012; Razooky *et al.*, 2015) and the chromatin accessibility within an infected cell are understood as critical to productive transcription and infection (Miller-Jensen *et al.*, 2012), the availability of host factors, proteins that regulate RNAPII, and transcriptional mechanisms are not fully appreciated. It is known that T cell activation is needed for both the activation of host factors

necessary for HIV-1 transcription (Acuto and Michel, 2003; Huang and Wange, 2004) as well as efficient viral integration. Therefore, T cell activation appears to be required for productive infection (Stevenson *et al.*, 1990; Oswald-Richter *et al.*, 2004). Indeed, signals from the TCR/CD3 complex and coreceptor CD28 substantially upregulate HIV-1 expression (Gruters *et al.*, 1991; Natarajan, August and Henderson, 2010). The HIV-1 protein Nef may co-opt this mechanism by amplifying TCR signaling (Fenard *et al.*, 2005; Neri *et al.*, 2011).

TCR signaling occurs through engagement of a T cell with its cognate antigen presented in the context of MHC Class I or II from the same genetic background (Dembic *et al.*, 1986; von Boehmer and Kisielow, 1990). CD4⁺ T cells require presentation from a Class II molecule, which are found on professional APCs (Wang and Reinherz, 2002). This engagement results in clustering of the TCR/CD3 complexes and CD28 proteins (Ohnishi *et al.*, 1995; Lillemeier *et al.*, 2010). When brought into proximity with one another, associated Src kinases, including Lck, phosphorylate both the critical Immunoreceptor Tyrosine-Based Activation Motifs or ITAMs contained within the CD3 protein as well as tyrosine residues within the cytoplasmic tail of CD28 (Gibson *et al.*, 1996; Rossy *et al.*, 2013). These phosphorylated residues then act as binding sites for the Syk-kinase, Zap70. In turn, Zap70 is phosphorylated and becomes a key component within a newly assembled network of proteins, such as LAT and the SH2-domain containing kinases (Neumeister *et al.*, 1995; Lo *et al.*, 2018). A proximal signaling complex is orchestrated around LAT (Figure 1.4), resulting in downstream actin rearrangements (Bunnell *et al.*, 2001). In addition, the SH2-containing enzyme PLC γ 1 is

recruited to the plasma membrane, where it cleaves $\text{PtdIns}(4,5)\text{P}_2$ (Rhee, 2001). As a result, multiple arms of the T cell receptor pathway are engaged, resulting in calcium release (Bilal *et al.*, 2015), MAP Kinase signaling (Frearson and Alexander, 1998), and NF- κ B activation downstream of Protein Kinase C (PKC) (Zhao *et al.*, 2014). Activation of these multiple cascades increases transcription for a number of host genes and differentiation-determining factors (Smith-Garvin, Koretzky and Jordan, 2009; Adair *et al.*, 2016).



Nature Reviews | Immunology

Figure 1.4: T cell receptor signaling results in activation of multiple pathways. TCR signaling leads to phosphorylation of critical tyrosine residues within ITAMs that enable the formation of a proximal signaling complex. Creation of this complex results in actin reorganization and stimulation of transcription factors downstream of $\text{PtdIns}(4,5)\text{P}_2$. Recreated here with permission, in its entirety from (Brownlie and Zamoyiska, 2013). Figure caption is the original work of the author of this dissertation.

In addition to roles upstream of gene transcription, T cell signaling impacts cell maturation (Brocker, 1997; Pepper and Jenkins, 2011). Naïve T cells which become activated by stimulation through their cognate antigen transition into either effector populations or memory cells. Latently infected cells isolated from patients on ART

predominately express memory phenotypes (Brenchley *et al.*, 2004; Chomont *et al.*, 2009). The Planelles model of HIV-1 latency attempts to recapitulate this by differentiating CD4⁺ T cells into central memory cells (Bosque and Planelles, 2009).

Several papers, including those from the Henderson lab, have implicated T cell signaling in the regulation of productive HIV-1 replication (Natarajan, August and Henderson, 2010; Schiralli Lester *et al.*, 2013). For example, studies have suggested that different antigen-presenting cell subsets alter HIV-1 replication by differentially activating T cells (Kumar *et al.*, 2015). Furthermore, it has been shown that cells with low levels of activated NF- κ B and decreased expression of activation markers may be biased towards harboring latent infections (Duverger *et al.*, 2009; Dahabieh *et al.*, 2014; Chavez, Calvanese and Verdin, 2015). Signals that predispose cells towards an anergic phenotype have also been linked to repression of HIV-1 (Seu *et al.*, 2015). However, these experiments fail to describe the actual signaling cascades that account for this correlation, and direct evidence is still needed that minimal TCR signaling during infection predisposes HIV-1 towards latency.

Understanding the establishment of latent HIV-1 is also essential since it has been shown that there are wide differences between the capacities to reactivate latent reservoirs from different patients. It was originally assumed that the majority of non-inducible proviruses were defective, most likely due to errors with reverse transcription. However, the Siliciano lab demonstrated that a portion of the non-inducible DNA reservoir is fully competent based on sequencing analysis, which is shown in Figure 1.5 (Ho *et al.*, 2013; Hosmane *et al.*, 2017). Our lack of knowledge regarding the exact

mechanisms which account for these various sub-populations of latently infected cells, some of which are refractory to the strongest LRAs identified so far, highlights the importance of understanding the role of the cellular environment at the time of infection on viral fate. A primary goal of my work was to understand the signaling requirements for HIV-1 infection and whether the input of signals at the time of infection shaped the size of the inducible latent reservoir.




Figure 1.5: A significant portion of the latent reservoir consists of non-inducible fully competent proviruses. Depiction of the DNA reservoir from various patients on antiretroviral therapy. The size of the eggshell is an indication of the number of proviruses. The yellow sphere represents the size of the latent reservoir as measured by the viral outgrowth assay. The magenta sphere represents the size of the latent reservoir as measured by sequencing. The blue sphere represents the total DNA load. Recreated here with permission, in its entirety from (Ho *et al.*, 2013). Figure caption is the original work of the author of this dissertation.

“Block and Lock”

With the future of “shock and kill” approaches to eradication of latent HIV-1 in doubt, increasing interest has focused on the formation of the latent reservoir. If we can

determine why some cells enable productive infections while others harbor latent proviruses, perhaps we can manipulate the balance between these two populations. In fact, a growing body of research has focused on a converse strategy to “shock and kill,” referred to as “block and lock.” This repressive approach imagines a permanent suppressive environment for the integrated provirus, allowing a patient to cease therapy indefinitely with only periodic clinical sampling to ensure a lack of viral replication (Méndez *et al.*, 2018; Debyser *et al.*, 2018). For example, the Valente lab has focused on Tat inhibition through the preferential binding of didehydro-Cortistatin A. This prevents engagement between the TAR region and the HIV-1 transactivator (Mousseau *et al.*, 2012; Mousseau *et al.*, 2015).

The global cellular environment not only affects levels of host transcription factors but also directly alters the local chromatin landscape where the virus has integrated. If we are to achieve a “block and lock” method to repress HIV-1, we will most likely have to modify the epigenome along the provirus. This level of precise gene editing can be achieved through the use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).

CRISPR associated protein 9 or Cas9 can be isolated from multiple bacterial species including *Streptococcus pyogenes* and *Staphylococcus aureus* (Cho *et al.*, 2013; Ran *et al.*, 2015). It forms an essential part of the CRISPR defense system in bacterial cells. Briefly, CRISPR works by extracting various segments of foreign DNA and inserting it into a CRISPR locus. In nature, this would often be phage DNA. When a bacterial cell is re-infected with DNA belonging to a pathogen that it has encountered

before, the complementary stored sequence will bind to the incoming DNA. This will target Cas9 to the pathogenic DNA, which will then perform its exonuclease activity to destroy the invader (Barrangou *et al.*, 2007; Mali, Esvelt and Church, 2013).

The ease with which this system works has led scientists to substitute complementary sequences to phage DNA with a guide RNA directed against a target gene of choice. In combination with the bacterial exonuclease, gene editing can then be achieved with minimal off-target effects (Kim *et al.*, 2015). A number of labs have shown promising results using CRISPR to excise HIV-1 DNA; however, it is expected that use of CRISPR in vivo will result in viral escape (Wang G *et al.*, 2016; Wang Z *et al.*, 2016). In addition, although CRISPR has relatively few off-target effects, any non-specific gene editing is a serious concern for therapeutic applications (Fu *et al.*, 2013). To prevent this occurrence, I propose using a disabled or nuclease-deficient Cas9 system (dCas9) to target chromatin repressors to HIV-1 DNA instead of an exonuclease.

Nuclease-deficient Cas9 was developed in an attempt to isolate the residues responsible for the exonuclease activity inherent to CRISPR. In order to cut both strands of DNA, Cas9 uses two separate domains, referred to as HNH and RuvC. Mutations in both domains render the Cas9 defective (Jinek *et al.*, 2012). However, dCas9 retains the targeting capabilities of CRISPR and can be used to bring transcription factors directly to a gene of interest (Zhang *et al.*, 2015). There are also attempts to modify dCas9 as an inducible system under the control of a stimulus such as rapamycin (Zetche, Volz and Zhang, 2015; Brocken, Tark-Dame and Dame, 2018).

Other labs have shown the potential for the CRISPR system to induce HIV-1 expression by fusing a nuclease-deficient Cas9 to various transcriptional activators (Zhang *et al.*, 2015; Saayman *et al.*, 2016). I propose the fusing of Cas9 to a Krüppel Associated Box (KRAB) Domain. KRAB domains are known to engage with cellular KRAB-Associated Protein-1 or Kap1 (also known as Trim28), which recruits various transcriptional repressors, resulting in gene silencing and spreading repressive chromatin marks (Friedman *et al.*, 1996; Groner *et al.*, 2010). These repressors are believed to include histone methyltransferases, histone deacetylases, and heterochromatin protein 1 (Groner *et al.*, 2010). KRAB-Kap1 has been identified as a key regulator of endogenous retroviral elements (Rowe *et al.*, 2010) and thus is a good candidate for both repressing HIV-1 and potentially mediating long-term epigenetic silencing of the provirus.




Illustration 1.1: dCas9-targeted repression of HIV-1. Nuclease-deficient Cas9 fused to a KRAB domain can be used to recruit cellular factors such as Kap1 to the integrated HIV-1 provirus in order to induce latency and remodel the local chromatin organization into a heterochromative state.

Specific Aims and Hypothesis

Significant progress has been achieved in the treatment of Human Immunodeficiency Virus. Antiretroviral therapies limit progression to AIDS through a combination of inhibitors. However, ART does not cure HIV-1 infection. If therapy is interrupted, patients experience a viral rebound due to the persistence of an inducible reservoir primarily consisting of latently infected CD4⁺ T cells. This forces patients to remain on ART indefinitely, but these medications have substantial side effects and do not prevent all pathologies associated with HIV-1. For these reasons, the scientific community has prioritized the search for a cure that will eliminate latent HIV-1, but more insights are needed regarding the establishment of the latent reservoir. In this dissertation, I both investigate the global cellular signals that lead to formation of latent infections and bias an infection towards latency by manipulating the local chromatin environment of the provirus.

Analysis of latently infected cells revealed that the HIV-1 long terminal repeat is associated with repressive transcription factors (Bernhard *et al.*, 2013). These repressors recruit histone deacetylases that modify the first nucleosome downstream of the transcriptional start site into a closed conformation (Williams *et al.*, 2006). As a result, RNAPII pauses prematurely and complete viral transcripts are not produced (Feinberg, Baltimore and Frankel, 1991; Zhang, Klatt, Gilmour and Henderson, 2007; Natarajan *et al.*, 2013). The host immune system then fails to recognize this latent reservoir. While data indicates a role for both integration site (Miller-Jensen *et al.*, 2012; Lelak *et al.*,

2015) and abundance of the HIV-1 transcriptional transactivator Tat in the establishment and maintenance of latency (Donahue *et al.*, 2012; Razooky *et al.*, 2015), recent work suggests that the level of cellular activation at the time of infection is also a key determinant (Duverger *et al.*, 2009; Dahabieh *et al.*, 2014; Chavez, Calvanese and Verdin, 2015). However, these studies have been correlative and direct evidence is still needed. To identify signaling cascades that participate in the establishment of HIV-1 latency, I have designed a tunable and regulated cell model that allows me to modulate T cell receptor signaling at the time of infection. Based on the evidence that increased cellular stimulation results in enhanced HIV-1 replication (Duverger *et al.*, 2009; Dahabieh *et al.*, 2014), I hypothesized that the global cellular environment at the time of HIV-1 infection determines the potential for inducible latent infection and that this axis can be bypassed by modification of the local chromatin environment. Accordingly, I addressed the following aims:

Specific Aim 1: Determine the effect of distinct T cell receptor signal strengths at the time of HIV-1 infection on viral expression within primary cells and reactivation of latent proviruses. I used a novel primary cell system to manipulate TCR signaling at the time of infection and examine the signaling requirements for efficient HIV-1 expression. To mimic TCR signaling, I transduced CD4⁺ T cells with chimeric antigen receptors that contain both the intracellular signaling domains of CD3 ζ and CD28 along with one of several extracellular Her2 binding domains with different affinities for Her2. I used flow cytometry to confirm CAR expression, *Alu*-PCR to determine HIV-1 integration, and both RT-PCR and luciferase analysis to measure HIV-1 transcription.

With this system, I verified my hypothesis that increased T cell signaling enhances HIV-1 transcription. I also infected primary T cells and stimulated them through either the low or high affinity CAR. I then restimulated sorted non-HIV expressing cells with latency-reversing agents to measure reactivation. These experiments revealed that differential signaling at the time of infection resulted in the formation of subsets of latently infected cells with varying capacities for proviral induction.

Specific Aim 2: Analyze transcriptional landscape of the provirus among cells receiving differential stimulation at the time of HIV-1 infection. I hypothesized that cells with minimal stimulation at the time of infection display a bias for the presence of host repressors and a lack of polymerase processivity. To test this, I used chromatin immunoprecipitation to examine RNAPII processivity and the recruitment of host regulators to the transcriptional start site. I also analyzed markers of chromatin accessibility such as histone acetylation. These studies identified downstream targets of TCR-associated signals that repress HIV-1 during acute infection.

Specific Aim 3: Use a nuclease-deficient Cas9 construct to recruit host repressors to the provirus and suppress HIV-1 expression. To determine if an infection can be biased towards latency after HIV-1 integration I used a nuclease-deficient Cas9 fused to a Krüppel associated box domain in order to recruit the repressor Kap1 to the provirus. HEK293T cells were infected with single-round HIV-Luciferase and transfected with a dCas9-KRAB construct. One day later, infected cells were transfected with HIV-1 specific guide RNAs to repress viral transcription. HIV-1 expression was measured by luciferase analysis. I also electroporated latently infected

Jurkat cells with the nuclease-deficient Cas9 and HIV-specific guide RNAs to block latency reactivation as measured by RT-PCR. I verified my hypothesis that transfection with dCas9-KRAB represses HIV-1 RNA and protein expression.

My findings elucidated how TCR signaling regulates HIV-1 transcription and latency. These experiments may inform both why such a large portion of the latent reservoir is non-reactivable as well as the efficacy of block and lock strategies, whether there are new druggable targets that can bias an infection towards or away from latency.

CHAPTER TWO: MATERIALS AND METHODS

Parts of this chapter were originally published in: Gagne M, Michaels D, Schiralli Lester G, Wong W, Gummuluru S, Henderson AJ. Strength of T Cell Signaling Regulates HIV-1 Replication and Establishment of Latency. *bioRxiv*. <https://doi.org/10.1101/432401>.

Cells

Jurkat CD4⁺ T cells (E6-1) and human embryonic kidney 293T (HEK293T) cells were obtained from American Type Culture Collection (ATCC). Jurkat cells were cultured in RPMI 1640, 5% FBS (Corning, Inc.), 100 ^{units}/mL penicillin (Invitrogen), 100 ^{µg}/mL streptomycin (Invitrogen), and 2mM L-glutamine (Invitrogen). HEK293T cells were cultured in Dulbecco's Modified Eagle Medium, 10% FBS, 100 ^{units}/mL penicillin, 100 ^{µg}/mL streptomycin, and 2mM L-glutamine. Cells were grown at 37° C with 5% CO₂.

Primary CD4⁺ T cells were derived from de-identified healthy blood leukapheresis packs purchased from NY Biologic. Mononuclear cells were enriched from leukopacks by centrifugation through Histopaque gradient (Sigma-Aldrich). CD4⁺ T cells were isolated by negative selection using EasySep Human CD4⁺ T Cell Enrichment Kits from StemCell Technologies. CD4⁺ cells were maintained in RPMI 1640, 10% FBS, 100 ^{units}/mL penicillin, 100 ^{µg}/mL streptomycin, and 2mM L-glutamine at 37° C with 5% CO₂. Prior to transduction with CARs, primary cells were supplemented with 10 ^{units}/mL IL-2 and 10 ^{ng}/mL IL-7. Following transduction, IL-2 was removed from most culture conditions.

J-Lat cells (6.3) were obtained from NIH AIDS Reagent Program and were cultured in RPMI 1640, 10% FBS, 100 ^{units}/mL penicillin, 100 ^{µg}/mL streptomycin, and 2mM L-glutamine. Cells were grown at 37° C with 5% CO₂. Following transduction with dCas9, J-Lat cells were cultured with 10 ^{µg}/mL Blasticidin as a selection marker. Blasticidin was removed from media 2 days prior to electroporation. All cells and cell lines were split every 2-3 days.

sgRNA Screen

dsaCas9 sgRNAs were designed using the online program Benchling (Benchling, 2019) by searching the NL4-3 sequence for 23-base pair long binding sites that contained the required PAM sequence of 5'-(N)NGRRT-3'. All chosen sites (see Table 2.1) had an efficiency score of > 50% and a specificity score of > 75%. dsaCas9 sgRNAs were expressed under the control of a SFFV promoter and were fused to the required tracrRNA sequence within the lentiviral vector pHR. In addition, blank dsaCas9 sgRNAs were obtained that contained only the tracrRNA component. All dsaCas9 sgRNA plasmids were constructed in the Wilson Wong laboratory at the BU School of Biomedical Engineering.

dspCas9 sgRNAs were chosen based on a literature search (see Table 2.1), with sg361 modified from “sg362F T” (in Saayman *et al.*, 2016) in order to not exceed the required 20 base pairs for dspCas9. sg397 was obtained from “Protospacer D” in Hu *et al.*, 2014. Both sequences were purchased from IDT as Alt-R CRISPR-Cas9 crRNAs and

fused to the required sequence (GUUUUAGAGCUAUGCU) necessary to bind to the Alt-R CRISPR-Cas9 tracrRNA. Annealing of the two strands of RNA occurred as follows: 1 μ L of 100 μ M crRNA and 1 μ L of 100 μ M tracrRNA were mixed in 98 μ L Nuclease-Free Duplex Buffer (IDT) at 95°C for 5 m. Annealed solutions were stored at -20°C. In addition, Scramble sgRNAs were obtained from IDT that bound to no known region of the human genome (Alt-R CRISPR-Cas9 Negative Control crRNA #1, 1072544).

| crRNA Sequences | | |
|------------------------|--------------|--------------------------------|
| sgRNA | sgRNA format | Sequence |
| dsa397 | Plasmid DNA | 5'- GGTGTGGCCTGGGCGGGACTG - 3' |
| dsa518 | Plasmid DNA | 5'- AGCTTTATTGAGGCTTAAGCA - 3' |
| dsa705 | Plasmid DNA | 5'- TGCCGTGCGCGCTTCAGCAAG - 3' |
| dsa818 | Plasmid DNA | 5'- GAGCGTCAGTATTAAGCGGGG - 3' |
| dsa2285 | Plasmid DNA | 5'- CCCCTATCTTTACTTTGACG - 3' |
| dsa2839 | Plasmid DNA | 5'- AATTAGGAATACCACATCCCG - 3' |
| dsa5876 | Plasmid DNA | 5'- AAGCAGTTTTAGGCTGACTTC - 3' |
| dsp361 | RNA | 5'- CUACAAGGGACUUUCCGCUG - 3' |
| dsp397 | RNA | 5'- GUGUGGCCUGGGCGGGACUG - 3' |

Table 2.1: Sequences used for crRNA screen. dsaCas9 sgRNAs and dspCas9 sgRNA sequences are listed.

Viruses, Transfections, and Transductions

CARs were driven by a SFFV promoter in the lentiviral vector pHR (Schier *et al.*, 1996; Chmielewski *et al.*, 2004). pNL4-3.Luc.R-E- was obtained from NIH AIDS Reagent Program. BRU-ΔEnv-GFP was a gift from Dr. Gregory Viglianti (Boston University). CAR lentiviruses were made by transfection of lentiviral expression vectors, VSV-G env, Rev, Tat, and Gag-Pol constructs into HEK293T cells with 45 μL polyethylenimine (1 mg/mL) per 6x10⁶ cells. Transfections of HIV-1 included only viral plasmids and envelope plasmids. Supernatants of lentiviruses were collected, filtered with 0.45 μm syringe filter (Corning), concentrated by centrifuging through a 20% sucrose gradient, and titered on CEM cells (Janas and Wu, 2009). I used a range of multiplicity of infections, but most viruses and lentiviruses within this paper were concentrated to approximately 1x10⁶ IU/mL.

Transfections of dCas9-KRAB in Chapter Four for the purposes of making lentiviral vectors were performed similarly. Cotransfections of pNL4-3.Luc.R-E-, dCas9-KRAB, and sgRNAs into HEK293T cells were also performed similarly but without any additional accessory or structural gene plasmids.

For transductions with CAR vectors, primary cells were stimulated for 5-6 h with 10 μg/mL PHA, washed in PBS, and spinoculated by spinning cells with lentivirus and 5 μg/mL polybrene (Millipore) at 1200g for 90 min. Cells were then supplemented with fresh RPMI and IL-7, cultured overnight, and washed in PBS 18 h later. Cells were rested for

one week to return to a resting state as confirmed by low CD69 expression prior to HIV-1 infection.

Transductions of Jurkat cells with CAR vectors and J-Lat cells with dCas9 vectors were performed similarly. However, no PHA stimulation or cytokine treatment was required. CAR-expressing Jurkat cells were sorted based on mCherry expression and cultured as pure populations. For sorting details, see Flow Cytometry Methods below.

CAR Stimulation and Infections

Non-tissue culture treated plates were coated overnight at 37°C with 1 $\mu\text{g}/\text{mL}$ Her2 (Recombinant Human ErbB2/Her2 Fc Chimera Protein from R&D Systems, 1129-ER). Her2 solution was removed from wells, plates were washed 3 times in PBS, and wells were blocked for 1 h with a 5% FBS-PBS solution.

CAR+ Jurkat or primary CD4+ T cells were infected with HIV-1 and simultaneously plated in Her2-treated wells. For experiments in which latently infected cells were generated, cells were spinoculated in the Her2-treated wells at 1200xg for 90 min and then supplemented with fresh RPMI and IL-7. Following overnight infection, cells were washed and either lysed or maintained in fresh media in the absence of Her2.

For some experiments, CAR-expressing cells were treated with 10 μM PP2 or PP3 (Calbiochem - Millipore Sigma), Src kinase inhibitor and pharmacologically inactive analog respectively, at the time of HIV-1 infection.

Infections of HEK293T cells with HIV-1 were performed 24 h prior to dCas9-KRAB and sgRNA transfection.

Electroporations

For electroporations, 1×10^6 J-Lat cells were centrifuged for 10 min at 90xg. Cells were then resuspended in 90 μ L 1SM buffer. 1SM buffer (5mM KCl, 15mM MgCl₂, 120mM Na₂HPO₄ pH 7.2, 25mM sodium succinate, 25mM manitol) was prepared as described in (Chicaybam *et al.*, 2013). Cells were incubated with 10 μ L sgRNA (1000 nM) in cuvettes. Electroporation was performed in Amaxa Biosystems Nucleofactor I with program setting X-005. After electroporation, cells were cultured in RPMI 1640, 20% FBS (Corning, Inc.), 100 ^{units}/_{mL} penicillin (Invitrogen), 100 ^{µg}/_{mL} streptomycin (Invitrogen), and 2mM L-glutamine (Invitrogen) at 37° C with 5% CO₂. 24 h later, cells were washed in PBS and replated in normal culture media as described above.

Latency Reversal

For reactivation of latent CAR-expressing primary cells, mCherry (CAR) positive and GFP (HIV-1) negative cells were sorted at 6 or 7 days post HIV-1 infection. Cells were cultured with the following concentrations of LRAs: 5 ^{ng}/_{mL} PMA and either 10 or 100uM ionomycin for 2.5 h, Dynabeads human T-activator CD3/CD28 beads at a ratio to cells of 1:1 for 24 h, 50 μ M SBHA for 24 h, and 25nM Bryostatin for 24 h. Cells

reactivated with PMA were washed in PBS and re-plated in media. All reactivated cells were incubated with $10^{\text{ng}}/\text{mL}$ IL-7. Cells were cultured overnight prior to fixation for flow analysis.

J-Lat cells were treated with 10 ng/mL TNF- α in order to induce latency reversal. Stimulation took place five days following electroporation. RNA was isolated for qRT-PCR 24 h post latency reversal.

Luciferase Analysis

Jurkat cells were washed and lysed for luciferase analysis 24 h post infection, while primary T cells were measured at 4 days post infection. HEK293T cells were washed and lysed for luciferase analysis 48 h post sgRNA and dCas9-KRAB transfection. Luciferin (Promega) was added and luciferase activity was measured via BioTek Synergy HT Microplate Reader.

Flow Cytometry

Flow data were collected on an LSRII from BD Biosciences. Zombie UV Fixable Viability Kit (BioLegend) was used as live/dead stain for reactivation experiments. All cells were washed and fixed in a final concentration of 2% paraformaldehyde prior to analysis. Cell sorting was performed on a MoFlo Astrios from Beckman Coulter. All flow experiments performed at Boston University School of Medicine Flow Cytometry Core Facility.

CAR stimulation was determined by CD69 expression (Brilliant Violet 421 anti-human CD69 antibody; Clone FN50, BioLegend).

Memory cell phenotypes were characterized based upon CCR7 and CD45RA expression (Pe/Cy7 anti-human CCR7 antibody; Clone G043H7, BioLegend and PerCP/Cy5.5 anti-human CD45RA antibody; Clone HI100, BioLegend).

Microarray Analysis and Heatmap Formulation

Primary CD4⁺ T cells were transduced with chimeric antigen receptors and allowed to return to a resting state for 1 week. Cells were then stimulated overnight with plate-bound Her2 as described above. Untransduced CD4⁺ T cells were left unstimulated or were plated in a solution of 1 $\mu\text{g}/\text{mL}$ CD28 (Mouse Anti-Human CD28, #555725, BD Biosciences) on previously coated wells of 1 $\mu\text{g}/\text{mL}$ CD3 (Mouse Anti-Human CD3, #555329, BD Biosciences). Cells were then washed in PBS and lysed for RNA extraction using Qiagen miRNeasy Mini Kit (#217004). RNA was stored at -80°C until delivery to the BU Microarray and Sequence Resource Core Facility. At the Microarray core, cDNA was made and samples were run on a Human Clariom S Array. The Microarray core also provide the statistical support described here.

Human Clariom S CEL files were normalized to unstimulated cells to produce gene-level expression values using the implementation of the Robust Multiarray Average (RMA) (Irizarry *et al.*, 2003) in the *affy* package (version 1.36.1) (Gautier *et al.*, 2004) including in the Bioconductor software suite (version 2.11) (Gentleman *et al.*, 2004) and

an Entrez Gene – specific probeset mapping (21.0.0) from the Molecular and Behavioral Neuroscience Institute (Brainarray) at the University of Michigan (Dai *et al.*, 2005, University of Michigan, 2019). Array quality was assessed by computing Relative Log Expression (RLE) and Normalized Unscaled Error (NUSE) using the *affyPLM* package (version 1.34.0). Analyses of variance were performed using the *f.pvalue* function in the *sva* package (version 3.4.0). Differential expression was assessed by performing Student's *t* test on the coefficients of linear models created using the *lmFit* function in the *limma* package (version 3.14.4). In this way, a one-way ANOVA *p* value was obtained using a linear mixed effects modeling approach to account for differences between donors.

Correction for multiple hypothesis testing was accomplished using the Benjamini-Hochberg false discovery rate (FDR) (Benjamini and Hochberg, 1995). All microarray analyses were performed using the R environment for statistical computing (version 2.15.1). All genes with FDR *q* values below 0.01 were plotted on a heatmap and arbitrarily separated into 5 clusters based on expression profiles.

Principal Component Analysis (PCA) was performed using the *prcomp* R function with expression values that had been normalized across all samples to a mean of zero and a standard deviation of one. The separation of samples by treatment group along the PC1 axis explains 29% of all variance in the experiment.

Measurement of HIV-1 Provirus Using Nested *Alu*-PCR

For measuring integrated HIV-1 provirus, a nested PCR strategy was adapted from (Agosto *et al.*, 2007). Briefly, integrated HIV-1 DNA was amplified using forward primers for the luciferase sequence and reverse primers for human *Alu* (see Table 2.2). The first reaction was performed on a TProfessional Thermocycler from Biometra according to the following conditions: 4 m at 95° followed by 20 cycles of 15 s at 93°, 15 s at 50°, and 2.5 m at 70°. A second round of amplification was then performed using a forward primer, a reverse primer, and a probe for real time PCR within the HIV-1 3' R / U5 region (see Table 2.2). The amount of amplified copies of HIV-1 was determined based on an NL4-3 plasmid copy standard. The second reaction was performed on an Applied Biosystems QuantStudio 3 Real-Time PCR system with heating for 4 m at 95° and real-time PCR conditions of denaturation for 15 s at 95°, annealing for 30 s at 60°, and extension for 1 m at 72°.

| Oligos Used for <i>Alu</i>-PCR | | | |
|---------------------------------------|---------------|------------------|--------------------------------------|
| Reaction | Gene / Target | Primer Direction | Primer Sequence |
| 1 st Step | <i>Alu</i> | Forward | 5'-CGTCGCCAGTCAAGTAAC-3' |
| | <i>luc</i> | Reverse | 5'-CTGTAATCCCAGCAGTTTGGGAGGC-3' |
| 2 nd Step | 3' R/U5 | Forward | 5'-GCCTCAATAAAGCTTGCCTTGA-3' |
| | | Reverse | 5'-TCCACACTGACTAAAAGGGTCTGA-3' |
| | | Probe | 5'-FAM-CCAGAGTCACACAACAGACG-TAMRA-3' |

Table 2.2: Oligos used for *Alu*-PCR. Oligos are listed for each reaction step.

Measurement of HIV-1 mRNA by RT-PCR

RT-PCR for Chapter Three

RT-PCR for HIV-1 mRNA spliced variants was performed using forward primers and reverse primers for spliced HIV-1 *env* and *tat* sequences. RT-PCR for HIV-1 mRNA after latency reversal was performed using forward primers and reverse primers for unspliced HIV-1 *tat* sequence. All values for both assays were normalized against beta-actin as a housekeeping gene (see Table 2.3). The reaction was performed on an Applied Biosystems QuantStudio 3 Real-Time PCR system with heating for 15 m at 94° and real-time PCR conditions of denaturation for 15 s at 94°, annealing for 30 s at 60°, and

extension for 30 s at 72°. Relative levels of HIV-1 mRNA were determined by delta-delta CT.

| Oligos Used for RT-PCR in Chapter Three | | |
|--|------------------|------------------------------------|
| Gene / Target | Primer Direction | Primer Sequence |
| <i>env</i> (spliced) | Forward | 5'-TCCCTCAGACCCTTTTAGTCAG-3' |
| | Reverse | 5'-GATTACTATGGACCACACAACACTATTG-3' |
| <i>tat</i> (spliced) | Forward | 5'-TCCCTCAGACCCTTTTAGTCAG-3' |
| | Reverse | 5'-CATCTGTCCTCTGTCAGTTTC-3' |
| <i>tat</i> (unspliced) | Forward | 5'-GGAGCCAGTAGATCCTAGAC-3' |
| | Reverse | 5'-CTTGGCAATGAAAGCAACAC-3' |
| <i>ACTB</i> | Forward | 5'-TGGGACGACATGGAGAA-3' |
| | Reverse | 5'-GGGTGTTGAAGGTCTCAAA-3' |

Table 2.3: Oligos used for RT-PCR in Chapter Three. Oligos are listed for each gene of interest or spliced transcript.

RT-PCR for Chapter Four

RT-PCR for HIV-1 mRNA after latency reversal was performed using forward primers and reverse primers for unspliced HIV-1 *gag* sequence, and all values were normalized against beta-globin as a housekeeping gene (see Table 2.4). The reaction was performed on an Applied Biosystems QuantStudio 3 Real-Time PCR system with heating

for 15 m at 94° and real-time PCR conditions of denaturation for 15 s at 94°, annealing for 30 s at 60°, and extension for 30 s at 72°. Primers for HIV-1 were based on Malnati *et al.*, 2008. Relative levels of HIV-1 mRNA were determined by delta-delta CT.

| Oligos Used for RT-PCR in Chapter Four | | |
|---|------------------|--|
| Gene / Target | Primer Direction | Primer Sequence |
| <i>gag</i> | Forward | 5'-TACTGACGCTCTCGCACC-3' |
| | Probe | 5'-FAM-CTCTCTCCTTCTAGCCTC-NFQMGB-3' |
| | Reverse | 5'-TCTCGACGCAGGACTCG-3' |
| β -globin | Forward | 5'-CCCTTGGACCCAGAGGTTCT-3' |
| | Probe | 5'-FAM-GCGAGCATCTGTCCACTCCTGATGCTGTTATGGGCGCTCGC-NFQMGB-3' |
| | Reverse | 5'-CGAGCACTTTCTTGCCATGA-3' |

Table 2.4: Oligos used for RT-PCR in Chapter Four. Oligos are listed for each gene of interest. HIV-1 primers span an unspliced region.

Chromatin Immunoprecipitation (ChIP)

ChIP was performed according to Natarajan *et al.*, 2013 with the addition of a nuclei isolation step using Farnham Lysis Buffer prior to sonication with a BioRupter Pico. Briefly, cells were washed in PBS and fixed in a final concentration of 1% formaldehyde in methanol. Crosslinking was quenched by addition of glycine to a final

concentration of 240mM. Cells were then washed, centrifuged, and flash frozen in liquid nitrogen. Pellet was lysed in Farnham Lysis Buffer (5mM PIPES pH 8.0, 85mM KCl, 0.5% NP-40) with addition of Halt Protease and Phosphatase Inhibitor Single-Use Cocktail from ThermoFisher before centrifugation to obtain nuclei fraction. Nuclei were lysed in RIPA buffer prior to sonication in BioRupter Pico for 15 m with alternating 30 s cycles. Samples were centrifuged to remove debris and pre-cleared with addition of 50% protein A sepharose bead for 30 m at 4°C. Beads were then pelleted and supernatants were split into 100µL portions as input DNA and multiple 300µL portions for sample analysis. Samples were incubated with antibodies overnight at 4°C. Antibody-bound proteins and cross-linked DNA were isolated by addition of 50% protein A sepharose beads for 2 h at 4°C prior to centrifugation. Immunoprecipitates were washed with low salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 150mM NaCl), high salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 500mM NaCl), lithium wash (0.25M LiCl, 1% NP-40, 1% sodium deoxycholate, 1mM EDTA, 10mM Tris-HCl), and Tris-EDTA buffers (10mM Tris, 1mM EDTA) before use of elution buffer (1% SDS, 0.1M NaHCO₃). Cross-linking was reversed with addition of 5M NaCl overnight at 65°C to both samples and input DNA before addition of proteinase K to isolate DNA. Sample DNA was purified using ChIP DNA Clean & Concentrator Kit (Zymo Research).

Antibodies used included anti-NELF-d (Antibody TH1L from Proteintech Group), anti-RNAPII antibody (Clone N20 from Santa Cruz Biotechnology), anti-histone

H3 antibody (Product 06-599 from Millipore Sigma), and Normal Rabbit IgG (Product 12-370 from Millipore Sigma).

Primers used for the transcriptional start site include the forward primer at +30 and the reverse primer at +239. Primers used for transcriptional elongation include the forward and reverse primers within the *tat* gene (see Table 2.5).

| Oligos Used for Chromatin Immunoprecipitation Assays | | |
|---|------------------|------------------------------|
| Gene / Target | Primer Direction | Primer Sequence |
| TSS* (+30) | Forward | 5'-CTGGGAGCTCTCTGGCTAACTA-3' |
| TSS* (+239) | Reverse | 5'-AGATCTCCTCTGGCTTTAC-3' |
| <i>tat</i> (+5379) | Forward | 5'-GGAGCCAGTAGATCCTAGAC-3' |
| <i>tat</i> (+5482) | Reverse | 5'-CTTGGCAATGAAAGCAACAC-3' |

Table 2.5: Oligos used for chromatin immunoprecipitation. Oligos are listed for each gene region of interest. Asterisk (*) refers to HIV-1 transcriptional start site.

Statistical Analysis

All statistical analysis performed using unpaired student's *t* test except for Microarray Analysis as detailed above.

CHAPTER THREE: STRENGTH OF T CELL SIGNALING REGULATES HIV-1 REPLICATION AND ESTABLISHMENT OF LATENCY

Parts of this chapter were originally published in: Gagne M, Michaels D, Schiralli Lester G, Wong W, Gummuluru S, Henderson AJ. Strength of T Cell Signaling Regulates HIV-1 Replication and Establishment of Latency. *bioRxiv*.
<https://doi.org/10.1101/432401>.

INTRODUCTION

Experimental Rationale

HIV-1 persists in a transcriptionally silent latent state in long-lived memory T cells. Although antiretroviral therapies suppress HIV-1 replication, interruption of treatment results in rapid viral rebound. Therefore, HIV-1 patients must remain on ART indefinitely, despite long term side effects, development of treatment resistance, and viral-induced inflammation (Wong *et al.*, 1997; Chun *et al.*, 1997; Harrigan, Whaley and Montaner, 1999). For this reason, one strategy currently being explored for cure efforts is “shock and kill,” in which latent HIV-1 is reactivated in conjunction with ART using latency-reversing agents. Following reactivation, infected cells are predicted to be eliminated by HIV-specific immunity or virally induced apoptosis. However, clinical trials using LRAs have only minimally perturbed the size of the viral reservoir (Sagot-Lerolle *et al.*, 2008; Archin *et al.*, 2010; Archin *et al.*, 2012).

A cure for latent HIV-1 will require a better understanding of the biochemical factors involved. Latency in chronically infected primary cells and cell lines is regulated by multiple transcriptional mechanisms including NF- κ B activation, chromatin accessibility, provirus transcription initiation, Tat availability, P-TEFb sequestration, and transcriptional elongation (Quivy, De Walque and Van Lint, 2007; Ruelas and Greene, 2013; Agosto, Gagne and Henderson, 2015; Cary, Fujinaga and Peterlin, 2016; Agosto and Henderson, 2018). However, what is not understood is how latency is initially established within a cell and if events at the time of HIV-1 infection influence the transcriptional status of the provirus. These questions are relevant since the latent reservoir is established within the first two weeks of infection (Chun *et al.*, 1998; Whitney *et al.*, 2014). New cure strategies will need to limit the size of the reservoir at early time points.

One mechanism that could predispose HIV-1 towards active replication or transcriptional repression and latency is signaling through the T cell receptor. Engagement of the TCR and costimulatory CD28 molecule result in a multitude of cellular outcomes that influence HIV-1 replication including cytoskeleton reorganization, the activation of transcription factors, enhanced RNAPII processivity, and chromatin remodeling (Huang and Wange, 2004; Kim *et al.*, 2011; Allison *et al.*, 2016). I hypothesized that the magnitude of T cell signaling during HIV-1 infection will dictate the course of the infection. In order to manipulate signal strength received by a T cell at the time of HIV-1 infection, I utilized chimeric antigen receptors (CARs) that recapitulate T cell receptor and CD28 signaling.

Chimeric Antigen Receptors

Chimeric antigen receptors or CARs are engineered ligand binding domains fused to signaling domains of interest. In this way, researchers can approximate endogenous receptor signaling but via a mechanism that they can control (Gross and Eshhar, 1992). CARs are widely used as cancer therapeutics where they can repurpose either NK cells or T cells to specifically recognize an oncogenic marker (Sommermeyer *et al.*, 2016; Romanski *et al.*, 2016). One potential target is human epidermal growth factor receptor 2. Her2 is a receptor tyrosine kinase involved in cellular activation (Lee *et al.*, 1989); its overexpression correlates with several pathologies including breast cancer (Berns *et al.*, 1992), pancreatic cancer (Yamanaka *et al.*, 1993), and glioblastomas (Ahmed *et al.*, 2010). Therefore, multiple labs have attempted to use chimeric antigen receptors specific for Her2 in order to drive CD8⁺ T cells towards elimination of Her2⁺ cells. For instance, in a Phase I clinical trial for patients with Her2-specific pancreatic cancer, at least one patient achieved a 50% reduction in the number of his lesions (Feng *et al.*, 2018).

The recognition component of the Her2 chimeric antigen receptor used in my system consists of a single-chain variable fragment (scFv). Single-chain variable fragments engineered to bind Her2 were originally developed in the 1990's. Schier *et al.* screened a scFv library and discovered the C6.5 fragment, which was later mutated to produce a number of other scFvs with differing affinities for the Her2 ligand (Schier *et al.*, 1996). This panel of Her2 receptors span 3 logs of affinity for their cognate antigen. The Wong laboratory at Boston University cloned these ligand-binding domains onto a

receptor with the intracellular signaling domains of CD3 ζ and CD28, the two main components of the T cell receptor signaling complex. CD3 ζ contains the six critical ITAMs (immunoreceptor tyrosine-based activation motifs) that are responsible for signal transduction due to their capacity to become phosphorylated (Bettini *et al.*, 2017). CD28 also contains multiple tyrosine residues that become phosphorylated, although they do not form a classic ITAM motif (Natarajan, August and Henderson, 2010; Ogawa *et al.*, 2013). By providing Her2 to this system, I aimed to induce similar signaling cascades to those activated by T cell receptor recognition of a MHC-peptide complex. Through these chimeric antigen receptors, which are identical apart from their Her2-binding domain, I was able to modulate the strength of signal that a cell receives. Differences in Her2 binding correlated with differential induction of T cell responses, providing our lab with a tool to manipulate cellular stimulation at the time of viral infection. A similar approach, in which various CD3 ζ ITAMs were mutated to prevent phosphorylation, resulted in phenotypic and functional differences in CAR-expressing CD8⁺ T cells (Feucht *et al.*, 2018). This study provided supporting evidence for my hypothesis that signaling differences downstream from a TCR-based CAR could be used to interrogate the role of the TCR on HIV-1 expression.

Using these CARs, I demonstrate that induction of stronger T cell receptor signaling at the time of HIV-1 infection increases subsequent HIV-1 transcription and replication. Robust signals also facilitated the formation of latently infected cells that were readily inducible upon secondary stimulation with phorbol esters, as well as PKC agonists. Minimal signaling through CARs, although sufficient for HIV-1 integration,

failed to support robust viral expression and interestingly, generated a deep-seated latent infection. Transcriptional elongation of HIV-1 provirus was limited by RNAPII pausing in the absence of CAR signaling; however, strong CAR signaling correlated with decreased Negative Elongation Factor binding and enhanced RNAPII processivity. My results suggest a model in which signaling strength influences HIV-1 transcription and establishment of latency at the time of initial infection of CD4⁺ T cells.

RESULTS

CARs Induce T Cell Signaling

To examine how signaling cascades downstream from the T cell receptor regulate HIV-1 transcription, I utilized CARs as can be seen in Figure 3.1A. Intracellular signaling domains for the CARs include CD3 ζ with its ITAMs and the CD28 costimulatory domain with its four critical tyrosine residues (Chmielewski, Hombach and Abken, 2014). Furthermore, a mCherry tag provides a marker for positive selection of CAR⁺ cells. The extracellular ligand-binding domains of the CARs consist of a single chain variable fragment that recognizes receptor tyrosine-protein kinase erbB-2 (Her2) (Schier *et al.*, 1996; Chmielewski, *et al.*, 2004). By using different scFvs, a library of CARs with variable binding affinities for Her2 ligand spanning three logs was generated (Figure 3.1B). CARs were transduced into Jurkat T cells and primary CD4⁺ T cells. By enriching for mCherry, I obtained CAR⁺ populations that were >90% pure (Figure 3.1C).




Figure 3.1: Chimeric antigen receptors used for tunable T cell signaling. (A) The design of CARs including CD3 ζ and CD28 signaling domains. (B) CAR single chain variable fragments with their corresponding dissociation constants for the Her2 ligand. I refer to these CARs by their relative ligand affinity. (C) Enrichment of primary CD4⁺ T cells based on mCherry expression following CAR transduction. See also Figures 3.2 and 3.3.

I examined whether stimulation through the CARs lead to global transcriptional changes consistent with T cell receptor engagement. These changes would include both upregulation of activation markers and key cytokines as well as corresponding downregulation of other gene networks in order to dampen the level of immune activation. To analyze the effect of Her2 stimulation on CAR-expressing cells, I cultured low affinity and high affinity CAR-expressing primary CD4⁺ T cells with plate-bound Her2 ligand for 24 h as well as untransduced CD4⁺ T cells with or without CD3 and CD28 antibodies. I then extracted the RNA and performed microarray analysis using a Human Clariom S array. All gene expression levels were compared to the baseline of unstimulated cells, and those genes whose one-way Anova FDR-corrected q values were less than 0.01 were selected. This allowed for the creation of a heatmap of 4,966 significantly modified genes clustered based on their expression profiles. Clusters 4 and 5 represent genes that are downregulated upon cell activation, while Clusters 1 and 3 represent genes that are clearly upregulated upon cellular stimulation. As can be seen in Figure 3.2, stimulation through the low or high affinity CARs represents intermediate phenotypes between that of the unstimulated or TCR-engaged populations. The log₂ expression of a selection of well-known genes from Clusters 1 and 3 are listed in Table 3.1. Our lab is interested in further exploring how suboptimal cellular activation leads to unique phenotypes. However, for the purposes of this paper, the pathways and genes expected to be activated downstream from the T cell receptor pathway are indeed being engaged, confirming that binding of the receptors provide me with a way to activate a range of signaling inputs at the time of infection.

| | Untransduced CD4 ⁺ | | | Low Affinity + Her2 | | | High Affinity + Her2 | | | Anti – CD3/CD28 | | |
|-------|-------------------------------|---------|---------|---------------------|---------|---------|----------------------|---------|---------|-----------------|---------|---------|
| | Donor 1 | Donor 2 | Donor 3 | Donor 1 | Donor 2 | Donor 3 | Donor 1 | Donor 2 | Donor 3 | Donor 1 | Donor 2 | Donor 3 |
| CD69 | 6.6 | 6.7 | 7.2 | 7.9 | 7.9 | 8.0 | 8.3 | 8.3 | 8.2 | 8.3 | 8.2 | 7.8 |
| PDCD1 | 5.6 | 5.9 | 5.6 | 6.0 | 6.2 | 6.5 | 6.7 | 6.4 | 6.9 | 6.6 | 7.0 | 7.3 |
| CTLA4 | 4.5 | 4.6 | 5.4 | 5.8 | 6.1 | 6.0 | 6.3 | 6.5 | 6.4 | 6.9 | 6.9 | 6.8 |
| IL2 | 1.7 | 1.5 | 1.3 | 3.5 | 4.3 | 3.7 | 4.8 | 4.9 | 4.9 | 6.9 | 7.8 | 7.3 |
| IL21R | 3.4 | 3.3 | 3.6 | 4.5 | 4.5 | 4.1 | 4.7 | 4.6 | 4.3 | 5.1 | 4.7 | 4.7 |
| IRF4 | 7.8 | 7.7 | 7.3 | 8.7 | 9.5 | 9.3 | 9.0 | 9.3 | 9.3 | 9.1 | 9.1 | 9.3 |
| IFNG | 2.3 | 4.7 | 6.4 | 3.4 | 5.2 | 6.7 | 4.3 | 6.7 | 7.5 | 8.3 | 9.2 | 10.8 |
| TNF | 6.5 | 6.5 | 7.2 | 6.7 | 6.5 | 7.1 | 7.1 | 7.3 | 7.6 | 8.3 | 8.5 | 8.8 |
| TRAF1 | 7.5 | 7.6 | 7.8 | 8.3 | 8.0 | 8.1 | 8.5 | 8.0 | 8.3 | 8.2 | 8.1 | 8.4 |
| KLF10 | 6.0 | 7.0 | 6.4 | 7.8 | 7.9 | 7.9 | 8.1 | 8.1 | 8.3 | 8.1 | 8.4 | 8.6 |
| JUN | 4.2 | 4.8 | 5.2 | 5.5 | 5.3 | 6.0 | 5.7 | 5.9 | 6.1 | 5.5 | 6.0 | 6.2 |
| FOXP3 | 6.9 | 6.4 | 6.9 | 6.6 | 6.6 | 6.7 | 6.6 | 6.5 | 6.4 | 7.7 | 7.0 | 7.3 |
| CDK2 | 7.0 | 7.8 | 7.7 | 7.7 | 8.4 | 7.5 | 8.0 | 8.6 | 7.6 | 9.2 | 9.1 | 8.8 |

Table 3.1: Log2 expression of differentially regulated genes upon cell activation. A selection of commonly described genes located in Clusters 1 and 3 from the heatmap shown in Figure 3.2 are presented along with their log2 expression values. This list is in no way comprehensive and is shown as an example of the types of genes upregulated upon CAR stimulation.

Principal component analysis was also performed on the genes identified as significantly different from the unstimulated CD4⁺ T cell condition. This analysis, along with the full list of genes used for the creation of the heatmap in Figure 3.2 is provided in the Appendix.

Cells were also examined for the expression of phenotypic markers following stimulation. I monitored CD69, a transmembrane lectin and a marker for CD4⁺ T cell activation, by flow cytometry before and after receptor activation with Her 2 (Figure 3.3). Primary CD4⁺ T cells transduced with either the low affinity or the high affinity receptors were stimulated with plate-bound Her2 ligand for 24 h. In the absence of ligand, less than 7% of the cells were positive for CD69, verifying that there is no ectopic

CAR signaling. Activating cells with Her2 induced CD69 expression in the low affinity and high affinity receptors relative to their affinity for ligand.

I also looked at markers associated with T cell maturation. One week post stimulation, primary cells stimulated through either the low or high affinity receptor were analyzed for expression of memory markers CCR7 and CD45RA. CCR7 is a lymph node homing receptor, and CD45RA is downregulated upon memory cell differentiation. Activation through the endogenous T cell receptor using antibodies to CD3 and CD28 resulted in the expansion of the CCR7⁺ CD45RA⁻ central memory population and to a lesser extent a CCR7⁻ CD45RA⁻ pool of effector memory cells (Figure 3.4). CAR engagement regardless of receptor affinity polarized cells towards similar memory cell phenotypes. Taken together, these data demonstrate that CARs can be used to activate a spectrum of T cell responses and provide a tool to modulate T cell signaling. Importantly, the CARs do not drive cells towards an aberrant phenotype.




Figure 3.2: Signaling through chimeric antigen receptors alters the expression of genes downstream from the T cell receptor. CD4⁺ T cells isolated from healthy human donors were transduced with low affinity or high affinity CARs and then allowed to return to a resting state. Cells were either then stimulated through the receptor or left unstimulated. RNA was isolated 24 h later and converted to cDNA before being run on a Human Clariom S array. Gene expression levels for both cell types and TCR-stimulated CD4⁺ T cells were compared to unstimulated cells. All genes with a one-way Anova FDR-corrected q value of < 0.01 were plotted in a heatmap and clustered according to expression profiles. Data is presented as a heatmap based on RNA expression and represents three independent donors.




Figure 3.3: Differential signaling through chimeric antigen receptors. CD4⁺ T cells isolated from healthy human donors were transduced with low affinity or high affinity CARs and then allowed to return to a resting state. Cells were either then stimulated through the receptor or left unstimulated. CD69 expression was compared to a negative control of untransduced cells one day after Her2 stimulation. Data is presented as dot plots based on flow cytometry analysis and is from a representative experiment that has been performed four times with different donors.




Figure 3.4: Signaling through chimeric antigen receptors polarizes cells towards a central memory phenotype. CD4⁺ T cells isolated from healthy human donors were transduced with low affinity or high affinity CARs and then allowed to return to a resting state. Cells were then stimulated through the receptor for two days and compared to untransduced cells treated with or without antibodies to CD3 and CD28 at a ratio of 1:1. Analysis was performed 7 days post stimulation, and cells were cultured in IL-7 and IL-2 during the intervening period. The use of CCR7 and CD45RA can be used to classify cells into three distinct populations: CCR7⁺ CD45RA⁺ naïve-like cells, CCR7⁺ CD45RA⁻ central memory cells, and CCR7⁻ CD45RA⁻ effector memory cells. Data is presented as dot plots based on flow cytometry analysis and is from a representative experiment that has been performed three times with different donors.

T Cell Signaling at the Time of HIV-1 Infection Regulates Provirus Expression

To determine whether T cell signaling influences viral infection, Jurkat T cells expressing low affinity or high affinity CARs were plated on Her2-coated wells and simultaneously infected with VSV-G pseudotyped NL4-3.Luc, a single-cycle HIV-1 clone which contains a luciferase reporter gene in place of *nef*. VSV-G or Vesicular Stomatitis Virus Envelope Glycoprotein G allowed me to bypass potentially confounding effects from receptor/chemokine receptor signaling due to gp120 binding (Davis *et al.*, 1997) and focus specifically on CAR-associated signaling cascades. To assess whether signaling influenced the establishment of infection, I measured levels of HIV-1 proviral DNA using a previously described nested *Alu*-PCR approach (Agosto *et al.*, 2007). I modified the assay by designing primers to the luciferase open reading frame to estimate the relative frequency of HIV-1 integration without confounding signals from the lentiviral vectors used to express the CARs (see Chapter 2). CAR-associated signaling did not affect the infection of Jurkat cells since I detected comparable numbers of proviruses regardless of the presence or absence of CAR ligand (Figure 3.5A). When HIV-1 expression was measured by luciferase activity, Jurkat cells infected in the context of strong CAR signaling expressed greater than 10-fold more HIV-1 compared to untreated controls (Figure 3.5B). In contrast, engagement of the low affinity CAR led to a modest 3-fold expression compared to unstimulated cells despite a similar proviral load as the high affinity CAR-expressing cells. These data indicate that strong T cell signaling at the time of infection facilitates HIV-1 expression without enhancing provirus integration.




Figure 3.5: T cell signaling at the time of HIV-1 infection regulates provirus expression.

(A and B) Jurkat T cells were transduced with the high or low affinity CAR. Cells were stimulated through the CAR at the time of HIV-1 infection with VSV-G pseudotyped NL4-3.Luc. (A) Relative levels of integrated provirus 24 h post infection of high or low affinity Jurkat T cells using nested *Alu*-PCR. Uninfected CAR-expressing Jurkat T cells were a negative control. (B) Luciferase activity measured 24 h post-infection presented as fold difference in relative light units (RLUs) over unstimulated cells for each CAR+ cell line. ** $p < 0.005$, *** $p \leq 0.0005$. A and B were performed in triplicate and are representative of four independent experiments. Data are presented as mean \pm standard deviation. (C and D) Primary CD4⁺ T cells isolated from healthy human donors were transduced with CARs and given one week to return to a resting state. Cells were stimulated through the CAR at the time of HIV-1 infection with single-round VSV-G pseudotyped NL4-3.Luc. (C) Relative levels of integrated provirus 24 h after infection of high or low affinity CAR-expressing primary T cells (from the same donor) using nested *Alu*-PCR. Uninfected CAR-expressing primary T cells were a negative control. Results are from a single experiment performed in triplicate and are representative of two independent experiments. Data are presented as mean \pm standard deviation. (D) Luciferase activity measured 4 days post infection presented as fold difference in RLUs over unstimulated cells for each CAR+ cell line. Experiments from two separate donors are shown and are representative of three independent experiments. See also Figure 3.6 and 3.7.

I confirmed that these differences were due to downstream signaling cascades emanating from the CARs by using the Src kinase inhibitor, PP2. Src kinases are the first downstream targets of T cell receptor activation and are recruited to the phosphorylated ITAMs (Gibson *et al.*, 1996; Rossy *et al.*, 2013). In the presence of PP2, the increase in HIV-1 expression upon CAR stimulation was attenuated, consistent with T cell signaling as a regulator of HIV-1 expression (Figure 3.6). The pharmacologically inactive version of this inhibitor, PP3, had no effect on the ability of CARs to influence HIV-1 expression.

To confirm that differences in luciferase activity were a result of transcriptional upregulation and not post-transcriptional events, I examined production of spliced viral mRNAs in HIV-1 infected CAR-expressing Jurkat T cells. A major impediment to successful HIV-1 replication occurs at the level of splicing (Yukl *et al.*, 2018). I analyzed infected Jurkat cells to measure whether increased cellular activation resulted in increased expression of fully-spliced and partially-spliced viral transcripts. RT-PCR confirmed that increased cellular activation resulted in not only greater levels of fully-

spliced RNA transcripts but also partially-spliced transcripts (Figure 3.7). Although differences were detected between the amount of partially-spliced and fully-spliced mRNAs, this effect was most likely due to primer binding efficiencies or splicing kinetics (Klotman *et al.*, 1991; Puray-Chavez *et al.*, 2017). In addition, not all products are spliced in equal ratios, with *env* transcripts being relatively highly expressed (Ocwieja *et al.*, 2012). Regardless, the fact that all measured spliced products increased upon greater T cell stimulation indicated that transcription was the limiting step of HIV-1 expression in response to TCR signaling.

I validated the observation that signal strength influenced HIV-1 replication and transcription using primary CD4⁺ T cells that were transduced with either the low affinity or high affinity CAR. Following transduction, cells were allowed to return to a resting state as monitored by low CD69 expression before infection with HIV-1 in the absence or presence of the ligand Her2. Consistent with the data from Jurkat cells, similar levels of proviral DNA were detected in primary CD4⁺ T cells regardless of the strength of CAR signaling (Figure 3.5C). Cells that received robust stimulation at the time of infection expressed 1.5- to 4-fold more HIV-1 than cells stimulated through the low affinity receptor (Figure 3.5D).




Figure 3.6: Src kinase inhibitor PP2 inhibits CAR-mediated HIV-1 transcription. CAR+ Jurkat T cells were stimulated with or without Her2 in the absence or presence of 10 μ M PP2 or PP3 at the time of HIV-1 infection with single-round VSV-G pseudotyped NL4-3.Luc. 24 h post infection, cells were lysed to measure luciferase. Data are presented as fold difference in RLUs over unstimulated cells for each CAR+ population. ** $p < 0.005$, *** $p \leq 0.0005$. Figure 3.6 was performed in triplicate and is representative of five independent experiments. Data are presented as mean \pm standard deviation.




Figure 3.7: T cell signaling at the time of HIV-1 infection regulates provirus expression by inducing transcription. (A and B) CAR+ Jurkat T cells were stimulated with or without Her2 at the time of HIV-1 infection with VSV-G pseudotyped NL4-3.Luc. 24 h post infection, cells were lysed in order to measure HIV-1 transcripts by qRT-PCR. (A) Fold difference in HIV-1 *env* transcripts over corresponding unstimulated conditions as an indication of production of partially spliced RNAs. Although *env* gene is heavily deleted in provirus, the 5' end of the gene remains intact. (B) Fold difference in HIV-1 *tat* transcripts over corresponding unstimulated conditions as an indication of production of fully spliced RNAs. ** $p < 0.005$, *** $p < 0.0005$. A and B were performed in quadruplicate. Data are presented as mean \pm standard deviation.

To gain insight into whether there is a threshold or minimal T cell signal required for HIV-1 infection and replication, I transduced Jurkat T cells with CAR receptors that spanned a range of binding affinities (Figure 3.1B). These cells were infected with NL4-3.Luc as described above in the absence or presence of Her2. Although the high affinity condition supported HIV-1 infection and transcription, the intermediate and low affinity receptors did not support HIV-1 expression (Figure 3.8A). This was despite similar levels of infection as determined by measuring proviral DNA (Figure 3.8B). These data suggest

that T cell signaling controls HIV-1 expression by a digital on/off mechanism since viral expression does not linearly correlate with signal strength.




Figure 3.8: Robust T cell signaling is required for HIV-1 transcription. (A) Jurkat T cells were transduced and positively selected for indicated CARs and then infected with NL4-3.Luc. 24 h post infection, cells were lysed for luciferase analysis. Data are presented as fold difference in RLUs over unstimulated cells for each CAR⁺ population. ** $p < 0.005$, *** $p < 0.0001$. (B) Relative levels of integrated provirus after infection of CAR-expressing Jurkats using nested *Alu*-PCR. A and B were performed in triplicate and are representative of four independent experiments. Data are presented as mean \pm standard deviation.

Robust Signals During HIV-1 Infection Establishes an Inducible Latent Reservoir

I hypothesized that differential T cell signaling during infection alters the size of the inducible latent reservoir. To examine this, I infected CAR-expressing primary CD4⁺ T cells with VSV-G pseudotyped Bru-dENV-GFP (GFP-expressing single cycle HIV-1) in the presence of Her2 ligand. One week post infection, cells were sorted for both mCherry expression as a marker for CAR transduction and lack of GFP expression in order to enrich for latently infected cells. CAR⁺/GFP^{neg} cells were reactivated with PMA plus ionomycin or left unstimulated to control for spontaneous HIV-1 reactivation (Figure 3.9A). PMA, a phorbol ester, and ionomycin, a calcium ionophore, engage two separate arms of the T cell activation pathway. PMA and ionomycin significantly reactivated HIV-1 expression within cells that had been initially infected in the context of strong signaling, resulting in a 3- to 9-fold increase in the percentage of GFP positive cells and a 1000-fold induction of HIV-1 mRNA measured by qRT-PCR (Figure 3.9B and 3.9C). However, the observed reactivation of HIV-1 was modest in cells infected at the time of stimulation through the low affinity CAR. A 200-fold induction of HIV-1 RNA was detected in reactivated latently infected cells expressing low affinity CARs, and less than a 2-fold change was observed in the percentage of GFP⁺ cells. Therefore, despite both minimal and robust signaling resulting in comparable amounts of integrated HIV-1 provirus, robust signaling was not only necessary for active transcription but also supported the generation of a population of latently infected cells that could be readily induced to express HIV-1. The population of latent cells generated in response to weaker

CAR signaling was more resistant to reversal suggesting that HIV-1 in these cells was strongly repressed.




Figure 3.9: Robust signals during HIV-1 infection establish an inducible latent reservoir. (A) Outline of experimental plan to enrich for latently infected cells following infection. Primary CD4⁺ T cells are infected with BRU-dEnv-GFP and GFP-negative cells are sorted to enrich for latently infected cells. (B) Percent GFP⁺ HIV-expressing cells after stimulation of latent cells with various latency-reversing agents: PMA plus ionomycin, antibodies to endogenous CD3 and CD28, SBHA, and Bryostatin. Data are from seven separate donors, and each form of LRA stimulation was performed on cells from 2-3 donors. (C) Latently-infected cells were restimulated with PMA and ionomycin. HIV-1 expression was monitored by measuring Tat RNA by qRT-PCR. Values are shown as fold difference in HIV-1 transcripts over corresponding non-reactivated controls. All data in C are derived from 4-6 replicates and are representative of three independent experiments with different donors. Data are presented as mean \pm standard deviation. * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0001$.

I also used other common latency-reversing agents in order to determine if targeting alternative activation pathways could reverse the refractory nature of the low stimulation cells. Antibodies to CD3 and CD28, which would engage the endogenous T cell receptors and fully re-activate these cells, failed to reverse the repressed virus in cells that expressed the low affinity CAR. SBHA (an HDACi) and bryostatin (a PKC agonist) failed to significantly reactivate cells that had received either high or low levels of stimulation at the initial time of infection. (Figure 3.9B).

RNAPII Processivity Limits HIV-1 Transcription in the Absence of Robust Signaling

I was interested in mechanisms that governed HIV-1 repression following integration in the absence of sufficient T cell signaling; therefore, I examined the binding of transcriptional regulators on the HIV-1 LTR by chromatin immunoprecipitation (ChIP). Jurkat T cells expressing low or high affinity CARs were infected with NL4-3.Luc in the absence or presence of Her2 ligand. One day post-infection, cells were fixed and chromatin was prepared for ChIP.

Since HIV-1 proviral latency correlates with a positioned nucleosome that is downstream of the transcriptional start site, I explored whether the LTR was associated with post-translationally modified histones as an indicator of chromatin organization. ChIPs for acetylated histone H3 showed no significant difference in binding of the HIV-1 LTR between cells infected in the absence or presence of T cell signaling (Figure 3.10A). Taken together with the lack of effect of histone deacetylase inhibitors on latency reversal (Figure 3.9B), it would seem that chromatin accessibility does not appear to be limiting HIV-1 proviral transcription during the early stages of infection.

I then examined RNAPII processivity by measuring RNAPII occupancy at multiple points in the HIV-1 proviral genome, including the transcriptional start site and downstream in the HIV-1 *tat* gene. RNAPII was detected at the HIV-1 transcriptional start site whether cells were activated through a CAR or were unstimulated (Figure 3.10B). However, signaling through the high affinity receptor resulted in an increase in downstream RNAPII by greater than 4-fold, whereas only modest levels of RNAPII were found downstream in the absence of signals or following weak signaling (Figure 3.10C).

Since these data indicated a role for transcriptional pausing, I examined if CAR signaling altered the presence of the pausing factor NELF at the HIV-1 transcriptional start site. Using ChIPs, I determined that signaling through the high affinity receptor diminished binding of NELF at the HIV-1 LTR by greater than 85% (Figure 3.10D). These data support a model in which a lack of robust T cell signaling limits HIV-1 transcription by establishing a paused polymerase complex.




Figure 3.10: RNAPII processivity limits HIV-1 transcription in the absence of robust signaling.

CAR-expressing Jurkat T cells were infected with single-round VSV-G NL4-3.Luc and simultaneously plated with or without Her2 ligand. 24 h later, cells were fixed for chromatin immunoprecipitation. (A) ChIP for presence of acetylated H3 near the transcriptional start site (nuc-1). (B) ChIP for RNAPII at the HIV-1 transcriptional start site. (C) ChIP for RNAPII associated with the HIV-1 *tat* gene to measure polymerase processivity. Data from A-C are normalized to corresponding IgG controls for each stimulation condition. (D) ChIP for NELF-d at the HIV-1 transcriptional start site. Data is normalized to corresponding unstimulated condition for each CAR+ cell line. A-D were performed in triplicate and are representative of at least three independent experiments in Jurkat T cells. Data are presented as mean \pm standard deviation. Primers used for HIV-1 transcriptional start site are +30 and +239. Primers used for *tat* gene are +5379 and +5482. * $p < 0.05$, ** $p < 0.005$, *** $p \leq 0.0005$

DISCUSSION

Previous studies suggest that cell signaling may be a key regulator of HIV-1 expression and latency. The latent reservoir is enriched for antigen specific T cells, including those that respond to CMV, HSV, tuberculosis, and HIV (Douek *et al.*, 2002; Demoustier *et al.*, 2002; Casazza *et al.*, 2009; Geldmacher *et al.*, 2010; Hu *et al.*, 2016). Furthermore, the use of superantigens during viral entry increases HIV-1 replication (Laurence, Hodsse and Posnett, 1992). Partial activation, cellular polarization, cell-to-cell contact, and/or infection of resting quiescent cells through perturbation have also been suggested to bias infections towards latency (Agosto and Henderson, 2018; Saleh *et al.*, 2007; Bosque and Planelles, 2009; Pace *et al.*, 2011; Agosto *et al.*, 2018; Kumar *et al.*, 2018). Therefore, the extent of cell activation is a key determinant in regulating the course of HIV-1 infection including the formation of the reservoir.

I have shown that differential signaling through CARs, which mimic TCR signaling, influences HIV-1 transcription and latency. In the lymph node, the primary site for both HIV-1 replication and the persistent latent reservoir (Biberfeld *et al.*, 1986; Shen *et al.*, 2003; Aid *et al.*, 2018), T cells sample lymph node resident antigen presenting cells in search for antigen. Some of these interactions, facilitated by the presentation of the T cell cognate antigen, will result in robust T cell activation, clonal expansion, and changes in gene expression. However, most MHC complexes will lack cognate antigen and initiate weak signaling (Zehn, Lee and Bevan, 2009; Martinez *et al.*, 2016). Using multiple CARs whose affinities for the Her2 ligand span several logs, I delivered a range of signaling inputs to model the spectrum of T cell receptor signaling events. My data

indicates that stronger T cell activation at the time of infection, which would be akin to antigen-specific responses, correlates with robust HIV-1 expression as well as the establishment of inducible latently infected cells. I do not address here the possibility that additional factors may compensate for suboptimal T cell receptor signaling. Interactions with antigen presenting cells would engage a number of costimulatory molecules and inhibitory receptors. In addition, the presence of inflammatory cytokines, such as would be expected during the acute stages of HIV-1 infection, may alter the level of cellular activation. Whether the ability of T cell stimulation to regulate HIV-1 is a matter of quality or simply quantity of signal should be examined further.

Having a library of CARs with a range of binding affinities allowed me to determine if HIV-1 responds to signaling in an analog fashion correlating with signal input or digitally regulated by specific thresholds resulting in all-or-none responses (Zikherman and Au-Yeung, 2015). Signaling through the CARs with affinities that were intermediate did not support active transcription despite a greater than 10-fold increase in binding affinity compared to the low affinity receptor. These results would suggest that TCR signaling provides more of an on/off switch and that there exist signaling thresholds that must be overcome to assure efficient transcription and replication.

Signal transduction and gene expression are inherently noisy processes, and stochastic events are hypothesized to drive HIV-1 latency. That latency and HIV-1 replication are driven by episodic bursts of proviral transcription and Tat levels has been supported by mathematical modeling and experiments using engineered virus models (Burnett *et al.*, 2009; Donahue *et al.*, 2012; Razooky *et al.*, 2015). Even if latency is

driven by random fluctuations of provirus transcription, T cell associated signals are strong modulators of noise, and targeting these pathways could enhance treatments directed at HIV-1 reactivation (Dar *et al.*, 2014). However, it is important to appreciate that although signaling and transcription are subject to stochastic variation, these are coordinated and combinatorial processes that lead to defined patterns of gene expression and phenotypic outcomes (Banos, Agelopoulos and Thanos, 2013).

Regulated aspects of transcription include assembly of multi-subunit complexes such as RNAPII and associated cofactors, chromatin, and transcription factors at the LTR. Figure 3.10 suggests that the association of NELF with RNAPII is regulated by TCR signaling. Multiple positive and negative signals are known to converge on NELF-driven transcriptional pausing. P-TEFb relieves NELF repression through phosphorylation (Fujinaga, *et al.*, 2004) and is itself regulated by cellular stress and signals (Garriga *et al.*, 1998; Zhou and Yik, 2006; Fujinaga *et al.*, 2015).

My data regarding the lack of histone acetylation as a block to transcriptional elongation at the time of viral integration is in marked contrast to its acknowledged role in the maintenance of HIV-1 latency in chronically infected cell lines and patient samples *ex vivo* (He and Margolis, 2002; Archin *et al.*, 2009). However, our lab has shown that NELF interacts with co-repressors including NCoR1-GPS2-HDAC3 at the HIV-1 promoter (Natarajan *et al.*, 2013) which may reinforce HIV-1 latency, especially during chronic infection, by facilitating post-translational modifications of histones and chromatin organization.

I propose that strength of signal at the time of infection acts as a bifurcating event leading to *either* robust transcription and the establishment of an inducible latent reservoir *or* minimal transcription and deep-seated latency (Illustration 3.1). My observations are consistent with the previous characterization of patient reservoirs that identified three subsets of latently infected cells: a small population of cells carrying inducible provirus, larger populations of cells with intact proviruses that are difficult to reactivate, and many defective proviruses (Ho *et al.*, 2013). Successful purging of the latent reservoir may require the use of a cocktail of latency reversing agents or the development of novel strategies to block reactivation (Xing and Siliciano, 2013; Darcis *et al.*, 2015; Darcis *et al.*, 2017).




Illustration 3.1: T cell signaling during HIV-1 infection drives viral fate. Amplitude of TCR signaling cascade polarizes cells towards a favorable environment for productive HIV-1 infection and the formation of a readily inducible latent reservoir or an unfavorable environment for viral replication marked by uninducible latency.

CHAPTER FOUR: NUCLEASE-DEFICIENT CAS9-KRAB CAN BE USED TO SILENCE HIV-1 EXPRESSION THROUGH REDUCTION IN RNAPII INITIATION

INTRODUCTION

Discovery of CRISPR-Cas9 and Use as an HIV-1 Therapeutic

CRISPR-Cas9 offers significant advantages over other strategies for gene editing. TALENs (transcription activator-like effector nucleases) and zinc finger nucleases were widely considered the most accurate molecular tools to target specific sections of the genome (Miller *et al.*, 2007; Mussolino *et al.*, 2011), but the application of a CRISPR-based approach heralded a new era in gene editing. In 2013, the laboratories of Feng Zhang and George Church simultaneously demonstrated that a Cas9 system adapted from *Streptococcus pyogenes* could be used for genome editing in both cell lines and induced pluripotent stem cells (Cong *et al.*, 2013; Mali *et al.*, 2013). Both approaches were based on the capacity of the bacterial CRISPR system to excise foreign DNA and insert it between the palindromic repeats in a region known as the protospacer. This protospacer is then cleaved, along with an adjoining portion of the palindrome, inserted into CRISPR Associated Protein 9, and recruited to its complementary sequence located within an invading pathogen (Mali, Esvelt and Church, 2013). It should also be pointed out that any corresponding DNA sequence must be immediately upstream from a Protospacer Adjacent Motif (PAM) site. The PAM specific sequence for Cas9 isolated from

Staphylococcus aureus, the bacterial species used for some of the experiments outlined in this chapter, is 5'-(N)NGRRT-3'. N refers to any nucleotide, while R denotes a purine base (Xie *et al.*, 2018).

By operating under these particular requirements, the exonuclease is directly targeted to a specific gene with minimal off-target effects (Kim *et al.*, 2015). By providing their own protospacer sequence in the form a small guide RNA (sgRNA), the Church and Zhang labs were able to redirect the CRISPR system to bind to and excise a human gene of interest.

An immediate application of CRISPR-based gene editing was its potential as an HIV-1 therapeutic. Since HIV-1 persists as transcriptionally silent latent proviruses, CRISPR provides a possible mechanism that could be used to excise integrated HIV-1. The Khalili lab first demonstrated the capacity of CRISPR to remove integrated proviruses through the use of guide RNAs directed towards the U3 region of the HIV-1 LTR (Hu *et al.*, 2014). However, significant questions still remain regarding method of delivery *in vivo*, off-target effects (which, although minimal, could still pose significant health concerns), complete removal of all latent proviruses, and viral escape (Fu *et al.*, 2013; Wang G *et al.*, 2016; Wang Z *et al.*, 2016; Mout *et al.*, 2017). The Khalili lab performed *in vivo* experiments using humanized mice infected with HIV-1, but failed to completely excise all HIV-1 DNA. In addition, significant targeting differences were seen between various tissue sites, with reduced efficacy in the central nervous system (Kaminski *et al.*, 2016).

For these reasons, I propose the use of a nuclease-deficient Cas9 to recruit chromatin-modifying factors to the HIV-1 provirus instead of degrading the genome. This approach provides the additional benefit of removing any immune pressure resulting in viral escape as in theory no transcription and thus no replication would occur at all. New efforts at the use of adeno-associated vectors as a delivery system could bypass the current issues with cellular penetrance and might allow the system I describe here to be brought into the clinic (Platt *et al.*, 2014).

Cas9-KRAB Construct for Targeted Gene Repression

The first attempts to fuse a nuclease-deficient Cas9 to a Krüppel Associated Box Domain was first described by the Wang and Gersbach labs in the mid-2010's (Lawhorn, Ferreira and Wang, 2014; Thakore *et al.*, 2015). KRAB domains are known to bind to the endogenous host factor, Kap1 or KRAB-Associated Protein-1, which together target various repressors to the region of the genome to which the KRAB domain is bound. These repressors include histone deacetylases, histone lysine-methyltransferases, and DNA methyltransferases. As a result, the surrounding genes become silenced, and we can detect both the spreading of marks associated with heterochromatin and a lack of transcription (Friedman *et al.*, 1996; Groner *et al.*, 2010; Oleksiewicz *et al.*, 2017). It is hypothesized that KRAB-Kap1 may mediate this transcriptional effect through directly dislodging the RNAPII complex (Moosmann *et al.*, 1997; Groner *et al.*, 2010).

Most KRAB-containing proteins have been described in mouse embryonic cells, such as the zinc-finger protein ZFP809 that can repress murine leukemia virus and

murine endogenous retroviruses (Wolf and Goff, 2009; Wolf *et al.*, 2015). The human KRAB-containing zinc-finger protein ZNF93 has recently been discovered as a restriction factor for the long interspersed nuclear element 1 or L1 in human embryonic stem cells (Jacobs *et al.*, 2014). KRAB-Kap 1 has consistently been shown to play an important role in cellular gene regulation and its adaptation to the CRISPR-Cas9 system offers a novel approach to targeted epigenetic editing.

My goal was to introduce a nuclease-deficient Cas9-KRAB domain construct into cells at the time of infection with HIV-1. Together with sgRNAs directed against regions of the HIV-1 genome immediately upstream of the appropriate PAM site, our lab was able to successfully repress HIV-1 expression. We further illustrated the potential of this nuclease-deficient Cas9 system by electroporating it into latently infected T cells. The exonuclease was capable of preventing viral reactivation, highlighting its prospective role as an HIV-1 therapeutic. In this way, I aimed to bias an infection towards long-term transcriptional repression or inactivation.

RESULTS

Nuclease-Deficient Cas9-KRAB Suppresses HIV-1 Expression

I obtained nuclease-deficient Cas9-KRAB plasmids from the Wilson Wong laboratory at Boston University. They created two separate fusion constructs, one based on *Staphylococcus aureus* and a second on *Streptococcus pyogenes*. Although the dsCas9 is more specific due to its more stringent PAM sequence, dspCas9 is more

widely used and was the first variant isolated by the Church and Zhang labs. One sgRNA (dsp361) was modified from a sgRNA described in a paper using a dCas9 fused to an activating domain and overlaps the NF- κ B sites in the HIV-1 LTR (Saayman *et al.*, 2016). A separate sgRNA (dsp397) binds to the SP1 site in the LTR (Hu *et al.*, 2014). Alex Olson, a technician in the Henderson lab who performed several of the experiments described in this chapter, identified a panel of dsaCas9 guide RNAs that would bind to the NL4-3 HIV-1 sequence using the online tool Benchling (Illustration 4.1) (Benchling, 2019). These sgRNAs span the proviral genome.





Illustration 4.1: Selection of HIV-1 binding sgRNAs for CRISPR-mediated epigenetic silencing. Binding sites were selected using the online tool Benchling that spanned the HIV-1 genome, including sites in the LTR, *gag-pol*, and *tat*. Schematic based off of a figure modified from (Colin and Van Lint, 2009).

We first cotransfected the DNA sequences encoding for the dsaCas9 sgRNAs with NL4-3.Luc, a single-cycle luciferase construct, into HEK293T cells and measured luciferase at 48 hours post transfection. Both dsa397 and dsa518, located within the HIV-1 LTR, showed the greatest effect on luciferase repression and we focused primarily on

these guides (Figure 4.1A). We further illustrated the potential of this system to block HIV-1 expression by infecting HEK293T cells with VSV-G pseudotyped NL4-3.Luc while transfecting with dsaCas9. Twenty-four hours later, we transfected cells with plasmids encoding for the sgRNAs and measured luciferase units three days post-infection. We were able to block at least 50% of viral transcription resulting from HIV-1 infection (Figure 4.1B).

A



B




Figure 4.1: KRAB binding to the HIV-1 LTR inhibits viral expression. (A) HEK293T cells were co-transfected with VSV-G NL4-3.Luc, dsaCas9-KRAB, and the indicated sgRNA. 48 h later, cells were lysed for luciferase analysis. Data are presented as fold difference in RLUs over tracrRNA only control. (B) HEK293T cells were infected with VSV-G NL4-3.Luc and simultaneously transfected with dsaCas9-KRAB. 24 h later, cells were transfected with the indicated sgRNA. 48 h post infection, cells were lysed for luciferase analysis. Data are presented as fold difference in RLUs over “tracrRNA only” control and represent mean \pm standard deviation. Data in B was performed in triplicate. “tracrRNA only” refers to the addition of the sequence corresponding to the tracrRNA without the crRNA sequence necessary to bind HIV-1. “No Cas9” refers to HIV-1 transfection only.

Nuclease-Deficient Cas9-KRAB Prevents Latent HIV-1 Reactivation

J-Lat cells harbor an integrated latent copy of HIV-1 that is responsive to various Tat inducers including TNF- α and phorbol esters (Jordan, Bisgrove and Verdin, 2003; Williams *et al.*, 2007). We thus sought to determine if we could block HIV-1 reactivation in these cells through the use of our nuclease-deficient Cas9 construct. Because J-Lat cells are not easily transfected with plasmids, we used our dspCas9 system, for which we had RNA transcripts of our sgRNAs. Following transduction of the J-Lats with dspCas9 expressed in a lentiviral vector, cells with the exonuclease were enriched through the use of an antibiotic selection marker. We then electroporated the J-Lats with either of the sgRNAs for the *Streptococcus pyogenes* construct. Five days post electroporation, cells were restimulated using TNF- α . Although treatment with the LRA resulted in a baseline 9-fold increase in HIV-1 RNA as measured by qRT-PCR, this was reduced by more than 50% in the samples treated with the sgRNAs (Figure 4.2).




Figure 4.2: KRAB-Kap1 blocks HIV-1 latency reversal in J-Lat cells. J-Lat cells were transduced with a dCas9-KRAB plasmid within a selection vector. Cells were electroporated with sgRNAs indicated above and reactivated with 10 ng/mL TNFα five days post-electroporation. HIV-1 transcription was measured by qRT-PCR using *gag*-specific primers 24 h after stimulation. Values are shown as fold difference in HIV-1 RNA transcripts over corresponding non-reactivated controls. “sgScramble” refers to the selection of a sgRNA not known to bind to any predicted sequence in the human genome.

DISCUSSION

The use of latency-reversing agents to reactivate transcriptionally silent HIV-1 has so far been unable to eradicate the DNA reservoir in any clinical trial. In fact, most HDACi's have failed to result in any detectable reduction in proviral load (Sagot-Lerolle *et al.*, 2008; Archin *et al.*, 2010; Archin *et al.*, 2012). Efforts to permanently suppress

HIV-1 or to bias an infection during the early stages towards latency must be considered as potential therapeutics.

The most challenging aspect to permanent HIV-1 suppression is our ability to specifically target transcriptional host repressors to the provirus. CRISPR-based gene editing provides a substantial improvement over previous strategies, due to the specificity of its binding and the lack of off-target effects. However, the possibility of viral escape poses a major barrier to its successful use as a nuclease. I propose its adaptation, however, to a delivery system in which it can be used to bring binding partners, such as a KRAB domain, to the proviral genome. Other labs have used a nuclease-deficient Cas9 to deliver an activating domain to the HIV-1 LTR (Zhang *et al.*, 2015; Saayman *et al.*, 2016). While this approach seems feasible, the data presented in Chapter 3 illustrates the challenges at reversing latency once established. Host repressors recruit other transcription factors, which in turn target larger complexes such as HDACs, histone methyltransferases, and polymerase-binding factors such as NELF. In concert with one another, large transcriptional networks and scaffolds are formed, resulting in entrenched heterochromatin (Ivanov *et al.*, 2007; Natarajan *et al.*, 2013; Meier and Brehm, 2014). For instance, evidence exists that Kap1 may operate in conjunction with the newly discovered HUSH complex to silence endogenous retroviral elements in mouse embryonic stem cells (Robbez-Masson *et al.*, 2018). HUSH, or the human silencing hub, has been identified as a restriction factor for HIV-1 and HIV-2 expression and is targeted for ubiquitination by the HIV-2 protein Vpx or Viral Protein X (Chougui *et al.*, 2018;

Yurkovetskiy *et al.*, 2018). Future work will need to be performed to determine if HUSH and Kap1 interact directly or indirectly.

The existence of multiple layers of repressive factors that cooperate to silence HIV-1 expression suggests that the reverse strategy of “block and lock” may be viable (Darcis, Van Driessche and Van Lint, 2017). If we can bias latency towards a specific fate, we may be able to achieve a functional cure through intrinsic entrenchment of this repression. My data indicated that guide RNAs directed specifically against the HIV-1 LTR inhibit viral expression. These guides enabled us to suppress HIV-1 transcription shortly after infection and achieve a more than 50% block to latency reversal in chronically infected cells. The differences in efficacy of different guide RNAs indicate that a cocktail of multiple guides may be necessary to repress viral transcription beyond a point where a patient can interrupt therapy. It is not surprising that the most effective guides overlap with specific binding sites in the HIV-1 LTR, perhaps indicating a dual role of KRAB-Kap1 recruitment and a direct steric hindrance to transcription factor binding.

A major challenge to bringing this approach into clinical trials is the method of cellular delivery. However, multiple labs have seen success with adenovirus-based vectors, and I believe that an approach like this may be reasonable (Platt *et al.*, 2014; Kaminski *et al.*, 2016). Because the system described here does not result in gene deletion, I hypothesize that any of the already rare off-target effects will be minimal and that this strategy poses no risk of hereditary gene editing.

CHAPTER FIVE: DISCUSSION AND FUTURE IMPLICATIONS

Summary of Results

The results described within this dissertation highlight the importance of the cellular and local chromatin environments at the time of HIV-1 infection on the fate of the virus. They also enabled me to verify the hypotheses detailed within the Specific Aims that were listed in the first chapter. For Specific Aim 1, I determined the effect of distinct T cell receptor signal strengths at the time of HIV-1 infection on viral expression within primary cells and reactivation of latent proviruses. To study this, I manipulated the cellular activation state through the use of chimeric antigen receptors that mimicked the endogenous T cell receptor. Through the substitution of single chain variable fragments differing in antigen binding affinity, I modulated the strength of signal that a cell received at the time of viral infection. These CARs intersected the native T cell receptor signaling pathways, as demonstrated by similar global transcriptional changes (Figure 3.2) and increased CD69 expression (Figure 3.3). Further evidence of their effects can be seen via the differences observed in acute HIV-1 expression.

Stimulation of CAR-expressing cells with their cognate Her2 antigen resulted in an increase in viral expression, and this response correlated with the strength of cellular activation (Figure 3.5). However, I detected no similar increase in viral integration, implying that the observed effects were due to post-integration events. I further confirmed these results by direct measurement of RNA transcripts and saw a similar pattern as observed with the luciferase analysis (Figure 3.7).

It was reasonable to assume that cells which expressed higher levels of HIV-1 at early time points would be less likely to also harbor inducible latent proviruses since the total number of integrated proviruses was held constant. However, cells that received the greatest amount of stimulation during viral infection were also the most responsive to latency-reversing agents predicted to activate HIV-1 transcription through different biochemical pathways (Figure 3.9).

To address Specific Aim 2, for which I analyzed the transcriptional landscape of the provirus among cell receiving differential stimulation at the time of HIV-1 infection, I performed chromatin immunoprecipitation. I discovered that the local chromatin environment was open and accessible as measured by histone acetylation regardless of cellular activation. This is in agreement with multiple other studies that revealed a bias towards open chromatin that can be attenuated if host factors involved in nuclear import are knocked out or their interactions with HIV-1 capsid are blocked (Wang *et al.*, 2007; Koh *et al.*, 2013; Sowd *et al.*, 2016). The data in Figure 3.10 indicated that successful polymerase processivity only occurred under high activation conditions in concert with release of the pausing factor NELF from the HIV-1 LTR. Based on this evidence, I concluded that although HIV-1 preferentially integrates into regions of open chromatin, the level of global cellular activation regulates whether host repressors are recruited to the provirus. The lack of responsiveness of the virus within minimally activated cells to secondary stimulation suggests that early association with host repressors results in entrenched transcriptional repression and deep-seated latency.

These results led me to hypothesize that I could bias an infection towards deep-seated latency, which was the basis for Specific Aim 3. I hypothesized that I could use a nuclease-deficient Cas9 construct to recruit host repressors to the provirus and suppress HIV-1 expression. By fusing dCas9 to a KRAB domain, we were able to substantially block HIV-1 expression upon transfection with an HIV-1 plasmid and achieved a greater than 50% reduction in viral protein production after infection (Figure 4.1B). In order to determine whether KRAB-Kap1 could induce permanent repression, we electroporated a J-Lat line bearing both a silent copy of HIV-1 along with a nuclease-deficient Cas9 construct with LTR-specific sgRNAs. Treatment of these cells with TNF- α was not sufficient to achieve substantial viral reactivation as it did in the control condition, in which there was a 9-fold increase in viral protein production (Figure 4.2). This experiments listed here confirm my central hypothesis that the global cellular environment at the time of HIV-1 infection determines the potential for inducible latent infection and that this axis can be bypassed by modification of the local chromatin environment.

Latency: A Goal or an Obstacle?

Based on the data detailed in this defense as well as the failure of multiple clinical trials to clear the entire viral reservoir, I propose that a functional cure of HIV-1 cannot be achieved through latency reversal. There is growing evidence that the latent reservoir is not homogenous, but rather a collection of multiple subsets in which latency is both

regulated by different mechanisms and has differing capacities to be re-activated. I have illustrated here that the level of cellular activation at the time of infection may determine whether latently infected cells are inducible or non-inducible. It has been known for some time that significant portions of the viral reservoir are refractory to standard LRAs in spite of their intact genomic content (Ho *et al.*, 2013; Hosmane *et al.*, 2017). I have argued in this dissertation that the cellular conditions at the time of viral entry determine the long-term fate of the virus and their susceptibility to LRAs. Minimal levels of stimulation, which may be sufficient for viral entry and integration, are inadequate to recruit an activating transcriptional network at the time of infection or to remove a repressive network during secondary stimulation.

The existence of these multiple subsets also calls into question the accepted paradigm of chromatin in establishment of latency. Exactly why I did not detect any changes in histone acetylation are not clear, but my data suggests that initial proviral repression may recruit other host factors, resulting in an entrenched network of chromatin-modifying factors and other repressive complexes. Histone acetylation, then, may be a marker for specific subsets of latently infected cells and not the entire reservoir.

This may explain the discrepancy between the importance of histone acetylation in cell line models and the complete absence of any evidence that histone deacetylase inhibitors can perturb the viral reservoir *in vivo*. However, evidence exists that a cocktail of LRAs including HDACi's result in greater viral reactivation than a single drug, perhaps through interruption of multiple arms of whatever repressive transcriptional network eventually maintains a silent provirus in its latent state.

Regardless, no clinical drug may be capable of clearing the entire viral reservoir. Instead, based on my data indicating that multiple forms of latency exist, I propose that a functional cure may be achieved through treatments that bias infected cells towards deep-seated latency. Virus integrated into cells with the low-affinity chimeric antigen receptors was not easily responsive to PMA or antibodies against the endogenous CD3 and CD28 receptors, which are significantly stronger than any cocktail which may be brought into clinic. It is reasonable to assume then that no biological effect may achieve a greater level of stimulation either. Antigen presentation in the context of an antigen-presenting cell may provide multiple signals but it is unlikely that this interaction would persist for a full day, as in an *in vitro* anti-CD3/CD28 condition. These infected cells then might pose no direct harm to the host, although they may re-seed the latent reservoir through clonal proliferation.

Remaining Mechanistic Questions

My work does not address all suggested mechanisms that contribute to latency such as host integration site, proviral genomic integrity, and transcriptional interference from neighboring genes. Regarding polymerase interference, evidence from our lab has shown that RNAPII read-through from the host promoter contributes little to HIV-1 transcriptional regulation. Through analysis of multiple cell lines with integrated proviruses in differing orientation to the host gene, no differences could be detected in latency reversal (Kaczmarek Michaels *et al.*, 2015). However, binding of NELF appeared

to be the primary regulatory factor in all conditions, in agreement with the evidence presented in Chapter Three. Future work on this project should consist of genomic sequencing to determine if I am polarizing integration sites towards or away from heterochromatic regions under low activation conditions and further PCR analysis to verify the integration of the viral genome, similar to that outlined by the Siliciano group (Bruner *et al.*, 2016).

The Impact of TCR Signaling on T Cell Function and Differentiation

In an effort to verify that signaling through the chimeric antigen receptors recapitulated endogenous TCR signaling cascades, I analyzed the phenotypes of differentially stimulated CD4⁺ T cells in multiple experiments including a microarray and flow analysis of surface markers. In addition to validating the CAR system, these assays raise a number of intriguing questions regarding the impact of signal strength on T cell function. As can be seen in the microarray analysis in Figure 3.2, multiple genes are immediately induced or repressed upon the slightest level of cellular stimulation. These genes, including the transcription factor KLF10, appear to require a low signaling threshold in order to become expressed. Other genes, including IL2, are transcribed in a gradient fashion and directly correlated to the level of upstream activation. Finally, a subset of genes exists, including FOXP3, a differentiation marker for Tregs (Allan *et al.*, 2005), that is induced by robust signaling, only achieved through engagement of the endogenous receptor (Table 3.1).

Instead of the creation of distinct T cell subsets in which all cells that express the same surface antigens have similar gene profiles, our data suggest that there may be a functional spectrum regardless of T cell phenotype. A range of transcriptional activity can exist within the same cell subsets due to varying signaling thresholds that may or may not have been reached. TCR stimulation uniformly results in an expansion of the CCR7⁺ CD45RA⁻ population (Figure 3.4), often indicative of central memory cells (Okada *et al.*, 2008). However, the expression of most gene transcripts in Figure 3.2 are distinctly different between cells stimulated through the low affinity CAR and those activated by antibodies to CD3 and CD28. The impact of signaling on T cell cytokine production, further differentiation, and other functional outcomes within these memory populations may be considerable.

Some of the genes most differentially regulated upon TCR stimulation in Figure 3.2 and Table A.1 (see Appendix) are those involved in either DNA replication, such as the nuclease RNASEH1 and the replication protein RPA3, or metabolism, including the glycolysis enzymes ENO1 and PGK1. The metabolic profiles of T cell subsets and their role within the immune response are of significant interest. For instance, a recent study identified glycolysis-related gene networks as critical to the capacity of T_h17 cells to differentiate into T_h1 cells (Karmaus *et al.*, 2019). Further, it has been shown that the capacity of the host cell to conduct glycolysis is a key regulator of HIV-1 replication (Hegedus, Kavanagh Williamson and Huthoff, 2014) and may itself be increased upon viral infection (Hollenbaugh, Munger and Kim, 2011). My experiments highlight the importance of T cell signaling on both HIV-1 replication and cellular differentiation.

Study Limitations

While the research contained within this dissertation highlights several key mechanisms which regulate latent HIV-1, the findings presented here are in no way intended to be a complete summary of all factors which bias the balance between inducible and non-inducible latent reservoirs. I have thoroughly discussed the impact of signal amplitude on HIV-1 expression, but I have not analyzed signal quality. Future experiments within the Henderson lab will include the mutations of key residues within the CD28 and CD3 ζ signaling domains of the chimeric antigen receptors in order to determine which residues and more importantly which signaling cascades are critical for the increase in HIV-1 expression that is observed upon TCR engagement.

In addition, work done by a fellow graduate student, Kyle Pedro, has indicated that HIV-1 infections in the context of an immunological synapse between a CD4⁺ T cell and a dendritic cell can compensate for suboptimal signaling within the target cell. The exact nature of these compensatory signals, and if inhibitory signals from receptors such as CTLA-4, PD-1, and Tim-3 also modulate the TCR-HIV axis, is not explored here.

I have also not described the nature of timing on HIV-1 infection. It is known that T cell activation prior to viral entry facilitates robust HIV-1 replication; however, the role of weak T cell signaling at this time point has not been fully examined. Minimal cellular activation prior to HIV-1 fusion with the cell membrane may allow for the expression of necessary entry receptors without providing an optimal environment for reverse transcription of the viral RNA genome or transcription of the integrated provirus. For

instance, the Lewin model of HIV-1 latency manipulates cells via treatment with CCL19 and CCL21, which renders them susceptible to HIV-1 integration but is not sufficient for subsequent transcription (Saleh *et al.*, 2007). The fact that the CCL19 receptor CCR7 regulates HIV-1 integration via NF- κ B induction (Saleh *et al.*, 2016), but that this is inadequate for NF- κ B - mediated transcription, provides more evidence for our conclusions regarding the existence of signaling thresholds that control HIV-1 expression. In contrast to the effects of CCR7 ligands, culturing CD4⁺ T cells with IL-7 prior to infection has been shown to provide the necessary stimulation for efficient HIV-1 replication (Steffens *et al.*, 2002), while IL-27 restricts HIV-1 expression in PBMCs (Fakruddin *et al.*, 2007). The level of cellular activation prior to viral entry, and the exact quantity and quality of signaling cascades involved, should be explored in further studies.

My experiments focused on the impact of T cell receptor signaling at the time of infection on HIV-1 expression and latency reversal and revealed that this effect persisted for at least one week. However, latency in the context of a HIV⁺ individual may persist for the entire lifespan of an infected cell. With further optimization of our tunable model to extend the time of survival of CAR⁺ primary CD4⁺ T cells after HIV-1 infection, the Henderson lab will be able to address questions about the dynamics of latency reversal.

In addition, I have not discussed the mechanisms that contribute to HIV-1 latency in other cellular reservoirs. In Chapter One, I discussed the contributions of $\gamma\delta$ T cells and macrophages to HIV-1 persistence. Although evidence exists that establishment and maintenance of HIV-1 latency may require cell-specific factors, I do not address that here. For instance, HIV-1 inhibits apoptosis within infected macrophages by upregulating

the cell survival receptor TREM-1 or Triggering receptor expressed on myeloid cells-1 (Yuan *et al.*, 2017). This is a cell-specific mechanism, which relies upon signals downstream from TREM-1 to establish latency. The Cannon lab also identified the CoREST complex (Corepressor to RE1 silencing transcription factor) as a microglia-specific inhibitor of HIV-1 transcription in humanized mice. Because this is a unique mechanism for silencing of HIV-1 expression, microglia cells are especially responsive to LRAs that disrupt the CoREST complex (Llewellyn *et al.*, 2018). However, my experiments highlight the establishment of HIV-1 latency in CD4+ T cells and the LRAs that may disrupt viral repression in those cells. Future cure efforts will require both the manipulation of the balance between inducible and non-inducible latent CD4+ T cell subsets as well as strategies to target HIV-1 persistence in other cell types.

In regards to the use of nuclease-deficient Cas9-KRAB, I have only presented preliminary data here. I have not described a method of delivery or analyzed any off-target effects. Our lab is currently conducting experiments using multiple forms of latency reversing agents, and our eventual goal is to examine KRAB-Kap1 repression of HIV-1 in primary CD4+ T cells. KRAB-Kap1 is a promising complex for manipulating HIV-1 proviral expression. If we can better understand the function of other cellular host factors, additional key transcription factors might be utilized in a cell-specific manner.

Clinical Implications

A functional cure of HIV-1 would have profound benefits to those living with HIV/AIDS. In spite of all of the progress obtained since the height of the epidemic in the 1980's, a significant portion of the population remains at risk of contracting HIV-1 and living with lifelong immune dysfunction. Challenges at producing a broad-spectrum vaccine or at achieving a clinically viable cure using gene excision remain daunting. Instead, a functional cure, in which a patient can cease antiretroviral therapy for years or decades with only occasional follow-up, represents the gold standard of HIV-1 therapy going forward.

The existence of at least two latent reservoirs, one which is readily inducible to the strongest LRAs *ex vivo* and one which remains refractory to stimulation after multiple challenges (Hosmane *et al.*, 2017), suggests that a complete reversal of all potentially inducible latent proviruses may not be feasible. Instead, I present here the possibility of achieving permanent epigenetic silencing of all integrated HIV-1. Since cellular mechanisms that are recruited at the time of infection have long-term consequences on viral fate, there may be a therapeutic window in which to bias the balance between these two latent populations. My work also suggests that a two-step approach may be required: a cocktail of LRAs taken shortly after infection to remove the most easily reversible proviruses and then a gene editing based technique to further suppress all remaining infections into a deep-seated latency.

The viral reservoir after years of suppressive therapy will not resemble the original population of infected cells. Differences in clonal proliferation and changes to epigenetic marks may alter the chromatin environment so that it no longer mimics the layers of repression observed in the original infected ancestor cells (Zerihun *et al.*, 2015; Wang *et al.*, 2018). However, the ability of KRAB-Kap1 mediated repression to persist despite cellular division (Ayyanathan *et al.*, 2003) suggests that some of the epigenetic changes which occur during a new round of viral infection today may dictate the nature and dynamics of the latent reservoir for the remaining decades of a patient's life. While this poses serious challenges, the research conducted for this dissertation suggests that we may also be able to shape the future latent reservoir in a beneficial manner for the patient.

APPENDIX: MICROARRAY ANALYSIS OF DIFFERENTIALLY STIMULATED CD4+ T CELLS IN CHAPTER THREE

Principal Component Analysis

Principal component analysis was performed on the genes listed as significantly different from the baseline unstimulated CD4+ T cell condition in the microarray shown for Figure 3.2. The separation of samples by treatment along the PC1 axis explains 29% of all variance, while PC2 explains 16% of all variance (Figure A.1). Clear clustering can be seen between all experimental conditions, with the low and high affinity CAR-expressing cells appearing intermediate between the unstimulated and TCR-stimulated groups.




Figure A.1: Magnitude of T cell signaling differentially regulates genes in a gradient fashion.

Signaling from the low affinity and high affinity CAR display an intermediate phenotype between that of the unstimulated and TCR-stimulated conditions. Principal component analysis was performed on all genes listed as significantly differentially expressed between conditions. The percentage of variance across all conditions explained by each principal component axis is listed as a percentage. See also Figure 3.2.

Microarray Analysis

All genes shown in the microarray in Figure 3.2, each of which has a one-way Anova FDR-corrected q value of less than 0.01. Each gene is listed along with its Human Entrez Gene ID, accepted description, and cluster number.

Table A.1: List of genes whose expression is significantly altered upon TCR stimulation. All genes from the microarray listed in Figure 3.2 are described in the following pages. Genes were arbitrarily assigned to clusters based on gene expression patterns.

| Human Entrez Gene ID(s) | Symbol | Description | Cluster |
|-------------------------|----------|---|---------|
| 10952 | SEC61B | Sec61 translocon beta subunit | 1 |
| 51114 | ZDHHC9 | zinc finger DHHC-type containing 9 | 1 |
| 115098 | CCDC124 | coiled-coil domain containing 124 | 1 |
| 64118 | DUS1L | dihydrouridine synthase 1 like | 1 |
| 79644 | SRD5A3 | steroid 5 alpha-reductase 3 | 1 |
| 9643 | MORF4L2 | mortality factor 4 like 2 | 1 |
| 1802 | DPH2 | DPH2 homolog | 1 |
| 150223 | YDJC | YdjC homolog (bacterial) | 1 |
| 54998 | AURKAIP1 | aurora kinase A interacting protein 1 | 1 |
| 7277 | TUBA4A | tubulin alpha 4a | 1 |
| 55004 | LAMTOR1 | late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 | 1 |
| 8321 | FZD1 | frizzled class receptor 1 | 1 |
| 4074 | M6PR | mannose-6-phosphate receptor, cation dependent | 1 |
| 2720 | GLB1 | galactosidase beta 1 | 1 |
| 7469 | NELFA | negative elongation factor complex member A | 1 |
| 60496 | AASDHPPT | aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase | 1 |
| 5479 | PPIB | peptidylprolyl isomerase B | 1 |
| 84337 | ELOF1 | elongation factor 1 homolog | 1 |
| 27314 | RAB30 | RAB30, member RAS oncogene family | 1 |
| 27247 | NFU1 | NFU1 iron-sulfur cluster scaffold | 1 |
| 157922 | CAMSAP1 | calmodulin regulated spectrin associated protein 1 | 1 |
| 51629 | SLC25A39 | solute carrier family 25 member 39 | 1 |
| 64769 | MEAF6 | MYST/Esa1 associated factor 6 | 1 |
| 29081 | METTL5 | methyltransferase like 5 | 1 |
| 58527 | ABRACL | ABRA C-terminal like | 1 |
| 11315 | PARK7 | Parkinsonism associated deglycase | 1 |
| 1233 | CCR4 | C-C motif chemokine receptor 4 | 1 |
| 4726 | NDUFS6 | NADH:ubiquinone oxidoreductase subunit S6 | 1 |
| 6346 | CCL1 | C-C motif chemokine ligand 1 | 1 |
| 28974 | C19orf53 | chromosome 19 open reading frame 53 | 1 |
| 10286 | BCAS2 | breast carcinoma amplified sequence 2 | 1 |
| 5133 | PDCD1 | programmed cell death 1 | 1 |
| 6846 | XCL2 | X-C motif chemokine ligand 2 | 1 |
| 6375 | XCL1 | X-C motif chemokine ligand 1 | 1 |
| 11043 | MID2 | midline 2 | 1 |
| 83443 | SF3B5 | splicing factor 3b subunit 5 | 1 |
| 9764 | KIAA0513 | KIAA0513 | 1 |
| 4697 | NDUFA4 | NDUFA4, mitochondrial complex associated | 1 |
| 55852 | TEX2 | testis expressed 2 | 1 |
| 5777 | PTPN6 | protein tyrosine phosphatase, non-receptor type 6 | 1 |
| 5325 | PLAGL1 | PLAG1 like zinc finger 1 | 1 |
| 928 | CD9 | CD9 molecule | 1 |
| 10897 | YIF1A | Yip1 interacting factor homolog A, membrane trafficking protein | 1 |

| | | | |
|------------------------|----------|--|---|
| 26090 | ABHD12 | abhydrolase domain containing 12 | 1 |
| 89927 | C16orf45 | chromosome 16 open reading frame 45 | 1 |
| 8600 | TNFSF11 | tumor necrosis factor superfamily member 11 | 1 |
| 3394 | IRF8 | interferon regulatory factor 8 | 1 |
| 5606 | MAP2K3 | mitogen-activated protein kinase kinase 3 | 1 |
| 2539 | G6PD | glucose-6-phosphate dehydrogenase | 1 |
| 7074 | TIAM1 | T-cell lymphoma invasion and metastasis 1 | 1 |
| 518 | ATP5G3 | ATP synthase, H+ transporting, mitochondrial Fo complex subunit C3 (subunit 9) | 1 |
| 3732 | CD82 | CD82 molecule | 1 |
| 619279 | ZNF704 | zinc finger protein 704 | 1 |
| 51406 | NOL7 | nucleolar protein 7 | 1 |
| 6500 | SKP1 | S-phase kinase associated protein 1 | 1 |
| 1020 | CDK5 | cyclin dependent kinase 5 | 1 |
| 2787 | GNG5 | G protein subunit gamma 5 | 1 |
| 91582 | RPS19BP1 | ribosomal protein S19 binding protein 1 | 1 |
| 200894 | ARL13B | ADP ribosylation factor like GTPase 13B | 1 |
| 6367 | CCL22 | C-C motif chemokine ligand 22 | 1 |
| 55630 | SLC39A4 | solute carrier family 39 member 4 | 1 |
| 3682 | ITGAE | integrin subunit alpha E | 1 |
| 2589 | GALNT1 | polypeptide N-acetylgalactosaminyltransferase 1 | 1 |
| 22906 | TRAK1 | trafficking kinesin protein 1 | 1 |
| 9562 | MINPP1 | multiple inositol-polyphosphate phosphatase 1 | 1 |
| 5875 | RABGGTA | Rab geranylgeranyltransferase alpha subunit | 1 |
| 2182 | ACSL4 | acyl-CoA synthetase long-chain family member 4 | 1 |
| 5997 | RGS2 | regulator of G-protein signaling 2 | 1 |
| 5066 | PAM | peptidylglycine alpha-amidating monooxygenase | 1 |
| 51096 | UTP18 | UTP18, small subunit processome component | 1 |
| 51726 | DNAJB11 | DnaJ heat shock protein family (Hsp40) member B11 | 1 |
| 3320 | HSP90AA1 | heat shock protein 90 alpha family class A member 1 | 1 |
| 54438 | GFOD1 | glucose-fructose oxidoreductase domain containing 1 | 1 |
| 5569 | PKIA | protein kinase (cAMP-dependent, catalytic) inhibitor alpha | 1 |
| 90441 | ZNF622 | zinc finger protein 622 | 1 |
| 7133 | TNFRSF1B | TNF receptor superfamily member 1B | 1 |
| 27333 | GOLIM4 | golgi integral membrane protein 4 | 1 |
| 134637 | ADAT2 | adenosine deaminase, tRNA specific 2 | 1 |
| 7150 | TOP1 | topoisomerase (DNA) I | 1 |
| 10915 | TCERG1 | transcription elongation regulator 1 | 1 |
| 811 | CALR | calreticulin | 1 |
| 8425 | LTBP4 | latent transforming growth factor beta binding protein 4 | 1 |
| 5450 | POU2AF1 | POU class 2 associating factor 1 | 1 |
| 56253 | CRTAM | cytotoxic and regulatory T-cell molecule | 1 |
| 23305 | ACSL6 | acyl-CoA synthetase long-chain family member 6 | 1 |
| 57472 | CNOT6 | CCR4-NOT transcription complex subunit 6 | 1 |
| 58526 | MID1IP1 | MID1 interacting protein 1 | 1 |
| 11057 | ABHD2 | abhydrolase domain containing 2 | 1 |
| 25822 | DNAJB5 | DnaJ heat shock protein family (Hsp40) member B5 | 1 |
| 9882 | TBC1D4 | TBC1 domain family member 4 | 1 |
| 58493 | INIP | INTS3 and NABP interacting protein | 1 |
| 4023 | LPL | lipoprotein lipase | 1 |
| 79929 | MAP6D1 | MAP6 domain containing 1 | 1 |
| 3904 | LAIR2 | leukocyte associated immunoglobulin like receptor 2 | 1 |
| 11098 | PRSS23 | protease, serine 23 | 1 |
| 23012 | STK38L | serine/threonine kinase 38 like | 1 |
| 11022 | TDRKH | tudor and KH domain containing | 1 |
| 4151 | MB | myoglobin | 1 |
| 26090 | ABHD12 | abhydrolase domain containing 13 | 1 |
| 89927 | C16orf45 | chromosome 16 open reading frame 46 | 1 |
| 8600 | TNFSF11 | tumor necrosis factor superfamily member 12 | 1 |
| 3394 | IRF8 | interferon regulatory factor 9 | 1 |
| 5606 | MAP2K3 | mitogen-activated protein kinase kinase 4 | 1 |
| 2539 | G6PD | glucose-6-phosphate dehydrogenase | 1 |
| 7074 | TIAM1 | T-cell lymphoma invasion and metastasis 2 | 1 |
| 518 | ATP5G3 | ATP synthase, H+ transporting, mitochondrial Fo complex subunit C3 (subunit 9) | 1 |
| 3732 | CD82 | CD82 molecule | 1 |
| 619279 | ZNF704 | zinc finger protein 705 | 1 |

| | | |
|------------------------|----------|--|
| 5683 | PSMA2 | proteasome subunit alpha 2 |
| 5689 | PSMB1 | proteasome subunit beta 1 |
| 10808 | HSPH1 | heat shock protein family H (Hsp110) member 1 |
| 3274 | HRH2 | histamine receptor H2 |
| 10128 | LRPPRC | leucine rich pentatricopeptide repeat containing |
| 1718 | DHCR24 | 24-dehydrocholesterol reductase |
| 84679 | SLC9A7 | solute carrier family 9 member A7 |
| 80185 | TTI2 | TELO2 interacting protein 2 |
| 84890 | ADO | 2-aminoethanethiol dioxygenase |
| 388753 | COA6 | cytochrome c oxidase assembly factor 6 |
| 8140 | SLC7A5 | solute carrier family 7 member 5 |
| 55486 | PARL | presenilin associated rhomboid like |
| 7415 | VCP | valosin containing protein |
| 2180 | ACSL1 | acyl-CoA synthetase long-chain family member 1 |
| 7803 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 |
| 29107 | NXT1 | nuclear transport factor 2 like export factor 1 |
| 53615 | MBD3 | methyl-CpG binding domain protein 3 |
| 84328 | LZIC | leucine zipper and CTNNBIP1 domain containing |
| 51428 | DDX41 | DEAD-box helicase 41 |
| 150678 | COP9 | COP9 signalosome subunit 9 |
| 54915 | YTHDF1 | YTH N6-methyladenosine RNA binding protein 1 |
| 1368 | CPM | carboxypeptidase M |
| 7128 | TNFAIP3 | TNF alpha induced protein 3 |
| 81570 | CLPB | ClpB homolog, mitochondrial AAA ATPase chaperonin |
| 7071 | KLF10 | Kruppel like factor 10 |
| 3725 | JUN | Jun proto-oncogene, AP-1 transcription factor subunit |
| 22827 | PUF60 | poly(U) binding splicing factor 60 |
| 54733 | SLC35F2 | solute carrier family 35 member F2 |
| 2153 | F5 | coagulation factor V |
| 3516 | RBPJ | recombination signal binding protein for immunoglobulin kappa J region |
| 7203 | CCT3 | chaperonin containing TCP1 subunit 3 |
| 4869 | NPM1 | nucleophosmin |
| 22948 | CCT5 | chaperonin containing TCP1 subunit 5 |
| 54888 | NSUN2 | NOP2/Sun RNA methyltransferase family member 2 |
| 11001 | SLC27A2 | solute carrier family 27 member 2 |
| 11169 | WDHD1 | WD repeat and HMG-box DNA binding protein 1 |
| 2107 | ETF1 | eukaryotic translation termination factor 1 |
| 8568 | RRP1 | ribosomal RNA processing 1 |
| 2023 | ENO1 | enolase 1 |
| 50628 | GEMIN4 | gem nuclear organelle associated protein 4 |
| 9322 | TRIP10 | thyroid hormone receptor interactor 10 |
| 84295 | PHF6 | PHD finger protein 6 |
| 9939 | RBM8A | RNA binding motif protein 8A |
| 55605 | KIF21A | kinesin family member 21A |
| 1173 | AP2M1 | adaptor related protein complex 2 mu 1 subunit |
| 9618 | TRAF4 | TNF receptor associated factor 4 |
| 10098 | TSPAN5 | tetraspanin 5 |
| 23246 | BOP1 | block of proliferation 1 |
| 6385 | SDC4 | syndecan 4 |
| 908 | CCT6A | chaperonin containing TCP1 subunit 6A |
| 54206 | ERRFI1 | ERBB receptor feedback inhibitor 1 |
| 28984 | RGCC | regulator of cell cycle |
| 5315 | PKM | pyruvate kinase, muscle |
| 402055 | SRRD | SRR1 domain containing |
| 3028 | HSD17B10 | hydroxysteroid 17-beta dehydrogenase 10 |
| 10783 | NEK6 | NIMA related kinase 6 |
| 26521 | TIMM8B | translocase of inner mitochondrial membrane 8 homolog B |
| 10067 | SCAMP3 | secretory carrier membrane protein 3 |
| 4706 | NDUFAB1 | NADH:ubiquinone oxidoreductase subunit AB1 |
| 10514 | MYBBP1A | MYB binding protein 1a |
| 10541 | ANP32B | acidic nuclear phosphoprotein 32 family member B |
| 27044 | SND1 | staphylococcal nuclease and tudor domain containing 1 |
| 4121 | MAN1A1 | mannosidase alpha class 1A member 1 |
| 3945 | LDHB | lactate dehydrogenase B |
| 84946 | LTV1 | LTV1 ribosome biogenesis factor |

| | | |
|------------------------|----------|--|
| 9456 | HOMER1 | homer scaffolding protein 1 |
| 80896 | NPL | N-acetylneuraminase pyruvate lyase |
| 1026 | CDKN1A | cyclin dependent kinase inhibitor 1A |
| 50615 | IL21R | interleukin 21 receptor |
| 83858 | ATAD3B | ATPase family, AAA domain containing 3B |
| 3326 | HSP90AB1 | heat shock protein 90 alpha family class B member 1 |
| 1493 | CTLA4 | cytotoxic T-lymphocyte associated protein 4 |
| 8444 | DYRK3 | dual specificity tyrosine phosphorylation regulated kinase 3 |
| 23135 | KDM6B | lysine demethylase 6B |
| 23223 | RRP12 | ribosomal RNA processing 12 homolog |
| 25902 | MTHFD1L | methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
| 22856 | CHSY1 | chondroitin sulfate synthase 1 |
| 85458 | DIXDC1 | DIX domain containing 1 |
| 817 | CAMK2D | calcium/calmodulin dependent protein kinase II delta |
| 10252 | SPRY1 | sprouty RTK signaling antagonist 1 |
| 25911 | DPCD | deleted in primary ciliary dyskinesia homolog (mouse) |
| 219 | ALDH1B1 | aldehyde dehydrogenase 1 family member B1 |
| 57213 | SPRYD7 | SPRY domain containing 7 |
| 10171 | RCL1 | RNA terminal phosphate cyclase like 1 |
| 5516 | PPP2CB | protein phosphatase 2 catalytic subunit beta |
| 25929 | GEMIN5 | gem nuclear organelle associated protein 5 |
| 55161 | TMEM33 | transmembrane protein 33 |
| 25778 | DSTYK | dual serine/threonine and tyrosine protein kinase |
| 11338 | U2AF2 | U2 small nuclear RNA auxiliary factor 2 |
| 283871 | PGP | phosphoglycolate phosphatase |
| 8884 | SLC5A6 | solute carrier family 5 member 6 |
| 79586 | CHPF | chondroitin polymerizing factor |
| 283373 | ANKRD52 | ankyrin repeat domain 52 |
| 55319 | TMA16 | translation machinery associated 16 homolog |
| 55269 | PSPC1 | paraspeckle component 1 |
| 7511 | XPNPEP1 | X-prolyl aminopeptidase 1 |
| 1836 | SLC26A2 | solute carrier family 26 member 2 |
| 113251 | LARP4 | La ribonucleoprotein domain family member 4 |
| 9656 | MDC1 | mediator of DNA damage checkpoint 1 |
| 254428 | SLC41A1 | solute carrier family 41 member 1 |
| 8161 | COIL | coilin |
| 65059 | RAPH1 | Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 |
| 8807 | IL18RAP | interleukin 18 receptor accessory protein |
| 10018 | BCL2L11 | BCL2 like 11 |
| 2597 | GAPDH | glyceraldehyde-3-phosphate dehydrogenase |
| 6907 | TBL1X | transducin beta like 1X-linked |
| 9047 | SH2D2A | SH2 domain containing 2A |
| 64759 | TNS3 | tensin 3 |
| 200734 | SPRED2 | sprouty related EVH1 domain containing 2 |
| 6050 | RNH1 | ribonuclease/angiogenin inhibitor 1 |
| 1390 | CREM | cAMP responsive element modulator |
| 4810 | NHS | NHS actin remodeling regulator |
| 969 | CD69 | CD69 molecule |
| 597 | BCL2A1 | BCL2 related protein A1 |
| 1293 | COL6A3 | collagen type VI alpha 3 chain |
| 64218 | SEMA4A | semaphorin 4A |
| 8464 | SUPT3H | SPT3 homolog, SAGA and STAGA complex component |
| 3557 | IL1RN | interleukin 1 receptor antagonist |
| 6319 | SCD | stearoyl-CoA desaturase |
| 10849 | CD3EAP | CD3e molecule associated protein |
| 50 | ACO2 | aconitase 2 |
| 160760 | PPTC7 | PTC7 protein phosphatase homolog |
| 51255 | RNF181 | ring finger protein 181 |
| 90378 | SAMD1 | sterile alpha motif domain containing 1 |
| 191 | AHCY | adenosylhomocysteinase |
| 9446 | GSTO1 | glutathione S-transferase omega 1 |
| 6780 | STAU1 | stauflin double-stranded RNA binding protein 1 |
| 9112 | MTA1 | metastasis associated 1 |
| 2885 | GRB2 | growth factor receptor bound protein 2 |
| 4642 | MYO1D | myosin ID |

| | | | |
|------------------------|------------|---|---|
| 10273 | STUB1 | STIP1 homology and U-box containing protein 1 | 1 |
| 64651 | CSRNP1 | cysteine and serine rich nuclear protein 1 | 1 |
| 22822 | PHLDA1 | pleckstrin homology like domain family A member 1 | 1 |
| 8566 | PDXK | pyridoxal (pyridoxine, vitamin B6) kinase | 1 |
| 8482 | SEMA7A | semaphorin 7A (John Milton Hagen blood group) | 1 |
| 7421 | VDR | vitamin D (1,25- dihydroxyvitamin D3) receptor | 1 |
| 59269 | HIVFP3 | human immunodeficiency virus type I enhancer binding protein 3 | 1 |
| 54602 | NDFIP2 | Nedd4 family interacting protein 2 | 1 |
| 1958 | EGR1 | early growth response 1 | 1 |
| 1846 | DUSP4 | dual specificity phosphatase 4 | 1 |
| 1959 | EGR2 | early growth response 2 | 1 |
| 135228 | CD109 | CD109 molecule | 1 |
| 8013 | NR4A3 | nuclear receptor subfamily 4 group A member 3 | 1 |
| 4345 | CD200 | CD200 molecule | 1 |
| 3604 | TNFRSF9 | TNF receptor superfamily member 9 | 1 |
| 51320 | MEX3C | mex-3 RNA binding family member C | 1 |
| 9645 | MICAL2 | microtubule associated monooxygenase, calponin and LIM domain containing 2 | 1 |
| 5738 | PTGFRN | prostaglandin F2 receptor inhibitor | 1 |
| 6004 | RGS16 | regulator of G-protein signaling 16 | 1 |
| 9669 | EIF5B | eukaryotic translation initiation factor 5B | 1 |
| 3662 | IRF4 | interferon regulatory factor 4 | 1 |
| 57109 | REXO4 | REX4 homolog, 3'-5' exonuclease | 1 |
| 79814 | AGMAT | agmatinase | 1 |
| 55544 | RBM38 | RNA binding motif protein 38 | 1 |
| 9904 | RBM19 | RNA binding motif protein 19 | 1 |
| 10488 | CREB3 | cAMP responsive element binding protein 3 | 1 |
| 4791 | NFKB2 | nuclear factor kappa B subunit 2 | 1 |
| 54874 | FNBP1L | formin binding protein 1 like | 1 |
| 55640 | FLVCR2 | feline leukemia virus subgroup C cellular receptor family member 2 | 1 |
| 9513 | FXR2 | FMR1 autosomal homolog 2 | 1 |
| 29979 | UBQLN1 | ubiquilin 1 | 1 |
| 55341 | LSG1 | large 60S subunit nuclear export GTPase 1 | 1 |
| 9987 | HNRNPDL | heterogeneous nuclear ribonucleoprotein D like | 1 |
| 3783 | KCNN4 | potassium calcium-activated channel subfamily N member 4 | 1 |
| 6520 | SLC3A2 | solute carrier family 3 member 2 | 1 |
| 26574 | AATF | apoptosis antagonizing transcription factor | 1 |
| 56957 | OTUD7B | OTU deubiquitinase 7B | 1 |
| 65094 | JMJD4 | jumonji domain containing 4 | 1 |
| 56270 | WDR45B | WD repeat domain 45B | 1 |
| 5688 | PSMA7 | proteasome subunit alpha 7 | 1 |
| 51042 | ZNF593 | zinc finger protein 593 | 1 |
| 3727 | JUND | JunD proto-oncogene, AP-1 transcription factor subunit | 1 |
| 85437 | ZCRB1 | zinc finger CCHC-type and RNA binding motif containing 1 | 1 |
| 55813 | UTP6 | UTP6, small subunit processome component | 1 |
| 90480 | GADD45GIP1 | GADD45G interacting protein 1 | 1 |
| 5831 | PYCR1 | pyrroline-5-carboxylate reductase 1 | 1 |
| 4643 | MYO1E | myosin IE | 1 |
| 1407 | CRY1 | cryptochrome circadian clock 1 | 1 |
| 1329 | COX5B | cytochrome c oxidase subunit 5B | 1 |
| 7915 | ALDH5A1 | aldehyde dehydrogenase 5 family member A1 | 1 |
| 51529 | ANAPC11 | anaphase promoting complex subunit 11 | 1 |
| 31 | ACACA | acetyl-CoA carboxylase alpha | 1 |
| 57568 | SIPA1L2 | signal induced proliferation associated 1 like 2 | 1 |
| 6599 | SMARCC1 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 1 | 1 |
| 9486 | CHST10 | carbohydrate sulfotransferase 10 | 1 |
| 56938 | ARNTL2 | aryl hydrocarbon receptor nuclear translocator like 2 | 1 |
| 3192 | HNRNPU | heterogeneous nuclear ribonucleoprotein U | 1 |
| 23507 | LRRC8B | leucine rich repeat containing 8 family member B | 1 |
| 26031 | OSBPL3 | oxysterol binding protein like 3 | 1 |
| 7528 | YY1 | YY1 transcription factor | 1 |
| 23429 | RYBP | RING1 and YY1 binding protein | 1 |
| 5591 | PRKDC | protein kinase, DNA-activated, catalytic polypeptide | 1 |
| 7525 | YES1 | YES proto-oncogene 1, Src family tyrosine kinase | 1 |
| 8932 | MBD2 | methyl-CpG binding domain protein 2 | 1 |

| | | |
|------------------------|----------|---|
| 4779 | NFE2L1 | nuclear factor, erythroid 2 like 1 |
| 3054 | HCFC1 | host cell factor C1 |
| 2194 | FASN | fatty acid synthase |
| 28964 | GIT1 | GIT ArfGAP 1 |
| 29886 | SNX8 | sorting nexin 8 |
| 10153 | CEBPZ | CCAAT/enhancer binding protein zeta |
| 79050 | NOC4L | nucleolar complex associated 4 homolog |
| 10400 | PEMT | phosphatidylethanolamine N-methyltransferase |
| 115353 | LRRC42 | leucine rich repeat containing 42 |
| 57478 | USP31 | ubiquitin specific peptidase 31 |
| 1459 | CSNK2A2 | casein kinase 2 alpha 2 |
| 282969 | FUOM | fucose mutarotase |
| 84320 | ACBD6 | acyl-CoA binding domain containing 6 |
| 56259 | CTNBL1 | catenin beta like 1 |
| 254394 | MCM9 | minichromosome maintenance 9 homologous recombination repair factor |
| 4884 | NPTX1 | neuronal pentraxin 1 |
| 10804 | GJB6 | gap junction protein beta 6 |
| 6617 | SNAPC1 | small nuclear RNA activating complex polypeptide 1 |
| 57584 | ARHGAP21 | Rho GTPase activating protein 21 |
| 4763 | NF1 | neurofibromin 1 |
| 7486 | WRN | Werner syndrome RecQ like helicase |
| 11325 | DDX42 | DEAD-box helicase 42 |
| 10975 | UQCRC1 | ubiquinol-cytochrome c reductase, complex III subunit XI |
| 5424 | POLD1 | DNA polymerase delta 1, catalytic subunit |
| 9986 | RCE1 | Ras converting CAAX endopeptidase 1 |
| 90525 | SHF | Src homology 2 domain containing F |
| 55760 | DHX32 | DEAH-box helicase 32 (putative) |
| 1263 | PLK3 | polo like kinase 3 |
| 8651 | SOC3 | suppressor of cytokine signaling 1 |
| 54936 | ADPRHL2 | ADP-ribosylhydrolase like 2 |
| 5531 | PPP4C | protein phosphatase 4 catalytic subunit |
| 23640 | HSPBP1 | HSPA (Hsp70) binding protein 1 |
| 113000 | RPUSD1 | RNA pseudouridylation synthase domain containing 1 |
| 55527 | FEM1A | fem-1 homolog A |
| 1175 | AP2S1 | adaptor related protein complex 2 sigma 1 subunit |
| 148022 | TICAM1 | toll like receptor adaptor molecule 1 |
| 55684 | RABL6 | RAB, member RAS oncogene family-like 6 |
| 8175 | SF3A2 | splicing factor 3a subunit 2 |
| 284106 | CISD3 | CDGSH iron sulfur domain 3 |
| 125988 | C19orf70 | chromosome 19 open reading frame 70 |
| 84134 | TOMM40L | translocase of outer mitochondrial membrane 40 like |
| 5094 | PCBP2 | poly(rC) binding protein 2 |
| 11140 | CDC37 | cell division cycle 37 |
| 2354 | FOSB | FosB proto-oncogene, AP-1 transcription factor subunit |
| 84216 | TMEM117 | transmembrane protein 117 |
| 677 | ZFP36L1 | ZFP36 ring finger protein like 1 |
| 7040 | TGFB1 | transforming growth factor beta 1 |
| 9265 | CYTH3 | cytohesin 3 |
| 80700 | UBXN6 | UBX domain protein 6 |
| 10048 | RANBP9 | RAN binding protein 9 |
| 3560 | IL2RB | interleukin 2 receptor subunit beta |
| 7763 | ZFAND5 | zinc finger AN1-type containing 5 |
| 9249 | DHRS3 | dehydrogenase/reductase 3 |
| 51564 | HDAC7 | histone deacetylase 7 |
| 92558 | BICDL1 | BICD family like cargo adaptor 1 |
| 26262 | TSPAN17 | tetraspanin 17 |
| 54985 | HCFC1R1 | host cell factor C1 regulator 1 |
| 923 | CD6 | CD6 molecule |
| 10625 | IVNS1ABP | influenza virus NS1A binding protein |
| 57062 | DDX24 | DEAD-box helicase 24 |
| 22859 | ADGRL1 | adhesion G protein-coupled receptor L1 |
| 79169 | C1orf35 | chromosome 1 open reading frame 35 |
| 7057 | THBS1 | thrombospondin 1 |
| 1105 | CHD1 | chromodomain helicase DNA binding protein 1 |
| 113246 | C12orf57 | chromosome 12 open reading frame 57 |
| 6193 | RPS5 | ribosomal protein S5 |

| | | |
|------------------------|-----------|--|
| 353322 | ANKRD37 | ankyrin repeat domain 37 |
| 140823 | ROMO1 | reactive oxygen species modulator 1 |
| 401052 | LOC401052 | uncharacterized LOC401052 |
| 10948 | STARD3 | StAR related lipid transfer domain containing 3 |
| 80198 | MUS81 | MUS81 structure-specific endonuclease subunit |
| 1855 | DVL1 | dishevelled segment polarity protein 1 |
| 3556 | IL1RAP | interleukin 1 receptor accessory protein |
| 4602 | MYB | MYB proto-oncogene, transcription factor |
| 8496 | PPFIBP1 | PPFIA binding protein 1 |
| 1960 | EGR3 | early growth response 3 |
| 3164 | NR4A1 | nuclear receptor subfamily 4 group A member 1 |
| 4862 | NPAS2 | neuronal PAS domain protein 2 |
| 2672 | GFI1 | growth factor independent 1 transcriptional repressor |
| 5270 | SERPINE2 | serpin family E member 2 |
| 57190 | SELENON | selenoprotein N |
| 54815 | GATAD2A | GATA zinc finger domain containing 2A |
| 8270 | LAGE3 | L antigen family member 3 |
| 5524 | PTPA | protein phosphatase 2 phosphatase activator |
| 57688 | ZSWIM6 | zinc finger SWIM-type containing 6 |
| 51079 | NDUFA13 | NADH:ubiquinone oxidoreductase subunit A13 |
| 3720 | JARID2 | jumonji and AT-rich interaction domain containing 2 |
| 4851 | NOTCH1 | notch 1 |
| 23326 | USP22 | ubiquitin specific peptidase 22 |
| 6938 | TCF12 | transcription factor 12 |
| 9704 | DXH34 | DEAH-box helicase 34 |
| 26155 | NOC2L | NOC2 like nucleolar associated transcriptional repressor |
| 165 | AEBP1 | AE binding protein 1 |
| 115024 | NT5C3B | 5'-nucleotidase, cytosolic IIIB |
| 10865 | ARID5A | AT-rich interaction domain 5A |
| 26051 | PPP1R16B | protein phosphatase 1 regulatory subunit 16B |
| 728489 | DNLZ | DNL-type zinc finger |
| 8761 | PABPC4 | poly(A) binding protein cytoplasmic 4 |
| 2768 | GNA12 | G protein subunit alpha 12 |
| 6633 | SNRPD2 | small nuclear ribonucleoprotein D2 polypeptide |
| 7265 | TTC1 | tetratricopeptide repeat domain 1 |
| 2879 | GPX4 | glutathione peroxidase 4 |
| 59286 | UBL5 | ubiquitin like 5 |
| 5971 | RELB | RELB proto-oncogene, NF-kB subunit |
| 9092 | SART1 | squamous cell carcinoma antigen recognized by T-cells 1 |
| 23020 | SNRNP200 | small nuclear ribonucleoprotein U5 subunit 200 |
| 123169 | LEO1 | LEO1 homolog, Paf1/RNA polymerase II complex component |
| 3995 | FADS3 | fatty acid desaturase 3 |
| 4298 | MLLT1 | MLLT1, super elongation complex subunit |
| 54926 | UBE2R2 | ubiquitin conjugating enzyme E2 R2 |
| 3984 | LIMK1 | LIM domain kinase 1 |
| 5966 | REL | REL proto-oncogene, NF-kB subunit |
| 10451 | VAV3 | vav guanine nucleotide exchange factor 3 |
| 6713 | SQLE | squalene epoxidase |
| 3309 | HSPA5 | heat shock protein family A (Hsp70) member 5 |
| 79876 | UBA5 | ubiquitin like modifier activating enzyme 5 |
| 2534 | FYN | FYN proto-oncogene, Src family tyrosine kinase |
| 84524 | ZC3H8 | zinc finger CCCH-type containing 8 |
| 56937 | PMEPA1 | prostate transmembrane protein, androgen induced 1 |
| 7016 | TESK1 | testis-specific kinase 1 |
| 7185 | TRAF1 | TNF receptor associated factor 1 |
| 10746 | MAP3K2 | mitogen-activated protein kinase kinase kinase 2 |
| 51429 | SNX9 | sorting nexin 9 |
| 55342 | STRBP | spermatid perinuclear RNA binding protein |
| 56172 | ANKH | ANKH inorganic pyrophosphate transport regulator |
| 54880 | BCOR | BCL6 corepressor |
| 9766 | SUSD6 | sushi domain containing 6 |
| 6722 | SRF | serum response factor |
| 9603 | NFE2L3 | nuclear factor, erythroid 2 like 3 |
| 27161 | AGO2 | argonaute 2, RISC catalytic component |
| 29954 | POMT2 | protein O-mannosyltransferase 2 |

| | | |
|------------------------|----------|---|
| 8428 | STK24 | serine/threonine kinase 24 |
| 10072 | DPP3 | dipeptidyl peptidase 3 |
| 4282 | MIF | macrophage migration inhibitory factor (glycosylation-inhibiting factor) |
| 22876 | INPP5F | inositol polyphosphate-5-phosphatase F |
| 3399 | ID3 | inhibitor of DNA binding 3, HLH protein |
| 26018 | LRIG1 | leucine rich repeats and immunoglobulin like domains 1 |
| 2275 | FHL3 | four and a half LIM domains 3 |
| 153020 | RASGEF1B | RasGEF domain family member 1B |
| 55589 | BMP2K | BMP2 inducible kinase |
| 23683 | PRKD3 | protein kinase D3 |
| 25797 | QPCT | glutaminyl-peptide cyclotransferase |
| 23541 | SEC14L2 | SEC14 like lipid binding 2 |
| 4929 | NR4A2 | nuclear receptor subfamily 4 group A member 2 |
| 55573 | CDV3 | CDV3 homolog |
| 55353 | LAPTM4B | lysosomal protein transmembrane 4 beta |
| 5367 | PMCH | pro-melanin concentrating hormone |
| 9076 | CLDN1 | claudin 1 |
| 3267 | AGFG1 | ArfGAP with FG repeats 1 |
| 27076 | LYPD3 | LY6/PLAUR domain containing 3 |
| 521 | ATP5I | ATP synthase, H ⁺ transporting, mitochondrial Fo complex subunit E |
| 1340 | COX6B1 | cytochrome c oxidase subunit 6B1 |
| 51700 | CYB5R2 | cytochrome b5 reductase 2 |
| 2118 | ETV4 | ETS variant 4 |
| 54935 | DUSP23 | dual specificity phosphatase 23 |
| 6168 | RPL37A | ribosomal protein L37a |
| 79763 | ISOC2 | isochorismatase domain containing 2 |
| 55621 | TRMT1 | tRNA methyltransferase 1 |
| 11267 | SNF8 | SNF8, ESCRT-II complex subunit |
| 1347 | COX7A2 | cytochrome c oxidase subunit 7A2 |
| 79724 | ZNF768 | zinc finger protein 768 |
| 28955 | DEXI | Dexi homolog |
| 10555 | AGPAT2 | 1-acylglycerol-3-phosphate O-acyltransferase 2 |
| 143903 | LAYN | layilin |
| 283209 | PGM2L1 | phosphoglucomutase 2 like 1 |
| 8507 | ENC1 | ectodermal-neural cortex 1 |
| 9749 | PHACTR2 | phosphatase and actin regulator 2 |
| 7390 | UROS | uroporphyrinogen III synthase |
| 84293 | FAM213A | family with sequence similarity 213 member A |
| 169792 | GLIS3 | GLIS family zinc finger 3 |
| 11019 | LIAS | lipoic acid synthetase |
| 9537 | TP53I11 | tumor protein p53 inducible protein 11 |
| 64092 | SAMSN1 | SAM domain, SH3 domain and nuclear localization signals 1 |
| 9398 | CD101 | CD101 molecule |
| 128866 | CHMP4B | charged multivesicular body protein 4B |
| 914 | CD2 | CD2 molecule |
| 56941 | HMCES | 5-hydroxymethylcytosine (hmC) binding, ES cell-specific |
| 2744 | GLS | glutaminase |
| 481 | ATP1B1 | ATPase Na ⁺ /K ⁺ transporting subunit beta 1 |
| 7832 | BTG2 | BTG anti-proliferation factor 2 |
| 121260 | SLC15A4 | solute carrier family 15 member 4 |
| 91647 | ATPAF2 | ATP synthase mitochondrial F1 complex assembly factor 2 |
| 11319 | ECD | ecdysoneless cell cycle regulator |
| 473 | RERE | arginine-glutamic acid dipeptide repeats |
| 6830 | SUPT6H | SPT6 homolog, histone chaperone |
| 10428 | CFDP1 | craniofacial development protein 1 |
| 2969 | GTF2I | general transcription factor Iii |
| 23396 | PIPSK1C | phosphatidylinositol-4-phosphate 5-kinase type 1 gamma |
| 220213 | OTUD1 | OTU deubiquitinase 1 |
| 5937 | RBMS1 | RNA binding motif single stranded interacting protein 1 |
| 60436 | TGIF2 | TGFB induced factor homeobox 2 |
| 4772 | NFATC1 | nuclear factor of activated T-cells 1 |
| 2026 | ENO2 | enolase 2 |
| 6774 | STAT3 | signal transducer and activator of transcription 3 |
| 80233 | FAAP100 | Fanconi anemia core complex associated protein 100 |
| 9859 | CEP170 | centrosomal protein 170 |

| | | | |
|---------------------------|----------|--|---|
| 3091 | HIF1A | hypoxia inducible factor 1 alpha subunit | 1 |
| 26278 | SACS | sacsin molecular chaperone | 1 |
| 8202 | NCOA3 | nuclear receptor coactivator 3 | 1 |
| 4928 | NUP98 | nucleoporin 98 | 1 |
| 3446 | IFNA10 | interferon alpha 10 | 1 |
| 4637 | MYL6 | myosin light chain 6 | 1 |
| 51192 | CKLF | chemokine like factor | 1 |
| 11006 | LILRB4 | leukocyte immunoglobulin like receptor B4 | 1 |
| 29085 | PHPT1 | phosphohistidine phosphatase 1 | 1 |
| 10591 | DNPH1 | 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 | 1 |
| 8871 | SYNJ2 | synaptojanin 2 | 1 |
| 27151 | CPAMD8 | C3 and PZP like, alpha-2-macroglobulin domain containing 8 | 1 |
| 4122 | MAN2A2 | mannosidase alpha class 2A member 2 | 1 |
| 85450 | ITPRIP | inositol 1,4,5-trisphosphate receptor interacting protein | 1 |
| 115708 | TRMT61A | tRNA methyltransferase 61A | 1 |
| 119 | ADD2 | adducin 2 | 1 |
| 100506581 | C16orf95 | chromosome 16 open reading frame 95 | 1 |
| 25814 | ATXN10 | ataxin 10 | 1 |
| 2004 | ELK3 | ELK3, ETS transcription factor | 1 |
| 23670 | TMEM2 | transmembrane protein 2 | 1 |
| 1119 | CHKA | choline kinase alpha | 1 |
| 51530 | ZC3HC1 | zinc finger C3HC-type containing 1 | 1 |
| 84865 | CCDC142 | coiled-coil domain containing 142 | 1 |
| 94104 | PAXBP1 | PAX3 and PAX7 binding protein 1 | 1 |
| 23138 | N4BP3 | NEDD4 binding protein 3 | 1 |
| 55128 | TRIM68 | tripartite motif containing 68 | 1 |
| 8505 | PARG | poly(ADP-ribose) glycohydrolase | 1 |
| 7343 | UBTF | upstream binding transcription factor, RNA polymerase I | 1 |
| 56970 | ATXN7L3 | ataxin 7 like 3 | 1 |
| 2314 | FLII | FLII, actin remodeling protein | 1 |
| 2622 | GAS8 | growth arrest specific 8 | 1 |
| 7090 | TLE3 | transducin like enhancer of split 3 | 1 |
| 64718 | UNKL | unkempt family like zinc finger | 1 |
| 284654 | RSPO1 | R-spondin 1 | 1 |
| 79171 | RBM42 | RNA binding motif protein 42 | 1 |
| 7874 | USP7 | ubiquitin specific peptidase 7 | 1 |
| 9757 | KMT2B | lysine methyltransferase 2B | 1 |
| 37 | ACADVL | acyl-CoA dehydrogenase, very long chain | 1 |
| 26279 | PLA2G2D | phospholipase A2 group IID | 1 |
| 4296 | MAP3K11 | mitogen-activated protein kinase kinase 11 | 1 |
| 5739 | PTGIR | prostaglandin I2 (prostacyclin) receptor (IP) | 1 |
| 9058 | SLC13A2 | solute carrier family 13 member 2 | 1 |
| 79064 | TMEM223 | transmembrane protein 223 | 1 |
| 55206 | SBNO1 | strawberry notch homolog 1 | 1 |
| 24148 | PRPF6 | pre-mRNA processing factor 6 | 1 |
| 2535 | FZD2 | frizzled class receptor 2 | 1 |
| 7259 | TSPYL1 | TSPY like 1 | 1 |
| 8439 | NSMAF | neutral sphingomyelinase activation associated factor | 1 |
| 150946 | GAREM2 | GRB2 associated regulator of MAPK1 subtype 2 | 1 |
| 5213 | PFKM | phosphofructokinase, muscle | 2 |
| 6429 | SRSF4 | serine and arginine rich splicing factor 4 | 2 |
| 60481 | ELOVL5 | ELOVL fatty acid elongase 5 | 2 |
| 966 | CD59 | CD59 molecule | 2 |
| 9276 | COPB2 | coatamer protein complex subunit beta 2 | 2 |
| 51386 | EIF3L | eukaryotic translation initiation factor 3 subunit L | 2 |
| 2072 | ERCC4 | ERCC excision repair 4, endonuclease catalytic subunit | 2 |
| 4358 | MPV17 | MPV17, mitochondrial inner membrane protein | 2 |
| 8655 | DYNLL1 | dynein light chain LC8-type 1 | 2 |
| 80219 | COQ10B | coenzyme Q10B | 2 |
| 8992 | ATP6V0E1 | ATPase H+ transporting V0 subunit e1 | 2 |
| 148203 | ZNF738 | zinc finger protein 738 | 2 |
| 93380 | MMGT1 | membrane magnesium transporter 1 | 2 |
| 51060 | TXNDC12 | thioredoxin domain containing 12 | 2 |
| 6539 | SLC6A12 | solute carrier family 6 member 12 | 2 |
| 388591 | RNF207 | ring finger protein 207 | 2 |

| | | |
|------------------------|----------|--|
| 6727 | SRP14 | signal recognition particle 14 |
| 729852 | UMAD1 | UBAP1-MVB12-associated (UMA) domain containing 1 |
| 80381 | CD276 | CD276 molecule |
| 84258 | SYT3 | synaptotagmin 3 |
| 23251 | KIAA1024 | KIAA1024 |
| 114836 | SLAMF6 | SLAM family member 6 |
| 6207 | RPS13 | ribosomal protein S13 |
| 728798 | FRMPD2B | FERM and PDZ domain containing 2B, pseudogene |
| 51759 | C9orf78 | chromosome 9 open reading frame 78 |
| 8837 | CFLAR | CASP8 and FADD like apoptosis regulator |
| 55012 | PPP2R3C | protein phosphatase 2 regulatory subunit B"gamma |
| 118426 | BORCS5 | BLOC-1 related complex subunit 5 |
| 8804 | CREG1 | cellular repressor of E1A stimulated genes 1 |
| 51008 | ASCC1 | activating signal cointegrator 1 complex subunit 1 |
| 142 | PARP1 | poly(ADP-ribose) polymerase 1 |
| 90355 | C5orf30 | chromosome 5 open reading frame 30 |
| 4802 | NFYC | nuclear transcription factor Y subunit gamma |
| 51188 | SS18L2 | SS18 like 2 |
| 84318 | CCDC77 | coiled-coil domain containing 77 |
| 133015 | PACRGL | PARK2 coregulated like |
| 79691 | QTRT2 | queuine tRNA-ribosyltransferase accessory subunit 2 |
| 10055 | SAE1 | SUMO1 activating enzyme subunit 1 |
| 8030 | CCDC6 | coiled-coil domain containing 6 |
| 3383 | ICAM1 | intercellular adhesion molecule 1 |
| 81691 | LOC81691 | exonuclease NEF-sp |
| 90417 | KNSTRN | kinetochore localized astrin/SPAG5 binding protein |
| 7453 | WARS | tryptophanyl-tRNA synthetase |
| 9232 | PTTG1 | pituitary tumor-transforming 1 |
| 51155 | HN1 | hematological and neurological expressed 1 |
| 11244 | ZHX1 | zinc fingers and homeoboxes 1 |
| 6790 | AURKA | aurora kinase A |
| 7049 | TGFBR3 | transforming growth factor beta receptor 3 |
| 55165 | CEP55 | centrosomal protein 55 |
| 57405 | SPC25 | SPC25, NDC80 kinetochore complex component |
| 221150 | SKA3 | spindle and kinetochore associated complex subunit 3 |
| 157570 | ESCO2 | establishment of sister chromatid cohesion N-acetyltransferase 2 |
| 9055 | PRC1 | protein regulator of cytokinesis 1 |
| 157313 | CDCA2 | cell division cycle associated 2 |
| 51433 | ANAPC5 | anaphase promoting complex subunit 5 |
| 83540 | NUF2 | NUF2, NDC80 kinetochore complex component |
| 9738 | CCP110 | centriolar coiled-coil protein 110 |
| 11183 | MAP4K5 | mitogen-activated protein kinase kinase kinase kinase 5 |
| 22974 | TPX2 | TPX2, microtubule nucleation factor |
| 10112 | KIF20A | kinesin family member 20A |
| 3161 | HMMR | hyaluronan mediated motility receptor |
| 79840 | NHEJ1 | non-homologous end joining factor 1 |
| 3148 | HMGB2 | high mobility group box 2 |
| 9787 | DLGAP5 | DLG associated protein 5 |
| 9212 | AURKB | aurora kinase B |
| 699 | BUB1 | BUB1 mitotic checkpoint serine/threonine kinase |
| 11113 | CIT | citron rho-interacting serine/threonine kinase |
| 51203 | NUSAP1 | nucleolar and spindle associated protein 1 |
| 644 | BLVRA | biliverdin reductase A |
| 9928 | KIF14 | kinesin family member 14 |
| 7153 | TOP2A | topoisomerase (DNA) II alpha |
| 84548 | TMEM185A | transmembrane protein 185A |
| 54842 | MFS5D6 | major facilitator superfamily domain containing 6 |
| 860 | RUNX2 | runt related transcription factor 2 |
| 8501 | SLC43A1 | solute carrier family 43 member 1 |
| 255231 | MCOLN2 | mucolipin 2 |
| 1326 | MAP3K8 | mitogen-activated protein kinase kinase kinase 8 |
| 4818 | NGK7 | natural killer cell granule protein 7 |
| 347734 | SLC35B2 | solute carrier family 35 member B2 |
| 2786 | GNG4 | G protein subunit gamma 4 |
| 6574 | SLC20A1 | solute carrier family 20 member 1 |

| | | | |
|------------------------|-----------|---|---|
| 1889 | ECE1 | endothelin converting enzyme 1 | 2 |
| 54977 | SLC25A38 | solute carrier family 25 member 38 | 2 |
| 55362 | TMEM63B | transmembrane protein 63B | 2 |
| 81562 | LMAN2L | lectin, mannose binding 2 like | 2 |
| 55974 | SLC50A1 | solute carrier family 50 member 1 | 2 |
| 55432 | YOD1 | YOD1 deubiquitinase | 2 |
| 64776 | C11orf1 | chromosome 11 open reading frame 1 | 2 |
| 92335 | STRADA | STE20-related kinase adaptor alpha | 2 |
| 5603 | MAPK13 | mitogen-activated protein kinase 13 | 2 |
| 85235 | HIST1H2AH | histone cluster 1 H2A family member h | 2 |
| 8360 | HIST1H4D | histone cluster 1 H4 family member d | 2 |
| 3017 | HIST1H2BD | histone cluster 1 H2B family member d | 2 |
| 8334 | HIST1H2AC | histone cluster 1 H2A family member c | 2 |
| 3007 | HIST1H1D | histone cluster 1 H1 family member d | 2 |
| 9447 | AIM2 | absent in melanoma 2 | 2 |
| 51510 | CHMP5 | charged multivesicular body protein 5 | 2 |
| 8969 | HIST1H2AG | histone cluster 1 H2A family member g | 2 |
| 8336 | HIST1H2AM | histone cluster 1 H2A family member m | 2 |
| 8339 | HIST1H2BG | histone cluster 1 H2B family member g | 2 |
| 8329 | HIST1H2AI | histone cluster 1 H2A family member i | 2 |
| 3012 | HIST1H2AE | histone cluster 1 H2A family member e | 2 |
| 55145 | THAP1 | THAP domain containing 1 | 2 |
| 55143 | CDCA8 | cell division cycle associated 8 | 2 |
| 1870 | E2F2 | E2F transcription factor 2 | 2 |
| 8365 | HIST1H4H | histone cluster 1 H4 family member h | 2 |
| 10682 | EBP | emopamil binding protein (sterol isomerase) | 2 |
| 51512 | GTSE1 | G2 and S-phase expressed 1 | 2 |
| 8331 | HIST1H2AJ | histone cluster 1 H2A family member j | 2 |
| 64792 | IFT22 | intraflagellar transport 22 | 2 |
| 8342 | HIST1H2BM | histone cluster 1 H2B family member m | 2 |
| 94120 | SYTL3 | synaptotagmin like 3 | 2 |
| 64782 | AEN | apoptosis enhancing nuclease | 2 |
| 64793 | CEP85 | centrosomal protein 85 | 2 |
| 4717 | NDUFC1 | NADH:ubiquinone oxidoreductase subunit C1 | 2 |
| 92815 | HIST3H2A | histone cluster 3 H2A | 2 |
| 291 | SLC25A4 | solute carrier family 25 member 4 | 2 |
| 10459 | MAD2L2 | MAD2 mitotic arrest deficient-like 2 (yeast) | 2 |
| 9242 | MSC | musculin | 2 |
| 332 | BIRC5 | baculoviral IAP repeat containing 5 | 2 |
| 3835 | KIF22 | kinesin family member 22 | 2 |
| 1398 | CRK | CRK proto-oncogene, adaptor protein | 2 |
| 8367 | HIST1H4E | histone cluster 1 H4 family member e | 2 |
| 10945 | KDELRL1 | KDEL endoplasmic reticulum protein retention receptor 1 | 2 |
| 79738 | BBS10 | Bardet-Biedl syndrome 10 | 2 |
| 63931 | MRPS14 | mitochondrial ribosomal protein S14 | 2 |
| 54987 | C1orf123 | chromosome 1 open reading frame 123 | 2 |
| 4090 | SMAD5 | SMAD family member 5 | 2 |
| 55831 | EMC3 | ER membrane protein complex subunit 3 | 2 |
| 255520 | ELMOD2 | ELMO domain containing 2 | 2 |
| 51128 | SAR1B | secretion associated Ras related GTPase 1B | 2 |
| 55140 | ELP3 | elongator acetyltransferase complex subunit 3 | 2 |
| 302 | ANXA2 | annexin A2 | 2 |
| 149420 | PDIK1L | PDLIM1 interacting kinase 1 like | 2 |
| 26586 | CKAP2 | cytoskeleton associated protein 2 | 2 |
| 135114 | HINT3 | histidine triad nucleotide binding protein 3 | 2 |
| 57102 | C12orf4 | chromosome 12 open reading frame 4 | 2 |
| 219790 | RTKN2 | rhotekin 2 | 2 |
| 80067 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 |
| 1654 | DDX3X | DEAD-box helicase 3, X-linked | 2 |
| 151188 | ARL6IP6 | ADP ribosylation factor like GTPase 6 interacting protein 6 | 2 |
| 10313 | RTN3 | reticulon 3 | 2 |
| 150468 | CKAP2L | cytoskeleton associated protein 2 like | 2 |
| 55182 | RNF220 | ring finger protein 220 | 2 |
| 9887 | SMG7 | SMG7, nonsense mediated mRNA decay factor | 2 |
| 5579 | PRKCB | protein kinase C beta | 2 |

| | | | |
|------------------------|----------|---|---|
| 55435 | AP1AR | adaptor related protein complex 1 associated regulatory protein | 2 |
| 253635 | GPATCH11 | G-patch domain containing 11 | 2 |
| 55033 | FKBP14 | FK506 binding protein 14 | 2 |
| 5355 | PLP2 | proteolipid protein 2 | 2 |
| 51227 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 |
| 11321 | GPN1 | GPN-loop GTPase 1 | 2 |
| 51573 | GDE1 | glycerophosphodiester phosphodiesterase 1 | 2 |
| 23786 | BCL2L13 | BCL2 like 13 | 2 |
| 6103 | RPGR | retinitis pigmentosa GTPase regulator | 2 |
| 26263 | FBXO22 | F-box protein 22 | 2 |
| 7163 | TPD52 | tumor protein D52 | 2 |
| 51068 | NMD3 | NMD3 ribosome export adaptor | 2 |
| 51026 | GOLT1B | golgi transport 1B | 2 |
| 122809 | SOCS4 | suppressor of cytokine signaling 4 | 2 |
| 83695 | RHNO1 | RAD9-HUS1-RAD1 interacting nuclear orphan 1 | 2 |
| 26040 | SETBP1 | SET binding protein 1 | 2 |
| 5378 | PMS1 | PMS1 homolog 1, mismatch repair system component | 2 |
| 10641 | NPRL2 | NPR2-like, GATOR1 complex subunit | 2 |
| 84967 | LSM10 | LSM10, U7 small nuclear RNA associated | 2 |
| 9702 | CEP57 | centrosomal protein 57 | 2 |
| 23062 | GGA2 | golgi associated, gamma adaptin ear containing, ARF binding protein 2 | 2 |
| 54780 | NSMCE4A | NSE4 homolog A, SMC5-SMC6 complex component | 2 |
| 199857 | ALG14 | ALG14, UDP-N-acetylglucosaminyltransferase subunit | 2 |
| 28977 | MRPL42 | mitochondrial ribosomal protein L42 | 2 |
| 25996 | REXO2 | RNA exonuclease 2 | 2 |
| 3364 | HUS1 | HUS1 checkpoint clamp component | 2 |
| 134359 | POC5 | POC5 centriolar protein | 2 |
| 64778 | FNDC3B | fibronectin type III domain containing 3B | 2 |
| 256356 | GK5 | glycerol kinase 5 (putative) | 2 |
| 9194 | SLC16A7 | solute carrier family 16 member 7 | 2 |
| 55037 | PTCD3 | pentatricopeptide repeat domain 3 | 2 |
| 8148 | TAF15 | TATA-box binding protein associated factor 15 | 2 |
| 285282 | RABL3 | RAB, member of RAS oncogene family like 3 | 2 |
| 51095 | TRNT1 | tRNA nucleotidyl transferase 1 | 2 |
| 8563 | THOC5 | THO complex 5 | 2 |
| 9317 | PTER | phosphotriesterase related | 2 |
| 1605 | DAG1 | dystroglycan 1 | 2 |
| 83939 | EIF2A | eukaryotic translation initiation factor 2A | 2 |
| 5877 | RABIF | RAB interacting factor | 2 |
| 10923 | SUB1 | SUB1 homolog, transcriptional regulator | 2 |
| 387263 | C6orf120 | chromosome 6 open reading frame 120 | 2 |
| 28972 | SPCS1 | signal peptidase complex subunit 1 | 2 |
| 10463 | SLC30A9 | solute carrier family 30 member 9 | 2 |
| 1974 | EIF4A2 | eukaryotic translation initiation factor 4A2 | 2 |
| 6993 | DYNLT1 | dynein light chain Tctex-type 1 | 2 |
| 285331 | CCDC66 | coiled-coil domain containing 66 | 2 |
| 51691 | LSM8 | LSM8 homolog, U6 small nuclear RNA associated | 2 |
| 84274 | COQ5 | coenzyme Q5, methyltransferase | 2 |
| 9046 | DOK2 | docking protein 2 | 2 |
| 80824 | DUSP16 | dual specificity phosphatase 16 | 2 |
| 11186 | RASSF1 | Ras association domain family member 1 | 2 |
| 9524 | TECR | trans-2,3-enoyl-CoA reductase | 2 |
| 55909 | BIN3 | bridging integrator 3 | 2 |
| 953 | ENTPD1 | ectonucleoside triphosphate diphosphohydrolase 1 | 2 |
| 8530 | CST7 | cystatin F | 2 |
| 11269 | DDX19B | DEAD-box helicase 19B | 2 |
| 8766 | RAB11A | RAB11A, member RAS oncogene family | 2 |
| 25977 | NECAP1 | NECAP endocytosis associated 1 | 2 |
| 2000 | ELF4 | E74 like ETS transcription factor 4 | 2 |
| 11040 | PIM2 | Pim-2 proto-oncogene, serine/threonine kinase | 2 |
| 2585 | GALK2 | galactokinase 2 | 2 |
| 144402 | CPNE8 | copine 8 | 2 |
| 79139 | DERL1 | derlin 1 | 2 |
| 80196 | RNF34 | ring finger protein 34 | 2 |
| 11262 | SP140 | SP140 nuclear body protein | 2 |

| | | |
|------------------------|----------|---|
| 55312 | RFK | riboflavin kinase |
| 64854 | USP46 | ubiquitin specific peptidase 46 |
| 387882 | C12orf75 | chromosome 12 open reading frame 75 |
| 11270 | NRM | nurim (nuclear envelope membrane protein) |
| 896 | CCND3 | cyclin D3 |
| 143888 | KDEL2 | KDEL motif containing 2 |
| 5008 | OSM | oncostatin M |
| 10602 | CDC42EP3 | CDC42 effector protein 3 |
| 54918 | CMTM6 | CKLF like MARVEL transmembrane domain containing 6 |
| 1063 | CENPF | centromere protein F |
| 84243 | ZDHHC18 | zinc finger DHHC-type containing 18 |
| 382 | ARF6 | ADP ribosylation factor 6 |
| 134266 | GRPEL2 | GrpE like 2, mitochondrial |
| 3001 | GZMA | granzyme A |
| 6352 | CCL5 | C-C motif chemokine ligand 5 |
| 55028 | C17orf80 | chromosome 17 open reading frame 80 |
| 23258 | DENND5A | DENN domain containing 5A |
| 56954 | NIT2 | nitrilase family member 2 |
| 93621 | MRFAP1 | Morf4 family associated protein 1 |
| 5347 | PLK1 | polo like kinase 1 |
| 58190 | CTDSP1 | CTD small phosphatase 1 |
| 2014 | EMP3 | epithelial membrane protein 3 |
| 5269 | SERPINB6 | serpin family B member 6 |
| 113802 | HENMT1 | HEN1 methyltransferase homolog 1 |
| 10578 | GNLY | granulysin |
| 5551 | PRF1 | perforin 1 |
| 26610 | ELP4 | elongator acetyltransferase complex subunit 4 |
| 9477 | MED20 | mediator complex subunit 20 |
| 8634 | RTCA | RNA 3'-terminal phosphate cyclase |
| 3428 | IFI16 | interferon gamma inducible protein 16 |
| 63901 | FAM111A | family with sequence similarity 111 member A |
| 55796 | MBNL3 | muscleblind like splicing regulator 3 |
| 2177 | FANCD2 | Fanconi anemia complementation group D2 |
| 86 | ACTL6A | actin like 6A |
| 57696 | DDX55 | DEAD-box helicase 55 |
| 54920 | DUS2 | dihydrouridine synthase 2 |
| 22809 | ATF5 | activating transcription factor 5 |
| 56052 | ALG1 | ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase |
| 51099 | ABHD5 | abhydrolase domain containing 5 |
| 142940 | TRUB1 | TruB pseudouridine synthase family member 1 |
| 23729 | SHPK | sedoheptulokinase |
| 9016 | SLC25A14 | solute carrier family 25 member 14 |
| 10352 | WARS2 | tryptophanyl tRNA synthetase 2, mitochondrial |
| 24140 | FTSJ1 | FtsJ RNA methyltransferase homolog 1 (E. coli) |
| 23463 | ICMT | isoprenylcysteine carboxyl methyltransferase |
| 54974 | THG1L | tRNA-histidine guanylyltransferase 1 like |
| 124808 | CCDC43 | coiled-coil domain containing 43 |
| 5306 | PITPNA | phosphatidylinositol transfer protein alpha |
| 643155 | SMIM15 | small integral membrane protein 15 |
| 51260 | PBDC1 | polysaccharide biosynthesis domain containing 1 |
| 10200 | MPHOSPH6 | M-phase phosphoprotein 6 |
| 283578 | TMED8 | transmembrane p24 trafficking protein family member 8 |
| 79154 | DHRS11 | dehydrogenase/reductase 11 |
| 1743 | DLST | dihydrolipoamide S-succinyltransferase |
| 5277 | PIGA | phosphatidylinositol glycan anchor biosynthesis class A |
| 995 | CDC25C | cell division cycle 25C |
| 3833 | KIFC1 | kinesin family member C1 |
| 1967 | EIF2B1 | eukaryotic translation initiation factor 2B subunit alpha |
| 119392 | SFR1 | SWI5 dependent homologous recombination repair protein 1 |
| 55795 | PCID2 | PCI domain containing 2 |
| 81542 | TMX1 | thioredoxin related transmembrane protein 1 |
| 55215 | FANCI | Fanconi anemia complementation group I |
| 23172 | FAM175B | family with sequence similarity 175 member B |
| 5711 | PSMD5 | proteasome 26S subunit, non-ATPase 5 |
| 153339 | TMEM167A | transmembrane protein 167A |

| | | | |
|------------------------|----------|--|---|
| 3842 | TNPO1 | transportin 1 | 3 |
| 84928 | TMEM209 | transmembrane protein 209 | 3 |
| 51263 | MRPL30 | mitochondrial ribosomal protein L30 | 3 |
| 7327 | UBE2G2 | ubiquitin conjugating enzyme E2 G2 | 3 |
| 23169 | SLC35D1 | solute carrier family 35 member D1 | 3 |
| 10617 | STAMBP | STAM binding protein | 3 |
| 8697 | CDC23 | cell division cycle 23 | 3 |
| 83930 | STARD3NL | STARD3 N-terminal like | 3 |
| 54556 | ING3 | inhibitor of growth family member 3 | 3 |
| 6185 | RPN2 | ribophorin II | 3 |
| 253558 | LCLAT1 | lysocardiolipin acyltransferase 1 | 3 |
| 64710 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 3 |
| 1635 | DCTD | dCMP deaminase | 3 |
| 91687 | CENPL | centromere protein L | 3 |
| 55308 | DDX19A | DEAD-box helicase 19A | 3 |
| 411 | ARSB | arylsulfatase B | 3 |
| 5889 | RAD51C | RAD51 paralog C | 3 |
| 7531 | YWHAE | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon | 3 |
| 79607 | FAM118B | family with sequence similarity 118 member B | 3 |
| 8883 | NAE1 | NEDD8 activating enzyme E1 subunit 1 | 3 |
| 2990 | GUSB | glucuronidase beta | 3 |
| 4076 | CAPRIN1 | cell cycle associated protein 1 | 3 |
| 4841 | NONO | non-POU domain containing, octamer-binding | 3 |
| 23511 | NUP188 | nucleoporin 188 | 3 |
| 54811 | ZNF562 | zinc finger protein 562 | 3 |
| 23279 | NUP160 | nucleoporin 160 | 3 |
| 10146 | G3BP1 | G3BP stress granule assembly factor 1 | 3 |
| 27085 | MTBP | MDM2 binding protein | 3 |
| 23310 | NCAPD3 | non-SMC condensin II complex subunit D3 | 3 |
| 6634 | SNRPD3 | small nuclear ribonucleoprotein D3 polypeptide | 3 |
| 10920 | COPS8 | COP9 signalosome subunit 8 | 3 |
| 1678 | TIMM8A | translocase of inner mitochondrial membrane 8 homolog A (yeast) | 3 |
| 1798 | DPAGT1 | dolichyl-phosphate N-acetylglucosaminophosphotransferase 1 | 3 |
| 79135 | APOO | apolipoprotein O | 3 |
| 3187 | HNRNPH1 | heterogeneous nuclear ribonucleoprotein H1 (H) | 3 |
| 89944 | GLB1L2 | galactosidase beta 1 like 2 | 3 |
| 5096 | PCCB | propionyl-CoA carboxylase beta subunit | 3 |
| 55254 | TMEM39A | transmembrane protein 39A | 3 |
| 6341 | SCO1 | SCO1, cytochrome c oxidase assembly protein | 3 |
| 59067 | IL21 | interleukin 21 | 3 |
| 166968 | MIER3 | MIER family member 3 | 3 |
| 51524 | TMEM138 | transmembrane protein 138 | 3 |
| 7555 | CNBP | CCHC-type zinc finger nucleic acid binding protein | 3 |
| 57645 | POGK | pogo transposable element with KRAB domain | 3 |
| 1622 | DBI | diazepam binding inhibitor, acyl-CoA binding protein | 3 |
| 23741 | EID1 | EP300 interacting inhibitor of differentiation 1 | 3 |
| 84881 | RPUSD4 | RNA pseudouridylation synthase domain containing 4 | 3 |
| 79868 | ALG13 | ALG13, UDP-N-acetylglucosaminyltransferase subunit | 3 |
| 10910 | SUGT1 | SGT1 homolog, MIS12 kinetochore complex assembly co-chaperone | 3 |
| 6902 | TBCA | tubulin folding cofactor A | 3 |
| 51094 | ADIPOR1 | adiponectin receptor 1 | 3 |
| 54534 | MRPL50 | mitochondrial ribosomal protein L50 | 3 |
| 5271 | SERPINF8 | serpin family B member 8 | 3 |
| 51318 | MRPL35 | mitochondrial ribosomal protein L35 | 3 |
| 9978 | RBX1 | ring-box 1 | 3 |
| 5885 | RAD21 | RAD21 cohesin complex component | 3 |
| 9184 | BUB3 | BUB3, mitotic checkpoint protein | 3 |
| 25847 | ANAPC13 | anaphase promoting complex subunit 13 | 3 |
| 25912 | C1orf43 | chromosome 1 open reading frame 43 | 3 |
| 9025 | RNF8 | ring finger protein 8 | 3 |
| 10959 | TMED2 | transmembrane p24 trafficking protein 2 | 3 |
| 1070 | CETN3 | centrin 3 | 3 |
| 7419 | VDAC3 | voltage dependent anion channel 3 | 3 |
| 5356 | PLRG1 | pleiotropic regulator 1 | 3 |
| 54529 | ASNSD1 | asparagine synthetase domain containing 1 | 3 |

| | | | |
|------------------------|------------|--|---|
| 51441 | YTHDF2 | YTH N6-methyladenosine RNA binding protein 2 | 3 |
| 5481 | PPID | peptidylprolyl isomerase D | 3 |
| 23098 | SARM1 | sterile alpha and TIR motif containing 1 | 3 |
| 22907 | DHX30 | DEAH-box helicase 30 | 3 |
| 65220 | NADK | NAD kinase | 3 |
| 201725 | C4orf46 | chromosome 4 open reading frame 46 | 3 |
| 2241 | FER | FER tyrosine kinase | 3 |
| 79598 | CEP97 | centrosomal protein 97 | 3 |
| 23760 | PITPNB | phosphatidylinositol transfer protein beta | 3 |
| 2965 | GTF2H1 | general transcription factor IIH subunit 1 | 3 |
| 6392 | SDHD | succinate dehydrogenase complex subunit D | 3 |
| 10001 | MED6 | mediator complex subunit 6 | 3 |
| 24145 | PANX1 | pannexin 1 | 3 |
| 26985 | AP3M1 | adaptor related protein complex 3 mu 1 subunit | 3 |
| 54853 | WDR55 | WD repeat domain 55 | 3 |
| 9839 | ZEB2 | zinc finger E-box binding homeobox 2 | 3 |
| 5710 | PSMD4 | proteasome 26S subunit, non-ATPase 4 | 3 |
| 284695 | ZNF326 | zinc finger protein 326 | 3 |
| 598 | BCL2L1 | BCL2 like 1 | 3 |
| 29927 | SEC61A1 | Sec61 translocon alpha 1 subunit | 3 |
| 91368 | CDKN2AIPNL | CDKN2A interacting protein N-terminal like | 3 |
| 51639 | SF3B6 | splicing factor 3b subunit 6 | 3 |
| 10483 | SEC23B | Sec23 homolog B, coat complex II component | 3 |
| 6732 | SRPK1 | SRSF protein kinase 1 | 3 |
| 9412 | MED21 | mediator complex subunit 21 | 3 |
| 80777 | CYB5B | cytochrome b5 type B | 3 |
| 5861 | RAB1A | RAB1A, member RAS oncogene family | 3 |
| 84191 | FAM96A | family with sequence similarity 96 member A | 3 |
| 4710 | NDUFB4 | NADH:ubiquinone oxidoreductase subunit B4 | 3 |
| 51538 | ZCCHC17 | zinc finger CCHC-type containing 17 | 3 |
| 7385 | UQCRC2 | ubiquinol-cytochrome c reductase core protein II | 3 |
| 221443 | OARD1 | O-acyl-ADP-ribose deacylase 1 | 3 |
| 55101 | ATP5SL | ATP5S like | 3 |
| 51300 | TIMMDC1 | translocase of inner mitochondrial membrane domain containing 1 | 3 |
| 375 | ARF1 | ADP ribosylation factor 1 | 3 |
| 7979 | SHFM1 | split hand/foot malformation (ectrodactyly) type 1 | 3 |
| 5706 | PSMC6 | proteasome 26S subunit, ATPase 6 | 3 |
| 5092 | PCBD1 | pterin-4 alpha-carbinolamine dehydratase 1 | 3 |
| 58517 | RBM25 | RNA binding motif protein 25 | 3 |
| 10298 | PAK4 | p21 (RAC1) activated kinase 4 | 3 |
| 91942 | NDUFAF2 | NADH:ubiquinone oxidoreductase complex assembly factor 2 | 3 |
| 195827 | AAED1 | AhpC/TSA antioxidant enzyme domain containing 1 | 3 |
| 2960 | GTF2E1 | general transcription factor IIE subunit 1 | 3 |
| 509 | ATP5C1 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 3 |
| 84268 | RPAIN | RPA interacting protein | 3 |
| 8089 | YEATS4 | YEATS domain containing 4 | 3 |
| 9416 | DDX23 | DEAD-box helicase 23 | 3 |
| 466 | ATF1 | activating transcription factor 1 | 3 |
| 55151 | TMEM38B | transmembrane protein 38B | 3 |
| 84964 | ALKBH6 | alkB homolog 6 | 3 |
| 84950 | PRPF38A | pre-mRNA processing factor 38A | 3 |
| 64981 | MRPL34 | mitochondrial ribosomal protein L34 | 3 |
| 1827 | RCAN1 | regulator of calcineurin 1 | 3 |
| 51569 | UFM1 | ubiquitin fold modifier 1 | 3 |
| 57117 | INTS12 | integrator complex subunit 12 | 3 |
| 9588 | PRDX6 | peroxiredoxin 6 | 3 |
| 28978 | TMEM14A | transmembrane protein 14A | 3 |
| 7332 | UBE2L3 | ubiquitin conjugating enzyme E2 L3 | 3 |
| 378 | ARF4 | ADP ribosylation factor 4 | 3 |
| 51495 | HACD3 | 3-hydroxyacyl-CoA dehydratase 3 | 3 |
| 9555 | H2AFY | H2A histone family member Y | 3 |
| 10635 | RAD51AP1 | RAD51 associated protein 1 | 3 |
| 11198 | SUPT16H | SPT16 homolog, facilitates chromatin remodeling subunit | 3 |
| 23595 | ORC3 | origin recognition complex subunit 3 | 3 |
| 30009 | TBX21 | T-box 21 | 3 |

| | | | |
|------------------------|-----------|---|---|
| 5167 | ENPP1 | ectonucleotide pyrophosphatase/phosphodiesterase 1 | 3 |
| 28987 | NOB1 | NIN1/PSMD8 binding protein 1 homolog | 3 |
| 7329 | UBE2I | ubiquitin conjugating enzyme E2 I | 3 |
| 246184 | CDC26 | cell division cycle 26 | 3 |
| 4712 | NDUFB6 | NADH:ubiquinone oxidoreductase subunit B6 | 3 |
| 253782 | CERS6 | ceramide synthase 6 | 3 |
| 11014 | KDEL2 | KDEL endoplasmic reticulum protein retention receptor 2 | 3 |
| 56943 | ENY2 | ENY2, transcription and export complex 2 subunit | 3 |
| 440145 | MZT1 | mitotic spindle organizing protein 1 | 3 |
| 84128 | WDR75 | WD repeat domain 75 | 3 |
| 55660 | PRPF40A | pre-mRNA processing factor 40 homolog A | 3 |
| 23322 | RPGRIP1L | RPGRIP1 like | 3 |
| 3178 | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 | 3 |
| 9275 | BCL7B | BCL tumor suppressor 7B | 3 |
| 65991 | FUNDC2 | FUN14 domain containing 2 | 3 |
| 64794 | DDX31 | DEAD-box helicase 31 | 3 |
| 8798 | DYRK4 | dual specificity tyrosine phosphorylation regulated kinase 4 | 3 |
| 55315 | SLC29A3 | solute carrier family 29 member 3 | 3 |
| 219541 | MED19 | mediator complex subunit 19 | 3 |
| 729993 | SHISA9 | shisa family member 9 | 3 |
| 8394 | PIP5K1A | phosphatidylinositol-4-phosphate 5-kinase type 1 alpha | 3 |
| 93487 | MAPK11P1L | mitogen-activated protein kinase 1 interacting protein 1 like | 3 |
| 25994 | HIGD1A | HIG1 hypoxia inducible domain family member 1A | 3 |
| 87178 | PNPT1 | polyribonucleotide nucleotidyltransferase 1 | 3 |
| 6629 | SNRPB2 | small nuclear ribonucleoprotein polypeptide B2 | 3 |
| 25879 | DCAF13 | DDB1 and CUL4 associated factor 13 | 3 |
| 134430 | WDR36 | WD repeat domain 36 | 3 |
| 23658 | LSM5 | LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated | 3 |
| 9128 | PRPF4 | pre-mRNA processing factor 4 | 3 |
| 8891 | EIF2B3 | eukaryotic translation initiation factor 2B subunit gamma | 3 |
| 10269 | ZMPSTE24 | zinc metalloproteinase STE24 | 3 |
| 498 | ATP5A1 | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle | 3 |
| 1738 | DLD | dihydrolipoamide dehydrogenase | 3 |
| 54332 | GDAP1 | ganglioside induced differentiation associated protein 1 | 3 |
| 85465 | SELENOI | selenoprotein I | 3 |
| 5701 | PSMC2 | proteasome 26S subunit, ATPase 2 | 3 |
| 3035 | HARS | histidyl-tRNA synthetase | 3 |
| 55361 | PI4K2A | phosphatidylinositol 4-kinase type 2 alpha | 3 |
| 5687 | PSMA6 | proteasome subunit alpha 6 | 3 |
| 23016 | EXOSC7 | exosome component 7 | 3 |
| 214 | ALCAM | activated leukocyte cell adhesion molecule | 3 |
| 2108 | ETFA | electron transfer flavoprotein alpha subunit | 3 |
| 29960 | MRM2 | mitochondrial rRNA methyltransferase 2 | 3 |
| 5690 | PSMB2 | proteasome subunit beta 2 | 3 |
| 3735 | KARS | lysyl-tRNA synthetase | 3 |
| 10666 | CD226 | CD226 molecule | 3 |
| 10237 | SLC35B1 | solute carrier family 35 member B1 | 3 |
| 80218 | NAA50 | N(alpha)-acetyltransferase 50, NatE catalytic subunit | 3 |
| 57476 | GRAMD1B | GRAM domain containing 1B | 3 |
| 10376 | TUBA1B | tubulin alpha 1b | 3 |
| 11102 | RPP14 | ribonuclease P/MRP subunit p14 | 3 |
| 11340 | EXOSC8 | exosome component 8 | 3 |
| 6717 | SRI | sorcin | 3 |
| 2395 | FXN | frataxin | 3 |
| 8872 | CDC123 | cell division cycle 123 | 3 |
| 8533 | COP3 | COP9 signalosome subunit 3 | 3 |
| 79869 | CPSF7 | cleavage and polyadenylation specific factor 7 | 3 |
| 493856 | CISD2 | CDGSH iron sulfur domain 2 | 3 |
| 9319 | TRIP13 | thyroid hormone receptor interactor 13 | 3 |
| 54927 | CHCHD3 | coiled-coil-helix-coiled-coil-helix domain containing 3 | 3 |
| 10042 | HMGXB4 | HMG-box containing 4 | 3 |
| 55787 | TXLNG | taxilin gamma | 3 |
| 4522 | MTHFD1 | methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 | 3 |

| | | | |
|------------------------|----------|---|---|
| 10007 | GNPDA1 | glucosamine-6-phosphate deaminase 1 | 3 |
| 10229 | COQ7 | coenzyme Q7, hydroxylase | 3 |
| 2079 | ERH | enhancer of rudimentary homolog (Drosophila) | 3 |
| 29796 | UQCR10 | ubiquinol-cytochrome c reductase, complex III subunit X | 3 |
| 5705 | PSMC5 | proteasome 26S subunit, ATPase 5 | 3 |
| 128061 | C1orf131 | chromosome 1 open reading frame 131 | 3 |
| 10284 | SAP18 | Sin3A associated protein 18 | 3 |
| 3015 | H2AFZ | H2A histone family member Z | 3 |
| 54957 | TXNL4B | thioredoxin like 4B | 3 |
| 10944 | C11orf58 | chromosome 11 open reading frame 58 | 3 |
| 23788 | MTCH2 | mitochondrial carrier 2 | 3 |
| 6118 | RPA2 | replication protein A2 | 3 |
| 65260 | COA7 | cytochrome c oxidase assembly factor 7 (putative) | 3 |
| 3419 | IDH3A | isocitrate dehydrogenase 3 (NAD(+)) alpha | 3 |
| 285381 | DPH3 | diphthamide biosynthesis 3 | 3 |
| 11103 | KRR1 | KRR1, small subunit processome component homolog | 3 |
| 56942 | CMC2 | C-X9-C motif containing 2 | 3 |
| 5440 | POLR2K | RNA polymerase II subunit K | 3 |
| 326625 | MMAB | methylmalonic aciduria (cobalamin deficiency) cblB type | 3 |
| 23587 | ELP5 | elongator acetyltransferase complex subunit 5 | 3 |
| 57129 | MRPL47 | mitochondrial ribosomal protein L47 | 3 |
| 51202 | DDX47 | DEAD-box helicase 47 | 3 |
| 80273 | GRPEL1 | GrpE like 1, mitochondrial | 3 |
| 79017 | GGCT | gamma-glutamylcyclotransferase | 3 |
| 401505 | TOMM5 | translocase of outer mitochondrial membrane 5 | 3 |
| 7353 | UFD1L | ubiquitin fusion degradation 1 like (yeast) | 3 |
| 54205 | CYCS | cytochrome c, somatic | 3 |
| 10289 | EIF1B | eukaryotic translation initiation factor 1B | 3 |
| 124637 | CYB5D1 | cytochrome b5 domain containing 1 | 3 |
| 27429 | HTRA2 | HtrA serine peptidase 2 | 3 |
| 5691 | PSMB3 | proteasome subunit beta 3 | 3 |
| 8683 | SRSF9 | serine and arginine rich splicing factor 9 | 3 |
| 78996 | C7orf49 | chromosome 7 open reading frame 49 | 3 |
| 81892 | SLRP | SRA stem-loop interacting RNA binding protein | 3 |
| 30968 | STOML2 | stomatin like 2 | 3 |
| 55052 | MRPL20 | mitochondrial ribosomal protein L20 | 3 |
| 441531 | PGAM4 | phosphoglycerate mutase family member 4 | 3 |
| 7019 | TFAM | transcription factor A, mitochondrial | 3 |
| 55239 | OGFOD1 | 2-oxoglutarate and iron dependent oxygenase domain containing 1 | 3 |
| 5515 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 3 |
| 4361 | MRE11A | MRE11 homolog A, double strand break repair nuclease | 3 |
| 5718 | PSMD12 | proteasome 26S subunit, non-ATPase 12 | 3 |
| 4528 | MTIF2 | mitochondrial translational initiation factor 2 | 3 |
| 10576 | CCT2 | chaperonin containing TCP1 subunit 2 | 3 |
| 529 | ATP6V1E1 | ATPase H+ transporting V1 subunit E1 | 3 |
| 150274 | HSCB | HscB mitochondrial iron-sulfur cluster cochaperone | 3 |
| 140609 | NEK7 | NIMA related kinase 7 | 3 |
| 113444 | SMIM12 | small integral membrane protein 12 | 3 |
| 10197 | PSME3 | proteasome activator subunit 3 | 3 |
| 152519 | NIPAL1 | NIPA like domain containing 1 | 3 |
| 506 | ATP5B | ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide | 3 |
| 5692 | PSMB4 | proteasome subunit beta 4 | 3 |
| 92400 | RBM18 | RNA binding motif protein 18 | 3 |
| 5110 | PCMT1 | protein-L-isoaspartate (D-aspartate) O-methyltransferase | 3 |
| 10480 | EIF3M | eukaryotic translation initiation factor 3 subunit M | 3 |
| 4520 | MTF1 | metal regulatory transcription factor 1 | 3 |
| 526 | ATP6V1B2 | ATPase H+ transporting V1 subunit B2 | 3 |
| 7319 | UBE2A | ubiquitin conjugating enzyme E2 A | 3 |
| 4836 | NMT1 | N-myristoyltransferase 1 | 3 |
| 54470 | ARMCX6 | armadillo repeat containing, X-linked 6 | 3 |
| 56852 | RAD18 | RAD18, E3 ubiquitin protein ligase | 3 |
| 10436 | EMG1 | EMG1, N1-specific pseudouridine methyltransferase | 3 |
| 4704 | NDUFA9 | NADH:ubiquinone oxidoreductase subunit A9 | 3 |
| 27257 | LSM1 | LSM1 homolog, mRNA degradation associated | 3 |
| 79719 | AAGAB | alpha- and gamma-adaptin binding protein | 3 |
| 25904 | CNOT10 | CCR4-NOT transcription complex subunit 10 | 3 |

| | | |
|------------------------|-----------|--|
| 8892 | EIF2B2 | eukaryotic translation initiation factor 2B subunit beta |
| 892 | CCNC | cyclin C |
| 169200 | TMEM64 | transmembrane protein 64 |
| 56984 | PSMG2 | proteasome assembly chaperone 2 |
| 223 | ALDH9A1 | aldehyde dehydrogenase 9 family member A1 |
| 9330 | GTF3C3 | general transcription factor IIIC subunit 3 |
| 6184 | RPN1 | ribophorin I |
| 116228 | COX20 | COX20, cytochrome c oxidase assembly factor |
| 9967 | THRAP3 | thyroid hormone receptor associated protein 3 |
| 4725 | NDUFS5 | NADH:ubiquinone oxidoreductase subunit S5 |
| 80135 | RPF1 | ribosome production factor 1 homolog |
| 5501 | PPP1CC | protein phosphatase 1 catalytic subunit gamma |
| 28511 | NKIRAS2 | NFKB inhibitor interacting Ras like 2 |
| 51234 | EMC4 | ER membrane protein complex subunit 4 |
| 10671 | DCTN6 | dynactin subunit 6 |
| 2631 | GBAS | glioblastoma amplified sequence |
| 23306 | NEMP1 | nuclear envelope integral membrane protein 1 |
| 10799 | RPP40 | ribonuclease P/MRP subunit p40 |
| 57563 | KLHL8 | kelch like family member 8 |
| 328 | APEX1 | apurinic/aprimidinic endodeoxyribonuclease 1 |
| 90701 | SEC11C | SEC11 homolog C, signal peptidase complex subunit |
| 23480 | SEC61G | Sec61 translocon gamma subunit |
| 8819 | SAP30 | Sin3A associated protein 30 |
| 52 | ACP1 | acid phosphatase 1, soluble |
| 1349 | COX7B | cytochrome c oxidase subunit 7B |
| 7386 | UQCRF51 | ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
| 26355 | FAM162A | family with sequence similarity 162 member A |
| 29074 | MRPL18 | mitochondrial ribosomal protein L18 |
| 79036 | KXD1 | KxDL motif containing 1 |
| 26156 | RSL1D1 | ribosomal L1 domain containing 1 |
| 55505 | NOP10 | NOP10 ribonucleoprotein |
| 522 | ATP5J | ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6 |
| 387521 | TMEM189 | transmembrane protein 189 |
| 5547 | PRCP | prolylcarboxypeptidase |
| 26995 | TRUB2 | TruB pseudouridine synthase family member 2 |
| 153527 | ZMAT2 | zinc finger matrin-type 2 |
| 84126 | ATRIP | ATR interacting protein |
| 201931 | TMEM192 | transmembrane protein 192 |
| 4719 | NDUFS1 | NADH:ubiquinone oxidoreductase core subunit S1 |
| 27095 | TRAPPC3 | trafficking protein particle complex 3 |
| 9217 | VAPB | VAMP associated protein B and C |
| 10548 | TM9SF1 | transmembrane 9 superfamily member 1 |
| 55110 | MAGOHB | mago homolog B, exon junction complex core component |
| 9512 | PMPCB | peptidase, mitochondrial processing beta subunit |
| 58505 | OSTC | oligosaccharyltransferase complex non-catalytic subunit |
| 55071 | C9orf40 | chromosome 9 open reading frame 40 |
| 29086 | BABAM1 | BRISC and BRCA1 A complex member 1 |
| 327 | APEH | acylaminoacyl-peptide hydrolase |
| 221120 | ALKBH3 | alkB homolog 3, alpha-ketoglutaratedependent dioxygenase |
| 79109 | MAPKAP1 | mitogen-activated protein kinase associated protein 1 |
| 375444 | C5orf34 | chromosome 5 open reading frame 34 |
| 113829 | SLC35A4 | solute carrier family 35 member A4 |
| 8350 | HIST1H3A | histone cluster 1 H3 family member a |
| 79760 | GEMIN7 | gem nuclear organelle associated protein 7 |
| 79002 | C19orf43 | chromosome 19 open reading frame 43 |
| 8407 | TAGLN2 | transgelin 2 |
| 5805 | PTS | 6-pyruvoyltetrahydropterin synthase |
| 8226 | PUDP | pseudouridine 5'-phosphatase |
| 8330 | HIST1H2AK | histone cluster 1 H2A family member k |
| 6944 | VPS72 | vacuolar protein sorting 72 homolog |
| 22913 | RALY | RALY heterogeneous nuclear ribonucleoprotein |
| 9793 | CKAP5 | cytoskeleton associated protein 5 |
| 11065 | UBE2C | ubiquitin conjugating enzyme E2 C |
| 81605 | URM1 | ubiquitin related modifier 1 |
| 6388 | SDF2 | stromal cell derived factor 2 |

| | | | |
|------------------------|-----------|---|---|
| 8970 | HIST1H2BJ | histone cluster 1 H2B family member j | 3 |
| 8345 | HIST1H2BH | histone cluster 1 H2B family member h | 3 |
| 2491 | CENPI | centromere protein I | 3 |
| 5090 | PBX3 | PBX homeobox 3 | 3 |
| 24137 | KIF4A | kinesin family member 4A | 3 |
| 50943 | FOXP3 | forkhead box P3 | 3 |
| 8346 | HIST1H2BI | histone cluster 1 H2B family member i | 3 |
| 8357 | HIST1H3H | histone cluster 1 H3 family member h | 3 |
| 8368 | HIST1H4L | histone cluster 1 H4 family member l | 3 |
| 8355 | HIST1H3G | histone cluster 1 H3 family member g | 3 |
| 8348 | HIST1H2BO | histone cluster 1 H2B family member o | 3 |
| 734 | OSGIN2 | oxidative stress induced growth inhibitor family member 2 | 3 |
| 968 | CD68 | CD68 molecule | 3 |
| 11004 | KIF2C | kinesin family member 2C | 3 |
| 80222 | TARS2 | threonyl-tRNA synthetase 2, mitochondrial (putative) | 3 |
| 81603 | TRIM8 | tripartite motif containing 8 | 3 |
| 123606 | NIPA1 | non imprinted in Prader-Willi/Angelman syndrome 1 | 3 |
| 6046 | BRD2 | bromodomain containing 2 | 3 |
| 3006 | HIST1H1C | histone cluster 1 H1 family member c | 3 |
| 29916 | SNX11 | sorting nexin 11 | 3 |
| 9817 | KEAP1 | kelch like ECH associated protein 1 | 3 |
| 3996 | LLGL1 | LLGL1, scribble cell polarity complex component | 3 |
| 5827 | PXMP2 | peroxisomal membrane protein 2 | 3 |
| 318 | NUDT2 | nudix hydrolase 2 | 3 |
| 117177 | RAB3IP | RAB3A interacting protein | 3 |
| 80227 | PAAF1 | proteasomal ATPase associated factor 1 | 3 |
| 116064 | LRRC58 | leucine rich repeat containing 58 | 3 |
| 56890 | MDM1 | Mdm1 nuclear protein | 3 |
| 84058 | WDR54 | WD repeat domain 54 | 3 |
| 4087 | SMAD2 | SMAD family member 2 | 3 |
| 899 | CCNF | cyclin F | 3 |
| 8349 | HIST2H2BE | histone cluster 2 H2B family member e | 3 |
| 84193 | SETD3 | SET domain containing 3 | 3 |
| 140901 | STK35 | serine/threonine kinase 35 | 3 |
| 55704 | CCDC88A | coiled-coil domain containing 88A | 3 |
| 23132 | RAD54L2 | RAD54-like 2 (S. cerevisiae) | 3 |
| 56672 | AKIP1 | A-kinase interacting protein 1 | 3 |
| 11218 | DDX20 | DEAD-box helicase 20 | 3 |
| 27291 | R3HCC1L | R3H domain and coiled-coil containing 1 like | 3 |
| 874 | CBR3 | carbonyl reductase 3 | 3 |
| 84959 | UBASH3B | ubiquitin associated and SH3 domain containing B | 3 |
| 10134 | BCAP31 | B-cell receptor-associated protein 31 | 3 |
| 4968 | OGG1 | 8-oxoguanine DNA glycosylase | 3 |
| 415116 | PIM3 | Pim-3 proto-oncogene, serine/threonine kinase | 3 |
| 80199 | FUZ | fuzzy planar cell polarity protein | 3 |
| 967 | CD63 | CD63 molecule | 3 |
| 84232 | MAF1 | MAF1 homolog, negative regulator of RNA polymerase III | 3 |
| 572 | BAD | BCL2 associated agonist of cell death | 3 |
| 26608 | TBL2 | transducin beta like 2 | 3 |
| 5538 | PPT1 | palmitoyl-protein thioesterase 1 | 3 |
| 3008 | HIST1H1E | histone cluster 1 H1 family member e | 3 |
| 65062 | TMEM237 | transmembrane protein 237 | 3 |
| 8294 | HIST1H4I | histone cluster 1 H4 family member i | 3 |
| 8335 | HIST1H2AB | histone cluster 1 H2A family member b | 3 |
| 3024 | HIST1H1A | histone cluster 1 H1 family member a | 3 |
| 439 | ASNA1 | arsA arsenite transporter, ATP-binding, homolog 1 (bacterial) | 3 |
| 2805 | GOT1 | glutamic-oxaloacetic transaminase 1 | 3 |
| 57539 | WDR35 | WD repeat domain 35 | 3 |
| 163786 | SASS6 | SAS-6 centriolar assembly protein | 3 |
| 3189 | HNRNP3 | heterogeneous nuclear ribonucleoprotein H3 | 3 |
| 85236 | HIST1H2BK | histone cluster 1 H2B family member k | 3 |
| 5881 | RAC3 | ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) | 3 |
| 10614 | HEXIM1 | hexamethylene bisacetamide inducible 1 | 3 |
| 283464 | GXYLT1 | glucoside xylosyltransferase 1 | 3 |

| | | |
|------------------------|-----------|---|
| 3014 | H2AFX | H2A histone family member X |
| 25853 | DCAF12 | DDB1 and CUL4 associated factor 12 |
| 56994 | CHPT1 | choline phosphotransferase 1 |
| 9551 | ATP5J2 | ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2 |
| 27304 | MOCS3 | molybdenum cofactor synthesis 3 |
| 113130 | CDCA5 | cell division cycle associated 5 |
| 81887 | LAS1L | LAS1 like, ribosome biogenesis factor |
| 5201 | PFDN1 | prefoldin subunit 1 |
| 91057 | CCDC34 | coiled-coil domain containing 34 |
| 468 | ATF4 | activating transcription factor 4 |
| 161823 | ADAL | adenosine deaminase like |
| 55723 | ASF1B | anti-silencing function 1B histone chaperone |
| 91442 | FAAP24 | Fanconi anemia core complex associated protein 24 |
| 220002 | CYB561A3 | cytochrome b561 family member A3 |
| 84759 | PCGF1 | polycomb group ring finger 1 |
| 112950 | MED8 | mediator complex subunit 8 |
| 587 | BCAT2 | branched chain amino acid transaminase 2 |
| 643 | CXCR5 | C-X-C motif chemokine receptor 5 |
| 55794 | DDX28 | DEAD-box helicase 28 |
| 6470 | SHMT1 | serine hydroxymethyltransferase 1 |
| 10651 | MTX2 | metaxin 2 |
| 54921 | CHTF8 | chromosome transmission fidelity factor 8 |
| 51283 | BFAR | bifunctional apoptosis regulator |
| 57456 | KIAA1143 | KIAA1143 |
| 54995 | OXSM | 3-oxoacyl-ACP synthase, mitochondrial |
| 79102 | RNF26 | ring finger protein 26 |
| 79000 | AUNIP | aurora kinase A and ninein interacting protein |
| 4947 | OAZ2 | ornithine decarboxylase antizyme 2 |
| 25979 | DHRS7B | dehydrogenase/reductase 7B |
| 23052 | ENDOD1 | endonuclease domain containing 1 |
| 728568 | C12orf73 | chromosome 12 open reading frame 73 |
| 54890 | ALKBH5 | alkB homolog 5, RNA demethylase |
| 348793 | WDR53 | WD repeat domain 53 |
| 57045 | TWSG1 | twisted gastrulation BMP signaling modulator 1 |
| 84844 | PHF5A | PHD finger protein 5A |
| 79228 | THOC6 | THO complex 6 |
| 27235 | COQ2 | coenzyme Q2, polyprenyltransferase |
| 170371 | C10orf128 | chromosome 10 open reading frame 128 |
| 1861 | TOR1A | torsin family 1 member A |
| 150771 | ITPR1L1 | inositol 1,4,5-trisphosphate receptor interacting protein-like 1 |
| 56180 | MOSPD1 | motile sperm domain containing 1 |
| 4702 | NDUFA8 | NADH:ubiquinone oxidoreductase subunit A8 |
| 55246 | CCDC25 | coiled-coil domain containing 25 |
| 5684 | PSMA3 | proteasome subunit alpha 3 |
| 54942 | FAM206A | family with sequence similarity 206 member A |
| 9836 | LCMT2 | leucine carboxyl methyltransferase 2 |
| 55344 | PLCXD1 | phosphatidylinositol specific phospholipase C X domain containing 1 |
| 49854 | ZBTB21 | zinc finger and BTB domain containing 21 |
| 25926 | NOL11 | nucleolar protein 11 |
| 1854 | DUT | deoxyuridine triphosphatase |
| 662 | BNIP1 | BCL2 interacting protein 1 |
| 29928 | TIMM22 | translocase of inner mitochondrial membrane 22 homolog |
| 78988 | MRPL57 | mitochondrial ribosomal protein L57 |
| 121642 | ALKBH2 | alkB homolog 2, alpha-ketoglutarate dependent dioxygenase |
| 10535 | RNASEH2A | ribonuclease H2 subunit A |
| 339230 | CCDC137 | coiled-coil domain containing 137 |
| 51399 | TRAPPC4 | trafficking protein particle complex 4 |
| 23239 | PHLPP1 | PH domain and leucine rich repeat protein phosphatase 1 |
| 23212 | RRS1 | ribosome biogenesis regulator homolog |
| 26520 | TIMM9 | translocase of inner mitochondrial membrane 9 |
| 84879 | MFS2A | major facilitator superfamily domain containing 2A |
| 28973 | MRPS18B | mitochondrial ribosomal protein S18B |
| 118472 | ZNFS11 | zinc finger protein 511 |
| 8531 | YBX3 | Y-box binding protein 3 |
| 746 | TMEM258 | transmembrane protein 258 |

| | | |
|------------------------|----------|---|
| 147007 | TMEM199 | transmembrane protein 199 |
| 55829 | SELENOS | selenoprotein S |
| 23478 | SEC11A | SEC11 homolog A, signal peptidase complex subunit |
| 5713 | PSMD7 | proteasome 26S subunit, non-ATPase 7 |
| 65005 | MRPL9 | mitochondrial ribosomal protein L9 |
| 27301 | APEX2 | apurinic/aprimidinic endodeoxyribonuclease 2 |
| 27315 | PGAP2 | post-GPI attachment to proteins 2 |
| 27075 | TSPAN13 | tetraspanin 13 |
| 6396 | SEC13 | SEC13 homolog, nuclear pore and COPII coat complex component |
| 29101 | SSU72 | SSU72 homolog, RNA polymerase II CTD phosphatase |
| 79035 | NABP2 | nucleic acid binding protein 2 |
| 5160 | PDHA1 | pyruvate dehydrogenase (lipoamide) alpha 1 |
| 115416 | MALSU1 | mitochondrial assembly of ribosomal large subunit 1 |
| 9218 | VAPA | VAMP associated protein A |
| 3396 | MRPL58 | mitochondrial ribosomal protein L58 |
| 64976 | MRPL40 | mitochondrial ribosomal protein L40 |
| 1123 | CHN1 | chimerin 1 |
| 149603 | RNF187 | ring finger protein 187 |
| 84246 | MED10 | mediator complex subunit 10 |
| 7260 | TSSC1 | tumor suppressing subtransferable candidate 1 |
| 10084 | PQBP1 | polyglutamine binding protein 1 |
| 661 | POLR3D | RNA polymerase III subunit D |
| 56257 | MEPCE | methylphosphate capping enzyme |
| 9371 | KIF3B | kinesin family member 3B |
| 92002 | FAM58A | family with sequence similarity 58 member A |
| 114049 | WBSR22 | Williams-Beuren syndrome chromosome region 22 |
| 55038 | CDCA4 | cell division cycle associated 4 |
| 339263 | C17orf51 | chromosome 17 open reading frame 51 |
| 11137 | PWP1 | PWP1 homolog, endonuclease |
| 55278 | QRSL1 | glutamyl-tRNA synthase (glutamine-hydrolyzing)-like 1 |
| 8811 | GALR2 | galanin receptor 2 |
| 118424 | UBE2J2 | ubiquitin conjugating enzyme E2 J2 |
| 3596 | IL13 | interleukin 13 |
| 7918 | GPANK1 | G-patch domain and ankyrin repeats 1 |
| 376267 | RAB15 | RAB15, member RAS oncogene family |
| 8754 | ADAM9 | ADAM metalloproteinase domain 9 |
| 22916 | NCBP2 | nuclear cap binding protein subunit 2 |
| 79172 | CENPO | centromere protein O |
| 84547 | PGBD1 | piggyBac transposable element derived 1 |
| 28960 | DCPS | decapping enzyme, scavenger |
| 10741 | RBBP9 | RB binding protein 9, serine hydrolase |
| 283106 | CSNK2A3 | casein kinase 2 alpha 3 |
| 84065 | TMEM222 | transmembrane protein 222 |
| 5686 | PSMA5 | proteasome subunit alpha 5 |
| 6573 | SLC19A1 | solute carrier family 19 member 1 |
| 51634 | RBMX2 | RNA binding motif protein, X-linked 2 |
| 54802 | TRIT1 | tRNA isopentenyltransferase 1 |
| 10280 | SIGMAR1 | sigma non-opioid intracellular receptor 1 |
| 5496 | PPM1G | protein phosphatase, Mg2+/Mn2+ dependent 1G |
| 970 | CD70 | CD70 molecule |
| 9289 | ADGRG1 | adhesion G protein-coupled receptor G1 |
| 115939 | TSR3 | TSR3, acp transferase ribosome maturation factor |
| 550 | AUP1 | ancient ubiquitous protein 1 |
| 9560 | CCL4L2 | C-C motif chemokine ligand 4 like 2 |
| 3567 | IL5 | interleukin 5 |
| 91319 | DERL3 | derlin 3 |
| 5743 | PTGS2 | prostaglandin-endoperoxide synthase 2 |
| 3703 | STT3A | STT3A, catalytic subunit of the oligosaccharyltransferase complex |
| 118980 | SFXN2 | sideroflexin 2 |
| 3578 | IL9 | interleukin 9 |
| 10276 | NET1 | neuroepithelial cell transforming 1 |
| 6348 | CCL3 | C-C motif chemokine ligand 3 |
| 10201 | NME6 | NME/NM23 nucleoside diphosphate kinase 6 |
| 84296 | GIN5A | GIN5 complex subunit 4 |
| 200933 | FBXO45 | F-box protein 45 |

| | | |
|------------------------|----------|---|
| 9050 | PSTPIP2 | proline-serine-threonine phosphatase interacting protein 2 |
| 8356 | HIST1H3J | histone cluster 1 H3 family member j |
| 64745 | METTL17 | methyltransferase like 17 |
| 53838 | C11orf24 | chromosome 11 open reading frame 24 |
| 10293 | TRAF1 | TRAF interacting protein |
| 51023 | MRPS18C | mitochondrial ribosomal protein S18C |
| 26150 | RIBC2 | RIB43A domain with coiled-coils 2 |
| 4049 | LTA | lymphotoxin alpha |
| 25828 | TXN2 | thioredoxin 2 |
| 5886 | RAD23A | RAD23 homolog A, nucleotide excision repair protein |
| 84522 | JAGN1 | jagunal homolog 1 |
| 128178 | EDARADD | EDAR associated death domain |
| 51163 | DBR1 | debranching RNA lariats 1 |
| 84545 | MRPL43 | mitochondrial ribosomal protein L43 |
| 84311 | MRPL45 | mitochondrial ribosomal protein L45 |
| 132720 | C4orf32 | chromosome 4 open reading frame 32 |
| 3775 | KCNK1 | potassium two pore domain channel subfamily K member 1 |
| 54069 | MIS18A | MIS18 kinetochore protein A |
| 55255 | WDR41 | WD repeat domain 41 |
| 9334 | B4GALT5 | beta-1,4-galactosyltransferase 5 |
| 80262 | C16orf70 | chromosome 16 open reading frame 70 |
| 55122 | AKIRIN2 | akirin 2 |
| 81610 | FAM83D | family with sequence similarity 83 member D |
| 55116 | TMEM39B | transmembrane protein 39B |
| 7976 | FZD3 | frizzled class receptor 3 |
| 83693 | HSDL1 | hydroxysteroid dehydrogenase like 1 |
| 5571 | PRKAG1 | protein kinase AMP-activated non-catalytic subunit gamma 1 |
| 6839 | SUV39H1 | suppressor of variegation 3-9 homolog 1 |
| 3052 | HCCS | holocytochrome c synthase |
| 1435 | CSF1 | colony stimulating factor 1 |
| 4682 | NUBP1 | nucleotide binding protein 1 |
| 873 | CBR1 | carbonyl reductase 1 |
| 4605 | MYBL2 | MYB proto-oncogene like 2 |
| 84057 | MND1 | meiotic nuclear divisions 1 |
| 2617 | GARS | glycyl-tRNA synthetase |
| 55148 | UBR7 | ubiquitin protein ligase E3 component n-recognin 7 (putative) |
| 6241 | RRM2 | ribonucleotide reductase regulatory subunit M2 |
| 91801 | ALKBH8 | alkB homolog 8, tRNA methyltransferase |
| 195828 | ZNF367 | zinc finger protein 367 |
| 54541 | DDIT4 | DNA damage inducible transcript 4 |
| 4292 | MLH1 | mutL homolog 1 |
| 9837 | GIN5 | GIN5 complex subunit 1 |
| 27000 | DNAJC2 | DnaJ heat shock protein family (Hsp40) member C2 |
| 55005 | RMND1 | required for meiotic nuclear division 1 homolog |
| 5715 | PSMD9 | proteasome 26S subunit, non-ATPase 9 |
| 220134 | SKA1 | spindle and kinetochore associated complex subunit 1 |
| 55322 | C5orf22 | chromosome 5 open reading frame 22 |
| 890 | CCNA2 | cyclin A2 |
| 9833 | MELK | maternal embryonic leucine zipper kinase |
| 64151 | NCAPG | non-SMC condensin I complex subunit G |
| 4860 | PNP | purine nucleoside phosphorylase |
| 8846 | ALKBH1 | alkB homolog 1, histone H2A dioxygenase |
| 23397 | NCAPH | non-SMC condensin I complex subunit H |
| 79733 | E2F8 | E2F transcription factor 8 |
| 55872 | PBK | PDZ binding kinase |
| 11079 | RER1 | retention in endoplasmic reticulum sorting receptor 1 |
| 51290 | ERGIC2 | ERGIC and golgi 2 |
| 6729 | SRP54 | signal recognition particle 54 |
| 121441 | NEDD1 | neural precursor cell expressed, developmentally down-regulated 1 |
| 983 | CDK1 | cyclin dependent kinase 1 |
| 6734 | SRPRA | SRP receptor alpha subunit |
| 10438 | C1D | C1D nuclear receptor corepressor |
| 11212 | PROSC | proline synthetase cotranscribed homolog (bacterial) |
| 79023 | NUP37 | nucleoporin 37 |
| 54433 | GAR1 | GAR1 ribonucleoprotein |

| | | | |
|------------------------|----------|---|---|
| 6504 | SLAMF1 | signaling lymphocytic activation molecule family member 1 | 3 |
| 23107 | MRPS27 | mitochondrial ribosomal protein S27 | 3 |
| 9585 | KIF20B | kinesin family member 20B | 3 |
| 959 | CD40LG | CD40 ligand | 3 |
| 4218 | RAB8A | RAB8A, member RAS oncogene family | 3 |
| 23549 | DNPEP | aspartyl aminopeptidase | 3 |
| 7272 | TTK | TTK protein kinase | 3 |
| 84920 | ALG10 | ALG10, alpha-1,2-glucosyltransferase | 3 |
| 2218 | FKTN | fukutin | 3 |
| 1786 | DNMT1 | DNA methyltransferase 1 | 3 |
| 29078 | NDUFAF4 | NADH:ubiquinone oxidoreductase complex assembly factor 4 | 3 |
| 144455 | E2F7 | E2F transcription factor 7 | 3 |
| 25983 | NGDN | neuroguidin | 3 |
| 11051 | NUDT21 | nudix hydrolase 21 | 3 |
| 6426 | SRSF1 | serine and arginine rich splicing factor 1 | 3 |
| 348995 | NUP43 | nucleoporin 43 | 3 |
| 81556 | VWA9 | von Willebrand factor A domain containing 9 | 3 |
| 286826 | LIN9 | lin-9 DREAM MuvB core complex component | 3 |
| 10615 | SPAG5 | sperm associated antigen 5 | 3 |
| 10721 | POLQ | DNA polymerase theta | 3 |
| 25800 | SLC39A6 | solute carrier family 39 member 6 | 3 |
| 26958 | COPG2 | coatamer protein complex subunit gamma 2 | 3 |
| 5894 | RAF1 | Raf-1 proto-oncogene, serine/threonine kinase | 3 |
| 8669 | EIF3J | eukaryotic translation initiation factor 3 subunit J | 3 |
| 9131 | AIFM1 | apoptosis inducing factor, mitochondria associated 1 | 3 |
| 28969 | BZW2 | basic leucine zipper and W2 domains 2 | 3 |
| | | ribosomal RNA processing 9, small subunit (SSU) processome component, homolog (yeast) | 3 |
| 9136 | RRP9 | | 3 |
| 11033 | ADAP1 | ArfGAP with dual PH domains 1 | 3 |
| 9377 | COX5A | cytochrome c oxidase subunit 5A | 3 |
| 51103 | NDUFAF1 | NADH:ubiquinone oxidoreductase complex assembly factor 1 | 3 |
| 196264 | MPZL3 | myelin protein zero like 3 | 3 |
| 83732 | RIOK1 | RIO kinase 1 | 3 |
| 116092 | DNTTIP1 | deoxynucleotidyltransferase terminal interacting protein 1 | 3 |
| 8480 | RAE1 | ribonucleic acid export 1 | 3 |
| 9556 | C14orf2 | chromosome 14 open reading frame 2 | 3 |
| 403 | ARL3 | ADP ribosylation factor like GTPase 3 | 3 |
| 10542 | LAMTOR5 | late endosomal/lysosomal adaptor, MAPK and MTOR activator 5 | 3 |
| 23365 | ARHGEF12 | Rho guanine nucleotide exchange factor 12 | 3 |
| 56947 | MFF | mitochondrial fission factor | 3 |
| 84233 | TMEM126A | transmembrane protein 126A | 3 |
| 3422 | IDI1 | isopentenyl-diphosphate delta isomerase 1 | 3 |
| 81502 | HM13 | histocompatibility minor 13 | 3 |
| 27339 | PRPF19 | pre-mRNA processing factor 19 | 3 |
| 9875 | URB1 | URB1 ribosome biogenesis 1 homolog (S. cerevisiae) | 3 |
| 8454 | CUL1 | cullin 1 | 3 |
| 51232 | CRIM1 | cysteine rich transmembrane BMP regulator 1 | 3 |
| 9675 | TTI1 | TELO2 interacting protein 1 | 3 |
| 9373 | PLAA | phospholipase A2 activating protein | 3 |
| 4849 | CNOT3 | CCR4-NOT transcription complex subunit 3 | 3 |
| 9261 | MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 | 3 |
| 2926 | GRSF1 | G-rich RNA sequence binding factor 1 | 3 |
| 54931 | TRMT10C | tRNA methyltransferase 10C, mitochondrial RNase P subunit | 3 |
| 140465 | MYL6B | myosin light chain 6B | 3 |
| 64374 | SIL1 | SIL1 nucleotide exchange factor | 3 |
| 51388 | NIP7 | NIP7, nucleolar pre-rRNA processing protein | 3 |
| 2037 | EPB41L2 | erythrocyte membrane protein band 4.1 like 2 | 3 |
| 2146 | EZH2 | enhancer of zeste 2 polycomb repressive complex 2 subunit | 3 |
| 1503 | CTPS1 | CTP synthase 1 | 3 |
| 51056 | LAP3 | leucine aminopeptidase 3 | 3 |
| 64422 | ATG3 | autophagy related 3 | 3 |
| 64425 | POLR1E | RNA polymerase I subunit E | 3 |
| 5876 | RABGGTB | Rab geranylgeranyltransferase beta subunit | 3 |
| 27340 | UTP20 | UTP20, small subunit processome component | 3 |
| 79954 | NOL10 | nucleolar protein 10 | 3 |

| | | |
|------------------------|-----------|---|
| 10885 | WDR3 | WD repeat domain 3 |
| 467 | ATF3 | activating transcription factor 3 |
| 10775 | POP4 | POP4 homolog, ribonuclease P/MRP subunit |
| 27166 | PRELID1 | PRELI domain containing 1 |
| 56945 | MRPS22 | mitochondrial ribosomal protein S22 |
| 821 | CANX | calnexin |
| 10525 | HYOU1 | hypoxia up-regulated 1 |
| 7037 | TFRC | transferrin receptor |
| 56005 | MYDGF | myeloid derived growth factor |
| 9879 | DDX46 | DEAD-box helicase 46 |
| 55131 | RBM28 | RNA binding motif protein 28 |
| 55920 | RCC2 | regulator of chromosome condensation 2 |
| 3954 | LETM1 | leucine zipper and EF-hand containing transmembrane protein 1 |
| 23603 | CORO1C | coronin 1C |
| 54948 | MRPL16 | mitochondrial ribosomal protein L16 |
| 22894 | DIS3 | DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease |
| 51249 | TMEM69 | transmembrane protein 69 |
| 7873 | MANF | mesencephalic astrocyte derived neurotrophic factor |
| 5393 | EXOSC9 | exosome component 9 |
| 23197 | FAF2 | Fas associated factor family member 2 |
| 5888 | RAD51 | RAD51 recombinase |
| 23761 | PISD | phosphatidylserine decarboxylase |
| 125061 | AFMID | arylformamidase |
| 5019 | OXCT1 | 3-oxoacid CoA-transferase 1 |
| 53371 | NUP54 | nucleoporin 54 |
| 23404 | EXOSC2 | exosome component 2 |
| 8208 | CHAF1B | chromatin assembly factor 1 subunit B |
| 6240 | RRM1 | ribonucleotide reductase catalytic subunit M1 |
| 78995 | C17orf53 | chromosome 17 open reading frame 53 |
| 84930 | MASTL | microtubule associated serine/threonine kinase like |
| 51514 | DTL | denticleless E3 ubiquitin protein ligase homolog |
| 3837 | KPNB1 | karyopherin subunit beta 1 |
| 9156 | EXO1 | exonuclease 1 |
| 51194 | IPO11 | importin 11 |
| 10036 | CHAF1A | chromatin assembly factor 1 subunit A |
| 160897 | GPR180 | G protein-coupled receptor 180 |
| 8243 | SMC1A | structural maintenance of chromosomes 1A |
| 1122 | CHML | CHM like, Rab escort protein 2 |
| 22984 | PDCD11 | programmed cell death 11 |
| 488 | ATP2A2 | ATPase sarcoplasmic/endoplasmic reticulum Ca ²⁺ transporting 2 |
| 1874 | E2F4 | E2F transcription factor 4 |
| 55746 | NUP133 | nucleoporin 133 |
| 55973 | BCAP29 | B-cell receptor associated protein 29 |
| 84271 | POLDIP3 | DNA polymerase delta interacting protein 3 |
| 55127 | HEATR1 | HEAT repeat containing 1 |
| 128869 | PIGU | phosphatidylinositol glycan anchor biosynthesis class U |
| 79053 | ALG8 | ALG8, alpha-1,3-glucosyltransferase |
| 2956 | MSH6 | mutS homolog 6 |
| 57678 | GPAM | glycerol-3-phosphate acyltransferase, mitochondrial |
| 9401 | RECQL4 | RecQ like helicase 4 |
| 79796 | ALG9 | ALG9, alpha-1,2-mannosyltransferase |
| 993 | CDC25A | cell division cycle 25A |
| 56926 | NCLN | nicalin |
| 9816 | URB2 | URB2 ribosome biogenesis 2 homolog (S. cerevisiae) |
| 10560 | SLC19A2 | solute carrier family 19 member 2 |
| 80223 | RAB11FIP1 | RAB11 family interacting protein 1 |
| 9733 | SART3 | squamous cell carcinoma antigen recognized by T-cells 3 |
| 22934 | RPIA | ribose 5-phosphate isomerase A |
| 10531 | PITRM1 | pitrilysin metalloproteinase 1 |
| 3251 | HPRT1 | hypoxanthine phosphoribosyltransferase 1 |
| 8833 | GMPS | guanine monophosphate synthase |
| 2175 | FANCA | Fanconi anemia complementation group A |
| 25788 | RAD54B | RAD54 homolog B (S. cerevisiae) |
| 80155 | NAA15 | N(alpha)-acetyltransferase 15, NatA auxiliary subunit |
| 79723 | SUV39H2 | suppressor of variegation 3-9 homolog 2 |
| 132789 | GNPDA2 | glucosamine-6-phosphate deaminase 2 |

| | | |
|------------------------|----------|---|
| 23234 | DNAJC9 | DnaJ heat shock protein family (Hsp40) member C9 |
| 57510 | XPO5 | exportin 5 |
| 6119 | RPA3 | replication protein A3 |
| 39 | ACAT2 | acetyl-CoA acetyltransferase 2 |
| 7993 | UBXN8 | UBX domain protein 8 |
| 10105 | PIIF | peptidylprolyl isomerase F |
| 57003 | CCDC47 | coiled-coil domain containing 47 |
| 57415 | C3orf14 | chromosome 3 open reading frame 14 |
| 10652 | YKT6 | YKT6 v-SNARE homolog (S. cerevisiae) |
| 7374 | UNG | uracil DNA glycosylase |
| 51602 | NOP58 | NOP58 ribonucleoprotein |
| 6566 | SLC16A1 | solute carrier family 16 member 1 |
| 4173 | MCM4 | minichromosome maintenance complex component 4 |
| 894 | CCND2 | cyclin D2 |
| 9790 | BMS1 | BMS1, ribosome biogenesis factor |
| 51118 | UTP11 | UTP11, small subunit processome component homolog (S. cerevisiae) |
| 51126 | NAA20 | N(alpha)-acetyltransferase 20, NatB catalytic subunit |
| 10950 | BTG3 | BTG anti-proliferation factor 3 |
| 10574 | CCT7 | chaperonin containing TCP1 subunit 7 |
| 55646 | LYAR | Ly1 antibody reactive |
| 84319 | CMSS1 | cms1 ribosomal small subunit homolog (yeast) |
| 120425 | JAML | junction adhesion molecule like |
| 10471 | PFDN6 | prefoldin subunit 6 |
| 51497 | NELFCD | negative elongation factor complex member C/D |
| 131076 | CCDC58 | coiled-coil domain containing 58 |
| 2067 | ERCC1 | ERCC excision repair 1, endonuclease non-catalytic subunit |
| 55299 | BRIX1 | BRX1, biogenesis of ribosomes |
| 8520 | HAT1 | histone acetyltransferase 1 |
| 1845 | DUSP3 | dual specificity phosphatase 3 |
| 2321 | FLT1 | fms related tyrosine kinase 1 |
| 5422 | POLA1 | DNA polymerase alpha 1, catalytic subunit |
| 55759 | WDR12 | WD repeat domain 12 |
| 26010 | SPATS2L | spermatogenesis associated serine rich 2 like |
| 5887 | RAD23B | RAD23 homolog B, nucleotide excision repair protein |
| 23516 | SLC39A14 | solute carrier family 39 member 14 |
| 83743 | GRWD1 | glutamate rich WD repeat containing 1 |
| 5702 | PSMC3 | proteasome 26S subunit, ATPase 3 |
| 54487 | DGCR8 | DGCR8, microprocessor complex subunit |
| 55720 | TSR1 | TSR1, ribosome maturation factor |
| 2547 | XRCC6 | X-ray repair cross complementing 6 |
| 5982 | RFC2 | replication factor C subunit 2 |
| 27346 | TMEM97 | transmembrane protein 97 |
| 80179 | MYO19 | myosin XIX |
| 9343 | EFTUD2 | elongation factor Tu GTP binding domain containing 2 |
| 220042 | DDIAS | DNA damage induced apoptosis suppressor |
| 8318 | CDC45 | cell division cycle 45 |
| 5471 | PPAT | phosphoribosyl pyrophosphate amidotransferase |
| 990 | CDC6 | cell division cycle 6 |
| 90861 | HN1L | hematological and neurological expressed 1 like |
| 29128 | UHRF1 | ubiquitin like with PHD and ring finger domains 1 |
| 1111 | CHEK1 | checkpoint kinase 1 |
| 55854 | ZC3H15 | zinc finger CCCH-type containing 15 |
| 4998 | ORC1 | origin recognition complex subunit 1 |
| 5111 | PCNA | proliferating cell nuclear antigen |
| 54962 | TIPIN | TIMELESS interacting protein |
| 51377 | UCHL5 | ubiquitin C-terminal hydrolase L5 |
| 9125 | CNOT9 | CCR4-NOT transcription complex subunit 9 |
| 11222 | MRPL3 | mitochondrial ribosomal protein L3 |
| 1965 | EIF2S1 | eukaryotic translation initiation factor 2 subunit alpha |
| 6427 | SRSF2 | serine and arginine rich splicing factor 2 |
| 10623 | POLR3C | RNA polymerase III subunit C |
| 7884 | SLBP | stem-loop binding protein |
| 79622 | SNRNP25 | small nuclear ribonucleoprotein U11/U12 subunit 25 |
| 4172 | MCM3 | minichromosome maintenance complex component 3 |
| 2237 | FEN1 | flap structure-specific endonuclease 1 |

| | | |
|------------------------|----------|---|
| 171568 | POLR3H | RNA polymerase III subunit H |
| 8704 | B4GALT2 | beta-1,4-galactosyltransferase 2 |
| 55388 | MCM10 | minichromosome maintenance 10 replication initiation factor |
| 26509 | MYOF | myoferlin |
| 94097 | SFXN5 | sideroflexin 5 |
| 55379 | LRRC59 | leucine rich repeat containing 59 |
| 2271 | FH | fumarate hydratase |
| 26284 | ERAL1 | Era like 12S mitochondrial rRNA chaperone 1 |
| 2958 | GTF2A2 | general transcription factor IIA subunit 2 |
| 1869 | E2F1 | E2F transcription factor 1 |
| 11332 | ACOT7 | acyl-CoA thioesterase 7 |
| 898 | CCNE1 | cyclin E1 |
| 5983 | RFC3 | replication factor C subunit 3 |
| 3021 | H3F3B | H3 histone family member 3B |
| 10419 | PRMT5 | protein arginine methyltransferase 5 |
| 64858 | DCLRE1B | DNA cross-link repair 1B |
| 10054 | UBA2 | ubiquitin like modifier activating enzyme 2 |
| 2176 | FANCC | Fanconi anemia complementation group C |
| 51124 | IER3IP1 | immediate early response 3 interacting protein 1 |
| 126526 | C19orf47 | chromosome 19 open reading frame 47 |
| 60386 | SLC25A19 | solute carrier family 25 member 19 |
| 56910 | STAR7 | StAR related lipid transfer domain containing 7 |
| 3976 | LIF | leukemia inhibitory factor |
| 1841 | DTYMK | deoxythymidylate kinase |
| 10556 | RPP30 | ribonuclease P/MRP subunit p30 |
| 10360 | NPM3 | nucleophosmin/nucleoplasmin 3 |
| 114034 | TOE1 | target of EGR1, member 1 (nuclear) |
| 79693 | YRDC | yrdc N6-threonylcarbamoyltransferase domain containing |
| 5631 | PRPS1 | phosphoribosyl pyrophosphate synthetase 1 |
| 56851 | EMC7 | ER membrane protein complex subunit 7 |
| 10949 | HNRNPA0 | heterogeneous nuclear ribonucleoprotein A0 |
| 51559 | NT5DC3 | 5'-nucleotidase domain containing 3 |
| 79682 | CENPU | centromere protein U |
| 9410 | SNRNP40 | small nuclear ribonucleoprotein U5 subunit 40 |
| 8624 | PSMG1 | proteasome assembly chaperone 1 |
| 5557 | PRIM1 | primase (DNA) subunit 1 |
| 55159 | RFWD3 | ring finger and WD repeat domain 3 |
| 29089 | UBE2T | ubiquitin conjugating enzyme E2 T |
| 84515 | MCM8 | minichromosome maintenance 8 homologous recombination repair factor |
| 11164 | NUDT5 | nudix hydrolase 5 |
| 203068 | TUBB | tubulin beta class I |
| 6472 | SHMT2 | serine hydroxymethyltransferase 2 |
| 132 | ADK | adenosine kinase |
| 401541 | CENPP | centromere protein P |
| 805 | CALM2 | calmodulin 2 |
| 4616 | GADD45B | growth arrest and DNA damage inducible beta |
| 10328 | EMC8 | ER membrane protein complex subunit 8 |
| 5546 | PRCC | papillary renal cell carcinoma (translocation-associated) |
| 1164 | CKS2 | CDC28 protein kinase regulatory subunit 2 |
| 27242 | TNFRSF21 | TNF receptor superfamily member 21 |
| 9318 | COPS2 | COP9 signalosome subunit 2 |
| 56993 | TOMM22 | translocase of outer mitochondrial membrane 22 |
| 84549 | MAK16 | MAK16 homolog |
| 5437 | POLR2H | RNA polymerase II subunit H |
| 388272 | C16orf87 | chromosome 16 open reading frame 87 |
| 113115 | MTFR2 | mitochondrial fission regulator 2 |
| 4043 | LRPAP1 | LDL receptor related protein associated protein 1 |
| 55347 | ABHD10 | abhydrolase domain containing 10 |
| 79968 | WDR76 | WD repeat domain 76 |
| 262 | AMD1 | adenosylmethionine decarboxylase 1 |
| 27131 | SNX5 | sorting nexin 5 |
| 93081 | TEX30 | testis expressed 30 |
| 200081 | TXLNA | taxilin alpha |
| 84334 | APOPT1 | apoptogenic 1, mitochondrial |
| 8836 | GGH | gamma-glutamyl hydrolase |

| | | | |
|------------------------|----------|--|---|
| 1528 | CYB5A | cytochrome b5 type A | 3 |
| 122769 | LRR1 | leucine rich repeat protein 1 | 3 |
| 8896 | BUD31 | BUD31 homolog | 3 |
| 7922 | SLC39A7 | solute carrier family 39 member 7 | 3 |
| 83903 | GSG2 | germ cell associated 2, haspin | 3 |
| 79019 | CENPM | centromere protein M | 3 |
| 10038 | PARP2 | poly(ADP-ribose) polymerase 2 | 3 |
| 11130 | ZWINT | ZW10 interacting kinetochore protein | 3 |
| 91 | ACVR1B | activin A receptor type 1B | 3 |
| 6742 | SSBP1 | single stranded DNA binding protein 1 | 3 |
| 7398 | USP1 | ubiquitin specific peptidase 1 | 3 |
| 79980 | DSN1 | DSN1 homolog, MIS12 kinetochore complex component | 3 |
| 9134 | CCNE2 | cyclin E2 | 3 |
| 387103 | CENPW | centromere protein W | 3 |
| 9984 | THOC1 | THO complex 1 | 3 |
| 23421 | ITGB3BP | integrin subunit beta 3 binding protein | 3 |
| 54108 | CHRC1 | chromatin accessibility complex 1 | 3 |
| 79801 | SHCBP1 | SHC binding and spindle associated 1 | 3 |
| 3185 | HNRNPF | heterogeneous nuclear ribonucleoprotein F | 3 |
| 813 | CALU | calumenin | 3 |
| 10733 | PLK4 | polo like kinase 4 | 3 |
| 211 | ALAS1 | 5'-aminolevulinate synthase 1 | 3 |
| 81831 | NETO2 | neuropilin and tolloid like 2 | 3 |
| 79001 | VKORC1 | vitamin K epoxide reductase complex subunit 1 | 3 |
| 26123 | TCTN3 | tectonic family member 3 | 3 |
| 25896 | INTS7 | integrator complex subunit 7 | 3 |
| 64834 | ELOVL1 | ELOVL fatty acid elongase 1 | 3 |
| 80304 | WDCP | WD repeat and coiled coil containing | 3 |
| 51550 | CINP | cyclin dependent kinase 2 interacting protein | 3 |
| 38 | ACAT1 | acetyl-CoA acetyltransferase 1 | 3 |
| 79084 | WDR77 | WD repeat domain 77 | 3 |
| 219988 | PATL1 | PAT1 homolog 1, processing body mRNA decay factor | 3 |
| 63979 | FIGNL1 | figetin like 1 | 3 |
| 10772 | SRSF10 | serine and arginine rich splicing factor 10 | 3 |
| 6788 | STK3 | serine/threonine kinase 3 | 3 |
| 85459 | CEP295 | centrosomal protein 295 | 3 |
| 2746 | GLUD1 | glutamate dehydrogenase 1 | 3 |
| 58490 | RPRD1B | regulation of nuclear pre-mRNA domain containing 1B | 3 |
| 3005 | H1FO | H1 histone family member 0 | 3 |
| 55163 | PNPO | pyridoxamine 5'-phosphate oxidase | 3 |
| 114134 | SLC2A13 | solute carrier family 2 member 13 | 3 |
| 7384 | UQCRC1 | ubiquinol-cytochrome c reductase core protein I | 3 |
| 23509 | POFUT1 | protein O-fucosyltransferase 1 | 3 |
| 975 | CD81 | CD81 molecule | 3 |
| 7408 | VASP | vasodilator-stimulated phosphoprotein | 3 |
| 93323 | HAUS8 | HAUS augmin like complex subunit 8 | 3 |
| 124535 | HSF5 | heat shock transcription factor 5 | 3 |
| 85444 | LRRCC1 | leucine rich repeat and coiled-coil centrosomal protein 1 | 3 |
| 51150 | SDF4 | stromal cell derived factor 4 | 3 |
| 56919 | DHX33 | DEAH-box helicase 33 | 3 |
| 23035 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 3 |
| 8879 | SGPL1 | sphingosine-1-phosphate lyase 1 | 3 |
| 51593 | SRRT | serrate, RNA effector molecule | 3 |
| 790 | CAD | carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase | 3 |
| 6541 | SLC7A1 | solute carrier family 7 member 1 | 3 |
| 6835 | SURF2 | surfeit 2 | 3 |
| 84306 | PDCD2L | programmed cell death 2 like | 3 |
| 51693 | TRAPPC2L | trafficking protein particle complex 2 like | 3 |
| 7001 | PRDX2 | peroxiredoxin 2 | 3 |
| 22976 | PAXIP1 | PAX interacting protein 1 | 3 |
| 51692 | CPSF3 | cleavage and polyadenylation specific factor 3 | 3 |
| 11193 | WBP4 | WW domain binding protein 4 | 3 |
| 6827 | SPT4H1 | SPT4 homolog, DSIF elongation factor subunit | 3 |
| 116224 | FAM122A | family with sequence similarity 122A | 3 |

| | | | |
|------------------------|----------|--|---|
| 51110 | LACTB2 | lactamase beta 2 | 3 |
| 29063 | ZCCHC4 | zinc finger CCHC-type containing 4 | 3 |
| 57552 | NCEH1 | neutral cholesterol ester hydrolase 1 | 3 |
| 60528 | ELAC2 | elaC ribonuclease Z 2 | 3 |
| 79174 | CRELD2 | cysteine rich with EGF like domains 2 | 3 |
| 83940 | TATDN1 | TatD DNase domain containing 1 | 3 |
| 117246 | FTSJ3 | FtsJ homolog 3 | 3 |
| 390916 | NUDT19 | nudix hydrolase 19 | 3 |
| 1478 | CSTF2 | cleavage stimulation factor subunit 2 | 3 |
| 1017 | CDK2 | cyclin dependent kinase 2 | 3 |
| 221830 | TWISTNB | TWIST neighbor | 3 |
| 10383 | TUBB4B | tubulin beta 4B class IVb | 3 |
| 65003 | MRPL11 | mitochondrial ribosomal protein L11 | 3 |
| 5366 | PMAIP1 | phorbol-12-myristate-13-acetate-induced protein 1 | 3 |
| 54939 | COMMMD4 | COMM domain containing 4 | 3 |
| 56912 | IFT46 | intraflagellar transport 46 | 3 |
| 51258 | MRPL51 | mitochondrial ribosomal protein L51 | 3 |
| 6478 | SIAH2 | siah E3 ubiquitin protein ligase 2 | 3 |
| 29093 | MRPL22 | mitochondrial ribosomal protein L22 | 3 |
| 79073 | TMEM109 | transmembrane protein 109 | 3 |
| 92745 | SLC38A5 | solute carrier family 38 member 5 | 3 |
| 9183 | ZW10 | zw10 kinetochore protein | 3 |
| 6390 | SDHB | succinate dehydrogenase complex iron sulfur subunit B | 3 |
| 64223 | MLST8 | MTOR associated protein, LST8 homolog | 3 |
| 55915 | LANCL2 | LanC like 2 | 3 |
| 57095 | PITHD1 | PITH domain containing 1 | 3 |
| 7917 | BAG6 | BCL2 associated athanogene 6 | 3 |
| 1603 | DAD1 | defender against cell death 1 | 3 |
| 533 | ATP6V0B | ATPase H+ transporting V0 subunit b | 3 |
| 130355 | C2orf76 | chromosome 2 open reading frame 76 | 3 |
| 9040 | UBE2M | ubiquitin conjugating enzyme E2 M | 3 |
| 5708 | PSMD2 | proteasome 26S subunit, non-ATPase 2 | 3 |
| 253714 | MMS22L | MMS22 like, DNA repair protein | 3 |
| 5685 | PSMA4 | proteasome subunit alpha 4 | 3 |
| 5203 | PFDN4 | prefoldin subunit 4 | 3 |
| 1376 | CPT2 | carnitine palmitoyltransferase 2 | 3 |
| 27229 | TUBGCP4 | tubulin gamma complex associated protein 4 | 3 |
| 83746 | L3MBTL2 | L3MBTL2 polycomb repressive complex 1 subunit | 3 |
| 334 | APLP2 | amyloid beta precursor like protein 2 | 3 |
| 1737 | DLAT | dihydrolipoamide S-acetyltransferase | 3 |
| 5034 | P4HB | prolyl 4-hydroxylase subunit beta | 3 |
| 51053 | GMNN | geminin, DNA replication inhibitor | 3 |
| 51728 | POLR3K | RNA polymerase III subunit K | 3 |
| 116138 | KLHDC3 | kelch domain containing 3 | 3 |
| 27249 | MMADHC | methylmalonic aciduria and homocystinuria, cbID type | 3 |
| 57019 | CIAPIN1 | cytokine induced apoptosis inhibitor 1 | 3 |
| 81037 | CLPTM1L | CLPTM1 like | 3 |
| 9862 | MED24 | mediator complex subunit 24 | 3 |
| 580 | BARD1 | BRCA1 associated RING domain 1 | 3 |
| 9703 | KIAA0100 | KIAA0100 | 3 |
| 9538 | EI24 | EI24, autophagy associated transmembrane protein | 3 |
| 28957 | MRPS28 | mitochondrial ribosomal protein S28 | 3 |
| 23534 | TNPO3 | transportin 3 | 3 |
| 54471 | MIEF1 | mitochondrial elongation factor 1 | 3 |
| 51264 | MRPL27 | mitochondrial ribosomal protein L27 | 3 |
| 689 | BTF3 | basic transcription factor 3 | 3 |
| 7982 | ST7 | suppression of tumorigenicity 7 | 3 |
| 5984 | RFC4 | replication factor C subunit 4 | 3 |
| 81875 | ISG20L2 | interferon stimulated exonuclease gene 20 like 2 | 3 |
| 80010 | RMI1 | RecQ mediated genome instability 1 | 3 |
| 127253 | TYW3 | tRNA-yW synthesizing protein 3 homolog | 3 |
| 8607 | RUVBL1 | RuvB like AAA ATPase 1 | 3 |
| 10971 | YWHAQ | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta | 3 |
| 51253 | MRPL37 | mitochondrial ribosomal protein L37 | 3 |

| | | |
|------------------------|----------|---|
| 740 | MRPL49 | mitochondrial ribosomal protein L49 |
| 92399 | MRRF | mitochondrial ribosome recycling factor |
| 6941 | TCF19 | transcription factor 19 |
| 4176 | MCM7 | minichromosome maintenance complex component 7 |
| 79751 | SLC25A22 | solute carrier family 25 member 22 |
| 129401 | NUP35 | nucleoporin 35 |
| 4085 | MAD2L1 | MAD2 mitotic arrest deficient-like 1 (yeast) |
| 79892 | MCMBP | minichromosome maintenance complex binding protein |
| 7705 | ZNF146 | zinc finger protein 146 |
| 10857 | PGRMC1 | progesterone receptor membrane component 1 |
| 140707 | BRI3BP | BRI3 binding protein |
| 84798 | C19orf48 | chromosome 19 open reading frame 48 |
| 4733 | DRG1 | developmentally regulated GTP binding protein 1 |
| 3458 | IFNG | interferon gamma |
| 7124 | TNF | tumor necrosis factor |
| 60678 | EEFSEC | eukaryotic elongation factor, selenocysteine-tRNA specific |
| 55706 | NDC1 | NDC1 transmembrane nucleoporin |
| 56006 | SMG9 | SMG9, nonsense mediated mRNA decay factor |
| 1437 | CSF2 | colony stimulating factor 2 |
| 9093 | DNAJA3 | DnaJ heat shock protein family (Hsp40) member A3 |
| 55536 | CDCA7L | cell division cycle associated 7 like |
| 23594 | ORC6 | origin recognition complex subunit 6 |
| 81611 | ANP32E | acidic nuclear phosphoprotein 32 family member E |
| 55166 | CENPQ | centromere protein Q |
| 90121 | TSR2 | TSR2, ribosome maturation factor |
| 64795 | RMND5A | required for meiotic nuclear division 5 homolog A |
| 2187 | FANCB | Fanconi anemia complementation group B |
| 3595 | IL12RB2 | interleukin 12 receptor subunit beta 2 |
| 2747 | GLUD2 | glutamate dehydrogenase 2 |
| 57001 | SDHAF3 | succinate dehydrogenase complex assembly factor 3 |
| 10714 | POLD3 | DNA polymerase delta 3, accessory subunit |
| 51522 | TMEM14C | transmembrane protein 14C |
| 8841 | HDAC3 | histone deacetylase 3 |
| 134145 | FAM173B | family with sequence similarity 173 member B |
| 10527 | IPO7 | importin 7 |
| 10768 | AHCYL1 | adenosylhomocysteinase like 1 |
| 29851 | ICOS | inducible T-cell costimulator |
| 5433 | POLR2D | RNA polymerase II subunit D |
| 9533 | POLR1C | RNA polymerase I subunit C |
| 54675 | CRLS1 | cardiolipin synthase 1 |
| 145173 | B3GLCT | beta 3-glucosyltransferase |
| 57602 | USP36 | ubiquitin specific peptidase 36 |
| 9801 | MRPL19 | mitochondrial ribosomal protein L19 |
| 10539 | GLRX3 | glutaredoxin 3 |
| 10921 | RNPS1 | RNA binding protein with serine rich domain 1 |
| 92856 | IMP4 | IMP4 homolog, U3 small nucleolar ribonucleoprotein |
| 5810 | RAD1 | RAD1 checkpoint DNA exonuclease methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, |
| 10797 | MTHFD2 | methylenetetrahydrofolate cyclohydrolase |
| 55735 | DNAJC11 | DnaJ heat shock protein family (Hsp40) member C11 |
| 10713 | USP39 | ubiquitin specific peptidase 39 |
| 81929 | SEH1L | SEH1 like nucleoporin |
| 5717 | PSMD11 | proteasome 26S subunit, non-ATPase 11 |
| 5917 | RARS | arginyl-tRNA synthetase |
| 27258 | LSM3 | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated |
| 51182 | HSPA14 | heat shock protein family A (Hsp70) member 14 |
| 6950 | TCP1 | t-complex 1 |
| 5860 | QDPR | quinoid dihydropteridine reductase |
| 8079 | MLF2 | myeloid leukemia factor 2 |
| 51645 | PPIL1 | peptidylprolyl isomerase like 1 |
| 5985 | RFC5 | replication factor C subunit 5 |
| 3843 | IPO5 | importin 5 |
| 22936 | ELL2 | elongation factor for RNA polymerase II 2 |
| 10166 | SLC25A15 | solute carrier family 25 member 15 |
| 55622 | TTC27 | tetratricopeptide repeat domain 27 |

| | | |
|------------------------|----------|--|
| 51002 | TPRKB | TP53RK binding protein |
| 23392 | KIAA0368 | KIAA0368 |
| 53407 | STX18 | syntaxin 18 |
| 10059 | DNM1L | dynamitin 1 like |
| 9774 | BCLAF1 | BCL2 associated transcription factor 1 |
| 84641 | MFS14B | major facilitator superfamily domain containing 14B |
| 8677 | STX10 | syntaxin 10 |
| 81873 | ARPC5L | actin related protein 2/3 complex subunit 5 like |
| 51575 | ESF1 | ESF1 nucleolar pre-rRNA processing protein homolog |
| 988 | CDC5L | cell division cycle 5 like |
| 2957 | GTF2A1 | general transcription factor IIA subunit 1 |
| 23597 | ACOT9 | acyl-CoA thioesterase 9 |
| 81554 | RCC1L | RCC1 like |
| 3654 | IRAK1 | interleukin 1 receptor associated kinase 1 |
| 55149 | MTPAP | mitochondrial poly(A) polymerase |
| 80775 | TMEM177 | transmembrane protein 177 |
| 64216 | TFB2M | transcription factor B2, mitochondrial |
| 10592 | SMC2 | structural maintenance of chromosomes 2 |
| 140735 | DYNLL2 | dynein light chain LC8-type 2 |
| 47 | ACLY | ATP citrate lyase |
| 5832 | ALDH18A1 | aldehyde dehydrogenase 18 family member A1 |
| 1138 | CHRNA5 | cholinergic receptor nicotinic alpha 5 subunit |
| 125228 | FAM210A | family with sequence similarity 210 member A |
| 23649 | POLA2 | DNA polymerase alpha 2, accessory subunit |
| 55627 | SMPD4 | sphingomyelin phosphodiesterase 4 |
| 6510 | SLC1A5 | solute carrier family 1 member 5 |
| 58478 | ENOPH1 | enolase-phosphatase 1 |
| 2806 | GOT2 | glutamic-oxaloacetic transaminase 2 |
| 5534 | PPP3R1 | protein phosphatase 3 regulatory subunit B, alpha |
| 88745 | RRP36 | ribosomal RNA processing 36 |
| 79863 | RBFA | ribosome binding factor A (putative) |
| 10884 | MRPS30 | mitochondrial ribosomal protein S30 |
| 9015 | TAF1A | TATA-box binding protein associated factor, RNA polymerase I subunit A |
| 79029 | SPATA5L1 | spermatogenesis associated 5 like 1 |
| 80311 | KLHL15 | kelch like family member 15 |
| 64946 | CENPH | centromere protein H |
| 8438 | RAD54L | RAD54-like (S. cerevisiae) |
| 7298 | TYMS | thymidylate synthetase |
| 9768 | KIAA0101 | KIAA0101 |
| 6502 | SKP2 | S-phase kinase associated protein 2 |
| 5427 | POLE2 | DNA polymerase epsilon 2, accessory subunit |
| 79902 | NUP85 | nucleoporin 85 |
| 8723 | SNX4 | sorting nexin 4 |
| 5932 | RBBP8 | RB binding protein 8, endonuclease |
| 3070 | HELLS | helicase, lymphoid-specific |
| 672 | BRCA1 | BRCA1, DNA repair associated |
| 79075 | DSCC1 | DNA replication and sister chromatid cohesion 1 |
| 7083 | TK1 | thymidine kinase 1 |
| 91768 | CABLES1 | Cdk5 and Abl enzyme substrate 1 |
| 10099 | TSPAN3 | tetraspanin 3 |
| 130074 | FAM168B | family with sequence similarity 168 member B |
| 79807 | GSTCD | glutathione S-transferase C-terminal domain containing |
| 83480 | PUS3 | pseudouridylate synthase 3 |
| 54442 | KCTD5 | potassium channel tetramerization domain containing 5 |
| 55559 | HAUS7 | HAUS augmin like complex subunit 7 |
| 79003 | MIS12 | MIS12, kinetochore complex component |
| 1763 | DNA2 | DNA replication helicase/nuclease 2 |
| 9328 | GTF3C5 | general transcription factor IIIC subunit 5 |
| 10552 | ARPC1A | actin related protein 2/3 complex subunit 1A |
| 29925 | GMPPB | GDP-mannose pyrophosphorylase B |
| 134353 | LSM11 | LSM11, U7 small nuclear RNA associated |
| 25914 | RTTN | rotatin |
| 207 | AKT1 | AKT serine/threonine kinase 1 |
| 64837 | KLC2 | kinesin light chain 2 |

| | | | |
|---------------------------|----------|--|---|
| 8131 | NPRL3 | NPR3 like, GATOR1 complex subunit | 3 |
| 116113 | FOXP4 | forkhead box P4 | 3 |
| 55677 | IWS1 | IWS1, SUPT6H interacting protein | 3 |
| 10749 | KIF1C | kinesin family member 1C | 3 |
| 9019 | MPZL1 | myelin protein zero like 1 | 3 |
| 84885 | ZDHHC12 | zinc finger DHHC-type containing 12 | 3 |
| 55509 | BATF3 | basic leucine zipper ATF-like transcription factor 3 | 3 |
| 54976 | C20orf27 | chromosome 20 open reading frame 27 | 3 |
| 56616 | DIABLO | diablo IAP-binding mitochondrial protein | 3 |
| 10856 | RUVBL2 | RuvB like AAA ATPase 2 | 3 |
| 55969 | C20orf24 | chromosome 20 open reading frame 24 | 3 |
| 100506012 | PPP5D1 | PPP5 tetratricopeptide repeat domain containing 1 | 3 |
| 57418 | WDR18 | WD repeat domain 18 | 3 |
| 10572 | SIVA1 | SIVA1 apoptosis inducing factor | 3 |
| 9653 | HS2ST1 | heparan sulfate 2-O-sulfotransferase 1 | 3 |
| 9031 | BAZ1B | bromodomain adjacent to zinc finger domain 1B | 3 |
| 55922 | NKRF | NFKB repressing factor | 3 |
| 10594 | PRPF8 | pre-mRNA processing factor 8 | 3 |
| 2235 | FECH | ferrochelatase | 3 |
| 54934 | KANSL2 | KAT8 regulatory NSL complex subunit 2 | 3 |
| 339231 | ARL16 | ADP ribosylation factor like GTPase 16 | 3 |
| 5514 | PPP1R10 | protein phosphatase 1 regulatory subunit 10 | 3 |
| 4193 | MDM2 | MDM2 proto-oncogene | 3 |
| 126731 | CCSAP | centriole, cilia and spindle associated protein | 3 |
| 387338 | NSUN4 | NOP2/Sun RNA methyltransferase family member 4 | 3 |
| 64318 | NOC3L | NOC3 like DNA replication regulator | 3 |
| 64083 | GOLPH3 | golgi phosphoprotein 3 | 3 |
| 10478 | SLC25A17 | solute carrier family 25 member 17 | 3 |
| 11157 | LSM6 | LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated | 3 |
| 79989 | TTC26 | tetratricopeptide repeat domain 26 | 3 |
| 56894 | AGPAT3 | 1-acylglycerol-3-phosphate O-acyltransferase 3 | 3 |
| 1983 | EIF5 | eukaryotic translation initiation factor 5 | 3 |
| 56652 | C10orf2 | chromosome 10 open reading frame 2 | 3 |
| 22891 | ZNF365 | zinc finger protein 365 | 3 |
| 221035 | REEP3 | receptor accessory protein 3 | 3 |
| 54707 | GPN2 | GPN-loop GTPase 2 | 3 |
| 51022 | GLRX2 | glutaredoxin 2 | 3 |
| 79066 | METTL16 | methyltransferase like 16 | 3 |
| 57862 | ZNF410 | zinc finger protein 410 | 3 |
| 9240 | PNMA1 | paraneoplastic Ma antigen 1 | 3 |
| 51204 | TACO1 | translational activator of cytochrome c oxidase I | 3 |
| 7292 | TNFSF4 | tumor necrosis factor superfamily member 4 | 3 |
| 79568 | C2orf47 | chromosome 2 open reading frame 47 | 3 |
| 7584 | ZNF35 | zinc finger protein 35 | 3 |
| 4709 | NDUFB3 | NADH:ubiquinone oxidoreductase subunit B3 | 3 |
| 55572 | FOXRED1 | FAD dependent oxidoreductase domain containing 1 | 3 |
| 56683 | C21orf59 | chromosome 21 open reading frame 59 | 3 |
| 23423 | TMED3 | transmembrane p24 trafficking protein 3 | 3 |
| 5134 | PDCD2 | programmed cell death 2 | 3 |
| 84289 | ING5 | inhibitor of growth family member 5 | 3 |
| 527 | ATP6V0C | ATPase H+ transporting V0 subunit c | 3 |
| 1978 | EIF4EBP1 | eukaryotic translation initiation factor 4E binding protein 1 | 3 |
| 6628 | SNRPB | small nuclear ribonucleoprotein polypeptides B and B1 | 3 |
| 1981 | EIF4G1 | eukaryotic translation initiation factor 4 gamma 1 | 3 |
| 10221 | TRIB1 | tribbles pseudokinase 1 | 3 |
| 157506 | RDH10 | retinol dehydrogenase 10 (all-trans) | 3 |
| 79413 | ZBED2 | zinc finger BED-type containing 2 | 3 |
| 6182 | MRPL12 | mitochondrial ribosomal protein L12 | 3 |
| 201514 | ZNF584 | zinc finger protein 584 | 3 |
| 7023 | TFAP4 | transcription factor AP-4 | 3 |
| 8228 | PNPLA4 | patatin like phospholipase domain containing 4 | 3 |
| 2593 | GAMT | guanidinoacetate N-methyltransferase | 3 |
| 9144 | SYNGR2 | synaptogyrin 2 | 3 |
| 2876 | GPX1 | glutathione peroxidase 1 | 3 |
| 29914 | UBIAD1 | UbiA prenyltransferase domain containing 1 | 3 |

| | | |
|------------------------|-----------|--|
| 5050 | PAFAH1B3 | platelet activating factor acetylhydrolase 1b catalytic subunit 3 |
| 23276 | KLHL18 | kelch like family member 18 |
| 51647 | FAM96B | family with sequence similarity 96 member B |
| 23381 | SMG5 | SMG5, nonsense mediated mRNA decay factor |
| 5714 | PSMD8 | proteasome 26S subunit, non-ATPase 8 |
| 4946 | OAZ1 | ornithine decarboxylase antizyme 1 |
| 6647 | SOD1 | superoxide dismutase 1, soluble |
| 4234 | METTL1 | methyltransferase like 1 |
| 116238 | TLCD1 | TLC domain containing 1 |
| 7167 | TPI1 | triosephosphate isomerase 1 |
| 10953 | TOMM34 | translocase of outer mitochondrial membrane 34 |
| 27341 | RRP7A | ribosomal RNA processing 7 homolog A |
| 65057 | ACD | adrenocortical dysplasia homolog |
| 64943 | NT5DC2 | 5'-nucleotidase domain containing 2 |
| 5425 | POLD2 | DNA polymerase delta 2, accessory subunit |
| 79143 | MBOAT7 | membrane bound O-acyltransferase domain containing 7 |
| 9361 | LONP1 | lon peptidase 1, mitochondrial |
| 6150 | MRPL23 | mitochondrial ribosomal protein L23 |
| 1337 | COX6A1 | cytochrome c oxidase subunit 6A1 |
| 10726 | NUDC | nuclear distribution C, dynein complex regulator |
| 51690 | LSM7 | LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated |
| 5441 | POLR2L | RNA polymerase II subunit L |
| 55272 | IMP3 | IMP3, U3 small nucleolar ribonucleoprotein |
| 11047 | ADRM1 | adhesion regulating molecule 1 |
| 23170 | TTLL12 | tubulin tyrosine ligase like 12 |
| 53354 | PANK1 | pantothenate kinase 1 |
| 3692 | EIF6 | eukaryotic translation initiation factor 6 |
| 5709 | PSMD3 | proteasome 26S subunit, non-ATPase 3 |
| 23543 | RBFOX2 | RNA binding protein, fox-1 homolog 2 |
| 56834 | GPR137 | G protein-coupled receptor 137 |
| 8402 | SLC25A11 | solute carrier family 25 member 11 |
| 5694 | PSMB6 | proteasome subunit beta 6 |
| 10113 | PREB | prolactin regulatory element binding |
| 26073 | POLDIP2 | DNA polymerase delta interacting protein 2 |
| 28989 | NTMT1 | N-terminal Xaa-Pro-Lys N-methyltransferase 1 |
| 55856 | ACOT13 | acyl-CoA thioesterase 13 |
| 29934 | SNX12 | sorting nexin 12 |
| 23645 | PPP1R15A | protein phosphatase 1 regulatory subunit 15A |
| 51278 | IER5 | immediate early response 5 |
| 10063 | COX17 | COX17, cytochrome c oxidase copper chaperone |
| 83706 | FERMT3 | fermitin family member 3 |
| 54973 | CPSF3L | cleavage and polyadenylation specific factor 3-like |
| 401466 | C8orf59 | chromosome 8 open reading frame 59 |
| 84287 | ZDHHC16 | zinc finger DHHC-type containing 16 |
| 10257 | ABCC4 | ATP binding cassette subfamily C member 4 |
| 23466 | CBX6 | chromobox 6 |
| 64965 | MRPS9 | mitochondrial ribosomal protein S9 |
| 51097 | SCCPDH | saccharopine dehydrogenase (putative) |
| 51659 | GINS2 | GINS complex subunit 2 |
| 6434 | TRA2B | transformer 2 beta homolog (Drosophila) |
| 471 | ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
| 23074 | UHRF1BP1L | UHRF1 binding protein 1 like |
| 10598 | AHSA1 | activator of Hsp90 ATPase activity 1 |
| 1653 | DDX1 | DEAD/H-box helicase 1 |
| 57695 | USP37 | ubiquitin specific peptidase 37 |
| 3840 | KPNA4 | karyopherin subunit alpha 4 |
| 54517 | PUS7 | pseudouridylate synthase 7 (putative) |
| 8870 | IER3 | immediate early response 3 |
| 9761 | MLEC | malectin |
| 116225 | ZMYND19 | zinc finger MYND-type containing 19 |
| 6183 | MRPS12 | mitochondrial ribosomal protein S12 |
| 9308 | CD83 | CD83 molecule |
| 10061 | ABCF2 | ATP binding cassette subfamily F member 2 |
| 6484 | ST3GAL4 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 |

| | | |
|------------------------|----------|---|
| 283742 | FAM98B | family with sequence similarity 98 member B |
| 27158 | NDOR1 | NADPH dependent diflavin oxidoreductase 1 |
| 126792 | B3GALT6 | beta-1,3-galactosyltransferase 6 |
| 51400 | PPME1 | protein phosphatase methylesterase 1 |
| 10694 | CCT8 | chaperonin containing TCP1 subunit 8 |
| 29090 | TIMM21 | translocase of inner mitochondrial membrane 21 |
| 4670 | HNRNPM | heterogeneous nuclear ribonucleoprotein M |
| 10988 | METAP2 | methionyl aminopeptidase 2 |
| 9868 | TOMM70 | translocase of outer mitochondrial membrane 70 |
| 1431 | CS | citrate synthase |
| 3157 | HMGCS1 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 |
| 11112 | HIBADH | 3-hydroxyisobutyrate dehydrogenase |
| 10213 | PSMD14 | proteasome 26S subunit, non-ATPase 14 |
| 1434 | CSE1L | chromosome segregation 1 like |
| 51081 | MRPS7 | mitochondrial ribosomal protein S7 |
| 23590 | PDSS1 | prenyl (decaprenyl) diphosphate synthase, subunit 1 |
| 6749 | SSRP1 | structure specific recognition protein 1 |
| 3562 | IL3 | interleukin 3 |
| 10189 | ALYREF | Aly/REF export factor |
| 6431 | SRSF6 | serine and arginine rich splicing factor 6 |
| 292 | SLC25A5 | solute carrier family 25 member 5 |
| 23160 | WDR43 | WD repeat domain 43 |
| 2030 | SLC29A1 | solute carrier family 29 member 1 (Augustine blood group) |
| 5536 | PPP5C | protein phosphatase 5 catalytic subunit |
| 9188 | DDX21 | DEAD-box helicase 21 |
| 8726 | EED | embryonic ectoderm development |
| 29889 | GNL2 | G protein nucleolar 2 |
| 4436 | MSH2 | mutS homolog 2 |
| 4175 | MCM6 | minichromosome maintenance complex component 6 |
| 10939 | AFG3L2 | AFG3 like matrix AAA peptidase subunit 2 |
| 1994 | ELAVL1 | ELAV like RNA binding protein 1 |
| 23450 | SF3B3 | splicing factor 3b subunit 3 |
| 29781 | NCAPH2 | non-SMC condensin II complex subunit H2 |
| 5707 | PSMD1 | proteasome 26S subunit, non-ATPase 1 |
| 10657 | KHDRBS1 | KH RNA binding domain containing, signal transduction associated 1 |
| 10432 | RBM14 | RNA binding motif protein 14 |
| 7518 | XRCC4 | X-ray repair cross complementing 4 |
| 3301 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 |
| 2935 | GSPT1 | G1 to S phase transition 1 |
| 1982 | EIF4G2 | eukaryotic translation initiation factor 4 gamma 2 |
| 3184 | HNRNPD | heterogeneous nuclear ribonucleoprotein D |
| 23082 | PPRC1 | peroxisome proliferator-activated receptor gamma, coactivator-related 1 |
| 27089 | UQCRCQ | ubiquinol-cytochrome c reductase complex III subunit VII |
| 7165 | TPD52L2 | tumor protein D52 like 2 |
| 29098 | RANGRF | RAN guanine nucleotide release factor |
| 8260 | NAA10 | N(alpha)-acetyltransferase 10, NatA catalytic subunit |
| 51373 | MRPS17 | mitochondrial ribosomal protein S17 |
| 1892 | ECHS1 | enoyl-CoA hydratase, short chain 1 |
| 22868 | FASTKD2 | FAST kinase domains 2 |
| 5931 | RBBP7 | RB binding protein 7, chromatin remodeling factor |
| 84135 | UTP15 | UTP15, small subunit processome component |
| 23165 | NUP205 | nucleoporin 205 |
| 5202 | PFDN2 | prefoldin subunit 2 |
| 84331 | MCRIP2 | MAPK regulated corepressor interacting protein 2 |
| 705 | BYSL | bystin like |
| 3622 | ING2 | inhibitor of growth family member 2 |
| 9631 | NUP155 | nucleoporin 155 |
| 79711 | IPO4 | importin 4 |
| 1660 | DHX9 | DEAH-box helicase 9 |
| 7372 | UMPS | uridine monophosphate synthetase |
| 199953 | TMEM201 | transmembrane protein 201 |
| 3068 | HDGF | hepatoma-derived growth factor |
| 10295 | BCKDK | branched chain ketoacid dehydrogenase kinase |
| 144097 | C11orf84 | chromosome 11 open reading frame 84 |
| 4628 | MYH10 | myosin heavy chain 10 |
| 84649 | DGAT2 | diacylglycerol O-acyltransferase 2 |

| | | | |
|------------------------|----------|--|---|
| 516 | ATP5G1 | ATP synthase, H ⁺ transporting, mitochondrial Fo complex subunit C1 (subunit 9) | 3 |
| 5719 | PSMD13 | proteasome 26S subunit, non-ATPase 13 | 3 |
| 1212 | CLTB | clathrin light chain B | 3 |
| 8882 | ZPR1 | ZPR1 zinc finger | 3 |
| 10430 | TMEM147 | transmembrane protein 147 | 3 |
| 10534 | SSSCA1 | Sjogren syndrome/scleroderma autoantigen 1 | 3 |
| 8664 | EIF3D | eukaryotic translation initiation factor 3 subunit D | 3 |
| 79572 | ATP13A3 | ATPase 13A3 | 3 |
| 10452 | TOMM40 | translocase of outer mitochondrial membrane 40 | 3 |
| 3615 | IMPDH2 | inosine monophosphate dehydrogenase 2 | 3 |
| 85476 | GFM1 | G elongation factor mitochondrial 1 | 3 |
| 10575 | CCT4 | chaperonin containing TCP1 subunit 4 | 3 |
| 2184 | FAH | fumarylacetoacetate hydrolase | 3 |
| 201161 | CENPV | centromere protein V | 3 |
| 121053 | C12orf45 | chromosome 12 open reading frame 45 | 3 |
| 5198 | PFAS | phosphoribosylformylglycinamidine synthase | 3 |
| 113419 | TEX261 | testis expressed 261 | 3 |
| 3308 | HSPA4 | heat shock protein family A (Hsp70) member 4 | 3 |
| 9654 | TTL4 | tubulin tyrosine ligase like 4 | 3 |
| 23 | ABCF1 | ATP binding cassette subfamily F member 1 | 3 |
| 4171 | MCM2 | minichromosome maintenance complex component 2 | 3 |
| 9929 | JOSD1 | Josephin domain containing 1 | 3 |
| 949 | SCARB1 | scavenger receptor class B member 1 | 3 |
| 192111 | PGAM5 | PGAM family member 5, mitochondrial serine/threonine protein phosphatase | 3 |
| 23277 | CLUH | clustered mitochondria homolog | 3 |
| 27042 | DIEXF | digestive organ expansion factor homolog (zebrafish) | 3 |
| 10155 | TRIM28 | tripartite motif containing 28 | 3 |
| 54919 | DNAAF5 | dynein axonemal assembly factor 5 | 3 |
| 7517 | XRCC3 | X-ray repair cross complementing 3 | 3 |
| 4174 | MCM5 | minichromosome maintenance complex component 5 | 3 |
| 84817 | TXNDC17 | thioredoxin domain containing 17 | 3 |
| 5434 | POLR2E | RNA polymerase II subunit E | 3 |
| 9146 | HGS | hepatocyte growth factor-regulated tyrosine kinase substrate | 3 |
| 79709 | COLGALT1 | collagen beta(1-O)galactosyltransferase 1 | 3 |
| 2802 | GOLGA3 | golgin A3 | 3 |
| 2706 | GJB2 | gap junction protein beta 2 | 3 |
| 55120 | FANCL | Fanconi anemia complementation group L | 3 |
| 25885 | POLR1A | RNA polymerase I subunit A | 3 |
| 54107 | POLE3 | DNA polymerase epsilon 3, accessory subunit | 3 |
| 57464 | STRIP2 | striatin interacting protein 2 | 3 |
| 1848 | DUSP6 | dual specificity phosphatase 6 | 3 |
| 154807 | VKORC1L1 | vitamin K epoxide reductase complex subunit 1 like 1 | 3 |
| 127396 | ZNF684 | zinc finger protein 684 | 3 |
| 222229 | LRWD1 | leucine rich repeats and WD repeat domain containing 1 | 3 |
| 351 | APP | amyloid beta precursor protein | 3 |
| 63932 | CXorf56 | chromosome X open reading frame 56 | 3 |
| 65108 | MARCKSL1 | MARCKS like 1 | 3 |
| 23413 | NCS1 | neuronal calcium sensor 1 | 3 |
| 2963 | GTF2F2 | general transcription factor IIF subunit 2 | 3 |
| 548645 | DNAJC25 | DnaJ heat shock protein family (Hsp40) member C25 | 3 |
| 56655 | POLE4 | DNA polymerase epsilon 4, accessory subunit | 3 |
| 7532 | YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma | 3 |
| 84326 | METTL26 | methyltransferase like 26 | 3 |
| 51259 | TMEM216 | transmembrane protein 216 | 3 |
| 8662 | EIF3B | eukaryotic translation initiation factor 3 subunit B | 3 |
| 14 | AAMP | angio associated migratory cell protein | 3 |
| 29893 | PSMC3IP | PSMC3 interacting protein | 3 |
| 55142 | HAUS2 | HAUS augmin like complex subunit 2 | 3 |
| 10204 | NUTF2 | nuclear transport factor 2 | 3 |
| 81620 | CDT1 | chromatin licensing and DNA replication factor 1 | 3 |
| 11072 | DUSP14 | dual specificity phosphatase 14 | 3 |
| 10538 | BATF | basic leucine zipper ATF-like transcription factor | 3 |
| 1022 | CDK7 | cyclin dependent kinase 7 | 3 |
| 79080 | CCDC86 | coiled-coil domain containing 86 | 3 |
| 64979 | MRPL36 | mitochondrial ribosomal protein L36 | 3 |

| | | |
|------------------------|-------------|--|
| 112812 | FDX1L | ferredoxin 1 like |
| 1642 | DDB1 | damage specific DNA binding protein 1 |
| 84262 | PSMG3 | proteasome assembly chaperone 3 |
| 55862 | ECHDC1 | ethylmalonyl-CoA decarboxylase 1 |
| 64785 | GINS3 | GINS complex subunit 3 |
| 5438 | POLR2I | RNA polymerase II subunit I |
| 286 | ANK1 | ankyrin 1 |
| 51534 | VTA1 | vesicle trafficking 1 |
| 2717 | GLA | galactosidase alpha |
| 84916 | UTP4 | UTP4, small subunit processome component |
| 64963 | MRPS11 | mitochondrial ribosomal protein S11 |
| 6351 | CCL4 | C-C motif chemokine ligand 4 |
| 79022 | TMEM106C | transmembrane protein 106C |
| 8395 | PIP5K1B | phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
| 4809 | SNU13 | SNU13 homolog, small nuclear ribonucleoprotein (U4/U6.U5) |
| 60673 | ATG101 | autophagy related 101 |
| 29105 | CFAP20 | cilia and flagella associated protein 20 |
| 114971 | PTPMT1 | protein tyrosine phosphatase, mitochondrial 1 |
| 27020 | NPTN | neuroplastin |
| 10248 | POP7 | POP7 homolog, ribonuclease P/MRP subunit |
| 9775 | EIF4A3 | eukaryotic translation initiation factor 4A3 |
| 79155 | TNIP2 | TNFAIP3 interacting protein 2 |
| 1211 | CLTA | clathrin light chain A |
| 5693 | PSMB5 | proteasome subunit beta 5 |
| 7262 | PHLDA2 | pleckstrin homology like domain family A member 2 |
| 131566 | DCBLD2 | discoidin, CUB and LCCL domain containing 2 |
| 29902 | FAM216A | family with sequence similarity 216 member A |
| 51013 | EXOSC1 | exosome component 1 |
| 27309 | ZNF330 | zinc finger protein 330 |
| 64983 | MRPL32 | mitochondrial ribosomal protein L32 |
| 5036 | PA2G4 | proliferation-associated 2G4 |
| 51010 | EXOSC3 | exosome component 3 |
| 147184 | TMEM99 | transmembrane protein 99 |
| 60314 | C12orf10 | chromosome 12 open reading frame 10 |
| 79590 | MRPL24 | mitochondrial ribosomal protein L24 |
| 154467 | CCDC167 | coiled-coil domain containing 167 |
| 483 | ATP1B3 | ATPase Na ⁺ /K ⁺ transporting subunit beta 3 |
| 282991 | BLOC1S2 | biogenesis of lysosomal organelles complex 1 subunit 2 |
| 10322 | SMYD5 | SMYD family member 5 |
| 4000 | LMNA | lamin A/C |
| 1497 | CTNS | cystinosis, lysosomal cystine transporter |
| 51073 | MRPL4 | mitochondrial ribosomal protein L4 |
| 6449 | SGTA | small glutamine rich tetratricopeptide repeat containing alpha |
| 10186 | LHFP | lipoma HMGIC fusion partner |
| 55847 | CISD1 | CDGSH iron sulfur domain 1 |
| 25940 | FAM98A | family with sequence similarity 98 member A |
| 9861 | PSMD6 | proteasome 26S subunit, non-ATPase 6 |
| 356 | FASLG | Fas ligand |
| 79077 | DCTPP1 | dCTP pyrophosphatase 1 |
| 57514 | ARHGAP31 | Rho GTPase activating protein 31 |
| 84259 | DCUN1D5 | defective in cullin neddylation 1 domain containing 5 |
| 1104 | RCC1 | regulator of chromosome condensation 1 |
| 54555 | DDX49 | DEAD-box helicase 49 |
| 84769 | MPV17L2 | MPV17 mitochondrial inner membrane protein like 2 |
| 119559 | SFXN4 | sideroflexin 4 |
| 55968 | NSFL1C | NSFL1 cofactor |
| 3066 | HDAC2 | histone deacetylase 2 |
| 1984 | EIF5A | eukaryotic translation initiation factor 5A |
| 4792 | NFKBIA | NFKB inhibitor alpha |
| 7314 | UBB | ubiquitin B |
| 5704 | PSMC4 | proteasome 26S subunit, ATPase 4 |
| 125144 | LRRC75A-AS1 | LRRC75A antisense RNA 1 |
| 50486 | G0S2 | G0/G1 switch 2 |
| 54955 | C1orf109 | chromosome 1 open reading frame 109 |
| 25804 | LSM4 | LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated |

| | | |
|------------------------|----------|---|
| 51021 | MRPS16 | mitochondrial ribosomal protein S16 |
| 54475 | NLE1 | notchless homolog 1 |
| 56915 | EXOSC5 | exosome component 5 |
| 92579 | G6PC3 | glucose-6-phosphatase catalytic subunit 3 |
| 2590 | GALNT2 | polypeptide N-acetylgalactosaminyltransferase 2 |
| 54663 | WDR74 | WD repeat domain 74 |
| 4201 | MEA1 | male-enhanced antigen 1 |
| 3558 | IL2 | interleukin 2 |
| 5250 | SLC25A3 | solute carrier family 25 member 3 |
| 1844 | DUSP2 | dual specificity phosphatase 2 |
| 5326 | PLAGL2 | PLAG1 like zinc finger 2 |
| 83596 | BCL2L12 | BCL2 like 12 |
| 84285 | EIF1AD | eukaryotic translation initiation factor 1A domain containing |
| 5245 | PHB | prohibitin |
| 27351 | DES1 | desumoylating isopeptidase 1 |
| 5902 | RANBP1 | RAN binding protein 1 |
| 54982 | CLN6 | ceroid-lipofuscinosis, neuronal 6, late infantile, variant |
| 5725 | PTBP1 | polypyrimidine tract binding protein 1 |
| 30000 | TNPO2 | transportin 2 |
| 51144 | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 |
| 5552 | SRGN | serglycin |
| 5251 | PHEX | phosphate regulating endopeptidase homolog, X-linked |
| 4953 | ODC1 | ornithine decarboxylase 1 |
| 8740 | TNFSF14 | tumor necrosis factor superfamily member 14 |
| 6723 | SRM | spermidine synthase |
| 55352 | COPRS | coordinator of PRMT5 and differentiation stimulator |
| 7866 | IFRD2 | interferon related developmental regulator 2 |
| 23076 | RRP1B | ribosomal RNA processing 1B |
| 112464 | PRKCDBP | protein kinase C delta binding protein |
| 66005 | CHID1 | chitinase domain containing 1 |
| 388962 | BOLA3 | bolA family member 3 |
| 7293 | TNFRSF4 | TNF receptor superfamily member 4 |
| 4927 | NUP88 | nucleoporin 88 |
| 3002 | GZMB | granzyme B |
| 3559 | IL2RA | interleukin 2 receptor subunit alpha |
| 79033 | ERI3 | ERI1 exoribonuclease family member 3 |
| 494143 | CHAC2 | ChaC cation transport regulator homolog 2 |
| 84833 | USMG5 | up-regulated during skeletal muscle growth 5 homolog (mouse) |
| 7283 | TUBG1 | tubulin gamma 1 |
| 51371 | POMP | proteasome maturation protein |
| 51605 | TRMT6 | tRNA methyltransferase 6 |
| 54865 | GPATCH4 | G-patch domain containing 4 |
| 219927 | MRPL21 | mitochondrial ribosomal protein L21 |
| 2091 | FBL | fibrillarin |
| 5695 | PSMB7 | proteasome subunit beta 7 |
| 1460 | CSNK2B | casein kinase 2 beta |
| 7965 | AIMP2 | aminoacyl tRNA synthetase complex interacting multifunctional protein 2 |
| 200916 | RPL22L1 | ribosomal protein L22 like 1 |
| 4700 | NDUFA6 | NADH:ubiquinone oxidoreductase subunit A6 |
| 10549 | PRDX4 | peroxiredoxin 4 |
| 84807 | NFKBID | NFKB inhibitor delta |
| 2288 | FKBP4 | FK506 binding protein 4 |
| 3276 | PRMT1 | protein arginine methyltransferase 1 |
| 60488 | MRPS35 | mitochondrial ribosomal protein S35 |
| 23481 | PES1 | pescadillo ribosomal biogenesis factor 1 |
| 196383 | RILPL2 | Rab interacting lysosomal protein like 2 |
| 2224 | FDPS | farnesyl diphosphate synthase |
| 55003 | PAK1IP1 | PAK1 interacting protein 1 |
| 126382 | NR2C2AP | nuclear receptor 2C2 associated protein |
| 51504 | TRMT112 | tRNA methyltransferase 11-2 homolog (S. cerevisiae) |
| 92609 | TIMM50 | translocase of inner mitochondrial membrane 50 |
| 708 | C1QBP | complement C1q binding protein |
| 10327 | AKR1A1 | aldo-keto reductase family 1 member A1 |
| 6921 | TCEB1 | transcription elongation factor B subunit 1 |
| 26517 | TIMM13 | translocase of inner mitochondrial membrane 13 |

| | | |
|------------------------|----------|--|
| 84313 | VPS25 | vacuolar protein sorting 25 homolog |
| 63875 | MRPL17 | mitochondrial ribosomal protein L17 |
| 5435 | POLR2F | RNA polymerase II subunit F |
| 79833 | GEMIN6 | gem nuclear organelle associated protein 6 |
| 1736 | DKC1 | dyskerin pseudouridine synthase 1 |
| 23560 | GTPBP4 | GTP binding protein 4 |
| 7371 | UCK2 | uridine-cytidine kinase 2 |
| 3182 | HNRNPAB | heterogeneous nuclear ribonucleoprotein A/B |
| 4691 | NCL | nucleolin |
| 56902 | PNO1 | partner of NOB1 homolog |
| 3313 | HSPA9 | heat shock protein family A (Hsp70) member 9 |
| 1019 | CDK4 | cyclin dependent kinase 4 |
| 5901 | RAN | RAN, member RAS oncogene family |
| 10528 | NOP56 | NOP56 ribonucleoprotein |
| 29015 | SLC43A3 | solute carrier family 43 member 3 |
| 25819 | NOCT | nocturnin |
| 26230 | TIAM2 | T-cell lymphoma invasion and metastasis 2 |
| 10969 | EBNA1BP2 | EBNA1 binding protein 2 |
| 10135 | NAMPT | nicotinamide phosphoribosyltransferase |
| 10196 | PRMT3 | protein arginine methyltransferase 3 |
| 6626 | SNRPA | small nuclear ribonucleoprotein polypeptide A |
| 8668 | EIF3I | eukaryotic translation initiation factor 3 subunit I |
| 113174 | SAAL1 | serum amyloid A like 1 |
| 54984 | PINX1 | PIN2/TERF1 interacting, telomerase inhibitor 1 |
| 6636 | SNRPF | small nuclear ribonucleoprotein polypeptide F |
| 5052 | PRDX1 | peroxiredoxin 1 |
| 51493 | RTCB | RNA 2',3'-cyclic phosphate and 5'-OH ligase |
| 3608 | ILF2 | interleukin enhancer binding factor 2 |
| 11091 | WDR5 | WD repeat domain 5 |
| 10056 | FARSB | phenylalanyl-tRNA synthetase beta subunit |
| 10492 | SYNCRIP | synaptotagmin binding cytoplasmic RNA interacting protein |
| 8061 | FOSL1 | FOS like 1, AP-1 transcription factor subunit |
| 3329 | HSPD1 | heat shock protein family D (Hsp60) member 1 |
| 9221 | NOLC1 | nucleolar and coiled-body phosphoprotein 1 |
| 6631 | SNRPC | small nuclear ribonucleoprotein polypeptide C |
| 7416 | VDAC1 | voltage dependent anion channel 1 |
| 1647 | GADD45A | growth arrest and DNA damage inducible alpha |
| 3605 | IL17A | interleukin 17A |
| 617 | BCS1L | BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
| 93436 | ARMC6 | armadillo repeat containing 6 |
| 10227 | MFS10 | major facilitator superfamily domain containing 10 |
| 55624 | POMGNT1 | protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) |
| 64768 | IPPK | inositol-pentakisphosphate 2-kinase |
| 126321 | MFS12 | major facilitator superfamily domain containing 12 |
| 8192 | CLPP | caseinolytic mitochondrial matrix peptidase proteolytic subunit |
| 84300 | UQC2 | ubiquinol-cytochrome c reductase complex assembly factor 2 |
| 10244 | RABEPK | Rab9 effector protein with kelch motifs |
| 57819 | LSM2 | LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated |
| 28958 | COA3 | cytochrome c oxidase assembly factor 3 |
| 2109 | ETFB | electron transfer flavoprotein beta subunit |
| 11266 | DUSP12 | dual specificity phosphatase 12 |
| 51474 | LIMA1 | LIM domain and actin binding 1 |
| 4731 | NDUFV3 | NADH:ubiquinone oxidoreductase subunit V3 |
| 4701 | NDUFA7 | NADH:ubiquinone oxidoreductase subunit A7 |
| 9238 | TBRG4 | transforming growth factor beta regulator 4 |
| 29080 | CCDC59 | coiled-coil domain containing 59 |
| 29985 | SLC39A3 | solute carrier family 39 member 3 |
| 1537 | CYC1 | cytochrome c1 |
| 8784 | TNFRSF18 | TNF receptor superfamily member 18 |
| 9526 | MPDU1 | mannose-P-dolichol utilization defect 1 |
| 26121 | PRPF31 | pre-mRNA processing factor 31 |
| 977 | CD151 | CD151 molecule (Raph blood group) |
| 83460 | EMC6 | ER membrane protein complex subunit 6 |
| 64960 | MRPS15 | mitochondrial ribosomal protein S15 |
| 2950 | GSTP1 | glutathione S-transferase pi 1 |

| | | | |
|------------------------|-----------|---|---|
| 112939 | NACC1 | nucleus accumbens associated 1 | 3 |
| 51293 | CD320 | CD320 molecule | 3 |
| 5119 | CHMP1A | charged multivesicular body protein 1A | 3 |
| 8886 | DDX18 | DEAD-box helicase 18 | 3 |
| 8818 | DPM2 | dolichyl-phosphate mannosyltransferase subunit 2, regulatory | 3 |
| 26519 | TIMM10 | translocase of inner mitochondrial membrane 10 homolog (yeast) | 3 |
| 4236 | MFAP1 | microfibrillar associated protein 1 | 3 |
| 5214 | PFKP | phosphofructokinase, platelet | 3 |
| 79894 | ZNF672 | zinc finger protein 672 | 3 |
| 51116 | MRPS2 | mitochondrial ribosomal protein S2 | 3 |
| 29950 | SERTAD1 | SERTA domain containing 1 | 3 |
| 23399 | CTDNEP1 | CTD nuclear envelope phosphatase 1 | 3 |
| 54881 | TEX10 | testis expressed 10 | 3 |
| 10245 | TIMM17B | translocase of inner mitochondrial membrane 17 homolog B (yeast) | 3 |
| 51236 | HGH1 | HGH1 homolog | 3 |
| 55697 | VAC14 | Vac14, PIKFYVE complex component | 3 |
| 27183 | VPS4A | vacuolar protein sorting 4 homolog A | 3 |
| 5394 | EXOSC10 | exosome component 10 | 3 |
| 55157 | DARS2 | aspartyl-tRNA synthetase 2, mitochondrial | 3 |
| 3726 | JUNB | JunB proto-oncogene, AP-1 transcription factor subunit | 3 |
| 3281 | HSBP1 | heat shock factor binding protein 1 | 3 |
| 55658 | RNF126 | ring finger protein 126 | 3 |
| 9455 | HOMER2 | homer scaffolding protein 2 | 3 |
| 345630 | FBLL1 | fibrillarin-like 1 | 3 |
| 29923 | HILPDA | hypoxia inducible lipid droplet associated | 3 |
| 54968 | TMEM70 | transmembrane protein 70 | 3 |
| 84002 | B3GNT5 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 | 3 |
| 10573 | MRPL28 | mitochondrial ribosomal protein L28 | 3 |
| 55168 | MRPS18A | mitochondrial ribosomal protein S18A | 3 |
| 4817 | NIT1 | nitrilase 1 | 3 |
| 7247 | TSN | translin | 3 |
| 54148 | MRPL39 | mitochondrial ribosomal protein L39 | 3 |
| 29100 | TMEM208 | transmembrane protein 208 | 3 |
| 9326 | ZNHIT3 | zinc finger HIT-type containing 3 | 3 |
| 5682 | PSMA1 | proteasome subunit alpha 1 | 3 |
| 64708 | COP9B | COP9 signalosome subunit 7B | 3 |
| 6415 | SELENOW | selenoprotein W | 3 |
| 10069 | RWDD2B | RWD domain containing 2B | 3 |
| 54840 | APTX | aprataxin | 3 |
| 112495 | GTF3C6 | general transcription factor IIIC subunit 6 | 3 |
| 10102 | TSFM | Ts translation elongation factor, mitochondrial | 3 |
| 29097 | CNIH4 | cornichon family AMPA receptor auxiliary protein 4 | 3 |
| 9391 | CIAO1 | cytosolic iron-sulfur assembly component 1 | 3 |
| 221143 | EEF1AKMT1 | eukaryotic translation elongation factor 1 alpha lysine methyltransferase 1 | 3 |
| 4116 | MAGOH | mago homolog, exon junction complex core component | 3 |
| 54887 | UHRF1BP1 | UHRF1 binding protein 1 | 3 |
| 128553 | TSHZ2 | teashirt zinc finger homeobox 2 | 3 |
| 9088 | PKMYT1 | protein kinase, membrane associated tyrosine/threonine 1 | 3 |
| 51154 | MRT04 | MRT4 homolog, ribosome maturation factor | 3 |
| 10131 | TRAP1 | TNF receptor associated protein 1 | 3 |
| 63933 | MCUR1 | mitochondrial calcium uniporter regulator 1 | 3 |
| 10212 | DDX39A | DEAD-box helicase 39A | 3 |
| 51714 | SELENOT | selenoprotein T | 3 |
| 4191 | MDH2 | malate dehydrogenase 2 | 3 |
| 10498 | CARM1 | coactivator associated arginine methyltransferase 1 | 3 |
| 5817 | PVR | poliovirus receptor | 3 |
| 80764 | THAP7 | THAP domain containing 7 | 3 |
| 2193 | FARSA | phenylalanyl-tRNA synthetase alpha subunit | 3 |
| 7284 | TUFM | Tu translation elongation factor, mitochondrial | 3 |
| 5426 | POLE | DNA polymerase epsilon, catalytic subunit | 3 |
| 5962 | RDX | radixin | 3 |
| 10785 | WDR4 | WD repeat domain 4 | 3 |
| 27101 | CACYBP | calyculin binding protein | 3 |
| 23291 | FBXW11 | F-box and WD repeat domain containing 11 | 3 |
| 2632 | GBE1 | 1,4-alpha-glucan branching enzyme 1 | 3 |

| | | | |
|------------------------|----------|--|---|
| 84172 | POLR1B | RNA polymerase I subunit B | 3 |
| 55324 | ABCF3 | ATP binding cassette subfamily F member 3 | 3 |
| 60625 | DHX35 | DEAH-box helicase 35 | 3 |
| 8815 | BANF1 | barrier to autointegration factor 1 | 3 |
| 9937 | DCLRE1A | DNA cross-link repair 1A | 3 |
| 10980 | COPS6 | COP9 signalosome subunit 6 | 3 |
| 27069 | GHITM | growth hormone inducible transmembrane protein | 3 |
| 2827 | GPR3 | G protein-coupled receptor 3 | 3 |
| 5432 | POLR2C | RNA polymerase II subunit C | 3 |
| 7458 | EIF4H | eukaryotic translation initiation factor 4H | 3 |
| 51499 | TRIAF1 | TP53 regulated inhibitor of apoptosis 1 | 3 |
| 5781 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 | 3 |
| 53 | ACP2 | acid phosphatase 2, lysosomal | 3 |
| 653122 | LSM12P1 | LSM12 pseudogene 1 | 3 |
| 94081 | SFXN1 | sideroflexin 1 | 3 |
| 8125 | ANP32A | acidic nuclear phosphoprotein 32 family member A | 3 |
| 3312 | HSPA8 | heat shock protein family A (Hsp70) member 8 | 3 |
| 54994 | GID8 | GID complex subunit 8 homolog | 3 |
| 8898 | MTMR2 | myotubularin related protein 2 | 3 |
| 5905 | RANGAP1 | Ran GTPase activating protein 1 | 3 |
| 23141 | ANKLE2 | ankyrin repeat and LEM domain containing 2 | 3 |
| 196483 | EEF2KMT | eukaryotic elongation factor 2 lysine methyltransferase | 3 |
| 65083 | NOL6 | nucleolar protein 6 | 3 |
| 51001 | MTERF3 | mitochondrial transcription termination factor 3 | 3 |
| 51537 | MTFP1 | mitochondrial fission process 1 | 3 |
| 64065 | PERP | PERP, TP53 apoptosis effector | 3 |
| 6428 | SRSF3 | serine and arginine rich splicing factor 3 | 3 |
| 60592 | SCOC | short coiled-coil protein | 3 |
| 58477 | SRPRB | SRP receptor beta subunit | 3 |
| 51015 | ISOC1 | isochorismatase domain containing 1 | 3 |
| 3838 | KPNA2 | karyopherin subunit alpha 2 | 3 |
| 2553 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 3 |
| 57486 | NLN | neurolysin | 3 |
| 10130 | PDIA6 | protein disulfide isomerase family A member 6 | 3 |
| 65008 | MRPL1 | mitochondrial ribosomal protein L1 | 3 |
| 133957 | CCDC127 | coiled-coil domain containing 127 | 3 |
| 131474 | CHCHD4 | coiled-coil-helix-coiled-coil-helix domain containing 4 | 3 |
| 65265 | C8orf33 | chromosome 8 open reading frame 33 | 3 |
| 10440 | TIMM17A | translocase of inner mitochondrial membrane 17 homolog A (yeast) | 3 |
| 27292 | DIMT1 | DIM1 dimethyladenosine transferase 1 homolog | 3 |
| 7336 | UBE2V2 | ubiquitin conjugating enzyme E2 V2 | 3 |
| 80746 | TSEN2 | tRNA splicing endonuclease subunit 2 | 3 |
| 8914 | TIMELESS | timeless circadian clock | 3 |
| 2665 | GDI2 | GDP dissociation inhibitor 2 | 3 |
| 83877 | TM2D2 | TM2 domain containing 2 | 3 |
| 2618 | GART | phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase | 3 |
| 81034 | SLC25A32 | solute carrier family 25 member 32 | 3 |
| 29088 | MRPL15 | mitochondrial ribosomal protein L15 | 3 |
| 56647 | BCCIP | BRCA2 and CDKN1A interacting protein | 3 |
| 10935 | PRDX3 | peroxiredoxin 3 | 3 |
| 5464 | PPA1 | pyrophosphatase (inorganic) 1 | 3 |
| 55226 | NAT10 | N-acetyltransferase 10 | 3 |
| 27349 | MCAT | malonyl-CoA-acyl carrier protein transacylase | 3 |
| 11335 | CBX3 | chromobox 3 | 3 |
| 1267 | CNP | 2',3'-cyclic nucleotide 3' phosphodiesterase | 3 |
| 28998 | MRPL13 | mitochondrial ribosomal protein L13 | 3 |
| 6945 | MLX | MLX, MAX dimerization protein | 3 |
| 23203 | PMPCA | peptidase, mitochondrial processing alpha subunit | 3 |
| 4190 | MDH1 | malate dehydrogenase 1 | 3 |
| 84790 | TUBA1C | tubulin alpha 1c | 3 |
| 54997 | TESC | tescalcin | 3 |
| 153443 | SRFBP1 | serum response factor binding protein 1 | 3 |
| 55164 | SHQ1 | SHQ1, H/ACA ribonucleoprotein assembly factor | 3 |
| 8939 | FUBP3 | far upstream element binding protein 3 | 3 |

| | | | |
|---------------------------|----------|---|---|
| 84991 | RBM17 | RNA binding motif protein 17 | 3 |
| 26354 | GNL3 | G protein nucleolar 3 | 3 |
| 84154 | RPF2 | ribosome production factor 2 homolog | 3 |
| 10946 | SF3A3 | splicing factor 3a subunit 3 | 3 |
| 8727 | CTNNA1 | catenin alpha like 1 | 3 |
| 100287932 | TIMM23 | translocase of inner mitochondrial membrane 23 | 3 |
| 7027 | TFDP1 | transcription factor Dp-1 | 3 |
| 55775 | TDP1 | tyrosyl-DNA phosphodiesterase 1 | 3 |
| 4723 | NDUFB1 | NADH:ubiquinone oxidoreductase core subunit V1 | 3 |
| 9352 | TXNL1 | thioredoxin like 1 | 3 |
| 84541 | KBTBD8 | kelch repeat and BTB domain containing 8 | 3 |
| 10563 | CXCL13 | C-X-C motif chemokine ligand 13 | 3 |
| 5796 | PTPRK | protein tyrosine phosphatase, receptor type K | 3 |
| 10940 | POP1 | POP1 homolog, ribonuclease P/MRP subunit | 3 |
| 9818 | NUP58 | nucleoporin 58 | 3 |
| 8602 | NOP14 | NOP14 nucleolar protein | 3 |
| | | phosphoribosylaminoimidazole carboxylase; | |
| 10606 | PAICS | phosphoribosylaminoimidazolesuccinocarboxamide synthase | 3 |
| 10963 | STIP1 | stress induced phosphoprotein 1 | 3 |
| 51018 | RRP15 | ribosomal RNA processing 15 homolog | 3 |
| 284098 | PIGW | phosphatidylinositol glycan anchor biosynthesis class W | 3 |
| 8661 | EIF3A | eukaryotic translation initiation factor 3 subunit A | 3 |
| 79731 | NARS2 | asparaginyl-tRNA synthetase 2, mitochondrial (putative) | 3 |
| 54806 | AHI1 | Abelson helper integration site 1 | 3 |
| 55326 | AGPAT5 | 1-acylglycerol-3-phosphate O-acyltransferase 5 | 3 |
| 9277 | WDR46 | WD repeat domain 46 | 3 |
| 34 | ACADM | acyl-CoA dehydrogenase, C-4 to C-12 straight chain | 3 |
| 9933 | PUM3 | pumilio RNA binding family member 3 | 3 |
| 3183 | HNRNPC | heterogeneous nuclear ribonucleoprotein C (C1/C2) | 3 |
| 3609 | ILF3 | interleukin enhancer binding factor 3 | 3 |
| 8847 | DLEU2 | deleted in lymphocytic leukemia 2 (non-protein coding) | 3 |
| 84444 | DOT1L | DOT1 like histone lysine methyltransferase | 3 |
| 79728 | PALB2 | partner and localizer of BRCA2 | 3 |
| 7675 | ZNF121 | zinc finger protein 121 | 3 |
| 3190 | HNRNPK | heterogeneous nuclear ribonucleoprotein K | 3 |
| 54928 | IMPAD1 | inositol monophosphatase domain containing 1 | 3 |
| 55055 | ZWILCH | zwilch kinetochore protein | 3 |
| 51649 | MRPS23 | mitochondrial ribosomal protein S23 | 3 |
| 6432 | SRSF7 | serine and arginine rich splicing factor 7 | 3 |
| 9689 | BZW1 | basic leucine zipper and W2 domains 1 | 3 |
| 57122 | NUP107 | nucleoporin 107 | 3 |
| 55839 | CENPN | centromere protein N | 3 |
| 7337 | UBE3A | ubiquitin protein ligase E3A | 3 |
| 7520 | XRCC5 | X-ray repair cross complementing 5 | 3 |
| 29843 | SEN1 | SUMO1/sentrin specific peptidase 1 | 3 |
| 5981 | RFC1 | replication factor C subunit 1 | 3 |
| 87 | ACTN1 | actinin alpha 1 | 3 |
| 92162 | TMEM88 | transmembrane protein 88 | 3 |
| 10951 | CBX1 | chromobox 1 | 3 |
| 2821 | GPI | glucose-6-phosphate isomerase | 3 |
| 79931 | TNIP3 | TNFAIP3 interacting protein 3 | 3 |
| 54512 | EXOSC4 | exosome component 4 | 3 |
| 8682 | PEA15 | phosphoprotein enriched in astrocytes 15 | 3 |
| 5033 | P4HA1 | prolyl 4-hydroxylase subunit alpha 1 | 3 |
| 80762 | NDFIP1 | Nedd4 family interacting protein 1 | 3 |
| 10262 | SF3B4 | splicing factor 3b subunit 4 | 3 |
| 5230 | PGK1 | phosphoglycerate kinase 1 | 3 |
| 7334 | UBE2N | ubiquitin conjugating enzyme E2 N | 3 |
| 143279 | HECTD2 | HECT domain E3 ubiquitin protein ligase 2 | 3 |
| 440093 | H3F3C | H3 histone family member 3C | 3 |
| 760 | CA2 | carbonic anhydrase 2 | 3 |
| 6621 | SNAPC4 | small nuclear RNA activating complex polypeptide 4 | 3 |
| 4678 | NASP | nuclear autoantigenic sperm protein | 3 |
| 339448 | C1orf174 | chromosome 1 open reading frame 174 | 3 |
| 8099 | CDK2AP1 | cyclin dependent kinase 2 associated protein 1 | 3 |

| | | |
|------------------------|-----------|---|
| 2968 | GTF2H4 | general transcription factor IIH subunit 4 |
| 64928 | MRPL14 | mitochondrial ribosomal protein L14 |
| 51651 | PTRH2 | peptidyl-tRNA hydrolase 2 |
| 23583 | SMUG1 | single-strand-selective monofunctional uracil-DNA glycosylase 1 |
| 7295 | TXN | thioredoxin |
| 2017 | CTTN | cortactin |
| 8493 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D |
| 10813 | UTP14A | UTP14A small subunit processome component |
| 84267 | C9orf64 | chromosome 9 open reading frame 64 |
| 55276 | PGM2 | phosphoglucomutase 2 |
| 54606 | DDX56 | DEAD-box helicase 56 |
| 130367 | SGPP2 | sphingosine-1-phosphate phosphatase 2 |
| 1317 | SLC31A1 | solute carrier family 31 member 1 |
| 11333 | PDAP1 | PDGFA associated protein 1 |
| 51020 | HDHC2 | HD domain containing 2 |
| 23512 | SUZ12 | SUZ12 polycomb repressive complex 2 subunit |
| 9927 | MFN2 | mitofusin 2 |
| 84365 | NIFK | nucleolar protein interacting with the FHA domain of MKI67 |
| 80742 | PRR3 | proline rich 3 |
| 10557 | RPP38 | ribonuclease P/MRP subunit p38 |
| 26589 | MRPL46 | mitochondrial ribosomal protein L46 |
| 51491 | NOP16 | NOP16 nucleolar protein |
| 10899 | JTB | jumping translocation breakpoint |
| 51218 | GLRX5 | glutaredoxin 5 |
| 11331 | PHB2 | prohibitin 2 |
| 10195 | ALG3 | ALG3, alpha-1,3- mannosyltransferase |
| 6503 | SLA | Src-like-adaptor |
| 65993 | MRPS34 | mitochondrial ribosomal protein S34 |
| 6364 | CCL20 | C-C motif chemokine ligand 20 |
| 7551 | ZNF3 | zinc finger protein 3 |
| 53405 | CLIC5 | chloride intracellular channel 5 |
| 130589 | GALM | galactose mutarotase |
| 8574 | AKR7A2 | aldo-keto reductase family 7 member A2 |
| 29062 | WDR91 | WD repeat domain 91 |
| 6051 | RNPEP | arginyl aminopeptidase |
| 688 | KLF5 | Kruppel like factor 5 |
| 10620 | ARID3B | AT-rich interaction domain 3B |
| 144195 | SLC2A14 | solute carrier family 2 member 14 |
| 10475 | TRIM38 | tripartite motif containing 38 |
| 90529 | STPG1 | sperm tail PG-rich repeat containing 1 |
| 6195 | RPS6KA1 | ribosomal protein S6 kinase A1 |
| 864 | RUNX3 | runt related transcription factor 3 |
| 10474 | TADA3 | transcriptional adaptor 3 |
| 90589 | ZNF625 | zinc finger protein 625 |
| 84941 | HSH2D | hematopoietic SH2 domain containing |
| 127943 | FCRLB | Fc receptor like B |
| 54894 | RNF43 | ring finger protein 43 |
| 64121 | RRAGC | Ras related GTP binding C |
| 347732 | CATSPER3 | cation channel sperm associated 3 |
| 54914 | FOCAD | focadhesin |
| 90488 | TMEM263 | transmembrane protein 263 |
| 339201 | ASB16-AS1 | ASB16 antisense RNA 1 |
| 4641 | MYO1C | myosin IC |
| 92014 | SLC25A51 | solute carrier family 25 member 51 |
| 5871 | MAP4K2 | mitogen-activated protein kinase kinase kinase 2 |
| 27010 | TPK1 | thiamin pyrophosphokinase 1 |
| 2043 | EPHA4 | EPH receptor A4 |
| 4603 | MYBL1 | MYB proto-oncogene like 1 |
| 83988 | NCALD | neurocalcin delta |
| 79158 | GNPTAB | N-acetylglucosamine-1-phosphate transferase alpha and beta subunits |
| 57646 | USP28 | ubiquitin specific peptidase 28 |
| 23403 | FBXO46 | F-box protein 46 |
| 11059 | WWP1 | WW domain containing E3 ubiquitin protein ligase 1 |
| 7700 | ZNF141 | zinc finger protein 141 |
| 5311 | PKD2 | polycystin 2, transient receptor potential cation channel |

| | | |
|---------------------------|--------------|--|
| 79627 | OGFRL1 | opioid growth factor receptor like 1 |
| 286827 | TRIM59 | tripartite motif containing 59 |
| 10902 | BRD8 | bromodomain containing 8 |
| 26269 | FBXO8 | F-box protein 8 |
| 11153 | FICD | FIC domain containing |
| 9846 | GAB2 | GRB2 associated binding protein 2 |
| 57580 | PREX1 | phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 |
| 3248 | HPGD | hydroxyprostaglandin dehydrogenase 15-(NAD) |
| 133308 | SLC9B2 | solute carrier family 9 member B2 |
| 55650 | PIGV | phosphatidylinositol glycan anchor biosynthesis class V |
| 168374 | ZNF92 | zinc finger protein 92 |
| 115426 | UHRF2 | ubiquitin like with PHD and ring finger domains 2 |
| 100133211 | LOC100133211 | related RAS viral (r-ras) oncogene homolog 2 pseudogene |
| 2800 | GOLGA1 | golgin A1 |
| 22858 | ICK | intestinal cell kinase |
| 64005 | MYO1G | myosin IG |
| 54820 | NDE1 | nudE neurodevelopment protein 1 |
| 81602 | CDADC1 | cytidine and dCMP deaminase domain containing 1 |
| 920 | CD4 | CD4 molecule |
| 27013 | CNPPD1 | cyclin Pas1/PHO80 domain containing 1 |
| 84440 | RAB11FIP4 | RAB11 family interacting protein 4 |
| 9368 | SLC9A3R1 | SLC9A3 regulator 1 |
| 4798 | NFRKB | nuclear factor related to kappaB binding protein |
| 154141 | MBOAT1 | membrane bound O-acyltransferase domain containing 1 |
| 5867 | RAB4A | RAB4A, member RAS oncogene family |
| 54941 | RNF125 | ring finger protein 125 |
| 100131827 | ZNF717 | zinc finger protein 717 |
| 9814 | SFI1 | SFI1 centrin binding protein |
| 55758 | RCOR3 | REST corepressor 3 |
| 149840 | C20orf196 | chromosome 20 open reading frame 196 |
| 222068 | TMED4 | transmembrane p24 trafficking protein 4 |
| 84993 | UBL7 | ubiquitin like 7 |
| 57493 | HEG1 | heart development protein with EGF like domains 1 |
| 652 | BMP4 | bone morphogenetic protein 4 |
| 6448 | SGSH | N-sulfoglucosamine sulfohydrolase |
| 5635 | PRPSAP1 | phosphoribosyl pyrophosphate synthetase associated protein 1 |
| 340061 | TMEM173 | transmembrane protein 173 |
| 51164 | DCTN4 | dynactin subunit 4 |
| 83986 | FAM234A | family with sequence similarity 234 member A |
| 440515 | ZNF506 | zinc finger protein 506 |
| 2185 | PTK2B | protein tyrosine kinase 2 beta |
| 9159 | PCSK7 | proprotein convertase subtilisin/kexin type 7 |
| 148137 | PROSER3 | proline and serine rich 3 |
| 84196 | USP48 | ubiquitin specific peptidase 48 |
| 2909 | ARHGAP35 | Rho GTPase activating protein 35 |
| 10194 | TSHZ1 | teashirt zinc finger homeobox 1 |
| 6482 | ST3GAL1 | ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
| 165918 | RNF168 | ring finger protein 168 |
| 1027 | CDKN1B | cyclin dependent kinase inhibitor 1B |
| 162962 | ZNF836 | zinc finger protein 836 |
| 90233 | ZNF551 | zinc finger protein 551 |
| 58986 | TMEM8A | transmembrane protein 8A |
| 80017 | C14orf159 | chromosome 14 open reading frame 159 |
| 8707 | B3GALT2 | beta-1,3-galactosyltransferase 2 |
| 8717 | TRADD | TNFRSF1A associated via death domain |
| 6293 | VPS52 | VPS52, GARP complex subunit |
| 54843 | SYTL2 | synaptotagmin like 2 |
| 4126 | MANBA | mannosidase beta |
| 57589 | RIC1 | RIC1 homolog, RAB6A GEF complex partner 1 |
| 23233 | EXOC6B | exocyst complex component 6B |
| 22898 | DENND3 | DENN domain containing 3 |
| 157638 | FAM84B | family with sequence similarity 84 member B |
| 4644 | MYO5A | myosin VA |
| 51684 | SUFU | SUFU negative regulator of hedgehog signaling |
| 3956 | LGALS1 | galectin 1 |

| | | |
|------------------------|-----------|---|
| 79695 | GALNT12 | polypeptide N-acetylgalactosaminyltransferase 12 |
| 340252 | ZNF680 | zinc finger protein 680 |
| 8831 | SYNGAP1 | synaptic Ras GTPase activating protein 1 |
| 23625 | FAM89B | family with sequence similarity 89 member B |
| 92979 | MARCH9 | membrane associated ring-CH-type finger 9 |
| 9926 | LPGAT1 | lysophosphatidylglycerol acyltransferase 1 |
| 23218 | NBEAL2 | neurobeachin like 2 |
| 9975 | NR1D2 | nuclear receptor subfamily 1 group D member 2 |
| 11278 | KLF12 | Kruppel like factor 12 |
| 11184 | MAP4K1 | mitogen-activated protein kinase kinase kinase kinase 1 |
| 9467 | SH3BP5 | SH3 domain binding protein 5 |
| 4084 | MXD1 | MAX dimerization protein 1 |
| 23370 | ARHGEF18 | Rho/Rac guanine nucleotide exchange factor 18 |
| 5295 | PIK3R1 | phosphoinositide-3-kinase regulatory subunit 1 |
| 90139 | TSPAN18 | tetraspanin 18 |
| 11238 | CA5B | carbonic anhydrase 5B |
| 440068 | CARD17 | caspase recruitment domain family member 17 |
| 994 | CDC25B | cell division cycle 25B |
| 114804 | RNF157 | ring finger protein 157 |
| 84687 | PPP1R9B | protein phosphatase 1 regulatory subunit 9B |
| 5732 | PTGER2 | prostaglandin E receptor 2 |
| 6693 | SPN | sialophorin |
| 137835 | TMEM71 | transmembrane protein 71 |
| 818 | CAMK2G | calcium/calmodulin dependent protein kinase II gamma |
| 2081 | ERN1 | endoplasmic reticulum to nucleus signaling 1 |
| 373156 | GSTK1 | glutathione S-transferase kappa 1 |
| 9938 | ARHGAP25 | Rho GTPase activating protein 25 |
| 340547 | VSIG1 | V-set and immunoglobulin domain containing 1 |
| 6920 | TCEA3 | transcription elongation factor A3 |
| 8635 | RNASET2 | ribonuclease T2 |
| 114932 | MRFAP1L1 | Morf4 family associated protein 1 like 1 |
| 4615 | MYD88 | myeloid differentiation primary response 88 |
| 5443 | POMC | proopiomelanocortin |
| 10636 | RGS14 | regulator of G-protein signaling 14 |
| 6536 | SLC6A9 | solute carrier family 6 member 9 |
| 10125 | RASGRP1 | RAS guanyl releasing protein 1 |
| 441108 | C5orf56 | chromosome 5 open reading frame 56 |
| 51317 | PHF21A | PHD finger protein 21A |
| 11214 | AKAP13 | A-kinase anchoring protein 13 |
| 2035 | EPB41 | erythrocyte membrane protein band 4.1 |
| 10404 | CPQ | carboxypeptidase Q |
| 203328 | SUSD3 | sushi domain containing 3 |
| 4542 | MYO1F | myosin IF |
| 3587 | IL10RA | interleukin 10 receptor subunit alpha |
| 80321 | CEP70 | centrosomal protein 70 |
| 51135 | IRAK4 | interleukin 1 receptor associated kinase 4 |
| 54704 | PDP1 | pyruvate dehydrogenase phosphatase catalytic subunit 1 |
| 7096 | TLR1 | toll like receptor 1 |
| 57140 | RNPEPL1 | arginyl aminopeptidase like 1 |
| 79792 | GSDMD | gasdermin D |
| 2550 | GABBR1 | gamma-aminobutyric acid type B receptor subunit 1 |
| 8519 | IFITM1 | interferon induced transmembrane protein 1 |
| 3631 | INPP4A | inositol polyphosphate-4-phosphatase type I A |
| 22900 | CARD8 | caspase recruitment domain family member 8 |
| 7799 | PRDM2 | PR/SET domain 2 |
| 79865 | TREML2 | triggering receptor expressed on myeloid cells like 2 |
| 6311 | ATXN2 | ataxin 2 |
| 338799 | LINC01089 | long intergenic non-protein coding RNA 1089 |
| 1901 | S1PR1 | sphingosine-1-phosphate receptor 1 |
| 4194 | MDM4 | MDM4, p53 regulator |
| 8737 | RIPK1 | receptor interacting serine/threonine kinase 1 |
| 51185 | CRBN | cereblon |
| 64108 | RTP4 | receptor transporter protein 4 |
| 23351 | KHNYN | KH and NYN domain containing |
| 5899 | RALB | RAS like proto-oncogene B |

| | | |
|---------------------------|-----------|---|
| 100506334 | LINC00649 | long intergenic non-protein coding RNA 649 |
| 128338 | DRAM2 | DNA damage regulated autophagy modulator 2 |
| 283349 | RASSF3 | Ras association domain family member 3 |
| 222255 | ATXN7L1 | ataxin 7 like 1 |
| 409 | ARRB2 | arrestin beta 2 |
| 9674 | KIAA0040 | KIAA0040 |
| 7360 | UGP2 | UDP-glucose pyrophosphorylase 2 |
| 51246 | SHISA5 | shisa family member 5 |
| 9985 | REC8 | REC8 meiotic recombination protein |
| 283130 | SLC25A45 | solute carrier family 25 member 45 |
| 59339 | PLEKHA2 | pleckstrin homology domain containing A2 |
| 10577 | NPC2 | NPC intracellular cholesterol transporter 2 |
| 3120 | HLA-DQB2 | major histocompatibility complex, class II, DQ beta 2 |
| 54870 | QRICH1 | glutamine rich 1 |
| 78991 | PCYOX1L | prenylcysteine oxidase 1 like |
| 64863 | METTL4 | methyltransferase like 4 |
| 4240 | MFGE8 | milk fat globule-EGF factor 8 protein |
| 51439 | FAM8A1 | family with sequence similarity 8 member A1 |
| 10140 | TOB1 | transducer of ERBB2, 1 |
| 23484 | LEPROTL1 | leptin receptor overlapping transcript-like 1 |
| 51292 | GMPR2 | guanosine monophosphate reductase 2 |
| 120224 | TMEM45B | transmembrane protein 45B |
| 9337 | CNOT8 | CCR4-NOT transcription complex subunit 8 |
| 23582 | CCNDBP1 | cyclin D1 binding protein 1 |
| 284309 | ZNF776 | zinc finger protein 776 |
| 8440 | NCK2 | NCK adaptor protein 2 |
| 10581 | IFITM2 | interferon induced transmembrane protein 2 |
| 51390 | AIG1 | androgen induced 1 |
| 56477 | CCL28 | C-C motif chemokine ligand 28 |
| 201627 | DENND6A | DENN domain containing 6A |
| 101 | ADAM8 | ADAM metalloproteinase domain 8 |
| 10311 | DSCR3 | DSCR3 arrestin fold containing |
| 156 | GRK2 | G protein-coupled receptor kinase 2 |
| 55339 | WDR33 | WD repeat domain 33 |
| 90736 | FAM104B | family with sequence similarity 104 member B |
| 64857 | PLEKHG2 | pleckstrin homology and RhoGEF domain containing G2 |
| 54813 | KLHL28 | kelch like family member 28 |
| 140461 | ASB8 | ankyrin repeat and SOCS box containing 8 |
| 81846 | SBF2 | SET binding factor 2 |
| 25943 | C20orf194 | chromosome 20 open reading frame 194 |
| 54868 | TMEM104 | transmembrane protein 104 |
| 23171 | GPD1L | glycerol-3-phosphate dehydrogenase 1-like |
| 2745 | GLRX | glutaredoxin |
| 54970 | TTC12 | tetratricopeptide repeat domain 12 |
| 84614 | ZBTB37 | zinc finger and BTB domain containing 37 |
| 828 | CAPS | calcyphosine |
| 1659 | DHX8 | DEAH-box helicase 8 |
| 147694 | ZNF548 | zinc finger protein 548 |
| 26036 | ZNF451 | zinc finger protein 451 |
| 285550 | FAM200B | family with sequence similarity 200 member B |
| 147658 | ZNF534 | zinc finger protein 534 |
| 147923 | ZNF420 | zinc finger protein 420 |
| 7536 | SF1 | splicing factor 1 |
| 285596 | FAM153A | family with sequence similarity 153 member A |
| 57452 | GALNT16 | polypeptide N-acetylgalactosaminyltransferase 16 |
| 56339 | METTL3 | methyltransferase like 3 |
| 100129842 | ZNF737 | zinc finger protein 737 |
| 124460 | SNX20 | sorting nexin 20 |
| 51696 | HECA | hdc homolog, cell cycle regulator |
| 6811 | STX5 | syntaxin 5 |
| 51643 | TM6IM4 | transmembrane BAX inhibitor motif containing 4 |
| 388650 | FAM69A | family with sequence similarity 69 member A |
| 8027 | STAM | signal transducing adaptor molecule |
| 4850 | CNOT4 | CCR4-NOT transcription complex subunit 4 |
| 4676 | NAP1L4 | nucleosome assembly protein 1 like 4 |

| | | |
|---------------------------|--------------|---|
| 7690 | ZNF131 | zinc finger protein 131 |
| 6789 | STK4 | serine/threonine kinase 4 |
| 55634 | KRBOX4 | KRAB box domain containing 4 |
| 63897 | HEATR6 | HEAT repeat containing 6 |
| 1374 | CPT1A | carnitine palmitoyltransferase 1A |
| 6402 | SELL | selectin L |
| 7592 | ZNF41 | zinc finger protein 41 |
| 372 | ARCN1 | archain 1 |
| 23451 | SF3B1 | splicing factor 3b subunit 1 |
| 163081 | ZNF567 | zinc finger protein 567 |
| 7381 | UQCRB | ubiquinol-cytochrome c reductase binding protein |
| 6230 | RPS25 | ribosomal protein S25 |
| 83452 | RAB33B | RAB33B, member RAS oncogene family |
| 56987 | BBX | BBX, HMG-box containing |
| 9541 | CIR1 | corepressor interacting with RBPJ, 1 |
| 9534 | ZNF254 | zinc finger protein 254 |
| 54986 | ULK4 | unc-51 like kinase 4 |
| 64421 | DCLRE1C | DNA cross-link repair 1C |
| 51531 | TRMO | tRNA methyltransferase O |
| 114781 | BTBD9 | BTB domain containing 9 |
| 5150 | PDE7A | phosphodiesterase 7A |
| 55729 | ATF7IP | activating transcription factor 7 interacting protein |
| 285343 | TCAIM | T-cell activation inhibitor, mitochondrial |
| 6671 | SP4 | Sp4 transcription factor |
| 9252 | RPS6KA5 | ribosomal protein S6 kinase A5 |
| 64940 | STAG3L4 | stromal antigen 3-like 4 (pseudogene) |
| 10681 | GNB5 | G protein subunit beta 5 |
| 3845 | KRAS | KRAS proto-oncogene, GTPase |
| 54542 | RC3H2 | ring finger and CCCH-type domains 2 |
| 961 | CD47 | CD47 molecule |
| 84084 | RAB6C | RAB6C, member RAS oncogene family |
| 22883 | CLSTN1 | calsyntenin 1 |
| 3385 | ICAM3 | intercellular adhesion molecule 3 |
| 57533 | TBC1D14 | TBC1 domain family member 14 |
| 375743 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 |
| 3738 | KCNA3 | potassium voltage-gated channel subfamily A member 3 |
| 9697 | TRAM2 | translocation associated membrane protein 2 |
| 55296 | TBC1D19 | TBC1 domain family member 19 |
| 9873 | FCHSD2 | FCH and double SH3 domains 2 |
| 105371242 | LOC105371242 | peptidyl-prolyl cis-trans isomerase A-like 4C |
| 643836 | ZFP62 | ZFP62 zinc finger protein |
| 23161 | SNX13 | sorting nexin 13 |
| 9197 | SLC33A1 | solute carrier family 33 member 1 |
| 1955 | MEGF9 | multiple EGF like domains 9 |
| 57198 | ATP8B2 | ATPase phospholipid transporting 8B2 |
| 105372141 | LOC105372141 | uncharacterized LOC105372141 |
| 9798 | IST1 | IST1, ESCRT-III associated factor |
| 54521 | WDR44 | WD repeat domain 44 |
| 57534 | MIB1 | mindbomb E3 ubiquitin protein ligase 1 |
| 84124 | ZNF394 | zinc finger protein 394 |
| 25852 | ARMC8 | armadillo repeat containing 8 |
| 54739 | XAF1 | XIAP associated factor 1 |
| 8869 | ST3GAL5 | ST3 beta-galactoside alpha-2,3-sialyltransferase 5 |
| 5027 | P2RX7 | purinergic receptor P2X 7 |
| 51 | ACOX1 | acyl-CoA oxidase 1 |
| 9482 | STX8 | syntaxin 8 |
| 84079 | ANKRD27 | ankyrin repeat domain 27 |
| 10855 | HPSE | heparanase |
| 23097 | CDK19 | cyclin dependent kinase 19 |
| 54149 | C21orf91 | chromosome 21 open reading frame 91 |
| 9258 | MFHAS1 | malignant fibrous histiocytoma amplified sequence 1 |
| 5613 | PRKX | protein kinase, X-linked |
| 8237 | USP11 | ubiquitin specific peptidase 11 |
| 134553 | C5orf24 | chromosome 5 open reading frame 24 |
| 9913 | SUPT7L | SPT7-like STAGA complex gamma subunit |

| | | |
|------------------------|---------|--|
| 64077 | LHPP | phospholysine phosphohistidine inorganic pyrophosphate phosphatase |
| 28232 | SLCO3A1 | solute carrier organic anion transporter family member 3A1 |
| 51606 | ATP6V1H | ATPase H+ transporting V1 subunit H |
| 83541 | FAM110A | family with sequence similarity 110 member A |
| 146857 | SLFN13 | schlafen family member 13 |
| 136895 | C7orf31 | chromosome 7 open reading frame 31 |
| 360023 | ZBTB41 | zinc finger and BTB domain containing 41 |
| 56985 | ADPRM | ADP-ribose/CDP-alcohol diphosphatase, manganese dependent |
| 92799 | SHKBP1 | SH3KBP1 binding protein 1 |
| 23199 | GSE1 | Gse1 coiled-coil protein |
| 259197 | NCR3 | natural cytotoxicity triggering receptor 3 |
| 10299 | MARCH6 | membrane associated ring-CH-type finger 6 |
| 1757 | SARDH | sarcosine dehydrogenase |
| 27005 | USP21 | ubiquitin specific peptidase 21 |
| 51244 | CCDC174 | coiled-coil domain containing 174 |
| 8573 | CASK | calcium/calmodulin dependent serine protein kinase |
| 8603 | FAM193A | family with sequence similarity 193 member A |
| 26043 | UBXN7 | UBX domain protein 7 |
| 57105 | CYSLTR2 | cysteinyl leukotriene receptor 2 |
| 55180 | LINS1 | lines homolog 1 |
| 153642 | ARSK | arylsulfatase family member K |
| 91663 | MYADM | myeloid associated differentiation marker |
| 23131 | GPATCH8 | G-patch domain containing 8 |
| 11143 | KAT7 | lysine acetyltransferase 7 |
| 23259 | DDHD2 | DDHD domain containing 2 |
| 148268 | ZNF570 | zinc finger protein 570 |
| 50809 | HP1BP3 | heterochromatin protein 1 binding protein 3 |
| 9991 | PTBP3 | polypyrimidine tract binding protein 3 |
| 285513 | GPRIN3 | GPRIN family member 3 |
| 1859 | DYRK1A | dual specificity tyrosine phosphorylation regulated kinase 1A |
| 10513 | APPBP2 | amyloid beta precursor protein binding protein 2 |
| 27252 | KLHL20 | kelch like family member 20 |
| 374354 | NHLRC2 | NHL repeat containing 2 |
| 7159 | TP53BP2 | tumor protein p53 binding protein 2 |
| 27018 | BEX3 | brain expressed X-linked 3 |
| 7433 | VIPR1 | vasoactive intestinal peptide receptor 1 |
| 9946 | CRYZL1 | crystallin zeta like 1 |
| 23229 | ARHGEF9 | Cdc42 guanine nucleotide exchange factor 9 |
| 286336 | FAM78A | family with sequence similarity 78 member A |
| 6809 | STX3 | syntaxin 3 |
| 8776 | MTMR1 | myotubularin related protein 1 |
| 8545 | CGGBP1 | CGG triplet repeat binding protein 1 |
| 26136 | TES | testin LIM domain protein |
| 93594 | TBC1D31 | TBC1 domain family member 31 |
| 51281 | ANKMY1 | ankyrin repeat and MYND domain containing 1 |
| 58486 | ZBED5 | zinc finger BED-type containing 5 |
| 4253 | MIA2 | melanoma inhibitory activity 2 |
| 4170 | MCL1 | BCL2 family apoptosis regulator |
| 2272 | FHIT | fragile histidine triad |
| 10866 | HCP5 | HLA complex P5 (non-protein coding) |
| 57396 | CLK4 | CDC like kinase 4 |
| 171425 | CLYBL | citrate lyase beta like |
| 7248 | TSC1 | tuberous sclerosis 1 |
| 129685 | TAF8 | TATA-box binding protein associated factor 8 |
| 22920 | KIFAP3 | kinesin associated protein 3 |
| 159091 | FAM122C | family with sequence similarity 122C |
| 25957 | PNISR | PNN interacting serine and arginine rich protein |
| 91300 | R3HDM4 | R3H domain containing 4 |
| 51427 | ZNF107 | zinc finger protein 107 |
| 168850 | ZNF800 | zinc finger protein 800 |
| 2273 | FHL1 | four and a half LIM domains 1 |
| 10392 | NOD1 | nucleotide binding oligomerization domain containing 1 |
| 1656 | DDX6 | DEAD-box helicase 6 |
| 3991 | LIPE | lipase E, hormone sensitive type |
| 91949 | COG7 | component of oligomeric golgi complex 7 |

| | | |
|------------------------|----------|--|
| 57120 | GOPC | golgi associated PDZ and coiled-coil motif containing |
| 84911 | ZNF382 | zinc finger protein 382 |
| 125488 | TTC39C | tetratricopeptide repeat domain 39C |
| 51752 | ERAP1 | endoplasmic reticulum aminopeptidase 1 |
| 222236 | NAPEPLD | N-acyl phosphatidylethanolamine phospholipase D |
| 54331 | GNG2 | G protein subunit gamma 2 |
| 23248 | RPRD2 | regulation of nuclear pre-mRNA domain containing 2 |
| 4940 | OAS3 | 2'-5'-oligoadenylate synthetase 3 |
| 2011 | MARK2 | microtubule affinity regulating kinase 2 |
| 56882 | CDC42SE1 | CDC42 small effector 1 |
| 23635 | SSBP2 | single stranded DNA binding protein 2 |
| 4149 | MAX | MYC associated factor X |
| 51199 | NIN | ninein |
| 285195 | SLC9A9 | solute carrier family 9 member A9 |
| 8473 | OGT | O-linked N-acetylglucosamine (GlcNAc) transferase |
| 285440 | CYP4V2 | cytochrome P450 family 4 subfamily V member 2 |
| 9709 | HERPUD1 | homocysteine inducible ER protein with ubiquitin like domain 1 |
| 54816 | ZNF280D | zinc finger protein 280D |
| 26578 | OSTF1 | osteoclast stimulating factor 1 |
| 6815 | STYX | serine/threonine/tyrosine interacting protein |
| 663 | BNIP2 | BCL2 interacting protein 2 |
| 9779 | TBC1D5 | TBC1 domain family member 5 |
| 55773 | TBC1D23 | TBC1 domain family member 23 |
| 57185 | NIPAL3 | NIPA like domain containing 3 |
| 23204 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 |
| 8773 | SNAP23 | synaptosome associated protein 23 |
| 6303 | SAT1 | spermidine/spermine N1-acetyltransferase 1 |
| 57560 | IFT80 | intraflagellar transport 80 |
| 2948 | GSTM4 | glutathione S-transferase mu 4 |
| 3115 | HLA-DPB1 | major histocompatibility complex, class II, DP beta 1 |
| 79668 | PARP8 | poly(ADP-ribose) polymerase family member 8 |
| 4707 | NDUFB1 | NADH:ubiquinone oxidoreductase subunit B1 |
| 22901 | ARSG | arylsulfatase G |
| 84343 | HPS3 | HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
| 54407 | SLC38A2 | solute carrier family 38 member 2 |
| 50999 | TMED5 | transmembrane p24 trafficking protein 5 |
| 3958 | LGALS3 | galectin 3 |
| 64840 | PORCN | porcupine homolog (Drosophila) |
| 5562 | PRKAA1 | protein kinase AMP-activated catalytic subunit alpha 1 |
| 9039 | UBA3 | ubiquitin like modifier activating enzyme 3 |
| 57649 | PHF12 | PHD finger protein 12 |
| 90806 | ANGEL2 | angel homolog 2 |
| 7581 | ZNF33A | zinc finger protein 33A |
| 375248 | ANKRD36 | ankyrin repeat domain 36 |
| 8821 | INPP4B | inositol polyphosphate-4-phosphatase type II B |
| 23613 | ZMYND8 | zinc finger MYND-type containing 8 |
| 567 | B2M | beta-2-microglobulin |
| 9666 | DZIP3 | DAZ interacting zinc finger protein 3 |
| 3459 | IFNGR1 | interferon gamma receptor 1 |
| 55285 | RBM41 | RNA binding motif protein 41 |
| 201895 | SMIM14 | small integral membrane protein 14 |
| 29058 | TMEM230 | transmembrane protein 230 |
| 9958 | USP15 | ubiquitin specific peptidase 15 |
| 917 | CD3G | CD3g molecule |
| 10181 | RBM5 | RNA binding motif protein 5 |
| 55788 | LMBRD1 | LMBR1 domain containing 1 |
| 6814 | STXBP3 | syntaxin binding protein 3 |
| 1666 | DECR1 | 2,4-dienoyl-CoA reductase 1, mitochondrial |
| 51506 | UFC1 | ubiquitin-fold modifier conjugating enzyme 1 |
| 6281 | S100A10 | S100 calcium binding protein A10 |
| 28962 | OSTM1 | osteopetrosis associated transmembrane protein 1 |
| 54677 | CROT | carnitine O-octanoyltransferase |
| 8799 | PEX11B | peroxisomal biogenesis factor 11 beta |
| 1730 | DIAPH2 | diaphanous related formin 2 |
| 9694 | EMC2 | ER membrane protein complex subunit 2 |

| | | |
|------------------------|-----------|---|
| 7181 | NR2C1 | nuclear receptor subfamily 2 group C member 1 |
| 51108 | METTL9 | methyltransferase like 9 |
| 27141 | CIDEB | cell death-inducing DFFA-like effector b |
| 64376 | IKZF5 | IKAROS family zinc finger 5 |
| 7756 | ZNF207 | zinc finger protein 207 |
| 256471 | MFSD8 | major facilitator superfamily domain containing 8 |
| 3660 | IRF2 | interferon regulatory factor 2 |
| 64431 | ACTR6 | ARP6 actin-related protein 6 homolog |
| 79872 | CBLL1 | Cbl proto-oncogene like 1 |
| 337976 | KRTAP20-2 | keratin associated protein 20-2 |
| 51347 | TAOK3 | TAO kinase 3 |
| 1998 | ELF2 | E74 like ETS transcription factor 2 |
| 84236 | RHBDD1 | rhomboid domain containing 1 |
| 89978 | DPH6 | diphthamine biosynthesis 6 |
| 8767 | RIPK2 | receptor interacting serine/threonine kinase 2 |
| 79096 | C11orf49 | chromosome 11 open reading frame 49 |
| 5930 | RBBP6 | RB binding protein 6, ubiquitin ligase |
| 645142 | PPIAL4D | peptidylprolyl isomerase A like 4D |
| 148867 | SLC30A7 | solute carrier family 30 member 7 |
| 145389 | SLC38A6 | solute carrier family 38 member 6 |
| 26115 | TANC2 | tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 |
| 26515 | TIMM10B | translocase of inner mitochondrial membrane 10 homolog B (yeast) |
| 10491 | CRTAP | cartilage associated protein |
| 962 | CD48 | CD48 molecule |
| 3128 | HLA-DRB6 | major histocompatibility complex, class II, DR beta 6 (pseudogene) |
| 84333 | PCGF5 | polycomb group ring finger 5 |
| 6301 | SARS | seryl-tRNA synthetase |
| 148362 | BROX | BRO1 domain and CAAX motif containing |
| 51322 | WAC | WW domain containing adaptor with coiled-coil |
| 2060 | EPS15 | epidermal growth factor receptor pathway substrate 15 |
| 64747 | MFSD1 | major facilitator superfamily domain containing 1 |
| 79745 | CLIP4 | CAP-Gly domain containing linker protein family member 4 |
| 84272 | YIPF4 | Yip1 domain family member 4 |
| 3163 | HMOX2 | heme oxygenase 2 |
| 1521 | CTSW | cathepsin W |
| 85025 | TMEM60 | transmembrane protein 60 |
| 56674 | TMEM9B | TMEM9 domain family member B |
| 3384 | ICAM2 | intercellular adhesion molecule 2 |
| 26061 | HACL1 | 2-hydroxyacyl-CoA lyase 1 |
| 27065 | NSG1 | neuron specific gene family member 1 |
| 29994 | BAZ2B | bromodomain adjacent to zinc finger domain 2B |
| 6643 | SNX2 | sorting nexin 2 |
| 27240 | SIT1 | signaling threshold regulating transmembrane adaptor 1 |
| 3117 | HLA-DQA1 | major histocompatibility complex, class II, DQ alpha 1 |
| 27163 | NAAA | N-acylethanolamine acid amidase |
| 84795 | PYROXD2 | pyridine nucleotide-disulphide oxidoreductase domain 2 |
| 8667 | EIF3H | eukaryotic translation initiation factor 3 subunit H |
| 254887 | ZDHHC23 | zinc finger DHHC-type containing 23 |
| 124961 | ZFP3 | ZFP3 zinc finger protein |
| 26071 | FAM127B | family with sequence similarity 127 member B |
| 23149 | FCHO1 | FCH domain only 1 |
| 374395 | TMEM179B | transmembrane protein 179B |
| 3688 | ITGB1 | integrin subunit beta 1 |
| 4711 | NDUFB5 | NADH:ubiquinone oxidoreductase subunit B5 |
| 9871 | SEC24D | SEC24 homolog D, COPII coat complex component |
| 56898 | BDH2 | 3-hydroxybutyrate dehydrogenase, type 2 |
| 23585 | TMEM50A | transmembrane protein 50A |
| 3133 | HLA-E | major histocompatibility complex, class I, E |
| 124512 | METTL23 | methyltransferase like 23 |
| 11000 | SLC27A3 | solute carrier family 27 member 3 |
| 126626 | GABPB2 | GA binding protein transcription factor beta subunit 2 |
| 257160 | RNF214 | ring finger protein 214 |
| 9649 | RALGPS1 | Ral GEF with PH domain and SH3 binding motif 1 |
| 26273 | FBXO3 | F-box protein 3 |
| 54509 | RHOF | ras homolog family member F, filopodia associated |

| | | |
|------------------------|----------|---|
| 285093 | RTP5 | receptor transporter protein 5 (putative) |
| 25793 | FBXO7 | F-box protein 7 |
| 7770 | ZNF227 | zinc finger protein 227 |
| 85403 | EAF1 | ELL associated factor 1 |
| 4582 | MUC1 | mucin 1, cell surface associated |
| 1029 | CDKN2A | cyclin dependent kinase inhibitor 2A |
| 3717 | JAK2 | Janus kinase 2 |
| 1992 | SERPINB1 | serpin family B member 1 |
| 25821 | MTO1 | mitochondrial tRNA translation optimization 1 |
| 51635 | DHRS7 | dehydrogenase/reductase 7 |
| 51747 | LUC7L3 | LUC7 like 3 pre-mRNA splicing factor |
| 10628 | TXNIP | thioredoxin interacting protein |
| 5533 | PPP3CC | protein phosphatase 3 catalytic subunit gamma |
| 5130 | PCYT1A | phosphate cytidyltransferase 1, choline, alpha |
| 10219 | KLRG1 | killer cell lectin like receptor G1 |
| 3127 | HLA-DRB5 | major histocompatibility complex, class II, DR beta 5 |
| 253461 | ZBTB38 | zinc finger and BTB domain containing 38 |
| 80267 | EDEM3 | ER degradation enhancing alpha-mannosidase like protein 3 |
| 149628 | PYHIN1 | pyrin and HIN domain family member 1 |
| 55508 | SLC35E3 | solute carrier family 35 member E3 |
| 89853 | MVB12B | multivesicular body subunit 12B |
| 2313 | FLI1 | Flt-1 proto-oncogene, ETS transcription factor |
| 79591 | C10orf76 | chromosome 10 open reading frame 76 |
| 9204 | ZMYM6 | zinc finger MYM-type containing 6 |
| 25975 | EGFL6 | EGF like domain multiple 6 |
| 10039 | PARP3 | poly(ADP-ribose) polymerase family member 3 |
| 54855 | FAM46C | family with sequence similarity 46 member C |
| 171586 | ABHD3 | abhydrolase domain containing 3 |
| 55809 | TRERF1 | transcriptional regulating factor 1 |
| 115825 | WDFY2 | WD repeat and FYVE domain containing 2 |
| 23059 | CLUAP1 | clusterin associated protein 1 |
| 79877 | DCAKD | dephospho-CoA kinase domain containing |
| 84273 | NOA1 | nitric oxide associated 1 |
| 4835 | NQO2 | NAD(P)H quinone dehydrogenase 2 |
| 283237 | TTC9C | tetratricopeptide repeat domain 9C |
| 5797 | PTPRM | protein tyrosine phosphatase, receptor type M |
| 3820 | KLRB1 | killer cell lectin like receptor B1 |
| 4217 | MAP3K5 | mitogen-activated protein kinase kinase kinase 5 |
| 64773 | PCED1A | PC-esterase domain containing 1A |
| 2054 | STX2 | syntaxin 2 |
| 824 | CAPN2 | calpain 2 |
| 79577 | CDC73 | cell division cycle 73 |
| 3108 | HLA-DMA | major histocompatibility complex, class II, DM alpha |
| 154075 | SAMD3 | sterile alpha motif domain containing 3 |
| 7905 | REEP5 | receptor accessory protein 5 |
| 199704 | ZNF585A | zinc finger protein 585A |
| 88455 | ANKRD13A | ankyrin repeat domain 13A |
| 6668 | SP2 | Sp2 transcription factor |
| 1604 | CD55 | CD55 molecule (Cromer blood group) |
| 64420 | SUSD1 | sushi domain containing 1 |
| 1235 | CCR6 | C-C motif chemokine receptor 6 |
| 2838 | GPR15 | G protein-coupled receptor 15 |
| 440026 | TMEM41B | transmembrane protein 41B |
| 729230 | CCR2 | C-C motif chemokine receptor 2 |
| 94101 | ORMDL1 | ORMDL sphingolipid biosynthesis regulator 1 |
| 1075 | CTSC | cathepsin C |
| 90624 | LYRM7 | LYR motif containing 7 |
| 801 | CALM1 | calmodulin 1 |
| 55967 | NDUFA12 | NADH:ubiquinone oxidoreductase subunit A12 |
| 8477 | GPR65 | G protein-coupled receptor 65 |
| 57544 | TXNDC16 | thioredoxin domain containing 16 |
| 1512 | CTSH | cathepsin H |
| 84902 | CEP89 | centrosomal protein 89 |
| 7576 | ZNF28 | zinc finger protein 28 |
| 29116 | MYLIP | myosin regulatory light chain interacting protein |

| | | |
|---------------------------|-----------|---|
| 50808 | AK3 | adenylate kinase 3 |
| 7289 | TULP3 | tubby like protein 3 |
| 6166 | RPL36AL | ribosomal protein L36a like |
| 54414 | SIAE | sialic acid acetyltransferase |
| 23673 | STX12 | syntrophin 12 |
| 833 | CARS | cysteine-tRNA synthetase |
| 7940 | LST1 | leukocyte specific transcript 1 |
| 2040 | STOM | stomatin |
| 5720 | PSME1 | proteasome activator subunit 1 |
| 51101 | ZC2HC1A | zinc finger C2HC-type containing 1A |
| 1102 | RCC1 | RCC1 and BTB domain containing protein 2 |
| 2752 | GLUL | glutamate-ammonia ligase |
| 3123 | HLA-DRB1 | major histocompatibility complex, class II, DR beta 1 |
| 23608 | MKR1 | makorin ring finger protein 1 |
| 5429 | POLH | DNA polymerase eta |
| 100507463 | PSMB8-AS1 | PSMB8 antisense RNA 1 (head to head) |
| 4261 | CIITA | class II major histocompatibility complex transactivator |
| 6916 | TBXAS1 | thromboxane synthase 1 |
| 116496 | FAM129A | family with sequence similarity 129 member A |
| 643911 | CRNDE | colorectal neoplasia differentially expressed (non-protein coding) |
| 4094 | MAF | MAF bZIP transcription factor |
| 10788 | IQGAP2 | IQ motif containing GTPase activating protein 2 |
| 3122 | HLA-DRA | major histocompatibility complex, class II, DR alpha |
| 3113 | HLA-DPA1 | major histocompatibility complex, class II, DP alpha 1 |
| 196527 | ANO6 | anoctamin 6 |
| 10370 | CITED2 | Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 |
| 941 | CD80 | CD80 molecule |
| 202 | AIM1 | absent in melanoma 1 |
| 2664 | GDI1 | GDP dissociation inhibitor 1 |
| 6609 | SMPD1 | sphingomyelin phosphodiesterase 1 |
| 84138 | SLC7A6OS | solute carrier family 7 member 6 opposite strand |
| 254251 | LCORL | ligand dependent nuclear receptor corepressor like |
| 2643 | GCH1 | GTP cyclohydrolase 1 |
| 1633 | DKK | deoxycytidine kinase |
| 64127 | NOD2 | nucleotide binding oligomerization domain containing 2 |
| 51061 | TXNDC11 | thioredoxin domain containing 11 |
| 5451 | POU2F1 | POU class 2 homeobox 1 |
| 29968 | PSAT1 | phosphoserine aminotransferase 1 |
| 4939 | OAS2 | 2'-5'-oligoadenylate synthetase 2 |
| 669 | BPGM | bisphosphoglycerate mutase |
| 5165 | PKD3 | pyruvate dehydrogenase kinase 3 |
| 79823 | CAMKMT | calmodulin-lysine N-methyltransferase |
| 1979 | EIF4EBP2 | eukaryotic translation initiation factor 4E binding protein 2 |
| 54495 | TMX3 | thioredoxin related transmembrane protein 3 |
| 80350 | LPAL2 | lipoprotein(a) like 2, pseudogene |
| 51703 | ACSL5 | acyl-CoA synthetase long-chain family member 5 |
| 4267 | CD99 | CD99 molecule |
| 152007 | GLIPR2 | GLI pathogenesis related 2 |
| 79071 | ELOVL6 | ELOVL fatty acid elongase 6 |
| 26277 | TINF2 | TERF1 interacting nuclear factor 2 |
| 388323 | GLTPD2 | glycolipid transfer protein domain containing 2 |
| 348262 | MCRIP1 | MAPK regulated corepressor interacting protein 1 |
| 770 | CA11 | carbonic anhydrase 11 |
| 140606 | SELENOM | selenoprotein M |
| 7643 | ZNF90 | zinc finger protein 90 |
| 5118 | PCOLCE | procollagen C-endopeptidase enhancer |
| 27113 | BBC3 | BCL2 binding component 3 |
| 60 | ACTB | actin beta |
| 4137 | MAPT | microtubule associated protein tau |
| 2051 | EPHB6 | EPH receptor B6 |
| 9435 | CHST2 | carbohydrate sulfotransferase 2 |
| 810 | CALML3 | calmodulin like 3 |
| 84513 | PLPP5 | phospholipid phosphatase 5 |
| 1406 | CRX | cone-rod homeobox |
| 23178 | PASK | PAS domain containing serine/threonine kinase |

| | | |
|---------------------------|----------|--|
| 84310 | C7orf50 | chromosome 7 open reading frame 50 |
| 56125 | PCDHB11 | protocadherin beta 11 |
| 440073 | IQSEC3 | IQ motif and Sec7 domain 3 |
| 2889 | RAPGEF1 | Rap guanine nucleotide exchange factor 1 |
| 865 | CBFB | core-binding factor beta subunit |
| 157 | GRK3 | G protein-coupled receptor kinase 3 |
| 100462981 | MTRNR2L2 | MT-RNR2-like 2 |
| 51764 | GNG13 | G protein subunit gamma 13 |
| 353134 | LCE1D | late cornified envelope 1D |
| 64743 | WDR13 | WD repeat domain 13 |
| 80194 | TMEM134 | transmembrane protein 134 |
| 23678 | SGK3 | serum/glucocorticoid regulated kinase family member 3 |
| 115703 | ARHGAP33 | Rho GTPase activating protein 33 |
| 100316904 | SAP25 | Sin3A associated protein 25 |
| 256949 | KANK3 | KN motif and ankyrin repeat domains 3 |
| 9990 | SLC12A6 | solute carrier family 12 member 6 |
| 83593 | RASSF5 | Ras association domain family member 5 |
| 126695 | KDF1 | keratinocyte differentiation factor 1 |
| 100130958 | SYCE1L | synaptonemal complex central element protein 1 like |
| 286075 | ZNF707 | zinc finger protein 707 |
| 85407 | NKD1 | naked cuticle homolog 1 |
| 753 | LDLRAD4 | low density lipoprotein receptor class A domain containing 4 |
| 23417 | MLYCD | malonyl-CoA decarboxylase |
| 284723 | SLC25A34 | solute carrier family 25 member 34 |
| 348013 | TMEM255B | transmembrane protein 255B |
| 85027 | SMIM3 | small integral membrane protein 3 |
| 388595 | TMEM82 | transmembrane protein 82 |
| 535 | ATP6V0A1 | ATPase H ⁺ transporting V0 subunit a1 |
| 9531 | BAG3 | BCL2 associated athanogene 3 |
| 915 | CD3D | CD3d molecule |
| 10507 | SEMA4D | semaphorin 4D |
| 56940 | DUSP22 | dual specificity phosphatase 22 |
| 55030 | FBXO34 | F-box protein 34 |
| 10765 | KDM5B | lysine demethylase 5B |
| 921 | CD5 | CD5 molecule |
| 6223 | RPS19 | ribosomal protein S19 |
| 132299 | OCIAD2 | OCIA domain containing 2 |
| 341567 | H1FNT | H1 histone family member N, testis specific |
| 64061 | TSPYL2 | TSPY like 2 |
| 27086 | FOXP1 | forkhead box P1 |
| 6821 | SUOX | sulfite oxidase |
| 57092 | PCNP | PEST proteolytic signal containing nuclear protein |
| 93145 | OLFM2 | olfactomedin 2 |
| 129804 | FBLN7 | fibulin 7 |
| 79778 | MICALL2 | MICAL like 2 |
| 1514 | CTSL | cathepsin L |
| 1543 | CYP1A1 | cytochrome P450 family 1 subfamily A member 1 |
| 23275 | POFUT2 | protein O-fucosyltransferase 2 |
| 148223 | C19orf25 | chromosome 19 open reading frame 25 |
| 268 | AMH | anti-Mullerian hormone |
| 10362 | HMG20B | high mobility group 20B |
| 116983 | ACAP3 | ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 |
| 9792 | SERTAD2 | SERTA domain containing 2 |
| 9057 | SLC7A6 | solute carrier family 7 member 6 |
| 5209 | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
| 84947 | SERAC1 | serine active site containing 1 |
| 10927 | SPIN1 | spindlin 1 |
| 100463487 | MTRNR2L9 | MT-RNR2-like 9 |
| 203522 | INTS6L | integrator complex subunit 6 like |
| 94235 | GNG8 | G protein subunit gamma 8 |
| 6001 | RGS10 | regulator of G-protein signaling 10 |
| 54947 | LPCAT2 | lysophosphatidylcholine acyltransferase 2 |
| 659 | BMPR2 | bone morphogenetic protein receptor type 2 |
| 23479 | ISCU | iron-sulfur cluster assembly enzyme |
| 100287898 | TTC34 | tetratricopeptide repeat domain 34 |

| | | |
|------------------------|-----------|---|
| 2908 | NR3C1 | nuclear receptor subfamily 3 group C member 1 |
| 6229 | RPS24 | ribosomal protein S24 |
| 29121 | CLEC2D | C-type lectin domain family 2 member D |
| 25893 | TRIM58 | tripartite motif containing 58 |
| 29095 | ORMDL2 | ORMDL sphingolipid biosynthesis regulator 2 |
| 104 | ADARB1 | adenosine deaminase, RNA specific B1 |
| 5272 | SERPINB9 | serpin family B member 9 |
| 284611 | FAM102B | family with sequence similarity 102 member B |
| 27248 | ERLEC1 | endoplasmic reticulum lectin 1 |
| 10982 | MAPRE2 | microtubule associated protein RP/EB family member 2 |
| 6794 | STK11 | serine/threonine kinase 11 |
| 3831 | KLC1 | kinesin light chain 1 |
| 6242 | RTKN | rhoteikin |
| 57680 | CHD8 | chromodomain helicase DNA binding protein 8 |
| 85364 | ZCCHC3 | zinc finger CCHC-type containing 3 |
| 163126 | EID2 | EP300 interacting inhibitor of differentiation 2 |
| 650669 | GAS6-AS1 | GAS6 antisense RNA 1 |
| 55893 | ZNF395 | zinc finger protein 395 |
| 26228 | STAP1 | signal transducing adaptor family member 1 |
| 51225 | ABI3 | ABI family member 3 |
| 7187 | TRAF3 | TNF receptor associated factor 3 |
| 196 | AHR | aryl hydrocarbon receptor |
| 728747 | ANKRD20A4 | ankyrin repeat domain 20 family member A4 |
| 389333 | PROB1 | proline rich basic protein 1 |
| 11202 | KLK8 | kallikrein related peptidase 8 |
| 2530 | FUT8 | fucosyltransferase 8 |
| 6224 | RPS20 | ribosomal protein S20 |
| 55636 | CHD7 | chromodomain helicase DNA binding protein 7 |
| 10188 | TNK2 | tyrosine kinase non receptor 2 |
| 170067 | SUPT20HL2 | SPT20 homolog, SAGA complex component-like 2 |
| 4363 | ABCC1 | ATP binding cassette subfamily C member 1 |
| 581 | BAX | BCL2 associated X, apoptosis regulator |
| 7529 | YWHA8 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta |
| 60468 | BACH2 | BTB domain and CNC homolog 2 |
| 57491 | AHRR | aryl-hydrocarbon receptor repressor |
| 730098 | LOC730098 | uncharacterized LOC730098 |
| 221937 | FOXK1 | forkhead box K1 |
| 729020 | RPEL1 | ribulose-5-phosphate-3-epimerase like 1 |
| 4082 | MARCKS | myristoylated alanine rich protein kinase C substrate |
| 5290 | PIK3CA | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 63971 | KIF13A | kinesin family member 13A |
| 9794 | MAML1 | mastermind like transcriptional coactivator 1 |
| 80045 | GPR157 | G protein-coupled receptor 157 |
| 3097 | HIVBP2 | human immunodeficiency virus type I enhancer binding protein 2 |
| 7044 | LEFTY2 | left-right determination factor 2 |
| 222658 | KCTD20 | potassium channel tetramerization domain containing 20 |
| 399668 | SMIM10L2A | small integral membrane protein 10 like 2A |
| 125058 | TBC1D16 | TBC1 domain family member 16 |
| 5753 | PTK6 | protein tyrosine kinase 6 |
| 65986 | ZBTB10 | zinc finger and BTB domain containing 10 |
| 727957 | MROH1 | maestro heat like repeat family member 1 |
| 2779 | GNAT1 | G protein subunit alpha transducin 1 |
| 376497 | SLC27A1 | solute carrier family 27 member 1 |
| 1427 | CRYGS | crystallin gamma S |
| 440955 | TMEM89 | transmembrane protein 89 |
| 9883 | POM121 | POM121 transmembrane nucleoporin |
| 54863 | TOR4A | torsin family 4 member A |
| 8878 | SQSTM1 | sequestosome 1 |
| 414318 | C9orf106 | chromosome 9 open reading frame 106 |
| 7146 | TNXA | tenascin XA (pseudogene) |
| 6498 | SKIL | SKI like proto-oncogene |
| 3090 | HIC1 | hypermethylated in cancer 1 |
| 22877 | MLXIP | MLX interacting protein |
| 3853 | KRT6A | keratin 6A |
| 84878 | ZBTB45 | zinc finger and BTB domain containing 45 |

| | | |
|---------------------------|--------------|---|
| 359948 | IRF2BP2 | interferon regulatory factor 2 binding protein 2 |
| 23505 | TMEM131 | transmembrane protein 131 |
| 10489 | LRRC41 | leucine rich repeat containing 41 |
| 717 | C2 | complement C2 |
| 10014 | HDAC5 | histone deacetylase 5 |
| 3910 | LAMA4 | laminin subunit alpha 4 |
| 6623 | SNCG | synuclein gamma |
| 90427 | BMF | Bcl2 modifying factor |
| 6209 | RPS15 | ribosomal protein S15 |
| 6205 | RPS11 | ribosomal protein S11 |
| 6217 | RPS16 | ribosomal protein S16 |
| 158376 | LINC00961 | long intergenic non-protein coding RNA 961 |
| 79791 | FBXO31 | F-box protein 31 |
| 54795 | TRPM4 | transient receptor potential cation channel subfamily M member 4 |
| 7791 | ZYX | zyxin |
| 123920 | CMTM3 | CKLF like MARVEL transmembrane domain containing 3 |
| 3718 | JAK3 | Janus kinase 3 |
| 11336 | EXOC3 | exocyst complex component 3 |
| 23293 | SMG6 | SMG6, nonsense mediated mRNA decay factor |
| 7048 | TGFBR2 | transforming growth factor beta receptor 2 |
| 9094 | UNC119 | unc-119 lipid binding chaperone |
| 2869 | GRK5 | G protein-coupled receptor kinase 5 |
| 8728 | ADAM19 | ADAM metalloproteinase domain 19 |
| 10800 | CYSLTR1 | cysteinyl leukotriene receptor 1 |
| 4088 | SMAD3 | SMAD family member 3 |
| 3927 | LASP1 | LIM and SH3 protein 1 |
| 178 | AGL | amylase-1, 6-glucosidase, 4-alpha-glucanotransferase |
| 25766 | PRPF40B | pre-mRNA processing factor 40 homolog B |
| 1455 | CSNK1G2 | casein kinase 1 gamma 2 |
| 5878 | RAB5C | RAB5C, member RAS oncogene family |
| 2997 | GYS1 | glycogen synthase 1 |
| 80152 | CENPT | centromere protein T |
| 940 | CD28 | CD28 molecule |
| 79897 | RPP21 | ribonuclease P/MRP subunit p21 |
| 155061 | ZNF746 | zinc finger protein 746 |
| 6665 | SOX15 | SRY-box 15 |
| 79144 | PPDPF | pancreatic progenitor cell differentiation and proliferation factor |
| 169981 | SPIN3 | spindlin family member 3 |
| 23338 | JADE2 | jade family PHD finger 2 |
| 3707 | ITPKB | inositol-trisphosphate 3-kinase B |
| 9896 | FIG4 | FIG4 phosphoinositide 5-phosphatase |
| 23144 | ZC3H3 | zinc finger CCCH-type containing 3 |
| 57479 | PRR12 | proline rich 12 |
| 9143 | SYNGR3 | synaptogyrin 3 |
| 80774 | LIMD2 | LIM domain containing 2 |
| 11337 | GABARAP | GABA type A receptor-associated protein |
| 54543 | TOMM7 | translocase of outer mitochondrial membrane 7 |
| 10567 | RABAC1 | Rab acceptor 1 |
| 64319 | FBR5 | fibrosin |
| 6227 | RPS21 | ribosomal protein S21 |
| 29123 | ANKRD11 | ankyrin repeat domain 11 |
| 4041 | LRP5 | LDL receptor related protein 5 |
| 64375 | IKZF4 | IKAROS family zinc finger 4 |
| 100652768 | LOC100652768 | uncharacterized LOC100652768 |
| 6137 | RPL13 | ribosomal protein L13 |
| 219968 | ORSB21 | olfactory receptor family 5 subfamily B member 21 |
| 6135 | RPL11 | ribosomal protein L11 |
| 201163 | FLCN | folliculin |
| 100507347 | VIM-AS1 | VIM antisense RNA 1 |
| 57154 | SMURF1 | SMAD specific E3 ubiquitin protein ligase 1 |
| 5128 | CDK17 | cyclin dependent kinase 17 |
| 6208 | RPS14 | ribosomal protein S14 |
| 10169 | SERF2 | small EDRK-rich factor 2 |
| 4215 | MAP3K3 | mitogen-activated protein kinase kinase kinase 3 |
| 939 | CD27 | CD27 molecule |

| | | |
|---------------------------|--------------|---|
| 272 | AMPD3 | adenosine monophosphate deaminase 3 |
| 27287 | VENTX | VENT homeobox |
| 23094 | SIPA1L3 | signal induced proliferation associated 1 like 3 |
| 54463 | FAM134B | family with sequence similarity 134 member B |
| 57713 | SFMBT2 | Scm-like with four mbt domains 2 |
| 80003 | PCNX2 | pecanex homolog 2 (Drosophila) |
| 22852 | ANKRD26 | ankyrin repeat domain 26 |
| 55626 | AMBRA1 | autophagy and beclin 1 regulator 1 |
| 5339 | PLEC | plectin |
| 55914 | ERBIN | erbB2 interacting protein |
| 5900 | RALGDS | ral guanine nucleotide dissociation stimulator |
| 23196 | FAM120A | family with sequence similarity 120A |
| 2634 | GBP2 | guanylate binding protein 2 |
| 6156 | RPL30 | ribosomal protein L30 |
| 246175 | CNOT6L | CCR4-NOT transcription complex subunit 6 like |
| 9806 | SPOCK2 | SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2 |
| 29997 | GLTSCR2 | glioma tumor suppressor candidate region gene 2 |
| 5144 | PDE4D | phosphodiesterase 4D |
| 25976 | TIPARP | TCDD inducible poly(ADP-ribose) polymerase |
| 25865 | PRKD2 | protein kinase D2 |
| 4209 | MEF2D | myocyte enhancer factor 2D |
| 23077 | MYCBP2 | MYC binding protein 2, E3 ubiquitin protein ligase |
| 57448 | BIRC6 | baculoviral IAP repeat containing 6 |
| 645843 | TMEM14EP | transmembrane protein 14E, pseudogene |
| 10326 | SIRPB1 | signal regulatory protein beta 1 |
| 55668 | GPATCH2L | G-patch domain containing 2 like |
| 81855 | SFXN3 | sideroflexin 3 |
| 9404 | LPXN | leupaxin |
| 6575 | SLC20A2 | solute carrier family 20 member 2 |
| 64748 | PLPPR2 | phospholipid phosphatase related 2 |
| 284346 | ZNF575 | zinc finger protein 575 |
| 55558 | PLXNA3 | plexin A3 |
| 646962 | HRCT1 | histidine rich carboxyl terminus 1 |
| 1564 | CYP2D7 | cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene) |
| 7094 | TLN1 | talin 1 |
| 130013 | ACMSD | aminocarboxymuconate semialdehyde decarboxylase |
| 57787 | MARK4 | microtubule affinity regulating kinase 4 |
| 55690 | PACS1 | phosphofurin acidic cluster sorting protein 1 |
| 81844 | TRIM56 | tripartite motif containing 56 |
| 196743 | PAOX | polyamine oxidase |
| 116985 | ARAP1 | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 |
| 65056 | GPBP1 | GC-rich promoter binding protein 1 |
| 84033 | OBSCN | obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
| 283600 | SLC25A47 | solute carrier family 25 member 47 |
| 7291 | TWIST1 | twist family bHLH transcription factor 1 |
| 201294 | UNC13D | unc-13 homolog D |
| 100996693 | LOC100996693 | CAVP-target protein-like |
| 64781 | CERK | ceramide kinase |
| 146206 | CARMIL2 | capping protein regulator and myosin 1 linker 2 |
| 653583 | PHLDB3 | pleckstrin homology like domain family B member 3 |
| 283385 | MORN3 | MORN repeat containing 3 |
| 352954 | GATS | GATS, stromal antigen 3 opposite strand |
| 7379 | UPK2 | uroplakin 2 |
| 29882 | ANAPC2 | anaphase promoting complex subunit 2 |
| 1535 | CYBA | cytochrome b-245 alpha chain |
| 5093 | PCBP1 | poly(rC) binding protein 1 |
| 79958 | DENND1C | DENN domain containing 1C |
| 79156 | PLEKHF1 | pleckstrin homology and FYVE domain containing 1 |
| 60684 | TRAPP1 | trafficking protein particle complex 11 |
| 9821 | RB1CC1 | RB1 inducible coiled-coil 1 |
| 84256 | FLYWCH1 | FLYWCH-type zinc finger 1 |
| 51669 | SARAF | store-operated calcium entry associated regulatory factor |
| 51343 | FZR1 | fizzy/cell division cycle 20 related 1 |
| 8398 | PLA2G6 | phospholipase A2 group VI |
| 54434 | SSH1 | slingshot protein phosphatase 1 |

| | | |
|---------------------------|-----------|--|
| 2588 | GALNS | galactosamine (N-acetyl)-6-sulfatase |
| 399669 | ZNF321P | zinc finger protein 321, pseudogene |
| 2621 | GAS6 | growth arrest specific 6 |
| 57558 | USP35 | ubiquitin specific peptidase 35 |
| 284439 | SLC25A42 | solute carrier family 25 member 42 |
| 6181 | RPLP2 | ribosomal protein lateral stalk subunit P2 |
| 90625 | ERVH48-1 | endogenous retrovirus group 48 member 1 |
| 4753 | NELL2 | neural EGFL like 2 |
| 6222 | RPS18 | ribosomal protein S18 |
| 50840 | TAS2R14 | taste 2 receptor member 14 |
| 11215 | AKAP11 | A-kinase anchoring protein 11 |
| 81619 | TSPAN14 | tetraspanin 14 |
| 9448 | MAP4K4 | mitogen-activated protein kinase kinase kinase 4 |
| 7750 | ZMYM2 | zinc finger MYM-type containing 2 |
| 10806 | SDCCAG8 | serologically defined colon cancer antigen 8 |
| 158078 | EEF1A1P5 | eukaryotic translation elongation factor 1 alpha 1 pseudogene 5 |
| 6228 | RPS23 | ribosomal protein S23 |
| 55423 | SIRPG | signal regulatory protein gamma |
| 919 | CD247 | CD247 molecule |
| 1890 | TYMP | thymidine phosphorylase |
| 8553 | BHLHE40 | basic helix-loop-helix family member e40 |
| 162972 | ZNF550 | zinc finger protein 550 |
| 60401 | EDA2R | ectodysplasin A2 receptor |
| 192668 | CYS1 | cystin 1 |
| 57634 | EP400 | E1A binding protein p400 |
| 91252 | SLC39A13 | solute carrier family 39 member 13 |
| 11117 | EMILIN1 | elastin microfibril interfacer 1 |
| 51315 | KRCC1 | lysine rich coiled-coil 1 |
| 114132 | SIGLEC11 | sialic acid binding Ig like lectin 11 |
| 5498 | PPOX | protoporphyrinogen oxidase |
| 112574 | SNX18 | sorting nexin 18 |
| 58480 | RHOU | ras homolog family member U |
| 260425 | MAGI3 | membrane associated guanylate kinase, WW and PDZ domain containing 3 |
| 65998 | C11orf95 | chromosome 11 open reading frame 95 |
| 23743 | BHMT2 | betaine--homocysteine S-methyltransferase 2 |
| 23492 | CBX7 | chromobox 7 |
| 58509 | CACTIN | cactin, spliceosome C complex subunit |
| 27106 | ARRDC2 | arrestin domain containing 2 |
| 23053 | ZSWIM8 | zinc finger SWIM-type containing 8 |
| 1294 | COL7A1 | collagen type VII alpha 1 chain |
| 79095 | C9orf16 | chromosome 9 open reading frame 16 |
| 7753 | ZNF202 | zinc finger protein 202 |
| 116535 | MRGPRF | MAS related GPR family member F |
| 5199 | CFP | complement factor properdin |
| 8792 | TNFRSF11A | TNF receptor superfamily member 11a |
| 259234 | DSCR10 | Down syndrome critical region 10 (non-protein coding) |
| 6123 | RPL3L | ribosomal protein L3 like |
| 23352 | UBR4 | ubiquitin protein ligase E3 component n-recognin 4 |
| 375033 | PEAR1 | platelet endothelial aggregation receptor 1 |
| 10908 | PNPLA6 | patatin like phospholipase domain containing 6 |
| 22863 | ATG14 | autophagy related 14 |
| 4302 | MLLT6 | MLLT6, PHD finger domain containing |
| 23265 | EXOC7 | exocyst complex component 7 |
| 1236 | CCR7 | C-C motif chemokine receptor 7 |
| 126393 | HSPB6 | heat shock protein family B (small) member 6 |
| 9701 | PPP6R2 | protein phosphatase 6 regulatory subunit 2 |
| 5075 | PAX1 | paired box 1 |
| 126282 | TNFAIP8L1 | TNF alpha induced protein 8 like 1 |
| 25950 | RWDD3 | RWD domain containing 3 |
| 146542 | ZNF688 | zinc finger protein 688 |
| 56124 | PCDHB12 | protocadherin beta 12 |
| 90987 | ZNF251 | zinc finger protein 251 |
| 101060376 | TBC1D3L | TBC1 domain family member 3L |
| 337867 | UBAC2 | UBA domain containing 2 |
| 678 | ZFP36L2 | ZFP36 ring finger protein like 2 |

| | | |
|---------------------------|-------------|--|
| 6155 | RPL27 | ribosomal protein L27 |
| 924 | CD7 | CD7 molecule |
| 5869 | RAB5B | RAB5B, member RAS oncogene family |
| 2687 | GGT5 | gamma-glutamyltransferase 5 |
| 3455 | IFNAR2 | interferon alpha and beta receptor subunit 2 |
| 55114 | ARHGAP17 | Rho GTPase activating protein 17 |
| 23300 | ATMIN | ATM interactor |
| 23157 | SEPT6 | septin 6 |
| 84433 | CARD11 | caspase recruitment domain family member 11 |
| 9363 | RAB33A | RAB33A, member RAS oncogene family |
| 23410 | SIRT3 | sirtuin 3 |
| 6141 | RPL18 | ribosomal protein L18 |
| 4092 | SMAD7 | SMAD family member 7 |
| 256281 | NUDT14 | nudix hydrolase 14 |
| 222234 | FAM185A | family with sequence similarity 185 member A |
| 126259 | TMIGD2 | transmembrane and immunoglobulin domain containing 2 |
| 84441 | MAML2 | mastermind like transcriptional coactivator 2 |
| 80162 | PGGHG | protein-glucosylgalactosylhydroxylysine glucosidase |
| 56995 | TULP4 | tubby like protein 4 |
| 5013 | OTX1 | orthodenticle homeobox 1 |
| 79818 | ZNF552 | zinc finger protein 552 |
| 4356 | MPP3 | membrane palmitoylated protein 3 |
| 23770 | FKBP8 | FK506 binding protein 8 |
| 346689 | KLRG2 | killer cell lectin like receptor G2 |
| 256021 | LINC01619 | long intergenic non-protein coding RNA 1619 |
| 9644 | SH3PXD2A | SH3 and PX domains 2A |
| 1384 | CRAT | carnitine O-acetyltransferase |
| 4925 | NUCB2 | nucleobindin 2 |
| 8839 | WISP2 | WNT1 inducible signaling pathway protein 2 |
| 27243 | CHMP2A | charged multivesicular body protein 2A |
| 5333 | PLCD1 | phospholipase C delta 1 |
| 309 | ANXA6 | annexin A6 |
| 3561 | IL2RG | interleukin 2 receptor subunit gamma |
| 79705 | LRRK1 | leucine rich repeat kinase 1 |
| 100874214 | TM4SF19-AS1 | TM4SF19 antisense RNA 1 |
| 200035 | NUDT17 | nudix hydrolase 17 |
| 3299 | HSF4 | heat shock transcription factor 4 |
| 974 | CD79B | CD79b molecule |
| 9423 | NTN1 | netrin 1 |
| 100128675 | HPN-AS1 | HPN antisense RNA 1 |
| 51005 | AMDHD2 | amidohydrolase domain containing 2 |
| 64806 | IL25 | interleukin 25 |
| 26127 | FGFR1OP2 | FGFR1 oncogene partner 2 |
| 101060684 | NBPF26 | neuroblastoma breakpoint family member 26 |
| 55204 | GOLPH3L | golgi phosphoprotein 3 like |
| 163087 | ZNF383 | zinc finger protein 383 |
| 83941 | TM2D1 | TM2 domain containing 1 |
| 10780 | ZNF234 | zinc finger protein 234 |
| 55844 | PPP2R2D | protein phosphatase 2 regulatory subunit Bdelta |
| 36 | ACADSB | acyl-CoA dehydrogenase, short/branched chain |
| 6342 | SCP2 | sterol carrier protein 2 |
| 219749 | ZNF25 | zinc finger protein 25 |
| 348094 | ANKDD1A | ankyrin repeat and death domain containing 1A |
| 51111 | KMT5B | lysine methyltransferase 5B |
| 55337 | C19orf66 | chromosome 19 open reading frame 66 |
| 1731 | SEPT1 | septin 1 |
| 11226 | GALNT6 | polypeptide N-acetylgalactosaminyltransferase 6 |
| 55900 | ZNF302 | zinc finger protein 302 |
| 132160 | PPM1M | protein phosphatase, Mg ²⁺ /Mn ²⁺ dependent 1M |
| 6775 | STAT4 | signal transducer and activator of transcription 4 |
| 28951 | TRIB2 | tribbles pseudokinase 2 |
| 1891 | ECH1 | enoyl-CoA hydratase 1 |
| 8195 | MKKS | McKusick-Kaufman syndrome |
| 388969 | C2orf68 | chromosome 2 open reading frame 68 |
| 9087 | TMSB4Y | thymosin beta 4, Y-linked |

| | | | |
|---------------------------|----------|--|---|
| 51247 | PAIP2 | poly(A) binding protein interacting protein 2 | 5 |
| 11060 | WWP2 | WW domain containing E3 ubiquitin protein ligase 2 | 5 |
| 8434 | RECK | reversion inducing cysteine rich protein with kazal motifs | 5 |
| 5412 | UBL3 | ubiquitin like 3 | 5 |
| 55501 | CHST12 | carbohydrate sulfotransferase 12 | 5 |
| 83463 | MXD3 | MAX dimerization protein 3 | 5 |
| 55251 | PCMTD2 | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 | 5 |
| 115817 | DHRS1 | dehydrogenase/reductase 1 | 5 |
| 10916 | MAGED2 | MAGE family member D2 | 5 |
| 26152 | ZNF337 | zinc finger protein 337 | 5 |
| 6158 | RPL28 | ribosomal protein L28 | 5 |
| 54532 | USP53 | ubiquitin specific peptidase 53 | 5 |
| 1195 | CLK1 | CDC like kinase 1 | 5 |
| 55219 | TMEM57 | transmembrane protein 57 | 5 |
| 2778 | GNAS | GNAS complex locus | 5 |
| 9746 | CLSTN3 | calsyntenin 3 | 5 |
| 23523 | CABIN1 | calcineurin binding protein 1 | 5 |
| 100131187 | TSTD1 | thiosulfate sulfurtransferase like domain containing 1 | 5 |
| 4007 | PRICKLE3 | prickle planar cell polarity protein 3 | 5 |
| 339366 | ADAMTSL5 | ADAMTS like 5 | 5 |
| 10045 | SH2D3A | SH2 domain containing 3A | 5 |
| 79132 | DHX58 | DEXH-box helicase 58 | 5 |
| 9522 | SCAMP1 | secretory carrier membrane protein 1 | 5 |
| 11179 | ZNF277 | zinc finger protein 277 | 5 |
| 4926 | NUMA1 | nuclear mitotic apparatus protein 1 | 5 |
| 390927 | ZNF793 | zinc finger protein 793 | 5 |
| 729238 | SFTPA2 | surfactant protein A2 | 5 |
| 57132 | CHMP1B | charged multivesicular body protein 1B | 5 |
| 56925 | LXN | latexin | 5 |
| 3590 | IL11RA | interleukin 11 receptor subunit alpha | 5 |
| 474344 | GIMAP6 | GTPase, IMAP family member 6 | 5 |
| 1794 | DOCK2 | dedicator of cytokinesis 2 | 5 |
| 255967 | PAN3 | PAN3 poly(A) specific ribonuclease subunit | 5 |
| 4627 | MYH9 | myosin heavy chain 9 | 5 |
| 55187 | VPS13D | vacuolar protein sorting 13 homolog D | 5 |
| 80325 | ABTB1 | ankyrin repeat and BTB domain containing 1 | 5 |
| 8764 | TNFRSF14 | TNF receptor superfamily member 14 | 5 |
| 23503 | ZFYVE26 | zinc finger FYVE-type containing 26 | 5 |
| 9969 | MED13 | mediator complex subunit 13 | 5 |
| 23230 | VPS13A | vacuolar protein sorting 13 homolog A | 5 |
| 9354 | UBE4A | ubiquitination factor E4A | 5 |
| 22992 | KDM2A | lysine demethylase 2A | 5 |
| 113 | ADCY7 | adenylate cyclase 7 | 5 |
| 5289 | PIK3C3 | phosphatidylinositol 3-kinase catalytic subunit type 3 | 5 |
| 7155 | TOP2B | topoisomerase (DNA) II beta | 5 |
| 6942 | TCF20 | transcription factor 20 | 5 |
| 2316 | FLNA | filamin A | 5 |
| 23550 | PSD4 | pleckstrin and Sec7 domain containing 4 | 5 |
| 50839 | TAS2R10 | taste 2 receptor member 10 | 5 |
| 23215 | PRRC2C | proline rich coiled-coil 2C | 5 |
| 10838 | ZNF275 | zinc finger protein 275 | 5 |
| 256364 | EML3 | echinoderm microtubule associated protein like 3 | 5 |
| 56252 | YLP1M1 | YLP motif containing 1 | 5 |
| 25792 | CIZ1 | CDKN1A interacting zinc finger protein 1 | 5 |
| 126374 | WTIP | Wilms tumor 1 interacting protein | 5 |
| 147686 | ZNF418 | zinc finger protein 418 | 5 |
| 23005 | MAPKBP1 | mitogen-activated protein kinase binding protein 1 | 5 |
| 129530 | LYG1 | lysozyme g1 | 5 |
| 64772 | ENGASE | endo-beta-N-acetylglucosaminidase | 5 |
| 5585 | PKN1 | protein kinase N1 | 5 |
| 114904 | C1QTNF6 | C1q and tumor necrosis factor related protein 6 | 5 |
| 80320 | SP6 | Sp6 transcription factor | 5 |
| 63941 | NECAB3 | N-terminal EF-hand calcium binding protein 3 | 5 |
| 8547 | FCN3 | ficolin 3 | 5 |
| 115196 | ZNF554 | zinc finger protein 554 | 5 |

| | | |
|---------------------------|------------|---|
| 7786 | MAP3K12 | mitogen-activated protein kinase kinase kinase 12 |
| 673 | BRAF | B-Raf proto-oncogene, serine/threonine kinase |
| 290 | ANPEP | alanyl aminopeptidase, membrane |
| 64760 | FAM160B2 | family with sequence similarity 160 member B2 |
| 51043 | ZBTB7B | zinc finger and BTB domain containing 7B |
| 100126793 | GHRLOS | ghrelin opposite strand/antisense RNA |
| 23002 | DAAM1 | dishevelled associated activator of morphogenesis 1 |
| 9202 | ZMYM4 | zinc finger MYM-type containing 4 |
| 6651 | SON | SON DNA binding protein |
| 55209 | SETD5 | SET domain containing 5 |
| 23592 | LEMD3 | LEM domain containing 3 |
| 57683 | ZDBF2 | zinc finger DBF-type containing 2 |
| 5062 | PAK2 | p21 (RAC1) activated kinase 2 |
| 259282 | BOD1L1 | biorientation of chromosomes in cell division 1 like 1 |
| 10396 | ATP8A1 | ATPase phospholipid transporting 8A1 |
| 282809 | POC1B | POC1 centriolar protein B |
| 63908 | NAPB | NSF attachment protein beta |
| 284459 | HKR1 | HKR1, GLI-Kruppel zinc finger family member |
| 7392 | USF2 | upstream transcription factor 2, c-fos interacting |
| 221037 | JMJD1C | jumonji domain containing 1C |
| 3423 | IDS | iduronate 2-sulfatase |
| 26020 | LRP10 | LDL receptor related protein 10 |
| 91748 | ELMSAN1 | ELM2 and Myb/SANT domain containing 1 |
| 51177 | PLEKHO1 | pleckstrin homology domain containing O1 |
| 4736 | RPL10A | ribosomal protein L10a |
| 23262 | PIIP5K2 | diphosphoinositol pentakisphosphate kinase 2 |
| 22980 | TCF25 | transcription factor 25 |
| 118924 | FRA10AC1 | fragile site, folic acid type, rare, fra(10)(q23.3) or fra(10)(q24.2) candidate 1 |
| 23461 | ABCA5 | ATP binding cassette subfamily A member 5 |
| 57189 | KIAA1147 | KIAA1147 |
| 8085 | KMT2D | lysine methyltransferase 2D |
| 26235 | FBXL4 | F-box and leucine rich repeat protein 4 |
| 23162 | MAPK8IP3 | mitogen-activated protein kinase 8 interacting protein 3 |
| 23067 | SETD1B | SET domain containing 1B |
| 200539 | ANKRD23 | ankyrin repeat domain 23 |
| 23315 | SLC9A8 | solute carrier family 9 member A8 |
| 55125 | CEP192 | centrosomal protein 192 |
| 489 | ATP2A3 | ATPase sarcoplasmic/endoplasmic reticulum Ca ²⁺ transporting 3 |
| 83931 | STK40 | serine/threonine kinase 40 |
| 730094 | C16orf52 | chromosome 16 open reading frame 52 |
| 4899 | NRF1 | nuclear respiratory factor 1 |
| 50832 | TAS2R4 | taste 2 receptor member 4 |
| 26190 | FBXW2 | F-box and WD repeat domain containing 2 |
| 55827 | DCAF6 | DDB1 and CUL4 associated factor 6 |
| 27030 | MLH3 | mutL homolog 3 |
| 7620 | ZNF69 | zinc finger protein 69 |
| 126069 | ZNF491 | zinc finger protein 491 |
| 221496 | LEMD2 | LEM domain containing 2 |
| 55454 | CSGALNACT2 | chondroitin sulfate N-acetylgalactosaminyltransferase 2 |
| 85377 | MICAL1 | MICAL like 1 |
| 80208 | SPG11 | spastic paraplegia 11 (autosomal recessive) |
| 57614 | KIAA1468 | KIAA1468 |
| 25836 | NIPBL | NIPBL, cohesin loading factor |
| 54799 | MBTD1 | mbt domain containing 1 |
| 10009 | ZBTB33 | zinc finger and BTB domain containing 33 |
| 54681 | P4HTM | prolyl 4-hydroxylase, transmembrane |
| 55139 | ANKZF1 | ankyrin repeat and zinc finger domain containing 1 |
| 81932 | HDHD3 | haloacid dehalogenase like hydrolase domain containing 3 |
| 8924 | HERC2 | HECT and RLD domain containing E3 ubiquitin protein ligase 2 |
| 26260 | FBXO25 | F-box protein 25 |
| 51755 | CDK12 | cyclin dependent kinase 12 |
| 9205 | ZMYM5 | zinc finger MYM-type containing 5 |
| 257218 | SHPRH | SNF2 histone linker PHD RING helicase |
| 7073 | TIAL1 | TIA1 cytotoxic granule associated RNA binding protein like 1 |
| 57148 | RALGAPB | Ral GTPase activating protein non-catalytic beta subunit |

| | | |
|---------------------------|--------------|---|
| 3213 | HOXB3 | homeobox B3 |
| 23637 | RABGAP1 | RAB GTPase activating protein 1 |
| 339345 | NANOS2 | nanos C2HC-type zinc finger 2 |
| 100507424 | LOC100507424 | uncharacterized LOC100507424 |
| 642819 | ZNF487 | zinc finger protein 487 |
| 8419 | BFSP2 | beaded filament structural protein 2 |
| 1185 | CLCN6 | chloride voltage-gated channel 6 |
| 84527 | ZNF559 | zinc finger protein 559 |
| 388564 | TMEM238 | transmembrane protein 238 |
| 51105 | PHF20L1 | PHD finger protein 20-like 1 |
| 317662 | FAM149B1 | family with sequence similarity 149 member B1 |
| 8481 | OFD1 | OFD1, centriole and centriolar satellite protein |
| 89857 | KLHL6 | kelch like family member 6 |
| 27125 | AFF4 | AF4/FMR2 family member 4 |
| 7464 | CORO2A | coronin 2A |
| 51304 | ZDHHC3 | zinc finger DHHC-type containing 3 |
| 57690 | TNRC6C | trinucleotide repeat containing 6C |
| 83692 | CD99L2 | CD99 molecule like 2 |
| 50488 | MINK1 | misshapen like kinase 1 |
| 55054 | ATG16L1 | autophagy related 16 like 1 |
| 55683 | KANSL3 | KAT8 regulatory NSL complex subunit 3 |
| 5991 | RFX3 | regulatory factor X3 |
| 3570 | IL6R | interleukin 6 receptor |
| 54 | ACP5 | acid phosphatase 5, tartrate resistant |
| 160851 | DGKH | diacylglycerol kinase eta |
| 84914 | ZNF587 | zinc finger protein 587 |
| 22933 | SIRT2 | sirtuin 2 |
| 652968 | GATSL3 | GATS protein like 3 |
| 196403 | DTX3 | deltex E3 ubiquitin ligase 3 |
| 51191 | HERC5 | HECT and RLD domain containing E3 ubiquitin protein ligase 5 |
| 57498 | KIDINS220 | kinase D-interacting substrate 220kDa |
| 1389 | CREBL2 | cAMP responsive element binding protein like 2 |
| 9980 | DOPEY2 | dopey family member 2 |
| 8543 | LMO4 | LIM domain only 4 |
| 91782 | CHMP7 | charged multivesicular body protein 7 |
| 5530 | PPP3CA | protein phosphatase 3 catalytic subunit alpha |
| 9847 | C2CD5 | C2 calcium dependent domain containing 5 |
| 149041 | RC3H1 | ring finger and CCCH-type domains 1 |
| 5025 | P2RX4 | purinergic receptor P2X 4 |
| 29068 | ZBTB44 | zinc finger and BTB domain containing 44 |
| 10585 | POMT1 | protein O-mannosyltransferase 1 |
| 3140 | MR1 | major histocompatibility complex, class I-related |
| 8556 | CDC14A | cell division cycle 14A |
| 54981 | NMRK1 | nicotinamide riboside kinase 1 |
| 117584 | RFFL | ring finger and FYVE like domain containing E3 ubiquitin protein ligase |
| 841 | CASP8 | caspase 8 |
| 1387 | CREBBP | CREB binding protein |
| 10347 | ABCA7 | ATP binding cassette subfamily A member 7 |
| 4820 | NKTR | natural killer cell triggering receptor |
| 2323 | FLT3LG | fms related tyrosine kinase 3 ligand |
| 274 | BIN1 | bridging integrator 1 |
| 80830 | APOL6 | apolipoprotein L6 |
| 54904 | WHSC1L1 | Wolf-Hirschhorn syndrome candidate 1-like 1 |
| 6314 | ATXN7 | ataxin 7 |
| 8861 | LDB1 | LIM domain binding 1 |
| 5829 | PXN | paxillin |
| 58485 | TRAPPC1 | trafficking protein particle complex 1 |
| 10044 | SH2D3C | SH2 domain containing 3C |
| 143098 | MPP7 | membrane palmitoylated protein 7 |
| 11123 | RCAN3 | RCAN family member 3 |
| 4046 | LSP1 | lymphocyte-specific protein 1 |
| 6404 | SELPLG | selectin P ligand |
| 51585 | PCF11 | PCF11 cleavage and polyadenylation factor subunit |
| 3338 | DNAJC4 | DnaJ heat shock protein family (Hsp40) member C4 |
| 123036 | TC2N | tandem C2 domains, nuclear |

| | | | |
|------------------------|-----------|---|---|
| 53822 | FXYP7 | FXYP domain containing ion transport regulator 7 | 5 |
| 51411 | BIN2 | bridging integrator 2 | 5 |
| 79932 | KIAA0319L | KIAA0319 like | 5 |
| 25939 | SAMHD1 | SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 | 5 |
| 11342 | RNF13 | ring finger protein 13 | 5 |
| 53346 | TM6SF1 | transmembrane 6 superfamily member 1 | 5 |
| 10559 | SLC35A1 | solute carrier family 35 member A1 | 5 |
| 900 | CCNG1 | cyclin G1 | 5 |
| 84851 | TRIM52 | tripartite motif containing 52 | 5 |
| 84958 | SYTL1 | synaptotagmin like 1 | 5 |
| 9840 | TESPA1 | thymocyte expressed, positive selection associated 1 | 5 |
| 4050 | LTB | lymphotoxin beta | 5 |
| 150365 | MEI1 | meiotic double-stranded break formation protein 1 | 5 |
| 54847 | SIDT1 | SID1 transmembrane family member 1 | 5 |
| 11010 | GLIPR1 | GLI pathogenesis related 1 | 5 |
| 284129 | SLC26A11 | solute carrier family 26 member 11 | 5 |
| 837 | CASP4 | caspase 4 | 5 |
| 54622 | ARL15 | ADP ribosylation factor like GTPase 15 | 5 |
| 5527 | PPP2R5C | protein phosphatase 2 regulatory subunit B'gamma | 5 |
| 91523 | PCED1B | PC-esterase domain containing 1B | 5 |
| 3135 | HLA-G | major histocompatibility complex, class I, G | 5 |
| 91689 | SMDT1 | single-pass membrane protein with aspartate rich tail 1 | 5 |
| 23125 | CAMTA2 | calmodulin binding transcription activator 2 | 5 |
| 5920 | RARRES3 | retinoic acid receptor responder 3 | 5 |
| 3594 | IL12RB1 | interleukin 12 receptor subunit beta 1 | 5 |
| 360 | AQP3 | aquaporin 3 (Gill blood group) | 5 |
| 158830 | CXorf65 | chromosome X open reading frame 65 | 5 |
| 3955 | LFNG | LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase | 5 |
| 57489 | ODF2L | outer dense fiber of sperm tails 2 like | 5 |
| 7567 | ZNF19 | zinc finger protein 19 | 5 |
| 219402 | MTIF3 | mitochondrial translational initiation factor 3 | 5 |
| 123688 | HYKK | hydroxylysine kinase | 5 |
| 5588 | PRKCQ | protein kinase C theta | 5 |
| 6275 | S100A4 | S100 calcium binding protein A4 | 5 |
| 118429 | ANTXR2 | anthrax toxin receptor 2 | 5 |
| 177 | AGER | advanced glycosylation end-product specific receptor | 5 |
| 10365 | KLF2 | Kruppel like factor 2 | 5 |
| 51274 | KLF3 | Kruppel like factor 3 | 5 |
| 2537 | IFI6 | interferon alpha inducible protein 6 | 5 |
| 4063 | LY9 | lymphocyte antigen 9 | 5 |
| 201595 | STT3B | STT3B, catalytic subunit of the oligosaccharyltransferase complex | 5 |
| 151613 | TTC14 | tetratricopeptide repeat domain 14 | 5 |
| 9725 | TMEM63A | transmembrane protein 63A | 5 |
| 51586 | MED15 | mediator complex subunit 15 | 5 |
| 23515 | MORC3 | MORC family CW-type zinc finger 3 | 5 |
| 23046 | KIF21B | kinesin family member 21B | 5 |
| 2145 | EZH1 | enhancer of zeste 1 polycomb repressive complex 2 subunit | 5 |
| 5175 | PECAM1 | platelet and endothelial cell adhesion molecule 1 | 5 |
| 387357 | THEMIS | thymocyte selection associated | 5 |
| 29767 | TMOD2 | tropomodulin 2 | 5 |
| 4599 | MX1 | MX dynamin like GTPase 1 | 5 |
| 916 | CD3E | CD3e molecule | 5 |
| 972 | CD74 | CD74 molecule | 5 |
| 220972 | MARCH8 | membrane associated ring-CH-type finger 8 | 5 |
| 115209 | OMA1 | OMA1 zinc metalloproteinase | 5 |
| 84456 | L3MBTL3 | l(3)mbt-like 3 (Drosophila) | 5 |
| 4179 | CD46 | CD46 molecule | 5 |
| 51816 | CECR1 | cat eye syndrome chromosome region, candidate 1 | 5 |
| 51019 | CCDC53 | coiled-coil domain containing 53 | 5 |
| 196513 | DCP1B | decapping mRNA 1B | 5 |
| 23593 | HEBP2 | heme binding protein 2 | 5 |
| 10627 | MYL12A | myosin light chain 12A | 5 |
| 55217 | TMLHE | trimethyllysine hydroxylase, epsilon | 5 |
| 55281 | TMEM140 | transmembrane protein 140 | 5 |
| 5371 | PML | promyelocytic leukemia | 5 |

| | | |
|------------------------|-----------|--|
| 55906 | ZC4H2 | zinc finger C4H2-type containing |
| 9113 | LATS1 | large tumor suppressor kinase 1 |
| 4494 | MT1F | metallothionein 1F |
| 389289 | ANXA2R | annexin A2 receptor |
| 22884 | WDR37 | WD repeat domain 37 |
| 6430 | SRSF5 | serine and arginine rich splicing factor 5 |
| 317649 | EIF4E3 | eukaryotic translation initiation factor 4E family member 3 |
| 94241 | TP53INP1 | tumor protein p53 inducible nuclear protein 1 |
| 93550 | ZFAND4 | zinc finger AN1-type containing 4 |
| 10397 | NDRG1 | N-myc downstream regulated 1 |
| 8916 | HERC3 | HECT and RLD domain containing E3 ubiquitin protein ligase 3 |
| 6903 | TBCC | tubulin folding cofactor C |
| 301 | ANXA1 | annexin A1 |
| 79726 | WDR59 | WD repeat domain 59 |
| 159090 | FAM122B | family with sequence similarity 122B |
| 284004 | HEXDC | hexosaminidase D |
| 10781 | ZNF266 | zinc finger protein 266 |
| 151636 | DTX3L | deltex E3 ubiquitin ligase 3L |
| 7507 | XPA | XPA, DNA damage recognition and repair factor |
| 23287 | AGTPBP1 | ATP/GTP binding protein 1 |
| 146198 | ZFP90 | ZFP90 zinc finger protein |
| 405 | ARNT | aryl hydrocarbon receptor nuclear translocator |
| 9867 | PJA2 | praja ring finger ubiquitin ligase 2 |
| 79364 | ZXDC | ZXD family zinc finger C |
| 158219 | TTC39B | tetratricopeptide repeat domain 39B |
| 221178 | SPATA13 | spermatogenesis associated 13 |
| 128346 | C1orf162 | chromosome 1 open reading frame 162 |
| 9267 | CYTH1 | cytohesin 1 |
| 3431 | SP110 | SP110 nuclear body protein |
| 157378 | TMEM65 | transmembrane protein 65 |
| 152926 | PPM1K | protein phosphatase, Mg ²⁺ /Mn ²⁺ dependent 1K |
| 5775 | PTPN4 | protein tyrosine phosphatase, non-receptor type 4 |
| 92797 | HELB | DNA helicase B |
| 81704 | DOCK8 | dedicator of cytokinesis 8 |
| 29909 | GPR171 | G protein-coupled receptor 171 |
| 147138 | TMC8 | transmembrane channel like 8 |
| 10466 | COG5 | component of oligomeric golgi complex 5 |
| 6667 | SP1 | Sp1 transcription factor |
| 8554 | PIAS1 | protein inhibitor of activated STAT 1 |
| 757 | TMEM50B | transmembrane protein 50B |
| 55825 | PECR | peroxisomal trans-2-enoyl-CoA reductase |
| 493 | ATP2B4 | ATPase plasma membrane Ca ²⁺ transporting 4 |
| 3655 | ITGA6 | integrin subunit alpha 6 |
| 5292 | PIM1 | Pim-1 proto-oncogene, serine/threonine kinase |
| 9922 | IQSEC1 | IQ motif and Sec7 domain 1 |
| 152006 | RNF38 | ring finger protein 38 |
| 163049 | ZNF791 | zinc finger protein 791 |
| 4214 | MAP3K1 | mitogen-activated protein kinase kinase kinase 1 |
| 23032 | USP33 | ubiquitin specific peptidase 33 |
| 23033 | DOPEY1 | dopey family member 1 |
| 56605 | ERO1B | endoplasmic reticulum oxidoreductase 1 beta |
| 27430 | MAT2B | methionine adenosyltransferase 2B |
| 388558 | ZNF808 | zinc finger protein 808 |
| 8867 | SYNJ1 | synaptojanin 1 |
| 84719 | LINC00260 | long intergenic non-protein coding RNA 260 |
| 51667 | NUB1 | negative regulator of ubiquitin like proteins 1 |
| 79770 | TXNDC15 | thioredoxin domain containing 15 |
| 834 | CASP1 | caspase 1 |
| 64598 | MOSPD3 | motile sperm domain containing 3 |
| 3106 | HLA-B | major histocompatibility complex, class I, B |
| 3669 | ISG20 | interferon stimulated exonuclease gene 20 |
| 554223 | LOC554223 | histocompatibility antigen-related |
| 4077 | NBR1 | NBR1, autophagy cargo receptor |
| 10379 | IRF9 | interferon regulatory factor 9 |
| 64844 | MARCH7 | membrane associated ring-CH-type finger 7 |

| | | | |
|------------------------|-----------|---|---|
| 3841 | KPNA5 | karyopherin subunit alpha 5 | 5 |
| 8644 | AKR1C3 | aldo-keto reductase family 1 member C3 | 5 |
| 54464 | XRN1 | 5'-3' exoribonuclease 1 | 5 |
| 80342 | TRAF3IP3 | TRAF3 interacting protein 3 | 5 |
| 5335 | PLCG1 | phospholipase C gamma 1 | 5 |
| 55007 | FAM118A | family with sequence similarity 118 member A | 5 |
| 26999 | CYFIP2 | cytoplasmic FMR1 interacting protein 2 | 5 |
| 51478 | HSD17B7 | hydroxysteroid 17-beta dehydrogenase 7 | 5 |
| 91351 | DDX60L | DEAD-box helicase 60-like | 5 |
| 9445 | ITM2B | integral membrane protein 2B | 5 |
| 388552 | BLOC1S3 | biogenesis of lysosomal organelles complex 1 subunit 3 | 5 |
| 54809 | SAMD9 | sterile alpha motif domain containing 9 | 5 |
| 219285 | SAMD9L | sterile alpha motif domain containing 9 like | 5 |
| 80833 | APOL3 | apolipoprotein L3 | 5 |
| 3581 | IL9R | interleukin 9 receptor | 5 |
| 1519 | CTSO | cathepsin O | 5 |
| 63935 | PCIF1 | PDX1 C-terminal inhibiting factor 1 | 5 |
| 8615 | USO1 | USO1 vesicle transport factor | 5 |
| 1655 | DDX5 | DEAD-box helicase 5 | 5 |
| 28968 | SLC6A16 | solute carrier family 6 member 16 | 5 |
| 6786 | STIM1 | stromal interaction molecule 1 | 5 |
| 57018 | CCNL1 | cyclin L1 | 5 |
| 10455 | ECI2 | enoyl-CoA delta isomerase 2 | 5 |
| 7597 | ZBTB25 | zinc finger and BTB domain containing 25 | 5 |
| 114769 | CARD16 | caspase recruitment domain family member 16 | 5 |
| 54891 | INO80D | INO80 complex subunit D | 5 |
| 8875 | VNN2 | vanin 2 | 5 |
| 162394 | SLFN5 | schlafen family member 5 | 5 |
| 55196 | KIAA1551 | KIAA1551 | 5 |
| 397 | ARHGDIB | Rho GDP dissociation inhibitor beta | 5 |
| 91526 | ANKRD44 | ankyrin repeat domain 44 | 5 |
| 5934 | RBL2 | RB transcriptional corepressor like 2 | 5 |
| 23586 | DDX58 | DEXD/H-box helicase 58 | 5 |
| 1388 | ATF6B | activating transcription factor 6 beta | 5 |
| 10521 | DDX17 | DEAD-box helicase 17 | 5 |
| 64771 | C6orf106 | chromosome 6 open reading frame 106 | 5 |
| 89848 | FCHSD1 | FCH and double SH3 domains 1 | 5 |
| 9881 | TRANK1 | tetratricopeptide repeat and ankyrin repeat containing 1 | 5 |
| 3275 | PRMT2 | protein arginine methyltransferase 2 | 5 |
| 7059 | THBS3 | thrombospondin 3 | 5 |
| 9976 | CLEC2B | C-type lectin domain family 2 member B | 5 |
| 832 | CAPZB | capping actin protein of muscle Z-line beta subunit | 5 |
| 79903 | NAA60 | N(alpha)-acetyltransferase 60, NatF catalytic subunit | 5 |
| 57097 | PARP11 | poly(ADP-ribose) polymerase family member 11 | 5 |
| 51000 | SLC35B3 | solute carrier family 35 member B3 | 5 |
| 2633 | GBP1 | guanylate binding protein 1 | 5 |
| 112849 | L3HYPDH | trans-L-3-hydroxyproline dehydratase | 5 |
| 901 | CCNG2 | cyclin G2 | 5 |
| 1429 | CRYZ | crystallin zeta | 5 |
| 3105 | HLA-A | major histocompatibility complex, class I, A | 5 |
| 94240 | EPSTI1 | epithelial stromal interaction 1 (breast) | 5 |
| 3134 | HLA-F | major histocompatibility complex, class I, F | 5 |
| 11119 | BTN3A1 | butyrophilin subfamily 3 member A1 | 5 |
| 3139 | HLA-L | major histocompatibility complex, class I, L (pseudogene) | 5 |
| 10161 | LPAR6 | lysophosphatidic acid receptor 6 | 5 |
| 10154 | PLXNC1 | plexin C1 | 5 |
| 79603 | CERS4 | ceramide synthase 4 | 5 |
| 84173 | ELMOD3 | ELMO domain containing 3 | 5 |
| 55837 | EAPP | E2F associated phosphoprotein | 5 |
| 3107 | HLA-C | major histocompatibility complex, class I, C | 5 |
| 222223 | KIAA1324L | KIAA1324 like | 5 |
| 49855 | SCAPER | S-phase cyclin A associated protein in the ER | 5 |
| 64386 | MMP25 | matrix metalloproteinase 25 | 5 |
| 7538 | ZFP36 | ZFP36 ring finger protein | 5 |
| 55437 | STRADB | STE20-related kinase adaptor beta | 5 |

| | | |
|------------------------|-----------|---|
| 80298 | MTERF2 | mitochondrial transcription termination factor 2 |
| 1025 | CDK9 | cyclin dependent kinase 9 |
| 4943 | TBC1D25 | TBC1 domain family member 25 |
| 90826 | PRMT9 | protein arginine methyltransferase 9 |
| 54497 | HEATR5B | HEAT repeat containing 5B |
| 22878 | TRAPPC8 | trafficking protein particle complex 8 |
| 1513 | CTSK | cathepsin K |
| 79654 | HECTD3 | HECT domain E3 ubiquitin protein ligase 3 |
| 8450 | CUL4B | cullin 4B |
| 27241 | BBS9 | Bardet-Biedl syndrome 9 |
| 23060 | ZNF609 | zinc finger protein 609 |
| 8816 | DCAF5 | DDB1 and CUL4 associated factor 5 |
| 84727 | SPSB2 | splA/ryanodine receptor domain and SOCS box containing 2 |
| 51379 | CRLF3 | cytokine receptor like factor 3 |
| 3071 | NCKAP1L | NCK associated protein 1 like |
| 55288 | RHOT1 | ras homolog family member T1 |
| 10444 | ZER1 | zyg-11 related cell cycle regulator |
| 842 | CASP9 | caspase 9 |
| 92 | ACVR2A | activin A receptor type 2A |
| 4690 | NCK1 | NCK adaptor protein 1 |
| 84307 | ZNF397 | zinc finger protein 397 |
| 7716 | VEZF1 | vascular endothelial zinc finger 1 |
| 64091 | POPDC2 | popeye domain containing 2 |
| 8934 | RAB29 | RAB29, member RAS oncogene family |
| 55283 | MCOLN3 | mucolipin 3 |
| 23588 | KLHDC2 | kelch domain containing 2 |
| 4600 | MX2 | MX dynamin like GTPase 2 |
| 9860 | LRIG2 | leucine rich repeats and immunoglobulin like domains 2 |
| 7852 | CXCR4 | C-X-C motif chemokine receptor 4 |
| 64109 | CRLF2 | cytokine receptor-like factor 2 |
| 9528 | TMEM59 | transmembrane protein 59 |
| 2319 | FLOT2 | flotillin 2 |
| 686 | BTBD | biotinidase |
| 7046 | TGFBR1 | transforming growth factor beta receptor 1 |
| 3903 | LAIR1 | leukocyte associated immunoglobulin like receptor 1 |
| 22821 | RASA3 | RAS p21 protein activator 3 |
| 55070 | DET1 | de-etiolated homolog 1 (Arabidopsis) |
| 57184 | FAM219B | family with sequence similarity 219 member B |
| 153241 | CEP120 | centrosomal protein 120 |
| 25809 | TTL1 | tubulin tyrosine ligase like 1 |
| 55762 | ZNF701 | zinc finger protein 701 |
| 22841 | RAB11FIP2 | RAB11 family interacting protein 2 |
| 119504 | ANAPC16 | anaphase promoting complex subunit 16 |
| 286530 | P2RY8 | purinergic receptor P2Y8 |
| 55080 | TAPBPL | TAP binding protein like |
| 6746 | SSR2 | signal sequence receptor subunit 2 |
| 54103 | GSAP | gamma-secretase activating protein |
| 79991 | OBFC1 | oligonucleotide/oligosaccharide binding fold containing 1 |
| 51170 | HSD17B11 | hydroxysteroid 17-beta dehydrogenase 11 |
| 79758 | DHRS12 | dehydrogenase/reductase 12 |
| 283897 | C16orf54 | chromosome 16 open reading frame 54 |
| 29978 | UBQLN2 | ubiquilin 2 |
| 139716 | GAB3 | GRB2 associated binding protein 3 |
| 6619 | SNAPC3 | small nuclear RNA activating complex polypeptide 3 |
| 53347 | UBASH3A | ubiquitin associated and SH3 domain containing A |
| 57763 | ANKRA2 | ankyrin repeat family A member 2 |
| 6095 | RORA | RAR related orphan receptor A |
| 6777 | STAT5B | signal transducer and activator of transcription 5B |
| 7182 | NR2C2 | nuclear receptor subfamily 2 group C member 2 |
| 85007 | PHYKPL | 5-phosphohydroxy-L-lysine phospho-lyase |
| 84765 | ZNF577 | zinc finger protein 577 |
| 10144 | FAM13A | family with sequence similarity 13 member A |
| 1154 | CISH | cytokine inducible SH2 containing protein |
| 64418 | TMEM168 | transmembrane protein 168 |
| 4689 | NCF4 | neutrophil cytosolic factor 4 |

| | | |
|------------------------|-----------|---|
| 1520 | CTSS | cathepsin S |
| 59307 | SIGIRR | single Ig and TIR domain containing |
| 11329 | STK38 | serine/threonine kinase 38 |
| 54440 | SASH3 | SAM and SH3 domain containing 3 |
| 545 | ATR | ATR serine/threonine kinase |
| 7693 | ZNF134 | zinc finger protein 134 |
| 10947 | AP3M2 | adaptor related protein complex 3 mu 2 subunit |
| 728743 | LOC728743 | zinc finger protein pseudogene |
| 7311 | UBA52 | ubiquitin A-52 residue ribosomal protein fusion product 1 |
| 55357 | TBC1D2 | TBC1 domain family member 2 |
| 6468 | FBXW4 | F-box and WD repeat domain containing 4 |
| 8698 | S1PR4 | sphingosine-1-phosphate receptor 4 |
| 204851 | HIPK1 | homeodomain interacting protein kinase 1 |
| 54778 | RNF111 | ring finger protein 111 |
| 84532 | ACSS1 | acyl-CoA synthetase short-chain family member 1 |
| 80335 | WDR82 | WD repeat domain 82 |
| 9905 | SGSM2 | small G protein signaling modulator 2 |
| 4242 | MFNG | MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
| 388324 | INCA1 | inhibitor of CDK, cyclin A1 interacting protein 1 |
| 57567 | ZNF319 | zinc finger protein 319 |
| 25992 | SNED1 | sushi, nidogen and EGF like domains 1 |
| 79717 | PPCS | phosphopantothenoylcysteine synthetase |
| 51091 | SEPSECS | Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase |
| 55846 | ITFG2 | integrin alpha FG-GAP repeat containing 2 |
| 64174 | DPEP2 | dipeptidase 2 |
| 9834 | FAM30A | family with sequence similarity 30, member A |
| 24142 | NAT6 | N-acetyltransferase 6 |
| 57181 | SLC39A10 | solute carrier family 39 member 10 |
| 374986 | MIGA1 | mitoguardin 1 |
| 847 | CAT | catalase |
| 9842 | PLEKHM1 | pleckstrin homology and RUN domain containing M1 |
| 66035 | SLC2A11 | solute carrier family 2 member 11 |
| 6872 | TAF1 | TATA-box binding protein associated factor 1 |
| 80230 | RUFY1 | RUN and FYVE domain containing 1 |
| 259290 | TAS2R31 | taste 2 receptor member 31 |
| 51291 | GMIP | GEM interacting protein |
| 25900 | IFFO1 | intermediate filament family orphan 1 |
| 9736 | USP34 | ubiquitin specific peptidase 34 |
| 5494 | PPM1A | protein phosphatase, Mg2+/Mn2+ dependent 1A |
| 83874 | TBC1D10A | TBC1 domain family member 10A |
| 5287 | PIK3C2B | phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta |
| 53373 | TPCN1 | two pore segment channel 1 |
| 96459 | FNIP1 | folliculin interacting protein 1 |
| 51592 | TRIM33 | tripartite motif containing 33 |
| 8720 | MBTPS1 | membrane bound transcription factor peptidase, site 1 |
| 23167 | EFR3A | EFR3 homolog A |
| 221491 | C6orf1 | chromosome 6 open reading frame 1 |
| 887 | CCKBR | cholecystokinin B receptor |
| 1509 | CTSD | cathepsin D |
| 283149 | BCL9L | B-cell CLL/lymphoma 9-like |
| 6239 | RREB1 | ras responsive element binding protein 1 |
| 6497 | SKI | SKI proto-oncogene |
| 7745 | ZKSCAN8 | zinc finger with KRAB and SCAN domains 8 |
| 23389 | MED13L | mediator complex subunit 13 like |
| 8289 | ARID1A | AT-rich interaction domain 1A |
| 324 | APC | APC, WNT signaling pathway regulator |
| 4750 | NEK1 | NIMA related kinase 1 |
| 89845 | ABCC10 | ATP binding cassette subfamily C member 10 |
| 5058 | PAK1 | p21 (RAC1) activated kinase 1 |
| 4680 | CEACAM6 | carcinoembryonic antigen related cell adhesion molecule 6 |
| 1773 | DNASE1 | deoxyribonuclease 1 |
| 64219 | PJA1 | praja ring finger ubiquitin ligase 1 |
| 23339 | VPS39 | VPS39, HOPS complex subunit |
| 57610 | RANBP10 | RAN binding protein 10 |
| 80124 | VCPIP1 | valosin containing protein interacting protein 1 |

| | | |
|---------------------------|--------------|--|
| 143 | PARP4 | poly(ADP-ribose) polymerase family member 4 |
| 9682 | KDM4A | lysine demethylase 4A |
| 55088 | CCDC186 | coiled-coil domain containing 186 |
| 23398 | PPWD1 | peptidylprolyl isomerase domain and WD repeat containing 1 |
| 59348 | ZNF350 | zinc finger protein 350 |
| 57674 | RNF213 | ring finger protein 213 |
| 9583 | ENTPD4 | ectonucleoside triphosphate diphosphohydrolase 4 |
| 100506736 | SLFN12L | schlafen family member 12 like |
| 55667 | DENND4C | DENN domain containing 4C |
| 123283 | TARSL2 | threonyl-tRNA synthetase like 2 |
| 843 | CASP10 | caspase 10 |
| 102724748 | LOC102724748 | uncharacterized LOC102724748 |
| 100506639 | LOC100506639 | uncharacterized LOC100506639 |
| 7328 | UBE2H | ubiquitin conjugating enzyme E2 H |
| 9168 | TMSB10 | thymosin beta 10 |
| 84861 | KLHL22 | kelch like family member 22 |
| 26157 | GIMAP2 | GTPase, IMAP family member 2 |
| 8445 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 |
| 80256 | FAM214B | family with sequence similarity 214 member B |
| 116843 | SLC18B1 | solute carrier family 18 member B1 |
| 10077 | TSPAN32 | tetraspanin 32 |
| 4189 | DNAJB9 | DnaJ heat shock protein family (Hsp40) member B9 |
| 100505761 | RPARP-AS1 | RPARP antisense RNA 1 |
| 79573 | TTC13 | tetratricopeptide repeat domain 13 |
| 9214 | FCMR | Fc fragment of IgM receptor |
| 84265 | POLR3GL | RNA polymerase III subunit G like |
| 6167 | RPL37 | ribosomal protein L37 |
| 79722 | ANKRD55 | ankyrin repeat domain 55 |
| 130814 | PQLC3 | PQ loop repeat containing 3 |
| 9692 | KIAA0391 | KIAA0391 |
| 51449 | PCYOX1 | prenylcysteine oxidase 1 |
| 64919 | BCL11B | B-cell CLL/lymphoma 11B |
| 84264 | HAGHL | hydroxyacylglutathione hydrolase-like |
| 221908 | PPP1R35 | protein phosphatase 1 regulatory subunit 35 |
| 125958 | OR7D4 | olfactory receptor family 7 subfamily D member 4 |
| 6169 | RPL38 | ribosomal protein L38 |
| 116093 | DIRC1 | disrupted in renal carcinoma 1 |
| 57719 | ANO8 | anoctamin 8 |
| 283726 | SAXO2 | stabilizer of axonemal microtubules 2 |
| 11156 | PTP4A3 | protein tyrosine phosphatase type IVA, member 3 |
| 58473 | PLEKHB1 | pleckstrin homology domain containing B1 |
| 92714 | ARRDC1 | arrestin domain containing 1 |
| 55707 | NECAP2 | NECAP endocytosis associated 2 |
| 79699 | ZYG11B | zyg-11 family member B, cell cycle regulator |
| 5465 | PPARA | peroxisome proliferator activated receptor alpha |
| 54916 | TMEM260 | transmembrane protein 260 |
| 283232 | TMEM80 | transmembrane protein 80 |
| 285268 | ZNF621 | zinc finger protein 621 |
| 57194 | ATP10A | ATPase phospholipid transporting 10A (putative) |
| 63035 | BCORL1 | BCL6 corepressor-like 1 |
| 321 | APBA2 | amyloid beta precursor protein binding family A member 2 |
| 9919 | SEC16A | SEC16 homolog A, endoplasmic reticulum export factor |
| 56242 | ZNF253 | zinc finger protein 253 |
| 10235 | RASGRP2 | RAS guanyl releasing protein 2 |
| 9827 | RGP1 | RGP1 homolog, RAB6A GEF complex partner 1 |
| 7673 | ZNF222 | zinc finger protein 222 |
| 51279 | C1RL | complement C1r subcomponent like |
| 84925 | DIRC2 | disrupted in renal carcinoma 2 |
| 10801 | SEPT9 | septin 9 |
| 51763 | INPP5K | inositol polyphosphate-5-phosphatase K |
| 22864 | R3HDM2 | R3H domain containing 2 |
| 51063 | CALHM2 | calcium homeostasis modulator 2 |
| 163882 | CNST | consortin, connexin sorting protein |
| 254531 | LPCAT4 | lysophosphatidylcholine acyltransferase 4 |
| 90273 | CEACAM21 | carcinoembryonic antigen related cell adhesion molecule 21 |

| | | |
|---------------------------|--------------|--|
| 84142 | FAM175A | family with sequence similarity 175 member A |
| 23102 | TBC1D2B | TBC1 domain family member 2B |
| 50717 | DCAF8 | DDB1 and CUL4 associated factor 8 |
| 84447 | SYVN1 | synoviolin 1 |
| 84897 | TBRG1 | transforming growth factor beta regulator 1 |
| 9451 | EIF2AK3 | eukaryotic translation initiation factor 2 alpha kinase 3 |
| 8621 | CDK13 | cyclin dependent kinase 13 |
| 155435 | RBM33 | RNA binding motif protein 33 |
| 359845 | RFLNB | refilin B |
| 8535 | CBX4 | chromobox 4 |
| 79037 | PVRIG | poliovirus receptor related immunoglobulin domain containing |
| 80169 | CTC1 | CTS telomere maintenance complex component 1 |
| 3678 | ITGA5 | integrin subunit alpha 5 |
| 256987 | SERINC5 | serine incorporator 5 |
| 54462 | CCSER2 | coiled-coil serine rich protein 2 |
| 8527 | DGKD | diacylglycerol kinase delta |
| 9149 | DYRK1B | dual specificity tyrosine phosphorylation regulated kinase 1B |
| 246744 | STH | saitohin |
| 162515 | SLC16A11 | solute carrier family 16 member 11 |
| 348378 | FAM159A | family with sequence similarity 159 member A |
| 92840 | REEP6 | receptor accessory protein 6 |
| 8665 | EIF3F | eukaryotic translation initiation factor 3 subunit F |
| 393 | ARHGAP4 | Rho GTPase activating protein 4 |
| 84836 | ABHD14B | abhydrolase domain containing 14B |
| 9788 | MTSS1 | MTSS1, I-BAR domain containing |
| 113878 | DTX2 | deltex E3 ubiquitin ligase 2 |
| 51092 | SIDT2 | SID1 transmembrane family member 2 |
| 23295 | MGRN1 | mahogunin ring finger 1 |
| 401944 | LDLRAD2 | low density lipoprotein receptor class A domain containing 2 |
| 11322 | TMC6 | transmembrane channel like 6 |
| 168620 | BHLHA15 | basic helix-loop-helix family member a15 |
| 84270 | CARD19 | caspase recruitment domain family member 19 |
| 151176 | ERFE | erythroferrone |
| 84266 | ALKBH7 | alkB homolog 7 |
| 7508 | XPC | XPC complex subunit, DNA damage recognition and repair factor |
| 199746 | U2AF1L4 | U2 small nuclear RNA auxiliary factor 1 like 4 |
| 10043 | TOM1 | target of myb1 membrane trafficking protein |
| 4696 | NDUFA3 | NADH:ubiquinone oxidoreductase subunit A3 |
| 9498 | SLC4A8 | solute carrier family 4 member 8 |
| 3611 | ILK | integrin linked kinase |
| 6160 | RPL31 | ribosomal protein L31 |
| 283450 | HECTD4 | HECT domain E3 ubiquitin protein ligase 4 |
| 105371397 | LOC105371397 | uncharacterized LOC105371397 |
| 197358 | NLRC3 | NLR family CARD domain containing 3 |
| 6122 | RPL3 | ribosomal protein L3 |
| 30815 | ST6GALNAC6 | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 |
| 9022 | CLIC3 | chloride intracellular channel 3 |
| 56260 | C8orf44 | chromosome 8 open reading frame 44 |
| 5663 | PSEN1 | presenilin 1 |
| 23177 | CEP68 | centrosomal protein 68 |
| 9397 | NMT2 | N-myristoyltransferase 2 |
| 10868 | USP20 | ubiquitin specific peptidase 20 |
| 1107 | CHD3 | chromodomain helicase DNA binding protein 3 |
| 26112 | CCDC69 | coiled-coil domain containing 69 |
| 115992 | RNF166 | ring finger protein 166 |
| 51393 | TRPV2 | transient receptor potential cation channel subfamily V member 2 |
| 55229 | PANK4 | pantothenate kinase 4 |
| 113791 | PIK3IP1 | phosphoinositide-3-kinase interacting protein 1 |
| 92017 | SNX29 | sorting nexin 29 |
| 80095 | ZNF606 | zinc finger protein 606 |
| 51646 | YPEL5 | yippee like 5 |
| 3476 | IGBP1 | immunoglobulin (CD79A) binding protein 1 |
| 22997 | IGSF9B | immunoglobulin superfamily member 9B |
| 5790 | PTPRCAP | protein tyrosine phosphatase, receptor type C associated protein |
| 951 | CD37 | CD37 molecule |

| | | |
|------------------------|----------|--|
| 22861 | NLRP1 | NLR family pyrin domain containing 1 |
| 170622 | COMMD6 | COMM domain containing 6 |
| 2124 | EVI2B | ecotropic viral integration site 2B |
| 10346 | TRIM22 | tripartite motif containing 22 |
| 151556 | GPR155 | G protein-coupled receptor 155 |
| 50515 | CHST11 | carbohydrate sulfotransferase 11 |
| 472 | ATM | ATM serine/threonine kinase |
| 7626 | ZNF75D | zinc finger protein 75D |
| 7294 | TXK | TXK tyrosine kinase |
| 10957 | PNRC1 | proline rich nuclear receptor coactivator 1 |
| 339210 | C17orf67 | chromosome 17 open reading frame 67 |
| 51466 | EVL | Enah/Vasp-like |
| 9750 | FAM65B | family with sequence similarity 65 member B |
| 5140 | PDE3B | phosphodiesterase 3B |
| 4300 | MLLT3 | MLLT3, super elongation complex subunit |
| 5252 | PHF1 | PHD finger protein 1 |
| 5330 | PLCB2 | phospholipase C beta 2 |
| 4118 | MAL | mal, T-cell differentiation protein |
| 63940 | GPSM3 | G-protein signaling modulator 3 |
| 645432 | ARRDC5 | arrestin domain containing 5 |
| 3932 | LCK | LCK proto-oncogene, Src family tyrosine kinase |
| 255394 | TCP11L2 | t-complex 11 like 2 |
| 80853 | KDM7A | lysine demethylase 7A |
| 140688 | NOL4L | nucleolar protein 4 like |
| 55643 | BTBD2 | BTB domain containing 2 |
| 6277 | S100A6 | S100 calcium binding protein A6 |
| 5800 | PTPRO | protein tyrosine phosphatase, receptor type O |
| 126375 | ZNF792 | zinc finger protein 792 |
| 64761 | PARP12 | poly(ADP-ribose) polymerase family member 12 |
| 51614 | ERGIC3 | ERGIC and golgi 3 |
| 90592 | ZNF700 | zinc finger protein 700 |
| 66008 | TRAK2 | trafficking kinesin protein 2 |
| 64332 | NFKBIZ | NFKB inhibitor zeta |
| 9710 | KIAA0355 | KIAA0355 |
| 54665 | RSBN1 | round spermatid basic protein 1 |
| 9382 | COG1 | component of oligomeric golgi complex 1 |
| 22839 | DLGAP4 | DLG associated protein 4 |
| 11035 | RIPK3 | receptor interacting serine/threonine kinase 3 |
| 57639 | CCDC146 | coiled-coil domain containing 146 |
| 23152 | CIC | capicua transcriptional repressor |
| 113177 | IZUMO4 | IZUMO family member 4 |
| 55568 | GALNT10 | polypeptide N-acetylgalactosaminyltransferase 10 |
| 84101 | USP44 | ubiquitin specific peptidase 44 |
| 85378 | TUBGCP6 | tubulin gamma complex associated protein 6 |
| 10673 | TNFSF13B | tumor necrosis factor superfamily member 13b |
| 54674 | LRRN3 | leucine rich repeat neuronal 3 |
| 6282 | S100A11 | S100 calcium binding protein A11 |
| 53827 | FXVD5 | FXVD domain containing ion transport regulator 5 |
| 79864 | C11orf63 | chromosome 11 open reading frame 63 |
| 57060 | PCBP4 | poly(rC) binding protein 4 |
| 3566 | IL4R | interleukin 4 receptor |
| 50650 | ARHGEF3 | Rho guanine nucleotide exchange factor 3 |
| 64393 | ZMAT3 | zinc finger matrin-type 3 |
| 5147 | PDE6D | phosphodiesterase 6D |
| 491 | ATP2B2 | ATPase plasma membrane Ca2+ transporting 2 |
| 129293 | TRABD2A | TraB domain containing 2A |
| 284802 | FRG1BP | FSDH region gene 1 family member B, pseudogene |
| 3702 | ITK | IL2 inducible T-cell kinase |
| 23253 | ANKRD12 | ankyrin repeat domain 12 |
| 5788 | PTPRC | protein tyrosine phosphatase, receptor type C |
| 23471 | TRAM1 | translocation associated membrane protein 1 |
| 84910 | TMEM87B | transmembrane protein 87B |
| 50848 | F11R | F11 receptor |
| 4154 | MBNL1 | muscleblind like splicing regulator 1 |
| 9595 | CYTIP | cytohesin 1 interacting protein |

| | | | |
|------------------------|----------|---|---|
| 57591 | MKL1 | megakaryoblastic leukemia (translocation) 1 | 5 |
| 1386 | ATF2 | activating transcription factor 2 | 5 |
| 5324 | PLAG1 | PLAG1 zinc finger | 5 |
| 9781 | RNF144A | ring finger protein 144A | 5 |
| 284058 | KANSL1 | KAT8 regulatory NSL complex subunit 1 | 5 |
| 9663 | LPIN2 | lipin 2 | 5 |
| 23522 | KAT6B | lysine acetyltransferase 6B | 5 |
| 814 | CAMK4 | calcium/calmodulin dependent protein kinase IV | 5 |
| 406 | ARNTL | aryl hydrocarbon receptor nuclear translocator like | 5 |
| 143686 | SESN3 | sestrin 3 | 5 |
| 10225 | CD96 | CD96 molecule | 5 |
| 9262 | STK17B | serine/threonine kinase 17b | 5 |
| 6206 | RPS12 | ribosomal protein S12 | 5 |
| 3937 | LCP2 | lymphocyte cytosolic protein 2 | 5 |
| 8031 | NCOA4 | nuclear receptor coactivator 4 | 5 |
| 10142 | AKAP9 | A-kinase anchoring protein 9 | 5 |
| 22848 | AAK1 | AP2 associated kinase 1 | 5 |
| 129607 | CMPK2 | cytidine/uridine monophosphate kinase 2 | 5 |
| 113612 | CYP2U1 | cytochrome P450 family 2 subfamily U member 1 | 5 |
| 1508 | CTSB | cathepsin B | 5 |
| 18 | ABAT | 4-aminobutyrate aminotransferase | 5 |
| 391191 | OR2AK2 | olfactory receptor family 2 subfamily AK member 2 | 5 |
| 55664 | CDC37L1 | cell division cycle 37 like 1 | 5 |
| 5334 | PLCL1 | phospholipase C like 1 | 5 |
| 6940 | ZNF354A | zinc finger protein 354A | 5 |
| 116986 | AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | 5 |
| 3588 | IL10RB | interleukin 10 receptor subunit beta | 5 |
| 23064 | SETX | senataxin | 5 |
| 2771 | GNAI2 | G protein subunit alpha i2 | 5 |
| 26054 | SENP6 | SUMO1/sentrin specific peptidase 6 | 5 |
| 408 | ARRB1 | arrestin beta 1 | 5 |
| 9770 | RASSF2 | Ras association domain family member 2 | 5 |
| 54832 | VPS13C | vacuolar protein sorting 13 homolog C | 5 |
| 149951 | COMMMD7 | COMM domain containing 7 | 5 |
| 54469 | ZFAND6 | zinc finger AN1-type containing 6 | 5 |
| 7188 | TRAF5 | TNF receptor associated factor 5 | 5 |
| 399 | RHOH | ras homolog family member H | 5 |
| 60313 | GPBP1L1 | GC-rich promoter binding protein 1 like 1 | 5 |
| 4478 | MSN | moesin | 5 |
| 91543 | RSAD2 | radical S-adenosyl methionine domain containing 2 | 5 |
| 115362 | GBP5 | guanylate binding protein 5 | 5 |
| 29761 | USP25 | ubiquitin specific peptidase 25 | 5 |
| 399665 | FAM102A | family with sequence similarity 102 member A | 5 |
| 80709 | AKNA | AT-hook transcription factor | 5 |
| 3603 | IL16 | interleukin 16 | 5 |
| 64098 | PARVG | parvin gamma | 5 |
| 64839 | FBXL17 | F-box and leucine rich repeat protein 17 | 5 |
| 9263 | STK17A | serine/threonine kinase 17a | 5 |
| 51176 | LEF1 | lymphoid enhancer binding factor 1 | 5 |
| 9641 | IKBKE | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon | 5 |
| 27250 | PDCD4 | programmed cell death 4 (neoplastic transformation inhibitor) | 5 |
| 9402 | GRAP2 | GRB2-related adaptor protein 2 | 5 |
| 197131 | UBR1 | ubiquitin protein ligase E3 component n-recognin 1 | 5 |
| 26137 | ZBTB20 | zinc finger and BTB domain containing 20 | 5 |
| 51201 | ZDHHC2 | zinc finger DHHC-type containing 2 | 5 |
| 23112 | TNRC6B | trinucleotide repeat containing 6B | 5 |
| 11046 | SLC35D2 | solute carrier family 35 member D2 | 5 |
| 9665 | KIAA0430 | KIAA0430 | 5 |
| 151050 | KANSL1L | KAT8 regulatory NSL complex subunit 1 like | 5 |
| 7805 | LAPTM5 | lysosomal protein transmembrane 5 | 5 |
| 115294 | PCMTD1 | protein-L-isoadipate (D-aspartate) O-methyltransferase domain containing 1 | 5 |
| 10443 | N4BP2L2 | NEDD4 binding protein 2 like 2 | 5 |
| 89846 | FGD3 | FYVE, RhoGEF and PH domain containing 3 | 5 |
| 822 | CAPG | capping actin protein, gelsolin like | 5 |
| 83605 | CCM2 | CCM2 scaffolding protein | 5 |

| | | |
|------------------------|----------|---|
| 83719 | YPEL3 | yippee like 3 |
| 157697 | ERICH1 | glutamate rich 1 |
| 79090 | TRAPPC6A | trafficking protein particle complex 6A |
| 60682 | SMAP1 | small ArfGAP 1 |
| 57561 | ARRDC3 | arrestin domain containing 3 |
| 23348 | DOCK9 | dedicator of cytokinesis 9 |
| 6904 | TBCD | tubulin folding cofactor D |
| 375056 | MIA3 | MIA family member 3, ER export factor |
| 9877 | ZC3H11A | zinc finger CCCH-type containing 11A |
| 10608 | MXD4 | MAX dimerization protein 4 |
| 112936 | VPS26B | VPS26, retromer complex component B |
| 92241 | RCSD1 | RCSD domain containing 1 |
| 6709 | SPTAN1 | spectrin alpha, non-erythrocytic 1 |
| 643866 | CBLN3 | cerebellin 3 precursor |
| 9857 | CEP350 | centrosomal protein 350 |
| 57134 | MAN1C1 | mannosidase alpha class 1C member 1 |
| 81688 | C6orf62 | chromosome 6 open reading frame 62 |
| 9459 | ARHGEF6 | Rac/Cdc42 guanine nucleotide exchange factor 6 |
| 2113 | ETS1 | ETS proto-oncogene 1, transcription factor |
| 23118 | TAB2 | TGF-beta activated kinase 1/MAP3K7 binding protein 2 |
| 7267 | TTC3 | tetratricopeptide repeat domain 3 |
| 54014 | BRWD1 | bromodomain and WD repeat domain containing 1 |
| 157680 | VPS13B | vacuolar protein sorting 13 homolog B |
| 4863 | NPAT | nuclear protein, coactivator of histone transcription |
| 9563 | H6PD | hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase |
| 4650 | MYO9B | myosin IXB |
| 6655 | SOS2 | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| 7535 | ZAP70 | zeta chain of T cell receptor associated protein kinase 70 |
| 23240 | KIAA0922 | KIAA0922 |
| 57459 | GATAD2B | GATA zinc finger domain containing 2B |
| 311 | ANXA11 | annexin A11 |
| 54800 | KLHL24 | kelch like family member 24 |
| 114823 | LENG8 | leukocyte receptor cluster member 8 |
| 10659 | CEL2F | CUGBP, Elav-like family member 2 |
| 57551 | TAOK1 | TAO kinase 1 |
| 9815 | GIT2 | GIT ArfGAP 2 |
| 56261 | GPCPD1 | glycerophosphocholine phosphodiesterase 1 |
| 50619 | DEF6 | DEF6, guanine nucleotide exchange factor |
| 387082 | SUMO4 | small ubiquitin-like modifier 4 |
| 170954 | PPP1R18 | protein phosphatase 1 regulatory subunit 18 |
| 23031 | MAST3 | microtubule associated serine/threonine kinase 3 |
| 7764 | ZNF217 | zinc finger protein 217 |
| 9139 | CBFA2T2 | CBFA2/RUNX1 translocation partner 2 |
| 23508 | TTC9 | tetratricopeptide repeat domain 9 |
| 64131 | XYLT1 | xylosyltransferase 1 |
| 57594 | HOMEZ | homeobox and leucine zipper encoding |
| 55526 | DHTKD1 | dehydrogenase E1 and transketolase domain containing 1 |
| 57506 | MAVS | mitochondrial antiviral signaling protein |
| 55780 | ERMARD | ER membrane associated RNA degradation |
| 387119 | CEP85L | centrosomal protein 85 like |
| 57492 | ARID1B | AT-rich interaction domain 1B |
| 84726 | PRRC2B | proline rich coiled-coil 2B |
| 123720 | WHAMM | WAS protein homolog associated with actin, golgi membranes and microtubules |
| 9138 | ARHGEF1 | Rho guanine nucleotide exchange factor 1 |
| 10401 | PIAS3 | protein inhibitor of activated STAT 3 |
| 57038 | RARS2 | arginyl-tRNA synthetase 2, mitochondrial |
| 283219 | KCTD21 | potassium channel tetramerization domain containing 21 |
| 103910 | MYL12B | myosin light chain 12B |
| 51084 | CRYL1 | crystallin lambda 1 |
| 79982 | DNAJB14 | DnaJ heat shock protein family (Hsp40) member B14 |
| 90324 | CCDC97 | coiled-coil domain containing 97 |
| 374868 | ATP9B | ATPase phospholipid transporting 9B (putative) |
| 80146 | UXS1 | UDP-glucuronate decarboxylase 1 |
| 138050 | HGSNAT | heparan-alpha-glucosaminide N-acetyltransferase |
| 54467 | ANKIB1 | ankyrin repeat and IBR domain containing 1 |

| | | |
|---------------------------|-----------|--|
| 80232 | WDR26 | WD repeat domain 26 |
| 1785 | DNM2 | dynamain 2 |
| 9266 | CYTH2 | cytohesin 2 |
| 9870 | AREL1 | apoptosis resistant E3 ubiquitin protein ligase 1 |
| 93663 | ARHGAP18 | Rho GTPase activating protein 18 |
| 80790 | CMIP | c-Maf inducing protein |
| 752 | FMNL1 | formin like 1 |
| 10180 | RBM6 | RNA binding motif protein 6 |
| 23048 | FNBP1 | formin binding protein 1 |
| 374879 | ZNF699 | zinc finger protein 699 |
| 54838 | WBP1L | WW domain binding protein 1-like |
| 167153 | PAPD4 | poly(A) RNA polymerase D4, non-canonical |
| 132864 | CPEB2 | cytoplasmic polyadenylation element binding protein 2 |
| 10618 | TGOLN2 | trans-golgi network protein 2 |
| 5978 | REST | RE1 silencing transcription factor |
| 54454 | ATAD2B | ATPase family, AAA domain containing 2B |
| 221322 | TBC1D32 | TBC1 domain family member 32 |
| 107987150 | | |
| 55716 | LMBR1L | limb development membrane protein 1 like |
| 5291 | PIK3CB | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 55763 | EXOC1 | exocyst complex component 1 |
| 83989 | FAM172A | family with sequence similarity 172 member A |
| 23181 | DIP2A | disco interacting protein 2 homolog A |
| 197135 | PATL2 | PAT1 homolog 2 |
| 9813 | EFCAB14 | EF-hand calcium binding domain 14 |
| 55073 | LRRC37A4P | leucine rich repeat containing 37 member A4, pseudogene |
| 83752 | LONP2 | lon peptidase 2, peroxisomal |
| 84181 | CHD6 | chromodomain helicase DNA binding protein 6 |
| 29072 | SETD2 | SET domain containing 2 |
| 8850 | KAT2B | lysine acetyltransferase 2B |
| 11176 | BAZ2A | bromodomain adjacent to zinc finger domain 2A |
| 27436 | EML4 | echinoderm microtubule associated protein like 4 |
| 64224 | HERPUD2 | HERPUD family member 2 |
| 84678 | KDM2B | lysine demethylase 2B |
| 91749 | MFS4B | major facilitator superfamily domain containing 4B |
| 9439 | MED23 | mediator complex subunit 23 |
| 55761 | TTC17 | tetratricopeptide repeat domain 17 |
| 7110 | TMF1 | TATA element modulatory factor 1 |
| 3683 | ITGAL | integrin subunit alpha L |
| 80821 | DDHD1 | DDHD domain containing 1 |
| 51742 | ARID4B | AT-rich interaction domain 4B |
| 94103 | ORMDL3 | ORMDL sphingolipid biosynthesis regulator 3 |
| 51161 | C3orf18 | chromosome 3 open reading frame 18 |
| 23228 | PLCL2 | phospholipase C like 2 |
| 146057 | TTBK2 | tau tubulin kinase 2 |
| 10260 | DENND4A | DENN domain containing 4A |
| 79979 | TRMT2B | tRNA methyltransferase 2 homolog B |
| 23347 | SMCHD1 | structural maintenance of chromosomes flexible hinge domain containing 1 |
| 259293 | TAS2R30 | taste 2 receptor member 30 |
| 7072 | TIA1 | TIA1 cytotoxic granule associated RNA binding protein |
| 57474 | ZNF490 | zinc finger protein 490 |
| 79048 | SECISBP2 | SECIS binding protein 2 |
| 23081 | KDM4C | lysine demethylase 4C |
| 161176 | SYNE3 | spectrin repeat containing nuclear envelope family member 3 |
| 5095 | PCCA | propionyl-CoA carboxylase alpha subunit |
| 79618 | HMBX1 | homeobox containing 1 |
| 9731 | CEP104 | centrosomal protein 104 |
| 50804 | MYEF2 | myelin expression factor 2 |
| 64236 | PDLIM2 | PDZ and LIM domain 2 |
| 10956 | OS9 | OS9, endoplasmic reticulum lectin |
| 9517 | SPTLC2 | serine palmitoyltransferase long chain base subunit 2 |
| 5294 | PIK3CG | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
| 55062 | WIP1 | WD repeat domain, phosphoinositide interacting 1 |
| 64895 | PAPOLG | poly(A) polymerase gamma |
| 55106 | SLFN12 | schlafen family member 12 |

| | | | |
|------------------------|-----------|--|---|
| 9170 | LPAR2 | lysophosphatidic acid receptor 2 | 5 |
| 85315 | PAQR8 | progesterin and adipoQ receptor family member 8 | 5 |
| 222484 | LNK2 | ligand of numb-protein X 2 | 5 |
| 1739 | DLG1 | discs large MAGUK scaffold protein 1 | 5 |
| 6480 | ST6GAL1 | ST6 beta-galactoside alpha-2,6-sialyltransferase 1 | 5 |
| 9968 | MED12 | mediator complex subunit 12 | 5 |
| 54625 | PARP14 | poly(ADP-ribose) polymerase family member 14 | 5 |
| 25851 | TECPR1 | tectonin beta-propeller repeat containing 1 | 5 |
| 55008 | HERC6 | HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 | 5 |
| 22828 | SCAF8 | SR-related CTD associated factor 8 | 5 |
| 5862 | RAB2A | RAB2A, member RAS oncogene family | 5 |
| 9525 | VPS4B | vacuolar protein sorting 4 homolog B | 5 |
| 115361 | GBP4 | guanylate binding protein 4 | 5 |
| 57020 | C16orf62 | chromosome 16 open reading frame 62 | 5 |
| 93349 | SP140L | SP140 nuclear body protein like | 5 |
| 6464 | SHC1 | SHC adaptor protein 1 | 5 |
| 55601 | DDX60 | DEXD/H-box helicase 60 | 5 |
| 22887 | FOXJ3 | forkhead box J3 | 5 |
| 5870 | RAB6A | RAB6A, member RAS oncogene family | 5 |
| 30061 | SLC40A1 | solute carrier family 40 member 1 | 5 |
| 201799 | TMEM154 | transmembrane protein 154 | 5 |
| 80063 | ATF7IP2 | activating transcription factor 7 interacting protein 2 | 5 |
| 149086 | LINC01225 | long intergenic non-protein coding RNA 1225 | 5 |
| 4033 | LRMP | lymphoid restricted membrane protein | 5 |
| 55770 | EXOC2 | exocyst complex component 2 | 5 |
| 3575 | IL7R | interleukin 7 receptor | 5 |
| 7494 | XBP1 | X-box binding protein 1 | 5 |
| 10320 | IKZF1 | IKAROS family zinc finger 1 | 5 |
| 51149 | C5orf45 | chromosome 5 open reading frame 45 | 5 |
| 7562 | ZNF708 | zinc finger protein 708 | 5 |
| 80012 | PHC3 | polyhomeotic homolog 3 | 5 |
| 637 | BID | BH3 interacting domain death agonist | 5 |
| 3059 | HCLS1 | hematopoietic cell-specific Lyn substrate 1 | 5 |
| 80008 | TMEM156 | transmembrane protein 156 | 5 |
| 79893 | GGNBP2 | gametogenetin binding protein 2 | 5 |
| 11016 | ATF7 | activating transcription factor 7 | 5 |
| 80167 | ABHD18 | abhydrolase domain containing 18 | 5 |
| 1385 | CREB1 | cAMP responsive element binding protein 1 | 5 |
| 64864 | RFX7 | regulatory factor X7 | 5 |
| 114908 | TMEM123 | transmembrane protein 123 | 5 |
| 56990 | CDC42SE2 | CDC42 small effector 2 | 5 |
| 84923 | FAM104A | family with sequence similarity 104 member A | 5 |
| 10097 | ACTR2 | ARP2 actin related protein 2 homolog | 5 |
| 223082 | ZNRF2 | zinc and ring finger 2 | 5 |
| 80705 | TSGA10 | testis specific 10 | 5 |
| 79970 | ZNF767P | zinc finger family member 767, pseudogene | 5 |
| 22882 | ZHX2 | zinc fingers and homeoboxes 2 | 5 |
| 83548 | COG3 | component of oligomeric golgi complex 3 | 5 |
| 4891 | SLC11A2 | solute carrier family 11 member 2 | 5 |
| 56650 | CLDN1 | claudin domain containing 1 | 5 |
| 9235 | IL32 | interleukin 32 | 5 |
| 23533 | PIK3R5 | phosphoinositide-3-kinase regulatory subunit 5 | 5 |
| 8674 | VAMP4 | vesicle associated membrane protein 4 | 5 |
| 55303 | GIMAP4 | GTPase, IMAP family member 4 | 5 |
| 3676 | ITGA4 | integrin subunit alpha 4 | 5 |
| 1048 | CEACAM5 | carcinoembryonic antigen related cell adhesion molecule 5 | 5 |
| 6251 | RSU1 | Ras suppressor protein 1 | 5 |
| 596 | BCL2 | BCL2, apoptosis regulator | 5 |
| 137872 | ADHFE1 | alcohol dehydrogenase, iron containing 1 | 5 |
| 120 | ADD3 | adducin 3 | 5 |
| 7454 | WAS | Wiskott-Aldrich syndrome | 5 |
| 283537 | SLC46A3 | solute carrier family 46 member 3 | 5 |
| 79830 | ZMYM1 | zinc finger MYM-type containing 1 | 5 |
| 81558 | FAM117A | family with sequence similarity 117 member A | 5 |
| 22890 | ZBTB1 | zinc finger and BTB domain containing 1 | 5 |

| | | |
|---------------------------|--------------|--|
| 122773 | KLHDC1 | kelch domain containing 1 |
| 54893 | MTMR10 | myotubularin related protein 10 |
| 10068 | IL18BP | interleukin 18 binding protein |
| 90634 | N4BP2L1 | NEDD4 binding protein 2 like 1 |
| 50618 | ITSN2 | intersectin 2 |
| 1060 | CENPC | centromere protein C |
| 130872 | AHSA2 | AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) |
| 146691 | TOM1L2 | target of myb1 like 2 membrane trafficking protein |
| 2595 | GANC | glucosidase alpha, neutral C |
| 116068 | LYSMD3 | LysM domain containing 3 |
| 54557 | SGTB | small glutamine rich tetratricopeptide repeat containing beta |
| 98 | ACYP2 | acylphosphatase 2 |
| 2946 | GSTM2 | glutathione S-transferase mu 2 |
| 9786 | KIAA0586 | KIAA0586 |
| 196441 | ZFC3H1 | zinc finger C3H1-type containing |
| 5567 | PRKACB | protein kinase cAMP-activated catalytic subunit beta |
| 205717 | USF3 | upstream transcription factor family member 3 |
| 65981 | CAPRIN2 | caprin family member 2 |
| 25956 | SEC31B | SEC31 homolog B, COPII coat complex component |
| 401494 | HACD4 | 3-hydroxyacyl-CoA dehydratase 4 |
| 25988 | HINFP | histone H4 transcription factor |
| 57035 | RSRP1 | arginine and serine rich protein 1 |
| 133418 | EMB | embigin |
| 6793 | STK10 | serine/threonine kinase 10 |
| 10905 | MAN1A2 | mannosidase alpha class 1A member 2 |
| 92822 | ZNF276 | zinc finger protein 276 |
| 9910 | RABGAP1L | RAB GTPase activating protein 1 like |
| 94039 | ZNF101 | zinc finger protein 101 |
| 84450 | ZNF512 | zinc finger protein 512 |
| 2734 | GLG1 | golgi glycoprotein 1 |
| 26091 | HERC4 | HECT and RLD domain containing E3 ubiquitin protein ligase 4 |
| 101928361 | LOC101928361 | uncharacterized LOC101928361 |
| 23043 | TNIK | TRAF2 and NCK interacting kinase |
| 147657 | ZNF480 | zinc finger protein 480 |
| 64921 | CASD1 | CAS1 domain containing 1 |
| 867 | CBL | Cbl proto-oncogene |
| 55904 | KMT2E | lysine methyltransferase 2E |
| 55680 | RUFY2 | RUN and FYVE domain containing 2 |
| 23469 | PHF3 | PHD finger protein 3 |
| 1803 | DPP4 | dipeptidyl peptidase 4 |
| 128077 | LIX1L | limb and CNS expressed 1 like |
| 5305 | PIP4K2A | phosphatidylinositol-5-phosphate 4-kinase type 2 alpha |
| 192669 | AGO3 | argonaute 3, RISC catalytic component |
| 80055 | PGAP1 | post-GPI attachment to proteins 1 |
| 440193 | CCDC88C | coiled-coil domain containing 88C |
| 79956 | ERMP1 | endoplasmic reticulum metalloproteinase 1 |
| 440345 | NP1PB4 | nuclear pore complex interacting protein family member B4 |
| 23224 | SYNE2 | spectrin repeat containing nuclear envelope protein 2 |
| 11276 | SYNRG | synergin gamma |
| 114659 | LRRC37B | leucine rich repeat containing 37B |
| 225 | ABCD2 | ATP binding cassette subfamily D member 2 |
| 55823 | VPS11 | VPS11, CORVET/HOPS core subunit |
| 55843 | ARHGAP15 | Rho GTPase activating protein 15 |
| 342371 | ATXN1L | ataxin 1 like |
| 55754 | TMEM30A | transmembrane protein 30A |
| 83464 | APH1B | aph-1 homolog B, gamma-secretase subunit |
| 641339 | ZNF674 | zinc finger protein 674 |
| 23360 | FNBP4 | formin binding protein 4 |
| 57186 | RALGAPA2 | Ral GTPase activating protein catalytic alpha subunit 2 |
| 410 | ARSA | arylsulfatase A |
| 27244 | SESN1 | sestrin 1 |
| 376940 | ZC3H6 | zinc finger CCCH-type containing 6 |
| 22869 | ZNF510 | zinc finger protein 510 |
| 9988 | DMTF1 | cyclin D binding myb like transcription factor 1 |
| 81550 | TDRD3 | tudor domain containing 3 |

| | | | |
|---------------------------|--------------|---|---|
| 6672 | SP100 | SP100 nuclear antigen | 5 |
| 114803 | MYSM1 | Myb like, SWIRM and MPN domains 1 | 5 |
| 7431 | VIM | vimentin | 5 |
| 57577 | CCDC191 | coiled-coil domain containing 191 | 5 |
| 7318 | UBA7 | ubiquitin like modifier activating enzyme 7 | 5 |
| 254065 | BRWD3 | bromodomain and WD repeat domain containing 3 | 5 |
| 23200 | ATP11B | ATPase phospholipid transporting 11B (putative) | 5 |
| 55297 | CCDC91 | coiled-coil domain containing 91 | 5 |
| 64167 | ERAP2 | endoplasmic reticulum aminopeptidase 2 | 5 |
| 9759 | HDAC4 | histone deacetylase 4 | 5 |
| 100507419 | MMP25-AS1 | MMP25 antisense RNA 1 | 5 |
| 388585 | HES5 | hes family bHLH transcription factor 5 | 5 |
| 51621 | KLF13 | Kruppel like factor 13 | 5 |
| 150864 | FAM117B | family with sequence similarity 117 member B | 5 |
| 51316 | PLAC8 | placenta specific 8 | 5 |
| 57179 | KIAA1191 | KIAA1191 | 5 |
| 163050 | ZNF564 | zinc finger protein 564 | 5 |
| 2073 | ERCC5 | ERCC excision repair 5, endonuclease | 5 |
| 81669 | CCNL2 | cyclin L2 | 5 |
| | | | |
| 5880 | RAC2 | ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) | 5 |
| 10207 | PATJ | PATJ, crumbs cell polarity complex component | 5 |
| 1265 | CNN2 | calponin 2 | 5 |
| 634 | CEACAM1 | carcinoembryonic antigen related cell adhesion molecule 1 | 5 |
| 10123 | ARL4C | ADP ribosylation factor like GTPase 4C | 5 |
| 121506 | ERP27 | endoplasmic reticulum protein 27 | 5 |
| 6451 | SH3BGRL | SH3 domain binding glutamate rich protein like | 5 |
| 84166 | NLRC5 | NLR family CARD domain containing 5 | 5 |
| 30011 | SH3KBP1 | SH3 domain containing kinase binding protein 1 | 5 |
| 23499 | MACF1 | microtubule-actin crosslinking factor 1 | 5 |
| 2186 | BPTF | bromodomain PHD finger transcription factor | 5 |
| 1997 | ELF1 | E74 like ETS transcription factor 1 | 5 |
| 6654 | SOS1 | SOS Ras/Rac guanine nucleotide exchange factor 1 | 5 |
| 107984315 | | | 5 |
| 1200 | TPP1 | tripeptidyl peptidase 1 | 5 |
| 80212 | CCDC92 | coiled-coil domain containing 92 | 5 |
| 1486 | CTBS | chitinase | 5 |
| 27128 | CYTH4 | cytohesin 4 | 5 |
| 11261 | CHP1 | calcineurin like EF-hand protein 1 | 5 |
| 54518 | APBB1IP | amyloid beta precursor protein binding family B member 1 interacting protein | 5 |
| 1606 | DGKA | diacylglycerol kinase alpha | 5 |
| 153222 | CREBRF | CREB3 regulatory factor | 5 |
| 80024 | SLC8B1 | solute carrier family 8 member B1 | 5 |
| 2635 | GBP3 | guanylate binding protein 3 | 5 |
| 64784 | CRTC3 | CREB regulated transcription coactivator 3 | 5 |
| 79813 | EHMT1 | euchromatic histone lysine methyltransferase 1 | 5 |
| 8906 | AP1G2 | adaptor related protein complex 1 gamma 2 subunit | 5 |
| 155006 | TMEM213 | transmembrane protein 213 | 5 |
| 442582 | STAG3L2 | stromal antigen 3-like 2 (pseudogene) | 5 |
| 1182 | CLCN3 | chloride voltage-gated channel 3 | 5 |
| 51735 | RAPGEF6 | Rap guanine nucleotide exchange factor 6 | 5 |
| 92106 | OXNAD1 | oxidoreductase NAD binding domain containing 1 | 5 |
| 100420110 | LOC100420110 | SCY1 like pseudokinase 2 pseudogene | 5 |
| 6164 | RPL34 | ribosomal protein L34 | 5 |
| 4354 | MPP1 | membrane palmitoylated protein 1 | 5 |
| 1487 | CTBP1 | C-terminal binding protein 1 | 5 |
| 58487 | CREBZF | CREB/ATF bZIP transcription factor | 5 |
| 4026 | LPP | LIM domain containing preferred translocation partner in lipoma | 5 |
| 26259 | FBXW8 | F-box and WD repeat domain containing 8 | 5 |
| 51773 | RSF1 | remodeling and spacing factor 1 | 5 |
| 6641 | SNTB1 | syntrophin beta 1 | 5 |
| 79161 | TMEM243 | transmembrane protein 243 | 5 |
| 5586 | PKN2 | protein kinase N2 | 5 |
| 64766 | S100PBP | S100P binding protein | 5 |
| 3460 | IFNGR2 | interferon gamma receptor 2 (interferon gamma transducer 1) | 5 |

| | | | |
|---------------------------|-----------|--|---|
| 7273 | TTN | titin | 5 |
| 8835 | SOCS2 | suppressor of cytokine signaling 2 | 5 |
| 11320 | MGAT4A | mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A | 5 |
| 54861 | SNRK | SNF related kinase | 5 |
| 4012 | LNPEP | leucyl and cystinyl aminopeptidase | 5 |
| 128611 | ZNF831 | zinc finger protein 831 | 5 |
| 7456 | WIPF1 | WAS/WASL interacting protein family member 1 | 5 |
| 9830 | TRIM14 | tripartite motif containing 14 | 5 |
| 50852 | TRAT1 | T cell receptor associated transmembrane adaptor 1 | 5 |
| 22990 | PCNX1 | pecanex homolog 1 (Drosophila) | 5 |
| 11083 | DIDO1 | death inducer-obliterator 1 | 5 |
| 1106 | CHD2 | chromodomain helicase DNA binding protein 2 | 5 |
| 7644 | ZNF91 | zinc finger protein 91 | 5 |
| 1540 | CYLD | CYLD lysine 63 deubiquitinase | 5 |
| 643641 | ZNF862 | zinc finger protein 862 | 5 |
| 10106 | CTDSP2 | CTD small phosphatase 2 | 5 |
| 154881 | KCTD7 | potassium channel tetramerization domain containing 7 | 5 |
| 23164 | MPRIIP | myosin phosphatase Rho interacting protein | 5 |
| 4299 | AFF1 | AF4/FMR2 family member 1 | 5 |
| 93611 | FBXO44 | F-box protein 44 | 5 |
| 7402 | UTRN | utrophin | 5 |
| 56204 | FAM214A | family with sequence similarity 214 member A | 5 |
| 6844 | VAMP2 | vesicle associated membrane protein 2 | 5 |
| 9960 | USP3 | ubiquitin specific peptidase 3 | 5 |
| 4297 | KMT2A | lysine methyltransferase 2A | 5 |
| 56829 | ZC3HAV1 | zinc finger CCCH-type containing, antiviral 1 | 5 |
| 139818 | DOCK11 | dedicator of cytokinesis 11 | 5 |
| 25777 | SUN2 | Sad1 and UNC84 domain containing 2 | 5 |
| 9744 | ACAP1 | ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 | 5 |
| 23054 | NCOA6 | nuclear receptor coactivator 6 | 5 |
| 84162 | KIAA1109 | KIAA1109 | 5 |
| 23341 | DNAJC16 | DnaJ heat shock protein family (Hsp40) member C16 | 5 |
| 23324 | MAN2B2 | mannosidase alpha class 2B member 2 | 5 |
| 6711 | SPTBN1 | spectrin beta, non-erythrocytic 1 | 5 |
| 165631 | PARP15 | poly(ADP-ribose) polymerase family member 15 | 5 |
| 5786 | PTPRA | protein tyrosine phosphatase, receptor type A | 5 |
| 9535 | GMFG | glia maturation factor gamma | 5 |
| 256643 | CXorf23 | chromosome X open reading frame 23 | 5 |
| 55268 | ECHDC2 | enoyl-CoA hydratase domain containing 2 | 5 |
| 22838 | RNF44 | ring finger protein 44 | 5 |
| 55870 | ASH1L | ASH1 like histone lysine methyltransferase | 5 |
| 64780 | MICAL1 | microtubule associated monooxygenase, calponin and LIM domain containing 1 | 5 |
| 84460 | ZMAT1 | zinc finger matrin-type 1 | 5 |
| 200576 | PIKFYVE | phosphoinositide kinase, FYVE-type zinc finger containing | 5 |
| 58508 | KMT2C | lysine methyltransferase 2C | 5 |
| 8897 | MTMR3 | myotubularin related protein 3 | 5 |
| 2033 | EP300 | E1A binding protein p300 | 5 |
| 80351 | TNKS2 | tankyrase 2 | 5 |
| 9648 | GCC2 | GRIP and coiled-coil domain containing 2 | 5 |
| 163131 | ZNF780B | zinc finger protein 780B | 5 |
| 23335 | WDR7 | WD repeat domain 7 | 5 |
| 55599 | RNPC3 | RNA binding region (RNP1, RRM) containing 3 | 5 |
| 3716 | JAK1 | Janus kinase 1 | 5 |
| 493753 | COA5 | cytochrome c oxidase assembly factor 5 | 5 |
| 55824 | PAG1 | phosphoprotein membrane anchor with glycosphingolipid microdomains 1 | 5 |
| 114801 | TMEM200A | transmembrane protein 200A | 5 |
| 64750 | SMURF2 | SMAD specific E3 ubiquitin protein ligase 2 | 5 |
| 57337 | SENP7 | SUMO1/sentrin specific peptidase 7 | 5 |
| 831 | CAST | calpastatin | 5 |
| 257106 | ARHGAP30 | Rho GTPase activating protein 30 | 5 |
| 84945 | ABHD13 | abhydrolase domain containing 13 | 5 |
| 129285 | PPP1R21 | protein phosphatase 1 regulatory subunit 21 | 5 |
| 100507217 | LINC01578 | long intergenic non-protein coding RNA 1578 | 5 |
| 285025 | CCDC141 | coiled-coil domain containing 141 | 5 |

| | | |
|---------------------------|--------------|--|
| 387680 | FAM21A | family with sequence similarity 21 member A |
| 85464 | SSH2 | slingshot protein phosphatase 2 |
| 59338 | PLEKHA1 | pleckstrin homology domain containing A1 |
| 963 | CD53 | CD53 molecule |
| 57620 | STIM2 | stromal interaction molecule 2 |
| 10133 | OPTN | optineurin |
| 538 | ATP7A | ATPase copper transporting alpha |
| 23616 | SH3BP1 | SH3 domain binding protein 1 |
| 23304 | UBR2 | ubiquitin protein ligase E3 component n-recognin 2 |
| 10955 | SERINC3 | serine incorporator 3 |
| 22834 | ZNF652 | zinc finger protein 652 |
| 3635 | INPP5D | inositol polyphosphate-5-phosphatase D |
| 7767 | ZNF224 | zinc finger protein 224 |
| 92283 | ZNF461 | zinc finger protein 461 |
| 192670 | AGO4 | argonaute 4, RISC catalytic component |
| 8631 | SKAP1 | src kinase associated phosphoprotein 1 |
| 94134 | ARHGAP12 | Rho GTPase activating protein 12 |
| 10520 | ZNF211 | zinc finger protein 211 |
| 64112 | MOAP1 | modulator of apoptosis 1 |
| 51599 | LSR | lipolysis stimulated lipoprotein receptor |
| 55743 | CHFR | checkpoint with forkhead and ring finger domains |
| 6302 | TSPAN31 | tetraspanin 31 |
| 64333 | ARHGAP9 | Rho GTPase activating protein 9 |
| 256380 | SCML4 | sex comb on midleg-like 4 (Drosophila) |
| 83604 | TMEM47 | transmembrane protein 47 |
| 10157 | AASS | aminoadipate-semialdehyde synthase |
| 64926 | RASAL3 | RAS protein activator like 3 |
| 9473 | THEMIS2 | thymocyte selection associated family member 2 |
| 10983 | CCNI | cyclin I |
| 583 | BBS2 | Bardet-Biedl syndrome 2 |
| 25981 | DNAH1 | dynein axonemal heavy chain 1 |
| 285346 | ZNF852 | zinc finger protein 852 |
| 51088 | KLHL5 | kelch like family member 5 |
| 57707 | TLDC1 | TBC/LysM-associated domain containing 1 |
| 1523 | CUX1 | cut like homeobox 1 |
| 8509 | NDST2 | N-deacetylase and N-sulfotransferase 2 |
| 57446 | NDRG3 | NDRG family member 3 |
| 285464 | CRIPAK | cysteine rich PAK1 inhibitor |
| 7554 | ZNF8 | zinc finger protein 8 |
| 765 | CA6 | carbonic anhydrase 6 |
| 79567 | FAM65A | family with sequence similarity 65 member A |
| 23038 | WDTC1 | WD and tetratricopeptide repeats 1 |
| 9683 | N4BP1 | NEDD4 binding protein 1 |
| 5293 | PIK3CD | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 374403 | TBC1D10C | TBC1 domain family member 10C |
| 51339 | DACT1 | dishevelled binding antagonist of beta catenin 1 |
| 80305 | TRABD | TraB domain containing |
| 6932 | TCF7 | transcription factor 7 (T-cell specific, HMG-box) |
| 3983 | ABLIM1 | actin binding LIM protein 1 |
| 10013 | HDAC6 | histone deacetylase 6 |
| 102723458 | LOC102723458 | uncharacterized LOC102723458 |
| 9961 | MVP | major vault protein |
| 23765 | IL17RA | interleukin 17 receptor A |
| 93129 | ORAI3 | ORAI calcium release-activated calcium modulator 3 |
| 100505549 | LOC100505549 | uncharacterized LOC100505549 |
| 5927 | KDM5A | lysine demethylase 5A |
| 7569 | ZNF182 | zinc finger protein 182 |
| 51147 | ING4 | inhibitor of growth family member 4 |
| 26119 | LDLRAP1 | low density lipoprotein receptor adaptor protein 1 |
| 6016 | RIT1 | Ras like without CAAX 1 |
| 9550 | ATP6V1G1 | ATPase H+ transporting V1 subunit G1 |
| 2592 | GALT | galactose-1-phosphate uridylyltransferase |
| 148932 | MOB3C | MOB kinase activator 3C |
| 10943 | MSL3 | male-specific lethal 3 homolog (Drosophila) |
| 4752 | NEK3 | NIMA related kinase 3 |

| | | |
|------------------------|----------|---|
| 338657 | CCDC84 | coiled-coil domain containing 84 |
| 84899 | TMTC4 | transmembrane and tetratricopeptide repeat containing 4 |
| 23355 | VPS8 | VPS8, CORVET complex subunit |
| 23175 | LPIN1 | lipin 1 |
| 27334 | P2RY10 | purinergic receptor P2Y10 |
| 11067 | C10orf10 | chromosome 10 open reading frame 10 |
| 26959 | HBP1 | HMG-box transcription factor 1 |
| 168537 | GIMAP7 | GTPase, IMAP family member 7 |
| 10550 | ARL6IP5 | ADP ribosylation factor like GTPase 6 interacting protein 5 |
| 2005 | ELK4 | ELK4, ETS transcription factor |
| 253260 | RICTOR | RPTOR independent companion of MTOR complex 2 |
| 2533 | FYB | FYN binding protein |
| 1806 | DPYD | dihydropyrimidine dehydrogenase |
| 55249 | YY1AP1 | YY1 associated protein 1 |
| 55197 | RPRD1A | regulation of nuclear pre-mRNA domain containing 1A |
| 7586 | ZKSCAN1 | zinc finger with KRAB and SCAN domains 1 |
| 23086 | EXPH5 | exophilin 5 |
| 10006 | ABI1 | abl interactor 1 |
| 10241 | CALCOCO2 | calcium binding and coiled-coil domain 2 |
| 5926 | ARID4A | AT-rich interaction domain 4A |
| 5583 | PRKCH | protein kinase C eta |
| 7769 | ZNF226 | zinc finger protein 226 |
| 84223 | IQCG | IQ motif containing G |
| 284323 | ZNF780A | zinc finger protein 780A |
| 23476 | BRD4 | bromodomain containing 4 |
| 9611 | NCOR1 | nuclear receptor corepressor 1 |
| 51306 | FAM13B | family with sequence similarity 13 member B |
| 9802 | DAZAP2 | DAZ associated protein 2 |
| 5782 | PTPN12 | protein tyrosine phosphatase, non-receptor type 12 |
| 55876 | GSDMB | gasdermin B |
| 2804 | GOLGB1 | golgin B1 |
| 57658 | CALCOCO1 | calcium binding and coiled-coil domain 1 |
| 23558 | WBP2 | WW domain binding protein 2 |
| 147339 | C18orf25 | chromosome 18 open reading frame 25 |
| 79652 | TMEM204 | transmembrane protein 204 |
| 29108 | PYCARD | PYD and CARD domain containing |
| 23345 | SYNE1 | spectrin repeat containing nuclear envelope protein 1 |
| 79026 | AHNAK | AHNAK nucleoprotein |
| 57153 | SLC44A2 | solute carrier family 44 member 2 |
| 10505 | SEMA4F | ssemaphorin 4F |
| 6653 | SORL1 | sortilin related receptor 1 |
| 333929 | SNAI3 | snail family transcriptional repressor 3 |
| 1316 | KLF6 | Kruppel like factor 6 |
| 166 | AES | amino-terminal enhancer of split |
| 1043 | CD52 | CD52 molecule |
| 55728 | N4BP2 | NEDD4 binding protein 2 |
| 10791 | VAMP5 | vesicle associated membrane protein 5 |
| 5257 | PHKB | phosphorylase kinase regulatory subunit beta |
| 23646 | PLD3 | phospholipase D family member 3 |
| 492311 | IGIP | IgA inducing protein |
| 9885 | OSBPL2 | oxysterol binding protein like 2 |
| 10938 | EHD1 | EH domain containing 1 |
| 1774 | DNASE1L1 | deoxyribonuclease 1 like 1 |
| 2647 | BLOC1S1 | biogenesis of lysosomal organelles complex 1 subunit 1 |
| 10870 | HCST | hematopoietic cell signal transducer |
| 203523 | ZNF449 | zinc finger protein 449 |
| 9924 | PAN2 | PAN2 poly(A) specific ribonuclease subunit |
| 133619 | PRRC1 | proline rich coiled-coil 1 |
| 51276 | ZNF571 | zinc finger protein 571 |
| 144699 | FBXL14 | F-box and leucine rich repeat protein 14 |
| 389072 | PLEKHM3 | pleckstrin homology domain containing M3 |
| 23518 | R3HDM1 | R3H domain containing 1 |
| 23526 | ARHGAP45 | Rho GTPase activating protein 45 |
| 7011 | TEP1 | telomerase associated protein 1 |
| 54540 | FAM193B | family with sequence similarity 193 member B |

| | | | |
|---------------------------|----------|--|---|
| 284996 | RNF149 | ring finger protein 149 | 5 |
| 11104 | KATNA1 | katanin catalytic subunit A1 | 5 |
| 28971 | AAMDC | adipogenesis associated Mth938 domain containing | 5 |
| 26053 | AUTS2 | autism susceptibility candidate 2 | 5 |
| 399687 | MYO18A | myosin XVIIIa | 5 |
| 57659 | ZBTB4 | zinc finger and BTB domain containing 4 | 5 |
| 400986 | ANKRD36C | ankyrin repeat domain 36C | 5 |
| 79741 | CCDC7 | coiled-coil domain containing 7 | 5 |
| 1629 | DBT | dihydrolipoamide branched chain transacylase E2 | 5 |
| 93624 | TADA2B | transcriptional adaptor 2B | 5 |
| 162427 | FAM134C | family with sequence similarity 134 member C | 5 |
| 107984583 | | | 5 |
| 64788 | LMF1 | lipase maturation factor 1 | 5 |
| 7994 | KAT6A | lysine acetyltransferase 6A | 5 |
| 394 | ARHGAP5 | Rho GTPase activating protein 5 | 5 |
| 389 | RHOC | ras homolog family member C | 5 |
| 200186 | CRTC2 | CREB regulated transcription coactivator 2 | 5 |
| 10066 | SCAMP2 | secretory carrier membrane protein 2 | 5 |
| 9889 | ZBED4 | zinc finger BED-type containing 4 | 5 |
| 403313 | PLPP6 | phospholipid phosphatase 6 | 5 |
| 196528 | ARID2 | AT-rich interaction domain 2 | 5 |
| 51780 | KDM3B | lysine demethylase 3B | 5 |
| 5780 | PTPN9 | protein tyrosine phosphatase, non-receptor type 9 | 5 |
| 84498 | FAM120B | family with sequence similarity 120B | 5 |
| 23506 | GLTSCR1L | GLTSCR1 like | 5 |
| 26207 | PITPNC1 | phosphatidylinositol transfer protein, cytoplasmic 1 | 5 |
| 158358 | KIAA2026 | KIAA2026 | 5 |
| 387748 | OR56B1 | olfactory receptor family 56 subfamily B member 1 | 5 |
| 11201 | POL1 | DNA polymerase iota | 5 |
| 10211 | FLOT1 | flotillin 1 | 5 |
| 200765 | TIGD1 | tigger transposable element derived 1 | 5 |
| 118 | ADD1 | adducin 1 | 5 |
| 284371 | ZNF841 | zinc finger protein 841 | 5 |
| 5142 | PDE4B | phosphodiesterase 4B | 5 |
| 55619 | DOCK10 | dedicator of cytokinesis 10 | 5 |
| 23527 | ACAP2 | ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 | 5 |
| 23424 | TDRD7 | tudor domain containing 7 | 5 |
| 373 | TRIM23 | tripartite motif containing 23 | 5 |
| 338440 | ANO9 | anoctamin 9 | 5 |
| 10000 | AKT3 | AKT serine/threonine kinase 3 | 5 |
| 8569 | MKNK1 | MAP kinase interacting serine/threonine kinase 1 | 5 |
| 84159 | ARID5B | AT-rich interaction domain 5B | 5 |
| 26046 | LTN1 | listerin E3 ubiquitin protein ligase 1 | 5 |
| 23041 | MON2 | MON2 homolog, regulator of endosome-to-Golgi trafficking | 5 |
| 60412 | EXOC4 | exocyst complex component 4 | 5 |
| 4287 | ATXN3 | ataxin 3 | 5 |
| 4343 | MOV10 | Mov10 RISC complex RNA helicase | 5 |
| 79800 | CARF | calcium responsive transcription factor | 5 |
| 2776 | GNAQ | G protein subunit alpha q | 5 |
| 55167 | MSL2 | male-specific lethal 2 homolog (Drosophila) | 5 |
| 83744 | ZNF484 | zinc finger protein 484 | 5 |
| 64145 | RBSN | rabenosyn, RAB effector | 5 |
| 55500 | ETNK1 | ethanolamine kinase 1 | 5 |
| 317 | APAF1 | apoptotic peptidase activating factor 1 | 5 |
| 51380 | CSAD | cysteine sulfinic acid decarboxylase | 5 |
| 55902 | ACSS2 | acyl-CoA synthetase short-chain family member 2 | 5 |
| 8567 | MADD | MAP kinase activating death domain | 5 |
| 7776 | ZNF236 | zinc finger protein 236 | 5 |

BIBLIOGRAPHY

- Achuthan V, Perreira JM, Sowd GA, Puray-Chavez M, McDougall WM, Paulucci-Holthauzen A, Wu X, Fadel HJ, Poeschla EM, Multani AS, Hughes SH, Sarafianos SG, Brass AL, Engelman AN. Capsid-CPSF6 interaction licenses nuclear HIV-1 trafficking to sites of viral DNA integration. *Cell Host & Microbe*. 2018;24(3):392-404.e8.
- Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. *Nature Reviews. Immunology*. 2003;3(12):939-51.
- Adair P, Kim YC, Pratt KP, Scott DW. Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate. *Cellular Immunology*. 2016;299:30-41.
- Agosto LM, Gagne M, Henderson AJ. Impact of chromatin on HIV replication. *Genes (Basel)*. 2015;6(4):957-76.
- Agosto LM, Henderson AJ. CD4+ T cell subsets and pathways to HIV latency. *AIDS Research and Human Retroviruses*. 2018;34(9):780-9.
- Agosto LM, Herring MB, Mothes W, Henderson AJ. HIV-1-infected CD4+ T cells facilitate latent infection of resting CD4+ T cells through cell-cell contact. *Cell Reports*. 2018;24(8):2088-100.
- Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O'Doherty U. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. *Virology*. 2007;368(1):60-72.
- Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. *Clinical Cancer Research*. 2010;16(2):474-85.
- Aid M, Dupuy FP, Moysi E, Moir S, Haddad EK, Estes JD, Sekaly RP, Petrovas C, Ribeiro SP. Follicular CD4 T helper cells as a major HIV reservoir compartment: a molecular perspective. *Frontiers in Immunology*. 2018;9:895.
- Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Levings MK. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. *The Journal of Clinical Investigation*. 2005;115(11):3276-84.
- Allison KA, Sajti E, Collier JG, Gosselin D, Troutman TD, Stone EL, Hedrick SM, Glass CK. Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells. *eLife*. 2016;5:e10134.

- Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. *PloS One*. 2010;5(2):e9390.
- Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM, Margolis DM. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. *AIDS*. 2008;22(10):1131-5.
- Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. *AIDS Research and Human Retroviruses*. 2009;25(2):207-12.
- Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature*. 2012;487(7408):482-5.
- Armstrong JA, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. *Lancet*. 1984;2(8399):370-2.
- Avalos CR, Abreu CM, Queen SE, Li M, Price S, Shirk EN, Engle EL, Forsyth E, Bullock BT, Mac Gabhann F, Wietgreffe SW, Haase AT, Zink MC, Mankowski JL, Clements JE, Gama L. Brain macrophages in Simian Immunodeficiency Virus-infected, antiretroviral-suppressed macaques: a functional latent reservoir. *mBio*. 2017;8(4):e01186-17.
- Ayyanathan K, Lechner MS, Bell P, Maul GG, Schultz DC, Yamada Y, Tanaka K, Torigoe K, Rauscher FJ. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. *Genes & Development*. 2003;17(15):1855-69.
- Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. *Journal of Leukocyte Biology*. 2012;92(6):1147-54.
- Banos A, Agelopoulos M, Thanos D. Stochastic responses are not left to pure "chance". *Cell*. 2013;155(3):499-502.
- Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. *Molecular Cell*. 2001;8(2):327-37.

- Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. *Science*. 2007;315(5819):1709-12.
- Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science*. 1983;220(4599):868-71.
- Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. *The Journal of Biological Chemistry*. 2013;288(20):14400-7.
- Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. *The Journal of Biological Chemistry*. 2012;287(43):36609-16.
- Barton K, Hiener B, Winckelmann A, Rasmussen TA, Shao W, Byth K, Lanfear R, Solomon A, McMahon J, Harrington S, Buzon M, Lichterfeld M, Denton PW, Olesen R, Østergaard L, Tolstrup M, Lewin SR, Søgaard OS, Palmer S. Broad activation of latent HIV-1 in vivo. *Nature Communications*. 2016;7:12731.
- Benchling. <https://benchling.com>. Accessed February 16, 2019.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *The Journal of the Royal Statistical Society. Series B (Methodological)*. 1995; 57(1):289-300.
- Bernhard W, Barreto K, Raithatha S, Sadowski I. An upstream YY1 binding site on the HIV-1 LTR contributes to latent infection. *PloS One*. 2013;8(10):e77052.
- Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. *FEBS Letters*. 2011;585(22):3549-54.
- Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. *European Journal of Cancer*. 1992;28(2-3):697-700.
- Bettini ML, Chou PC, Guy CS, Lee T, Vignali KM, Vignali DAA. Cutting Edge: CD3 ITAM diversity is required for optimal TCR signaling and thymocyte development. *Journal of Immunology*. 2017;199(5):1555-60.

- Biberfeld P, Chayt KJ, Marselle LM, Biberfeld G, Gallo RC, Harper ME. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. *The American Journal of Pathology*. 1986;125(3):436-42.
- Bilal MY, Zhang EY, Dinkel B, Hardy D, Yankee TM, Houtman JC. GADS is required for TCR-mediated calcium influx and cytokine release, but not cellular adhesion, in human T cells. *Cellular Signalling*. 2015;27(4):841-50.
- Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(34):13690-5.
- Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, Nelson A, Hallahan CW, Moir S, Wender PA, Fauci AS. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. *The Journal of Infectious Diseases*. 2012;206(5):765-9.
- Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J, Hirsch I. CpG methylation controls reactivation of HIV from latency. *PLoS Pathogens*. 2009;5(8):e1000554.
- Boehm D, Jeng M, Camus G, Gramatica A, Schwarzer R, Johnson JR, Hull PA, Montano M, Sakane N, Pagans S, Godin R, Deeks SG, Krogan NJ, Greene WC, Ott M. SMYD2-mediated histone methylation contributes to HIV-1 latency. *Cell Host & Microbe*. 2017;21(5):569-579.e6.
- Boso G, Örvell C, Somia NV. The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles. *Journal of Virology*. 2015;89(2):1286-97.
- Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. *Blood*. 2009;113(1):58-65.
- Bostik P, Mayne AE, Villinger F, Greenberg KP, Powell JD, Ansari AA. Relative resistance in the development of T cell anergy in CD4+ T cells from simian immunodeficiency virus disease-resistant sooty mangabeys. *Journal of Immunology*. 2001;166(1):506-16.
- Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. *AIDS*. 2012;26(12):1473-82.

- Boyman O, Létourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naïve and memory T cells. *European Journal of Immunology*. 2009;39(8):2088-94.
- Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. *Journal of Virology*. 2004;78(3):1160-8.
- Brocken DJW, Tark-Dame M, Dame RT. dCas9: A versatile tool for epigenome editing. *Current Issues in Molecular Biology*. 2018;26:15-32.
- Brocker T. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. *The Journal of Experimental Medicine*. 1997;186(8):1223-32.
- Brownlie RJ, Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. *Nature Reviews. Immunology*. 2013;13(4):257-69.
- Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF. Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nature Medicine*. 2016;22(9):1043-9.
- Bunnell SC, Kapoor V, Tribble RP, Zhang W, Samelson LE. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. *Immunity*. 2001;14(3):315-29.
- Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. Control of stochastic gene expression by host factors at the HIV promoter. *PLoS Pathogens*. 2009;5(1):e1000260.
- Calman AF, Busch MP, Vyas GN, McHugh TM, Stites DP, Peterlin BM. Transcription and replication of human immunodeficiency virus-1 in B lymphocytes in vitro. *AIDS*. 1988;2(3):185-93.
- Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. *Science*. 1992;257(5068):383-7.
- Cary DC, Fujinaga K, Peterlin BM. Molecular mechanisms of HIV latency. *The Journal of Clinical Investigation*. 2016;126(2):448-54.
- Casazza JP, Brenchley JM, Hill BJ, Ayana R, Ambrozak D, Roederer M, Douek DC, Betts MR, Koup RA. Autocrine production of beta-chemokines protects CMV-specific CD4 T cells from HIV infection. *PLoS Pathogens*. 2009;5(10):e1000646.

- CDC. Estimated HIV incidence and prevalence in the United States, 2010-2015. HIV Surveillance Supplemental Report. 2018; 23(1).
- CDC. *Pneumocystis pneumonia* --- Los Angeles. MMWR. 1981;30:250-2.
- Chan DC, Kim PS. HIV entry and its inhibition. *Cell*. 1998;93(5):681-4.
- Chavez L, Calvanese V, Verdin E. HIV latency is established directly and early in both resting and activated primary CD4 T cells. *PLoS Pathogens*. 2015;11(6):e1004955.
- Chen J, Nikolaitchik O, Singh J, Wright A, Bencsics CE, Coffin JM, Ni N, Lockett S, Pathak VK, Hu WS. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(32):13535-40.
- Chicaybam L, Sodre AL, Curzio BA, Bonamino MH. An efficient low cost method for gene transfer to T lymphocytes. *PloS One*. 2013;8(3):e60298.
- Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. *Immunological Reviews*. 2014;257(1):83-90.
- Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. *Journal of Immunology*. 2004;173(12):7647-53.
- Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nature Biotechnology*. 2013;31(3):230-2.
- Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. *Nature Medicine*. 2009;15(8):893-900.
- Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*. 1998;95(15):8869-73.
- Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proceedings of the National Academy of Sciences of the United States of America*. 1997;94(24):13193-7.

- Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. *Retrovirology*. 2009;6:111.
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013;339(6121):819-23.
- Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. *The Journal of Experimental Medicine*. 1997;185(4):621-8.
- Conrad RJ, Fozouni P, Thomas S, Sy H, Zhang Q, Zhou MM, Ott M. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. *Molecular Cell*. 2017;67(6):1001-1012.e6.
- Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. *The Journal of Biological Chemistry*. 2009;284(11):6782-9.
- Dahabieh MS, Ooms M, Brumme C, Taylor J, Harrigan PR, Simon V, Sadowski I. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NF κ B. *Retrovirology*. 2014;11:17.
- Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. *Nucleic Acids Research*. 2005;33(20):e175.
- Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. Screening for noise in gene expression identifies drug synergies. *Science*. 2014;344(6190):1392-6.
- Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatins-1+JQ1 and Ingenol-B+JQ1 to potently reactivate viral gene expression. *PLoS Pathogens*. 2015;11(7):e1005063.
- Darcis G, Van Driessche B, Van Lint C. HIV latency: should we shock or lock. *Trends in Immunology*. 2017;38(3):217-28.
- Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA, Schlessinger J, Littman DR. Signal transduction due to HIV-1 envelope interactions

- with chemokine receptors CXCR4 or CCR5. *The Journal of Experimental Medicine*. 1997;186(10):1793-8.
- De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. *AIDS*. 2012;26(10):1205-13.
- Debyser Z, Vansant G, Bruggemans A, Janssens J, Christ F. Insight in HIV integration site selection provides a block-and-lock strategy for a functional cure of HIV infection. *Viruses*. 2018;11(1):E12.
- Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H, Steinmetz M. Transfer of specificity by murine alpha and beta T-cell receptor genes. *Nature*. 1986;320(6059):232-8.
- Demoustier A, Gubler B, Lambotte O, de Goër MG, Wallon C, Goujard C, Delfraissy JF, Taoufik Y. In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV-specific. *AIDS*. 2002;16(13):1749-54.
- Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. *Nature*. 1996;381(6584):661-6.
- Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. The viral protein Tat can inhibit the establishment of HIV-1 latency. *Journal of Virology*. 2012;86(6):3253-63.
- Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA. HIV preferentially infects HIV-specific CD4⁺ T cells. *Nature*. 2002;417(6884):95-8.
- Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4⁺ cells is mediated by the chemokine receptor CC-CKR-5. *Nature*. 1996;381(6584):667-73.
- Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O. Determinants of the establishment of human immunodeficiency virus type 1 latency. *Journal of Virology*. 2009;83(7):3078-93.
- Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR. Activation of HIV transcription with short-course vorinostat in HIV-

- infected patients on suppressive antiretroviral therapy. *PLoS Pathogens*. 2014;10(10):e1004473.
- Emery A, Zhou S, Pollom E, Swanstrom R. Characterizing HIV-1 splicing by using next-generation sequencing. *Journal of Virology*. 2017;91(6):e02515-16.
- Emiliani S, Van Lint C, Fischle W, Paras P, Ott M, Brady J, Verdin E. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;93(13):6377-81.
- Fakruddin JM, Lempicki RA, Gorelick RJ, Yang J, Adelsberger JW, Garcia-Pineros AJ, Pinto LA, Lane HC, Imamichi T. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. *Blood*. 2007;109(5):1841-9.
- Feinberg MB, Baltimore D, Frankel AD. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. *Proceedings of the National Academy of Sciences of the United States of America*. 1991;88(9):4045-9.
- Fenard D, Yonemoto W, de Noronha C, Cavois M, Williams SA, Greene WC. Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. *Journal of Immunology*. 2005;175(9):6050-7.
- Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. *Protein & Cell*. 2018;9(10):838-47.
- Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science*. 1996;272(5263):872-7.
- Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nature Medicine*. 2019;25(1):82-8.
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science*. 1997;278(5341):1295-300.
- Fischer U, Huber J, Boelens WC, Mattaj JW, Lührmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. *Cell*. 1995;82(3):475-83.

- Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. *Proceedings of the National Academy of Sciences of the United States of America*. 1989;86(7):2365-8.
- Frank GA, Narayan K, Bess JW, Del Prete GQ, Wu X, Moran A, Hartnell LM, Earl LA, Lifson JD, Subramaniam S. Maturation of the HIV-1 core by a non-diffusional phase transition. *Nature Communications*. 2015;6:5854.
- Franza BR, Rauscher FJ, Josephs SF, Curran T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. *Science*. 1988;239(4844):1150-3.
- Frazer IH, Mackay IR, Crapper RM, Jones B, Gust ID, Sarngadharan MG, Campbell DC, Ungar B. Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two years. *The Quarterly Journal of Medicine*. 1986;61(234):921-33.
- Frearson JA, Alexander DR. The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells. *The Journal of Experimental Medicine*. 1998;187(9):1417-26.
- Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. *JAMA Internal Medicine*. 2013;173(8):614-22.
- French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. *The Journal of Infectious Diseases*. 2009;200(8):1212-5.
- Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. *Journal of Virology*. 2011;85(17):9078-89.
- Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG, Rauscher FJ. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. *Genes & Development*. 1996;10(16):2067-78.

- Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nature Biotechnology*. 2013;31(9):822-6.
- Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. *Molecular and Cellular Biology*. 2004;24(2):787-95.
- Fujinaga K, Luo Z, Schaufele F, Peterlin BM. Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells. *The Journal of Biological Chemistry*. 2015;290(3):1829-36.
- Gagne M, Michaels D, Schiralli Lester G, Wong W, Gummuluru S, Henderson AJ. Strength of T cell signaling regulates HIV-1 replication and establishment of latency. *bioRxiv*. <https://doi.org/10.1101/432401>.
- Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. *The New England Journal of Medicine*. 2003;349(24):2283-5.
- Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. Origin of HIV-1 in the chimpanzee *Pan troglodytes*. *Nature*. 1999;397(6718):436-41.
- Garcia JA, Wu FK, Mitsuyasu R, Gaynor RB. Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. *The EMBO Journal*. 1987;6(12):3761-70.
- Garriga J, Peng J, Parreño M, Price DH, Henderson EE, Graña X. Upregulation of cyclin T1/CDK9 complexes during T cell activation. *Oncogene*. 1998;17(24):3093-102.
- Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics*. 2004;20(3):307-15.
- Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, Heeregrave EJ, Casazza JP, Ambrozak DR, Louder M, Ampofo W, Pollakis G, Hill B, Sanga E, Saathoff E, Maboko L, Roederer M, Paxton WA, Hoelscher M, Koup RA. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. *The Journal of Experimental Medicine*. 2010;207(13):2869-81.
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY,

- Zhang J. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biology*. 2004;5(10):R80.
- Gibson S, August A, Branch D, Dupont B, Mills GM. Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK. *The Journal of Biological Chemistry*. 1996;271(12):7079-83.
- Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *The New England Journal of Medicine*. 2010;363(27):2587-99.
- Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, Alexander S, Corey L, Ducar C, Duerr A, Eaton N, McElrath J, Holt R, Hural J, Kublin J, Wecker M, Escamilla G, Holman D, Metch B, Moodie Z, Self S, Allen M, Fix A, Follman D, Johnston P, Luzar MA, Martinez A, Casimiro D, Isaacs R, Kierstead L, Leavitt R, Mehrotra D, Robertson M, DeBruyn G, Gray G, Nkala B, Magopane T, Mkhise B, Lehobye I, Mathebula MP, Nchabeleng M, Bekker LG, Ronan A, Roux S, Churchyard G, Latka M, Lion-Cachet C, Mngadi K, Nielson T, Selepe P, Bennie T, Mlisana K, Naicker N, Puren A, Galetta D, Levendal E. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. *The Lancet. Infectious Diseases*. 2011;11(7):507-15.
- Groner AC, Meylan S, Ciuffi A, Zangger N, Ambrosini G, Dénervaud N, Bucher P, Trono D. KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. *PLoS Genetics*. 2010;6(3):e1000869.
- Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. *Federation of American Societies for Experimental Biology Journal*. 1992;6(15):3370-8.
- Gruters RA, Otto SA, Al BJ, Verhoeven AJ, Verweij CL, Van Lier RA, Miedema F. Non-mitogenic T cell activation signals are sufficient for induction of human immunodeficiency virus transcription. *European Journal of Immunology*. 1991;21(1):167-72.

- Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. *Clinical Infectious Diseases*. 2011;53(11):1120-6.
- Güerri-Fernández R, Molina-Morant D, Villar-García J, Herrera S, González-Mena A, Guelar A, Trenchs-Rodríguez M, Díez-Pérez A, Knobel H. Bone density, microarchitecture, and tissue quality after long-term treatment with Tenofovir/Emtricitabine or Abacavir/Lamivudine. *Journal of Acquired Immune Deficiency Syndromes*. 2017;75(3):322-7.
- Hamer DH. Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it. *Current HIV Research*. 2004;2(2):99-111.
- Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, Pierson TC, Margolick JB, Siliciano RF, Siliciano JD. Resting CD4⁺ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. *Journal of Virology*. 2004;78(12):6122-33.
- Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. *AIDS*. 1999;13(8):F59-62.
- Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4⁺ T cells. *The Journal of Infectious Diseases*. 2013;208(1):50-6.
- Hauber J, Cullen BR. Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat. *Journal of Virology*. 1988;62(3):673-9.
- He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. *Molecular and Cellular Biology*. 2002;22(9):2965-73.
- Hegedus A, Kavanagh Williamson M, Huthoff H. HIV-1 pathogenicity and virion production are dependent on the metabolic phenotype of activated CD4⁺ T cells. *Retrovirology*. 2014;11:98.
- Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. *Immunity*. 2007;26(2):257-70.

- Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. *Cell*. 2013;155(3):540-51.
- Hollenbaugh JA, Munger J, Kim B. Metabolite profiles of human immunodeficiency virus infected CD4⁺ T cells and macrophages using LC-MS/MS analysis. *Virology*. 2011;415(2):153-9.
- Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD, Garcia JV. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. *Nature Medicine*. 2017;23(5):638-43.
- Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DI, Keele BF, Ho YC, Siliciano JD, Siliciano RF. Proliferation of latently infected CD4⁺ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. *The Journal of Experimental Medicine*. 2017;214(4):959-72.
- Hu H, Liu F, Kim J, Ratto-Kim S. HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. *Expert Review of Vaccines*. 2016;15(6):709-17.
- Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J, Mo X, Khalili K. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(31):11461-6.
- Huang LM, Joshi A, Willey R, Orenstein J, Jeang KT. Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. *The EMBO Journal*. 1994;13(12):2886-96.
- Huang Y, Wange RL. T cell receptor signaling: beyond complex complexes. *The Journal of Biological Chemistry*. 2004;279(28):28827-30.
- Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4⁺ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. *The Journal of Infectious Diseases*. 2003;187(10):1534-43.
- Imlach S, Leen C, Bell JE, Simmonds P. Phenotypic analysis of peripheral blood gammadelta T lymphocytes and their targeting by human immunodeficiency virus type 1 in vivo. *Virology*. 2003;305(2):415-27.

- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics*. 2003;4(2):249-64.
- Ivanov AV, Peng H, Yurchenko V, Yap KL, Negorev DG, Schultz DC, Psulkowski E, Fredericks WJ, White DE, Maul GG, Sadofsky MJ, Zhou MM, Rauscher FJ. PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. *Molecular Cell*. 2007;28(5):823-37.
- Jacobs FM, Greenberg D, Nguyen N, Haeussler M, Ewing AD, Katzman S, Paten B, Salama SR, Haussler D. An evolutionary arms race between KRAB zinc-finger genes ZNF91/93 and SVA/L1 retrotransposons. *Nature*. 2014;516(7530):242-5.
- Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J. Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. *Molecular and Cellular Biology*. 2014;34(11):1911-28.
- Janas AM, Wu L. HIV-1 interactions with cells: from viral binding to cell-cell transmission. *Current Protocols in Cell Biology*. 2009;Chapter 26:Unit 26.5.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816-21.
- Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. *The EMBO Journal*. 2003;22(8):1868-77.
- Kaczmarek Michaels K, Wolschendorf F, Schiralli Lester GM, Natarajan M, Kutsch O, Henderson AJ. RNAP II processivity is a limiting step for HIV-1 transcription independent of orientation to and activity of endogenous neighboring promoters. *Virology*. 2015;486:7-14.
- Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE, Li H, Booze R, Gordon J, Hu W, Khalili K. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. *Gene Therapy*. 2016;23(8-9):690-5.
- Karmaus PWF, Chen X, Lim SA, Herrada AA, Nguyen TM, Xu B, Dhungana Y, Rankin S, Chen W, Rosencrance C, Yang K, Fan Y, Cheng Y, Easton J, Neale G, Vogel P, Chi H. Metabolic heterogeneity underlies reciprocal fates of T_H17 cell stemness and plasticity. *Nature*. 2019;565(7737):101-5.
- Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. *PLoS Pathogens*. 2009;5(6):e1000495.

- Kessl JJ, Kutluay SB, Townsend D, Rebensburg S, Slaughter A, Larue RC, Shkriabai N, Bakouche N, Fuchs JR, Bieniasz PD, Kvaratskhelia M. HIV-1 integrase binds the viral RNA genome and is essential during virion morphogenesis. *Cell*. 2016;166(5):1257-1268.e12.
- Kharsany AB, Karim QA. HIV infection and AIDS in sub-Saharan Africa: Current status, challenges and opportunities. *The Open AIDS Journal*. 2016;10:34-48.
- Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim JI, Kim JS. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. *Nature Methods*. 2015;12(3):237-43, 1 p following 243.
- Kim M, Hosmane NN, Bullen CK, Capoferri A, Yang HC, Siliciano JD, Siliciano RF. A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. *Nature Protocols*. 2014;9(12):2755-70.
- Kim YK, Mbonye U, Hokello J, Karn J. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. *Journal of Molecular Biology*. 2011;410(5):896-916.
- Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D, Wong-Staal F. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. *Proceedings of the National Academy of Sciences of the United States of America*. 1991;88(11):5011-5.
- Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. *Science*. 1986;233(4768):1089-93.
- Koh Y, Wu X, Ferris AL, Matreyek KA, Smith SJ, Lee K, KewalRamani VN, Hughes SH, Engelman A. Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration. *Journal of Virology*. 2013;87(1):648-58.
- Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *Journal of Virology*. 1994;68(7):4650-5.
- Kumar NA, Cheong K, Powell DR, da Fonseca Pereira C, Anderson J, Evans VA, Lewin SR, Cameron PU. The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4(+) T-cells. *Retrovirology*. 2015;12:76.

- Kumar NA, van der Sluis RM, Mota T, Pascoe R, Evans VA, Lewin SR, Cameron PU. Myeloid dendritic cells induce HIV latency in proliferating CD4⁺ T cells. *Journal of Immunology*. 2018;201(5):1468-77.
- Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. *PloS One*. 2012;7(1):e30176.
- Laurence J, Hodgev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V beta expression. *Nature*. 1992;358(6383):255-9.
- Lawhorn IE, Ferreira JP, Wang CL. Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53. *PloS One*. 2014;9(11):e113232.
- Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A. HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. *The EMBO Journal*. 1989;8(1):167-73.
- Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. *Lancet*. 2005;366(9485):549-55.
- Lelek M, Casartelli N, Pellin D, Rizzi E, Souque P, Severgnini M, Di Serio C, Fricke T, Diaz-Griffero F, Zimmer C, Charneau P, Di Nunzio F. Chromatin organization at the nuclear pore favours HIV replication. *Nature Communications*. 2015;6:6483.
- Li Z, Guo J, Wu Y, Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. *Nucleic Acids Research*. 2013;41(1):277-87.
- Lillemeier BF, Mörtelmaier MA, Forstner MB, Huppa JB, Groves JT, Davis MM. TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. *Nature Immunology*. 2010;11(1):90-6.
- Llewellyn GN, Alvarez-Carbonell D, Chateau M, Karn J, Cannon PM. HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. *Journal of Neurovirology*. 2018;24(2):192-203.
- Lo WL, Shah NH, Ahsan N, Horkova V, Stepanek O, Salomon AR, Kuriyan J, Weiss A. Lck promotes Zap70-dependent LAT phosphorylation by bridging Zap70 to LAT. *Nature Immunology*. 2018;19(7):733-41.

- Lu YC, Touzjian N, Stenzel M, Dorfman T, Sodroski JG, Haseltine WA. The NF kappa B independent cis-acting sequences in HIV-1 LTR responsive to T-cell activation. *Journal of Acquired Immune Deficiency Syndromes*. 1991;4(2):173-7.
- Maddon PJ, McDougal JS, Clapham PR, Dalglish AG, Jamal S, Weiss RA, Axel R. HIV infection does not require endocytosis of its receptor, CD4. *Cell*. 1988;54(6):865-74.
- Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, Verdin E. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. *The Journal of Biological Chemistry*. 2006;281(29):19960-8.
- Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. *Nature Methods*. 2013;10(10):957-63.
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. *Science*. 2013;339(6121):823-6.
- Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R, Lusso P. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. *Nature Protocols*. 2008;3(7):1240-8.
- Martinez RJ, Andargachew R, Martinez HA, Evavold BD. Low-affinity CD4+ T cells are major responders in the primary immune response. *Nature Communications*. 2016;7:13848.
- McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. *Science*. 2003;300(5623):1295-7.
- Meier K, Brehm A. Chromatin regulation: how complex does it get. *Epigenetics*. 2014;9(11):1485-95.
- Méndez C, Ledger S, Petoumenos K, Ahlenstiel C, Kelleher AD. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency. *Retrovirology*. 2018;15(1):67.
- Miller CM, Akiyama H, Agosto LM, Emery A, Ettinger CR, Swanstrom RI, Henderson AJ, Gummuluru S. Virion-associated Vpr alleviates a postintegration block to HIV-1 infection of dendritic cells. *Journal of Virology*. 2017;91(13):e00051-17.
- Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ. An improved zinc-finger nuclease architecture for highly specific genome editing. *Nature Biotechnology*. 2007;25(7):778-85.

- Miller-Jensen K, Dey SS, Pham N, Foley JE, Arkin AP, Schaffer DV. Chromatin accessibility at the HIV LTR promoter sets a threshold for NF- κ B mediated viral gene expression. *Integrative Biology: Quantitative Biosciences from Nano to Macro*. 2012;4(6):661-71.
- Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. *Proceedings of the National Academy of Sciences of the United States of America*. 1985;82(20):7096-100.
- Moosmann P, Georgiev O, Thiesen HJ, Hagmann M, Schaffner W. Silencing of RNA polymerases II and III-dependent transcription by the KRAB protein domain of KOX1, a Krüppel-type zinc finger factor. *Biological Chemistry*. 1997;378(7):669-77.
- Mousseau G, Clementz MA, Bakeman WN, Nagarsheth N, Cameron M, Shi J, Baran P, Fromentin R, Chomont N, Valente ST. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. *Cell Host & Microbe*. 2012;12(1):97-108.
- Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. *mBio*. 2015;6(4):e00465.
- Mout R, Ray M, Lee YW, Scaletti F, Rotello VM. In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges. *Bioconjugate Chemistry*. 2017;28(4):880-4.
- Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye T, Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. *Nucleic Acids Research*. 2011;39(21):9283-93.
- Napolitano G, Majello B, Licciardo P, Giordano A, Lania L. Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II. *Gene*. 2000;254(1-2):139-45.
- Natarajan M, August A, Henderson AJ. Combinatorial signals from CD28 differentially regulate human immunodeficiency virus transcription in T cells. *The Journal of Biological Chemistry*. 2010;285(23):17338-47.
- Natarajan M, Schiralli Lester GM, Lee C, Missra A, Wasserman GA, Steffen M, Gilmour DS, Henderson AJ. Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription. *The Journal of Biological Chemistry*. 2013;288(36):25995-6003.

- Neri F, Giolo G, Potestà M, Petrini S, Doria M. The HIV-1 Nef protein has a dual role in T cell receptor signaling in infected CD4⁺ T lymphocytes. *Virology*. 2011;410(2):316-26.
- Neumeister EN, Zhu Y, Richard S, Terhorst C, Chan AC, Shaw AS. Binding of ZAP-70 to phosphorylated T-cell receptor zeta and eta enhances its autophosphorylation and generates specific binding sites for SH2 domain-containing proteins. *Molecular and Cellular Biology*. 1995;15(6):3171-8.
- Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. *Journal of Virology*. 2000;74(7):3264-72.
- Ocwieja KE, Sherrill-Mix S, Mukherjee R, Custers-Allen R, David P, Brown M, Wang S, Link DR, Olson J, Travers K, Schadt E, Bushman FD. Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. *Nucleic Acids Research*. 2012;40(20):10345-55.
- Ogawa S, Watanabe M, Sakurai Y, Inutake Y, Watanabe S, Tai X, Abe R. CD28 signaling in primary CD4⁽⁺⁾ T cells: identification of both tyrosine phosphorylation-dependent and phosphorylation-independent pathways. *International Immunology*. 2013;25(12):671-81.
- Ohnishi H, Ledbetter JA, Kanner SB, Linsley PS, Tanaka T, Geller AM, Kotb M. CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses. *Journal of Immunology*. 1995;154(7):3180-93.
- Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M. Phenotypic classification of human CD4⁺ T cell subsets and their differentiation. *International Immunology*. 2008;20(9):1189-99.
- Oleksiewicz U, Gładych M, Raman AT, Heyn H, Mereu E, Chlebanowska P, Andrzejewska A, Sozańska B, Samant N, Fąk K, Auguścik P, Kosiński M, Wróblewska JP, Tomczak K, Kulcenty K, Płoski R, Biecek P, Esteller M, Shah PK, Rai K, Wiznerowicz M. TRIM28 and interacting KRAB-ZNFs control self-renewal of human pluripotent stem cells through epigenetic repression of pro-differentiation genes. *Stem Cell Reports*. 2017;9(6):2065-80.
- Oswald-Richter K, Grill SM, Leelawong M, Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. *European Journal of Immunology*. 2004;34(6):1705-14.
- Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. *Virology*. 2011;411(2):344-54.

- Patarca R, Heath C, Goldenberg GJ, Rosen CA, Sodroski JG, Haseltine WA, Hansen UM. Transcription directed by the HIV long terminal repeat in vitro. *AIDS Research and Human Retroviruses*. 1987;3(1):41-55.
- Paul S, Singh AK, Shilpi, Lal G. Phenotypic and functional plasticity of gamma-delta ($\gamma\delta$) T cells in inflammation and tolerance. *International Reviews of Immunology*. 2014;33(6):537-58.
- Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. *Nature Immunology*. 2011;12(6):467-71.
- Petravic J, Ellenberg P, Chan ML, Paukovics G, Smyth RP, Mak J, Davenport MP. Intracellular dynamics of HIV infection. *Journal of Virology*. 2014;88(2):1113-24.
- Ping YH, Rana TM. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. *The Journal of Biological Chemistry*. 2001;276(16):12951-8.
- Pitchenik AE, Fischl MA, Dickinson GM, Becker DM, Fournier AM, O'Connell MT, Colton RM, Spira TJ. Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state. *Annals of Internal Medicine*. 1983;98(3):277-84.
- Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. *Cell*. 2014;159(2):440-55.
- Puray-Chavez M, Tedbury PR, Huber AD, Ukah OB, Yapo V, Liu D, Ji J, Wolf JJ, Engelman AN, Sarafianos SG. Multiplex single-cell visualization of nucleic acids and protein during HIV infection. *Nature Communications*. 2017;8(1):1882.
- Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. *Journal of Virology*. 1993;67(11):6365-78.
- Puryear WB, Akiyama H, Geer SD, Ramirez NP, Yu X, Reinhard BM, Gummuluru S. Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. *PLoS Pathogens*. 2013;9(4):e1003291.
- Quivy V, De Walque S, Van Lint C. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. *Sub-cellular Biochemistry*. 2007;41:371-96.

- Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. *PLoS Biology*. 2011;9(11):e1001206.
- Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F. In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature*. 2015;520(7546):186-91.
- Rankovic S, Varadarajan J, Ramalho R, Aiken C, Rousso I. Reverse transcription mechanically initiates HIV-1 capsid disassembly. *Journal of Virology*. 2017;91(12):e00289-17.
- Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. A hardwired HIV latency program. *Cell*. 2015;160(5):990-1001.
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Prensri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, Rerks-Ngarm S, Chunsuttiwat S, Prensri N, Namwat C, Kunasol P, Thongcharoen P, Khamboonruang C, Pitisuttithum P, Bussaratid V, Maek-a-nantawat W, Dhitavat J, Suntharasamai P, Pungpak S, Vanijanonta S, Kaewkunwal J, Khamsiriwatchara A, Jarujareet P, Nitayaphan S, Easmla C, Tabprasit S, Chiu J, Paris R, Benenson M, Brown A, Morgan P, de Souza M, Trichavaroj R, Schuetz A, Thaitawat N, Gurunathan S, Tartaglia J, McNeil JG, Harkness R, Meric C, El Habib R, Baglyos L, Francis D, Lee C, Adams E, Kim JH, Robb ML, Michael NL, Milazzo M, Bolen A, Wessner B, Kim SR, Marovich M, Currier J, Birx DL, Stablein D, Germanson T, Dally L, Wiley R, Excler JL, Berenberg J. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *The New England Journal of Medicine*. 2009;361(23):2209-20.
- Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. *PloS One*. 2009;4(6):e6093.
- Rhee SG. Regulation of phosphoinositide-specific phospholipase C. *Annual Review of Biochemistry*. 2001;70:281-312.
- Ringler DJ, Hancock WW, King NW, Letvin NL, Daniel MD, Desrosiers RC, Murphy GF. Immunophenotypic characterization of the cutaneous exanthem of SIV-infected rhesus monkeys. Apposition of degenerative Langerhans cells and cytotoxic lymphocytes during the development of acquired immunodeficiency syndrome. *The American Journal of Pathology*. 1987;126(2):199-207.

- Robbez-Masson L, Tie CHC, Conde L, Tunbak H, Husovsky C, Tchasovnikarova IA, Timms RT, Herrero J, Lehner PJ, Rowe HM. The HUSH complex cooperates with TRIM28 to repress young retrotransposons and new genes. *Genome Research*. 2018;28(6):836-45.
- Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. *Nature Reviews. Immunology*. 2015;15(4):203-16.
- Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. *Journal of Immunology*. 2000;164(5):2338-46.
- Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. *Journal of Cellular and Molecular Medicine*. 2016;20(7):1287-94.
- Rossy J, Owen DM, Williamson DJ, Yang Z, Gaus K. Conformational states of the kinase Lck regulate clustering in early T cell signaling. *Nature Immunology*. 2013;14(1):82-9.
- Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. *HIV Medicine*. 2012;13(5):291-6.
- Rowe HM, Jakobsson J, Mesnard D, Rougemont J, Reynard S, Aktas T, Maillard PV, Layard-Liesching H, Verp S, Marquis J, Spitz F, Constam DB, Trono D. KAP1 controls endogenous retroviruses in embryonic stem cells. *Nature*. 2010;463(7278):237-40.
- Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. *Cell*. 2013;155(3):519-29.
- Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(30):11364-9.
- Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV, Weinberg MS. Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. *Molecular Therapy*. 2016;24(3):488-98.

- Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C, Paller C, Delfraissy JF, Lambotte O. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS*. 2008;22(10):1125-9.
- Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4⁺ T cells to HIV-1 infection: a novel model of HIV-1 latency. *Blood*. 2007;110(13):4161-4.
- Saleh S, Lu HK, Evans V, Harisson D, Zhou J, Jaworowski A, Sallmann G, Cheong KY, Mota TM, Tennakoon S, Angelovich TA, Anderson J, Harman A, Cunningham A, Gray L, Churchill M, Mak J, Drummer H, Vatakis DN, Lewin SR, Cameron PU. HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF- κ B. *Retrovirology*. 2016;13(1):49.
- Santos ASEAC, Silveira EAD, Falco MO, Nery MW, Turchi MD. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized clinical trial. *Clinical Nutrition*. 2017;36(3):680-5.
- Sauter D, Kirchhoff F. Key Viral Adaptations Preceding the AIDS Pandemic. *Cell Host & Microbe*. 2019;25(1):27-38.
- Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayoub A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatzioannou T, Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. *Cell Host & Microbe*. 2009;6(5):409-21.
- Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. *Journal of Molecular Biology*. 1996;263(4):551-67.
- Schiralli Lester GM, Akiyama H, Evans E, Singh J, Gummuluru S, Henderson AJ. Interleukin 2-inducible T cell kinase (ITK) facilitates efficient egress of HIV-1 by coordinating Gag distribution and actin organization. *Virology*. 2013;436(1):235-43.
- Sette P, O'Connor SK, Yerramilli VS, Dussupt V, Nagashima K, Chutiraka K, Lingappa J, Scarlata S, Bouamr F. HIV-1 nucleocapsid mimics the membrane adaptor syntenin PDZ to gain access to ESCRTs and promote virus budding. *Cell Host & Microbe*. 2016;19(3):336-48.
- Seu L, Sabbaj S, Duverger A, Wagner F, Anderson JC, Davies E, Wolschendorf F, Willey CD, Saag MS, Goepfert P, Kutsch O. Stable phenotypic changes of the host T

- cells are essential to the long-term stability of latent HIV-1 infection. *Journal of Virology*. 2015;89(13):6656-72.
- Shearer GM, Bernstein DC, Tung KS, Via CS, Redfield R, Salahuddin SZ, Gallo RC. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). *Journal of Immunology*. 1986;137(8):2514-21.
- Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, Li M, Clements JE, Siliciano RF. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. *Journal of Virology*. 2003;77(8):4938-49.
- Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. *Methods in Molecular Biology*. 2005;304:3-15.
- Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. *AIDS*. 2010;24(9):1243-50.
- Smith TF, Srinivasan A, Schochetman G, Marcus M, Myers G. The phylogenetic history of immunodeficiency viruses. *Nature*. 1988;333(6173):573-5.
- Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. *Annual Review of Immunology*. 2009;27:591-619.
- Sommermeier D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. *Leukemia*. 2016;30(2):492-500.
- Soriano-Sarabia N, Archin NM, Bateson R, Dahl NP, Crooks AM, Kuruc JD, Garrido C, Margolis DM. Peripheral V γ 9V δ 2 T cells are a novel reservoir of latent HIV infection. *PLoS pathogens*. 2015;11(10):e1005201.
- Sowd GA, Serrao E, Wang H, Wang W, Fadel HJ, Poeschla EM, Engelman AN. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(8):E1054-63.

- Steffens CM, Managlia EZ, Landay A, Al-Harthi L. Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. *Blood*. 2002;99(9):3310-8.
- Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. *The EMBO Journal*. 1990;9(5):1551-60.
- Stoltzfus CM. Chapter 1. Regulation of HIV-1 alternative RNA splicing and its role in virus replication. *Advances in virus research*. 2009;74:1-40.
- Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. *PloS One*. 2016;11(5):e0154893.
- Stuart RM, Grobicki L, Haghparast-Bidgoli H, Panovska-Griffiths J, Skordis J, Keiser O, Estill J, Baranczuk Z, Kelly SL, Reporter I, Kedziora DJ, Shattock AJ, Petravic J, Hussain SA, Grantham KL, Gray RT, Yap XF, Martin-Hughes R, Benedikt CJ, Fraser-Hurt N, Masaki E, Wilson DJ, Gorgens M, Mziray E, Cheikh N, Shubber Z, Kerr CC, Wilson DP. How should HIV resources be allocated? Lessons learnt from applying Optima HIV in 23 countries. *Journal of the International AIDS Society*. 2018;21(4):e25097.
- Sundquist WI, Kräusslich HG. HIV-1 assembly, budding, and maturation. *Cold Spring Harbor Perspectives in Medicine*. 2012;2(7):a006924.
- Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In *Retroviruses*, eds. Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1997.
- Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, Schretzenmair R, Theodosopoulos T, O'Doherty U. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. *Journal of Virology*. 2005;79(22):14179-88.
- Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. *Nature Methods*. 2015;12(12):1143-9.
- Thierry S, Marechal V, Rosenzwajg M, Sabbah M, Redeuilh G, Nicolas JC, Gozlan J. Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. *Journal of Virology*. 2004;78(22):12198-206.

- Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. *Proceedings of the National Academy of Sciences of the United States of America*. 1993;90(12):5653-6.
- UNAIDS. Global HIV & AIDS Statistics – 2018 Fact Sheet.
<http://www.unaids.org/en/resources/fact-sheet>. Accessed February 8, 2019.
- UNAIDS. Guidance Note on HIV and Sex Work.
http://www.unaids.org/en/resources/documents/2012/20120402_UNAIDS-guidance-note-HIV-sex-work. Accessed February 8, 2019.
- University of Michigan, Molecular and Behavioral Neuroscience Institute. Brainarray.
<http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF>. Accessed February 16, 2019.
- Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. *Retrovirology*. 2013;10:67.
- Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. *The EMBO Journal*. 1996;15(5):1112-20.
- Verdin E, Paras P, Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. *The EMBO Journal*. 1993;12(8):3249-59.
- von Boehmer H, Kisielow P. Self-nonsel self discrimination by T cells. *Science*. 1990;248(4961):1369-73.
- Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. *Molecular Therapy: The Journal of the American Society of Gene Therapy*. 2016;24(3):522-6.
- Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. *Genome Research*. 2007;17(8):1186-94.
- Wang H, Cohen AA, Galimidi RP, Gristick HB, Jensen GJ, Bjorkman PJ. Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(46):E7151-E7158.
- Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to MHC molecules. *Molecular Immunology*. 2002;38(14):1039-49.

- Wang Z, Gurule EE, Brennan TP, Gerold JM, Kwon KJ, Hosmane NN, Kumar MR, Beg SA, Capoferri AA, Ray SC, Ho YC, Hill AL, Siliciano JD, Siliciano RF. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115(11):E2575-E2584.
- Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, Wainberg MA, Liang C. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. *Cell Reports*. 2016;15(3):481-9.
- Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. *Cell*. 2005;122(2):169-82.
- Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. *Nature*. 2014;512(7512):74-7.
- Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. *The EMBO Journal*. 2006;25(1):139-49.
- Williams SA, Kwon H, Chen LF, Greene WC. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. *Journal of virology*. 2007;81(11):6043-56.
- Wolf D, Goff SP. Embryonic stem cells use ZFP809 to silence retroviral DNAs. *Nature*. 2009;458(7242):1201-4.
- Wolf G, Yang P, Fuchtbauer AC, Fuchtbauer EM, Silva AM, Park C, Wu W, Nielsen AL, Pedersen FS, Macfarlan TS. The KRAB zinc finger protein ZFP809 is required to initiate epigenetic silencing of endogenous retroviruses. *Genes & Development*. 2015;29(5):538-54.
- Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science*. 1997;278(5341):1291-5.
- Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-

- nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. *PloS One*. 2017;12(2):e0171596.
- Xie H, Tang L, He X, Liu X, Zhou C, Liu J, Ge X, Li J, Liu C, Zhao J, Qu J, Song Z, Gu F. SaCas9 requires 5'-NNGRRT-3' PAM for sufficient cleavage and possesses higher cleavage activity than SpCas9 or FnCpf1 in human cells. *Biotechnology Journal*. 2018;13(4):e1700561.
- Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. *Drug Discovery Today*. 2013;18(11-12):541-51.
- Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Beger HG, Korc M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. *Human Pathology*. 1993;24(10):1127-34.
- Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. *Nature*. 2001;414(6861):317-22.
- Yuan Z, Fan X, Staitieh B, Bedi C, Spearman P, Guidot DM, Sadikot RT. HIV-related proteins prolong macrophage survival through induction of Triggering receptor expressed on myeloid cells-1. *Scientific Reports*. 2017;7:42028.
- Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, Lampiris H, Wong JK. HIV latency in isolated patient CD4⁺ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. *Science Translational Medicine*. 2018;10(430):eaap9927.
- Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. *AIDS*. 2004;18(8):1101-8.
- Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. *Nature*. 2009;458(7235):211-4.
- Zerihun MB, Vaillant C, Jost D. Effect of replication on epigenetic memory and consequences on gene transcription. *Physical Biology*. 2015;12(2):026007.
- Zetsche B, Volz SE, Zhang F. A split-Cas9 architecture for inducible genome editing and transcription modulation. *Nature Biotechnology*. 2015;33(2):139-42.
- Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R, Fagan PR, Putatunda R, Young WB, Khalili K, Hu W. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. *Scientific Reports*. 2015;5:16277.

- Zhang Z, Klatt A, Gilmour DS, Henderson AJ. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. *The Journal of Biological Chemistry*. 2007;282(23):16981-8.
- Zhang Z, Klatt A, Henderson AJ, Gilmour DS. Transcription termination factor Pcf11 limits the processivity of Pol II on an HIV provirus to repress gene expression. *Genes & Development*. 2007;21(13):1609-14.
- Zhao Y, Lei M, Wang Z, Qiao G, Yang T, Zhang J. TCR-induced, PKC- θ -mediated NF- κ B activation is regulated by a caspase-8-caspase-9-caspase-3 cascade. *Biochemical and Biophysical Research Communications*. 2014;450(1):526-31.
- Zhou Q, Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. *Microbiology and Molecular Biology Reviews*. 2006;70(3):646-59.
- Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, Gao G, Qu H, Walker BD, Elledge SJ, Brass AL. Reactivation of latent HIV-1 by inhibition of BRD4. *Cell Reports*. 2012;2(4):807-16.
- Zhu P, Liu J, Bess J, Chertova E, Lifson JD, Grisé H, Ofek GA, Taylor KA, Roux KH. Distribution and three-dimensional structure of AIDS virus envelope spikes. *Nature*. 2006;441(7095):847-52.
- Zikherman J, Au-Yeung B. The role of T cell receptor signaling thresholds in guiding T cell fate decisions. *Current Opinion in Immunology*. 2015;33:43-8.

CURRICULUM VITAE